U.S. patent application number 17/602584 was filed with the patent office on 2022-06-09 for hmox1 inducers.
The applicant listed for this patent is Mitobridge Inc.. Invention is credited to Eric Bell, Margaret Biddle, Arthur Kluge, Bharat Lagu, Takashi Ogiyama, Sanjita Sasmal, Xinyuan Wu.
Application Number | 20220177460 17/602584 |
Document ID | / |
Family ID | |
Filed Date | 2022-06-09 |
United States Patent
Application |
20220177460 |
Kind Code |
A1 |
Biddle; Margaret ; et
al. |
June 9, 2022 |
HMOX1 INDUCERS
Abstract
The present invention is related to compounds of structure (I)
as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present
invention is also related a method of controlling the activity or
the amount, or both the activity and the amount, of heme-oxygenase
1 in a mammalian subject. The definitions of the variables are
provided herein. ##STR00001##
Inventors: |
Biddle; Margaret;
(Cambridge, MA) ; Kluge; Arthur; (Lincoln, MA)
; Sasmal; Sanjita; (Bangalore, IN) ; Lagu;
Bharat; (Acton, MA) ; Wu; Xinyuan; (Chestnut
Hill, MA) ; Ogiyama; Takashi; (Ibaraki, JP) ;
Bell; Eric; (Somerville, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mitobridge Inc. |
Cambridge |
MA |
US |
|
|
Appl. No.: |
17/602584 |
Filed: |
April 8, 2020 |
PCT Filed: |
April 8, 2020 |
PCT NO: |
PCT/US2020/027240 |
371 Date: |
October 8, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62932629 |
Nov 8, 2019 |
|
|
|
62833031 |
Apr 12, 2019 |
|
|
|
International
Class: |
C07D 413/14 20060101
C07D413/14; C07D 413/12 20060101 C07D413/12; A61P 9/08 20060101
A61P009/08 |
Claims
1. A compound represented by structural formula (I): ##STR00262##
or a pharmaceutically acceptable salt thereof, wherein: Ring A is
5-7 membered monocyclic cycloalkyl, 5-7 membered monocyclic
heterocyclyl, 5-6 membered heteroaryl, or phenyl; X is --S--,
--O--, or --NR.sup.b--; when X is --S-- and ring A is phenyl, then
R is 3-7 membered monocyclic heterocyclyl optionally substituted
with one or more groups selected from the group consisting of halo,
--CN, --OH, --(C.sub.1-C.sub.4)alkyl, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, and --NR.sup.aR.sup.a; when X is
--S-- and ring A is 5-7 membered monocyclic cycloalkyl, 5-7
membered monocyclic heterocyclyl, or 5-6 membered heteroaryl; or
when X is --O-- or --NR.sup.b--; then R is --H,
--(C.sub.1-C.sub.4)alkyl, or --(CH.sub.2).sub.i3-7 membered
monocyclic heterocyclyl, wherein the --(C.sub.1-C.sub.4)alkyl or
3-7 membered monocyclic heterocyclyl represented by R is optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)haloalkyl, --(C.sub.1-C.sub.4)hydroxyalkyl,
--(C.sub.1-C.sub.4)alkoxy, --(C.sub.1-C.sub.4)haloalkoxy,
--SO.sub.2R.sup.a, and --NR.sup.aR.sup.a; each R.sub.1 is
independently --H, halogen, --(CH.sub.2).sub.kCOOH,
--(CH.sub.2).sub.kCO(C.sub.1-C.sub.4)alkyl,
--(CH.sub.2).sub.kCOO(C.sub.1-C.sub.4)alkyl,
--(CH.sub.2).sub.pC(.dbd.O)NR.sup.aR.sub.3,
--CH(CF.sub.3)NR.sup.aR.sub.3, --C(.dbd.NOH)CF.sub.3, or
--CH(CF.sub.3)OR.sub.3, wherein the (C.sub.1-C.sub.4)alkyl in the
group represented by R.sub.1 is optionally substituted with one or
more groups selected from the group consisting of halo, --CN, --OH,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, and --NR.sup.aR.sup.a; each R.sub.2
is independently --H, halo, CN, --(C.sub.1-C.sub.4)alkyl, --OH,
--(C.sub.1-C.sub.4)alkoxy, --COOH,
--C(.dbd.O)(C.sub.1-C.sub.4)alkyl,
--C(.dbd.O)O(C.sub.1-C.sub.4)alkyl,
--C(.dbd.O)NR.sup.a(C.sub.1-C.sub.4)alkyl, --NR.sup.aR.sup.a, 3-6
membered monocyclic cycloalkyl, --O(CH.sub.2).sub.i3-7 membered
monocyclic heterocyclyl, 3-7 membered monocyclic heterocyclyl, or
5-6 membered heteroaryl, wherein the --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)alkoxy, heterocyclyl, or heteroaryl represented
by R.sub.2 or in the group represented by R.sub.2 is optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)alkoxy, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)haloalkoxy, and
--NR.sup.aR.sup.a; each R.sub.3 is independently H,
(C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
--(CH.sub.2).sub.p13-7 membered monocyclic heterocyclyl,
--(CH.sub.2).sub.p1NH3-7 membered monocyclic heterocyclyl, 5-6
membered heteroaryl,
--O(CH.sub.2).sub.p2NR.sup.aC(.dbd.O)(C.sub.1-C.sub.4)alkyl,
--(CH.sub.2).sub.p2O(CH.sub.2).sub.p2O(C.dbd.O)(C.sub.1-C.sub.4)alkyl,
or (CH.sub.2).sub.p2NR.sup.aC(.dbd.O)(C.sub.1-C.sub.4)alkyl,
wherein the alkyl, alkoxy, heteroaryl, or heterocyclyl represented
by R.sub.3 or in the group represented by R.sub.3 is optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)haloalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)haloalkoxy,
--(C.sub.1-C.sub.4)carboxyalkoxy,
--S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)hydroxyalkoxy, and --NR.sup.aR.sup.a; each
R.sup.a is independently --H or --(C.sub.1-C.sub.4)alkyl; each
R.sup.b is independently --H or --(C.sub.1-C.sub.4)alkyl; wherein
the --(C.sub.1-C.sub.4)alkyl represented by R.sup.b is optionally
substituted with one or more groups selected from halo, --CN, --OH,
--(C.sub.3-C.sub.6)cycloalkyl, phenyl, 3-7 membered monocyclic
heterocyclyl, and 5-6 membered heteroaryl; i is 0 or 1; k is 0, 1,
2, 3, or 4; m is 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4; p is 0,
1, 2, 3, or 4; p.sub.1 is 0, 1, 2, 3, or 4; and p.sub.2 is 2, 3, or
4.
2. The compound of claim 1, wherein the compound is represented by
structural formula (II) or formula (II'): ##STR00263## ##STR00264##
or a pharmaceutically acceptable salt thereof.
3. (canceled)
4. The compound of claim 1, wherein the compound is represented by
structural formula (II-A): ##STR00265## or a pharmaceutically
acceptable salt thereof.
5. The compound of claim 1, wherein the compound is represented by
structural formula (II-B) or formula (II-C): ##STR00266## or a
pharmaceutically acceptable salt thereof, wherein R.sup.b is --H or
--(C.sub.1-C.sub.4)alkyl, wherein the --(C.sub.1-C.sub.4)alkyl
represented by R.sup.b is optionally substituted with one or more
groups selected from halo, --CN, and --OH.
6-8. (canceled)
9. The compound of claim 5, or a pharmaceutically acceptable salt
thereof, wherein R is --(C.sub.1-C.sub.4)alkyl optionally
substituted with --(C.sub.1-C.sub.4)alkoxy; or
--(CH.sub.2).sub.i3-6 membered monocyclic heterocyclyl optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)haloalkyl, --(C.sub.1-C.sub.4)hydroxyalkyl,
--(C.sub.1-C.sub.4)alkoxy, --(C.sub.1-C.sub.4)haloalkoxy, and
--NR.sup.aR.sup.a.
10. The compound of claim 2, or a pharmaceutically acceptable salt
thereof, wherein R is azetidinyl, azepanyl, morpholinyl,
pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl,
tetrahydrofuranyl, or tetrahydropyranyl, each of which is
optionally substituted with one or more groups selected from the
group consisting of halo, --OH, --(C.sub.1-C.sub.4)alkyl, and
--NH.sub.2.
11. The compound of claim 10, or a pharmaceutically acceptable salt
thereof, wherein R.sub.1 is --(CH.sub.2).sub.kCOOH,
--(CH.sub.2).sub.kCO(C.sub.1-C.sub.4)alkyl optionally substituted
with halo, --(CH.sub.2).sub.pC(.dbd.O)NR.sup.aR.sub.3,
--C(.dbd.NOH)CF.sub.3, or --CH(CF.sub.3)NR.sup.aR.sub.3; and
R.sub.2 is H; halogen; CN; --(C.sub.1-C.sub.4)alkyl optionally
substituted with halo; --(C.sub.1-C.sub.4)alkoxy optionally
substituted with halo, hydroxy, methoxy, or ethoxy;
--C(.dbd.O)(C.sub.1-C.sub.4)alkyl; 3-4 membered monocyclic
cycloalkyl; --O(CH.sub.2).sub.i3-7 membered monocyclic
heterocyclyl, 3-7 membered monocyclic heterocyclyl, or 5-6 membered
heteroaryl, wherein the heterocyclyl, or heteroaryl represented by
R.sub.2 or in the group represented by R.sub.2 is optionally
substituted with halo, hydroxy, or --(C.sub.1-C.sub.4)alkoxy.
12. (canceled)
13. The compound of claim 5, or a pharmaceutically acceptable salt
thereof, wherein R is --(C.sub.1-C.sub.4)alkyl optionally
substituted with methoxy or --SO.sub.2CH.sub.3;
--(CH.sub.2)tetrohydrofuranyl; --(CH.sub.2)oxetanyl optionally
substituted with hydroxy; pyrrolidinyl; piperidinyl; or
tetrahydropyranyl; wherein the pyrrolidinyl or piperidinyl is
optionally substituted with --(C.sub.1-C.sub.4)alkyl.
14. The compound of claim 13, or a pharmaceutically acceptable salt
thereof, wherein R.sub.1 is --COOH, --C(.dbd.O)CF.sub.3,
--CH(CF.sub.3)(NH.sub.2), --C(.dbd.NOH)CF.sub.3, or
--C(.dbd.O)NHR.sub.3; R.sub.3 is (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, (CH.sub.2).sub.p13-6 membered monocyclic
heterocyclyl, or
(CH.sub.2).sub.p2NHC(.dbd.O)(C.sub.1-C.sub.4)alkyl, wherein the
alkyl, alkoxy, or heterocyclyl represented by R.sub.3 or in the
group represented by R.sub.3 is optionally substituted with one or
more groups selected from the group consisting of halo, --OH,
--(C.sub.1-C.sub.4)alkyl, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, --S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)hydroxyalkoxy, and --NR.sup.aR.sup.a; and
R.sub.2 is H; halogen; CN; --(C.sub.1-C.sub.4)alkyl optionally
substituted with halo; --(C.sub.1-C.sub.4)alkoxy optionally
substituted with halo, hydroxy, methoxy, or ethoxy;
--C(.dbd.O)(C.sub.1-C.sub.4)alkyl; cyclopropyl;
O-tetrahydropyranyl; N-pyrolidinyl; or thiazolyl.
15-16. (canceled)
17. The compound of claim 5, wherein the compound is represented by
structural formula (III-B): ##STR00267## or a pharmaceutically
acceptable salt thereof.
18. The compound of claim 17, or a pharmaceutically acceptable salt
thereof, wherein R.sub.1 is --COOH or --C(.dbd.O)NHR.sub.3, R.sub.3
is --(C.sub.1-C.sub.4)alkyl, -hydroxy(C.sub.1-C.sub.4)alkyl,
-methoxy(C.sub.1-C.sub.4)alkyl, -amino(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)hydroxyalkoxy(C.sub.1-C.sub.4)alkyl, or
--(CH.sub.2).sub.p2NHC(.dbd.O)(dimethylamino(C.sub.1-C.sub.4)alkyl);
and R.sub.2 is H, halo, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)haloalkoxy, --(C.sub.1-C.sub.4)alkoxy optionally
substituted with methoxy, or --N-pyrrolidinyl.
19-20. (canceled)
21. The compound of claim 18, or a pharmaceutically acceptable salt
thereof, wherein R.sub.2 is H, R.sub.1 is
--C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl optionally substituted with
--OH, NH.sub.2, oxetanyl, or --(C.sub.1-C.sub.4)hydroxyalkoxy; or
--C(.dbd.O)NH(CH.sub.2).sub.p2NHC(.dbd.O)(dimethylamino(C.sub.1-C.sub.4)a-
lkyl); or R.sub.2 is F, R.sub.1 is
--C(.dbd.O)NH(methoxy(C.sub.1-C.sub.4)alkyl); or R.sub.2 is
--N-pyrrolidinyl, R.sub.1 is
--C(.dbd.O)NH((C.sub.1-C.sub.4)hydroxyalkoxy(C.sub.1-C.sub.4)alkyl),
or R.sub.2 is CF.sub.3, OCHF.sub.2, or OCF.sub.3, R.sub.1 is
--COOH; or R.sub.2 is OCH.sub.2CH.sub.2OCH.sub.3, R.sub.1 is
--C(.dbd.O)NH((C.sub.1-C.sub.4)hydroxyalkoxy(C.sub.1-C.sub.4)alkyl),
--C(.dbd.O)NH(hydroxy(C.sub.1-C.sub.4)alkyl),
--C(.dbd.O)NH(methoxy(C.sub.1-C.sub.4)alkyl), or
--C(.dbd.O)NH(hydroxy(C.sub.1-C.sub.4)alkoxy).
22. The compound of 14, or a pharmaceutically acceptable salt
thereof, wherein R.sub.1 is --C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl
optionally substituted with --OH, NH.sub.2, --(C.sub.1-C.sub.4)--
alkoxy, or --(C.sub.1-C.sub.4)hydroxyalkoxy, and R.sub.2 is H, or
OCH.sub.2CH.sub.2OCH.sub.3.
23. The compound of 22, or a pharmaceutically acceptable salt
thereof, wherein (i) R.sub.2 is H and R.sub.1 is
--C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl substituted with
--(C.sub.1-C.sub.4)hydroxyalkoxy; or (ii) R.sub.2 is
OCH.sub.2CH.sub.2OCH.sub.3 and R.sub.1 is
--C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl substituted with
--(C.sub.1-C.sub.4)alkoxy.
24-26. (canceled)
27. The compound of 26, wherein the compound is:
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide or a pharmaceutically
acceptable salt thereof.
28. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein the compound is ##STR00268##
29. (canceled)
30. A method of increasing the activity of or the amount of HMOX-1
in a human subject comprising: administering to a human subject an
effective amount of the compound of claim 1, or a pharmaceutically
acceptable salt thereof, or an effective amount of a pharmaceutical
composition comprising a pharmaceutically acceptable carrier or
diluent and a compound of claim 1 or a pharmaceutically acceptable
salt thereof.
31. A method of activating transcription factor Nrf2 in a human
subject comprising: administering to a human subject an effective
amount of the compound of claim 1, or a pharmaceutically acceptable
salt thereof, or an effective amount of a pharmaceutical
composition comprising a pharmaceutically acceptable carrier or
diluent and a compound of claim 1 or a pharmaceutically acceptable
salt thereof.
32. A method of reducing the amount of ROS in a human subject
comprising: administering to a human subject an effective amount of
the compound of claim 1, or a pharmaceutically acceptable salt
thereof, or an effective amount of a pharmaceutical composition
comprising a pharmaceutically acceptable carrier or diluent and a
compound of claim 1 or a pharmaceutically acceptable salt
thereof.
33. A method of treating a disease, disorder, or condition
comprising administering to a human subject an effective amount of
the compound of claim 1, or a pharmaceutically acceptable salt
thereof, or an effective amount of a pharmaceutical composition
comprising a pharmaceutically acceptable carrier or diluent and a
compound of claim 1 or a pharmaceutically acceptable salt thereof
wherein the disease, disorder, or condition is: (i) a fibrotic
disease, including a fibrotic disease of the lung, chronic
obstructive pulmonary disease (COPD), idiopathic pulmonary
fibrosis, sarcoidosis, a fibrotic disease of the liver including
those caused by alcoholic cirrhosis, steatosis, cholestasis, drug
side effect, and viral infection, a fibrotic diseases of the skin,
scleroderma, or psoriasis; (ii) a neurodegenerative disease,
including Friedreich's ataxia, Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, multiple sclerosis,
cerebral nerve degenerative disease, or Charcot-Marie-Tooth
syndrome; (iii) a cardiovascular disease, including hypertension,
hypercholesterolaemia, atherosclerosis, arteriosclerosis,
thrombosis, acute coronary thrombosis, deep vein thrombosis,
peripheral vascular disease, congestive heart failure, acute
coronary syndrome, failure of arterial fistula for dialysis,
ischemia-reperfusion injury, primary pulmonary hypertension,
primary pulmonary arterial hypertension, or secondary pulmonary
arterial hypertension; (iv) a renal disease, including acute kidney
injury, polycystic kidney disease, Alport syndrome, diabetic
nephropathy, glomerular nephritis, lupus nephritis, sickle cell
nephropathy, and acute tubular necrosis; (v) an inflammatory
disease, including asthma, chronic obstructive pulmonary disease,
idiopathic pulmonary fibrosis, inflammatory bowel syndrome, Crohn's
disease, celiac disease, ulcerative colitis, chronic inflammatory
bowel disease, scleroderma, dermatitis, systemic lupus
erythematosus, esophagitis, vasculitis, pancreatitis, tendonitis,
osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, or
chronic inflammation of the brain; (vi) a liver disease, including
drug induced liver toxicity, nonalcoholic steatohepatitis,
hepatitis B infection, or hepatitis C infection; (vii) an eye
disease, including conjunctivitis, glaucoma, uveitis, an eye wound,
eye trauma, corneal grafts, Fuchs' endothelial corneal dystrophy,
macular degeneration, cataracts, light retinopathy, retinitis
pigmentosa, diabetic retinopathy, and retinopathy of prematurity;
(viii) a thyroid disease, including Graves' disease, follicular
adenoma, or papillary and follicular carcinomas; (ix) a viral
infection, including infections from human immunodeficiency virus,
hepatitis B, hepatitis C, or herpesvirus; (x) osteoporosis; (xi) a
pregnancy disorder; (xii) endometriosis; (xiii) diabetes, including
type 1 diabetes mellitus, type 2 diabetes mellitus, gestational
diabetes, pre-diabetes, hyperglycemia, metabolic syndrome, or a
secondary condition resulting from a diabetic condition; (xiv)
cancer; (xv) a skin disease, including dermatitis, scleroderma, or
psoriasis; (xvi) a mitochondrial diseases such as mitochondrial
myopathies, Leber's hereditary optic neuropathy (LHON), myoclonic
epilepsy with ragged red fibers (MERFF), mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS)
or Leigh's Syndrome; (xvii) a hematological disorder such as
Diamond Blackfan anemia, myelodysplasic syndrome, sickle cell
disease and beta-thalessemia; or (xviii) a muscle diseases, such as
Duchenne muscular dystrophy, limb girdle muscular dystrophy, Becker
muscular dystrophy, myotonic dystrophy and rhabdomyolysis.
34.-36. (canceled)
37. A method of treating sickle cell disease, comprising
administering to a human subject an effective amount of the
compound of claim 1, or a pharmaceutically acceptable salt thereof,
or an effective amount of a pharmaceutical composition comprising a
pharmaceutically acceptable carrier or diluent and a compound of
claim 1 or a pharmaceutically acceptable salt thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 62/833,031, filed on Apr. 12, 2019 and U.S.
Provisional Application No. 62/932,629, filed on Nov. 8, 2019. The
entire teachings of the aforementioned applications are
incorporated herein by reference.
FIELD OF THE INVENTION
[0002] This application is directed to HMOX1 (heme oxygenase 1)
inducers, and methods for their use, such as to control the
activity or the amount, or both the activity and the amount, of
heme-oxygenase in a mammalian subject.
BACKGROUND OF THE INVENTION
[0003] Oxidative stress represents an imbalance between cellular
reactive oxygen species (ROS) production and cellular responses to
ROS such as degrading ROS species and producing endogenous
anti-oxidant molecules.
[0004] ROS serve critical cellular signaling needs, but can have
deleterious effects if overproduced or left unchecked. Increased
ROS levels in a cell can result in damage to components such as
lipids, proteins, polysaccharides, and DNA. Prolonged oxidative
stress is also linked to chronic diseases that affect nearly every
major organ system. For example, prolonged oxidative stress is
implicated in the onset or progression of disease states such as
neurodegenerative diseases, lung diseases, cardiovascular diseases,
renal diseases, diabetes, inflammatory pain, and cancer.
Accordingly, strategies to mitigate oxidative stress are desirable
for a number of therapeutic settings.
[0005] Under normal physiological conditions, production of ROS is
counterbalanced by a well-defined and conserved set of cellular
pathways that respond to, limit, and repair the damage due to ROS.
This adaptive set of genes are called the phase II system. They
encode enzymes that degrade ROS directly as well as increase levels
of cells' endogenous antioxidant molecules, including glutathione
and bilirubin.
[0006] Of the phase II enzyme system, HMOX1, a human gene that
encodes for the enzyme heme oxygenase 1, has been found to be a key
component. The role of HMOX1 is to metabolize heme into bilirubin,
carbon monoxide, and free iron by a two-step process. The first and
rate-limiting step is the production of biliverdin and carbon
monoxide from heme by HMOX1. The second step is the production of
bilirubin from biliverdin by biliverdin reductase. Both bilirubin
and carbon monoxide have been shown to scavenge ROS and to have
potent anti-oxidant and anti-inflammatory activities.
[0007] Agents that induce production of HMOX1 have been shown to
have beneficial activity in models of diabetes, cardiovascular
disease, hypertension, and pulmonary function. Heme, heavy metal
ions (e.g., arsenite, cadmium, iron, lead, chromium and mercury),
and electrophiles (e.g., natural products such as sulforaphane and
curcumin) can all induce production of HMOX1. Induction of HMOX1
and other phase II genes are controlled by a number of
transcription factors that are responsive to heavy metals, heme,
and electrophiles. The transcription factors Nrf2, Bach1, and small
Maf proteins are particularly important in this process. For
example, a common sequence called antioxidant responsive element
(ARE) is present in a promoter of each gene of the phase II
enzymes, and its expression is induced by the transcription factor
Nrf2 (NF-E2 related factor 2).
[0008] HMOX1 is also induced as part of a generalized stress
response to stimuli such as thermal shock, oxidative stress and
cytokines such as interleukin-1 (IL-1), tumor necrosis factor and
interleukin-6 (IL-6). This stress response is seen as beneficial in
that it results in protection of vulnerable cells from multiple
insults.
[0009] It has been reported that HMOX1 can be induced by small
molecules that bind to the transcription factor Bach1. Heme binding
to Bach1 has been shown to reduce DNA binding activity of Bach1 and
induce gene transcription. See Ogawa K et al. EMBO J (2001)
20:2835-284. Additionally, a small molecule has been reported to
induce HMOX1 through binding to Bach1. See Attucks O C et al. PLOS
ONE (2014) 9(7): e101044, WO2011/103018 and WO2012/094580.
[0010] As such, there is a need for new HMOX1 inducers and/or Bach
1 binders/inhibitors for the above referenced therapeutic
indications.
SUMMARY OF THE INVENTION
[0011] The applicant has discovered novel compounds which are
effective HMOX1 inducers (see Examples 1-142). In particular, it
has been demonstrated that certain compounds of the present
invention effectively induced production of HMOX1 (see Example
143). Also, certain compounds of the invention have a combination
of desirable properties, including potent HMOX1 induction activity
(Example 143), significantly reduced hERG inhibition compared to
certain comparator compounds (see Example 145), good solubility
(Example 144) and a strong impact on HMOX1 protein expression in
vivo (Example 151). Moreover, the applicant has also discovered
that the compounds disclosed herein bind to Bach 1 (see Example
146).
[0012] In one embodiment, provided herein is a compound represented
by the following structural Formula (I):
##STR00002##
or a pharmaceutically acceptable salt thereof, the definition of
each variable is provided below.
[0013] Pharmaceutical compositions of the compounds of the
invention are also disclosed herein. Particular embodiments
comprise a pharmaceutically acceptable carrier or diluent and one
or more of the compounds of the invention, or a pharmaceutically
acceptable salt thereof.
[0014] The compounds of Formula (I) and pharmaceutically acceptable
salts thereof are useful as agents that induce the production of
and/or increase the activity of HMOX1, and thus may be useful to
treat various chronic diseases that are associated, at least in
part, with oxidative stress including, but not limited to: fibrotic
diseases, neurodegenerative disease, cardiovascular disease, renal
disease, inflammatory disease, liver disease, eye disease, thyroid
disease, viral infection, osteoporosis, pregnancy disorders,
endometriosis, diabetes, cancers, skin diseases, mitochondrial
diseases, hematological disorders, and muscle diseases.
[0015] Another embodiment of the present invention comprises
treating the above-referenced diseases or conditions in a subject
by administering to the subject an effective amount of one or more
compounds of the invention, or a pharmaceutically acceptable salt
thereof, or a pharmaceutical composition comprising the disclosed
compound(s).
[0016] Also provided herein is the use of one or more compounds of
the invention, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition comprising one or more compounds of the
invention, for the preparation of a medicament for the treatment of
the above-referenced diseases or conditions.
[0017] In another embodiment, provided herein is the compounds of
the invention, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition comprising one or more of the disclosed
compounds for use in treating the above-referenced diseases or
conditions.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIGS. 1A and 1B depict graphs showing significant fold
change of Gene-Specific mRNA in HepG2 cells treated with the
compound of Example 17 or Nrf2 activator DMF.
[0019] FIG. 1A depicts that the compound of Example 17 induces
HMOX1 expression much more strongly than DMF. FIG. 1B depicts that
the compound of Example 17 and DMF induce FTH1 expression with
comparable fold increases.
[0020] FIG. 2 depicts a graph showing that the compound of Example
17 dose responsively inhibit microvascular stasis in Townes-SS
sickle mice. Townes-SS mice were gavaged once daily with Vehicle or
the compound of Example 17 for 8 days. After the last gavage dorsal
skin-fold chambers were implanted on the mice and 20-22 flowing
venules were selected and mapped in the subcutaneous skin using
intravital microscopy. Mice were then infused via the tail vein
with Panhematin (3.2 .mu.mols heme/kg body weight). One hour after
infusion each venule was re-examined for microvascular stasis (no
flow) and data are expressed as % stasis. Stasis values are
means+SD. One-Way ANOVA with Dunnett's Multiple comparison to
Vehicle ****P<0.0001
[0021] FIG. 3 depicts a graph showing the percentage of F-cells
increase in Townes-SS mice treated with the compound of Example 17.
Blood smears were made using heparinized whole blood for F-cells
staining. Stained F-cells and total red blood cells were counted on
the blood smears in four fields; mean=77 red blood cells/field.
F-cells are expressed as a percentage of total red blood cells.
Values are means+SD. One-Way ANOVA with Dunnett's Multiple
comparison to Vehicle **p.ltoreq.0.01, ***p.ltoreq.0.001,
****p.ltoreq.0.0001
[0022] FIG. 4 depicts a graph showing the glutathione (GSH) levels
in primary human endothelial cells. Two-Tailed Unpaired t test
compared to DMSO ####p.ltoreq.0.0001, One-Way ANOVA with Dunnett's
Multiple comparison to Hemin (GSH Graph) ****p.ltoreq.0.0001
[0023] FIG. 5 depicts a graph showing fold change of gene
expression in primary human endothelial cells. ####p.ltoreq.0.0001,
One-Way ANOVA with Dunnett's Multiple comparison to TNFa (VCAM
graph) ****p.ltoreq.0.0001
DETAILED DESCRIPTION
[0024] In response to elevated reactive oxygen species (ROS)
levels, cells induce expression of oxidative stress-responsive
genes, such as genes encoding proteins that degrade ROS or increase
levels of the cell's endogenous antioxidant molecules. One such
gene is HMOX1. Induction of expression of HMOX1 and other oxidative
stress-responsive genes is regulated in part by the transcription
factor Nrf2. Under basal conditions, the adaptor protein Keap1
forms a heterodimer with Nrf2, targeting Nrf2 for proteolysis and
suppressing Nrf2-mediated transcription. Upon exposure of cells to
chemical electrophiles or agents that elevate ROS, the interaction
of Keap1 with Nrf2 is weakened and Nrf2 levels in the cell
increase, which in turn increases Nrf2 levels in the nucleus and
leads to induction of oxidative stress-responsive genes. Nrf2
activity is also regulated by the transcriptional repressor Bach1,
which occludes binding of Nrf2 to the promoter region of oxidative
stress-responsive genes.
[0025] In order to mitigate the effects of oxidative stress in a
cell, e.g., in disease settings, it is therefore desirable to
identify compounds that promote the induction of expression of
oxidative stress-responsive genes, for example, compounds that
modulate the interaction of Nrf2 with Keap1 or the interaction of
Bach1 with the Maf recognition element (MARE) to increase
cytoprotective gene transcription. However, it is also desirable
that such compounds not act as electrophiles or otherwise incite a
stress response in the cell.
Compounds of the Invention
[0026] Disclosed herein are embodiments of compounds having a
general structure of Formula (I).
[0027] In a first embodiment, the invention provides a compound
represented by the following structural formula (I):
##STR00003##
or a pharmaceutically acceptable salt thereof, wherein:
[0028] Ring A is 5-7 membered monocyclic cycloalkyl, 5-7 membered
monocyclic heterocyclyl, 5-6 membered heteroaryl, or phenyl;
[0029] X is --S--, --O--, or --NR.sup.b--;
[0030] when X is --S-- and ring A is phenyl, then R is 3-7 membered
monocyclic heterocyclyl optionally substituted with one or more
groups selected from the group consisting of halo, --CN, --OH,
--(C.sub.1-C.sub.4)alkyl, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, and --NR.sup.aR.sup.a;
[0031] when X is --S-- and ring A is 5-7 membered monocyclic
cycloalkyl, 5-7 membered monocyclic heterocyclyl, or 5-6 membered
heteroaryl; or when X is --O-- or --NR.sup.b--; then R is --H,
--(C.sub.1-C.sub.4)alkyl, or --(CH.sub.2).sub.i3-7 membered
monocyclic heterocyclyl, wherein the --(C.sub.1-C.sub.4)alkyl or
3-7 membered monocyclic heterocyclyl represented by R is optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)haloalkyl, --(C.sub.1-C.sub.4)hydroxyalkyl,
--(C.sub.1-C.sub.4)alkoxy, --(C.sub.1-C.sub.4)haloalkoxy,
--SO.sub.2R.sup.a, and --NR.sup.aR.sup.a;
[0032] each R.sub.1 is independently --H, halogen,
--(CH.sub.2).sub.kCOOH, --(CH.sub.2).sub.kCO(C.sub.1-C.sub.4)alkyl,
--(CH.sub.2).sub.kCOO(C.sub.1-C.sub.4)alkyl,
--(CH.sub.2).sub.pC(.dbd.O)NR.sup.aR.sub.3,
--CH(CF.sub.3)NR.sup.aR.sub.3, --C(.dbd.NOH)CF.sub.3, or
--CH(CF.sub.3)OR.sub.3, wherein the (C.sub.1-C.sub.4)alkyl in the
group represented by R.sub.1 is optionally substituted with one or
more groups selected from the group consisting of halo, --CN, --OH,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, and --NR.sup.aR.sup.a;
[0033] each R.sub.2 is independently --H, halo, CN,
--(C.sub.1-C.sub.4)alkyl, --OH, --(C.sub.1-C.sub.4)alkoxy, --COOH,
--C(.dbd.O)(C.sub.1-C.sub.4)alkyl,
--C(.dbd.O)O(C.sub.1-C.sub.4)alkyl,
--C(.dbd.O)NR.sup.a(C.sub.1-C.sub.4)alkyl, --NR.sup.aR.sup.a, 3-6
membered monocyclic cycloalkyl, --O(CH.sub.2).sub.i3-7 membered
monocyclic heterocyclyl, 3-7 membered monocyclic heterocyclyl, or
5-6 membered heteroaryl, wherein the --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)alkoxy, heterocyclyl, or heteroaryl represented
by R.sub.2 or in the group represented by R.sub.2 is optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)alkoxy, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)haloalkoxy, and
--NR.sup.aR.sup.a;
[0034] each R.sub.3 is independently H, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, --(CH.sub.2).sub.p13-7 membered monocyclic
heterocyclyl, --(CH.sub.2).sub.p1NH3-7 membered monocyclic
heterocyclyl, 5-6 membered heteroaryl,
--O(CH.sub.2).sub.p2NR.sup.aC(.dbd.O)(C.sub.1-C.sub.4)alkyl,
--(CH.sub.2).sub.p2O(CH.sub.2).sub.p2O(C.dbd.O)(C.sub.1-C.sub.4)alkyl,
or (CH.sub.2).sub.p2NR.sup.aC(.dbd.O)(C.sub.1-C.sub.4)alkyl,
wherein the alkyl, alkoxy, heteroaryl, or heterocyclyl represented
by R.sub.3 or in the group represented by R.sub.3 is optionally
substituted with one or more groups selected from the group
consisting of halo, --CN, --OH, --(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)haloalkyl, --(C.sub.1-C.sub.4)hydroxyalkyl,
--(C.sub.1-C.sub.4)alkoxy, --(C.sub.1-C.sub.4)haloalkoxy,
--(C.sub.1-C.sub.4)carboxyalkoxy,
--S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)hydroxyalkoxy, and --NR.sup.aR.sup.a;
[0035] each R.sup.a is independently --H or
--(C.sub.1-C.sub.4)alkyl;
[0036] each R.sup.b is independently --H or
--(C.sub.1-C.sub.4)alkyl; wherein the --(C.sub.1-C.sub.4)alkyl
represented by R.sup.b is optionally substituted with one or more
groups selected from halo, --CN, --OH,
--(C.sub.3-C.sub.6)cycloalkyl, phenyl, 3-7 membered monocyclic
heterocyclyl, and 5-6 membered heteroaryl;
[0037] i is 0 or 1;
[0038] k is 0, 1, 2, 3, or 4;
[0039] m is 0, 1, 2, 3, or 4;
[0040] n is 0, 1, 2, 3, or 4;
[0041] p is 0, 1, 2, 3, or 4;
[0042] p.sub.1 is 0, 1, 2, 3, or 4; and
[0043] p.sub.2 is 2, 3, or 4.
[0044] In a second embodiment, the invention provides a compound
according to the previous embodiment, wherein the compound is
represented by the following structural formula (II):
##STR00004##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0045] In a third embodiment, the invention provides a compound
according to the first embodiment, wherein the compound is
represented by structural formula (II'):
##STR00005##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0046] In a fourth embodiment, the invention provides a compound
according to the first or second embodiment, wherein the compound
is represented by structural formula (II-A):
##STR00006##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0047] In a fifth embodiment, the invention provides a compound
according to the first or second embodiment, wherein the compound
is represented by structural formula (II-B):
##STR00007##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0048] In a sixth embodiment, the invention provides a compound
according to the first or second embodiment, wherein the compound
is represented by structural formula (II-C):
##STR00008##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0049] In a seventh embodiment, the invention provides a compound
according to the first or third embodiment, wherein the compound is
represented by structural formula (II'-A):
##STR00009##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0050] In an eighth embodiment, the invention provides a compound
according to the sixth embodiment, or a pharmaceutically acceptable
salt thereof, wherein R.sup.b is --H or --(C.sub.1-C.sub.4)alkyl,
wherein the --(C.sub.1-C.sub.4)alkyl represented by R.sup.b is
optionally substituted with one or more groups selected from halo,
--CN, and --OH. wherein the remainder of the variables are as
defined in the first embodiment. In a preferred embodiment, R.sup.b
is --H.
[0051] In a ninth embodiment, the invention provides a compound
according to the first, second, third, fifth, sixth, seventh, and
eighth embodiment, or a pharmaceutically acceptable salt thereof,
wherein R is --(C.sub.1-C.sub.4)alkyl optionally substituted with
--(C.sub.1-C.sub.4)alkoxy; or --(CH.sub.2).sub.i3-6 membered
monocyclic heterocyclyl optionally substituted with one or more
groups selected from the group consisting of halo, --CN, --OH,
--(C.sub.1-C.sub.4)alkyl, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, and --NR.sup.aR.sup.a, wherein the
remainder of the variables are as defined in the first or eighth
embodiment.
[0052] In a tenth embodiment, the invention provides a compound
according to the first, second, third, fourth, fifth, sixth,
seventh, or eighth embodiment, or a pharmaceutically acceptable
salt thereof, wherein R is azetidinyl, azepanyl, morpholinyl,
pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl,
tetrahydrofuranyl, or tetrahydropyranyl, each of which is
optionally substituted with one or more groups selected from the
group consisting of halo, --OH, --(C.sub.1-C.sub.4)alkyl, and
--NH.sub.2, wherein the remainder of the variables are as defined
in the first or eighth embodiment.
[0053] In an eleventh embodiment, the invention provides a compound
according to the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, or tenth embodiment, or a pharmaceutically
acceptable salt thereof, wherein R.sub.1 is --(CH.sub.2).sub.kCOOH,
--(CH.sub.2).sub.kCO(C.sub.1-C.sub.4)alkyl optionally substituted
with halo, --(CH.sub.2).sub.pC(.dbd.O)NR.sup.aR.sub.3,
--C(.dbd.NOH)CF.sub.3, or --CH(CF.sub.3)NR.sup.aR.sub.3, wherein
the remainder of the variables are as defined in the first, eighth,
ninth or tenth embodiment.
[0054] In a twelfth embodiment, the invention provides a compound
according to the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, or eleventh embodiment, or a
pharmaceutically acceptable salt thereof, wherein R.sub.2 is H;
halogen; CN; --(C.sub.1-C.sub.4)alkyl optionally substituted with
halo; --(C.sub.1-C.sub.4)alkoxy optionally substituted with halo,
hydroxy, methoxy, or ethoxy; --C(.dbd.O)(C.sub.1-C.sub.4)alkyl; 3-4
membered monocyclic cycloalkyl; --O(CH.sub.2).sub.i3-7 membered
monocyclic heterocyclyl, 3-7 membered monocyclic heterocyclyl, or
5-6 membered heteroaryl, wherein the heterocyclyl, or heteroaryl
represented by R.sub.2 or in the group represented by R.sub.2 is
optionally substituted with halo, hydroxy, or
--(C.sub.1-C.sub.4)alkoxy, wherein the remainder of the variables
are as defined in the first, eighth, ninth, tenth, or eleventh
embodiment. In a preferred embodiment, R.sub.2 is H or
--OCF.sub.3.
[0055] In a thirteenth embodiment, the invention provides a
compound according to the first, second, third, fifth, sixth,
seventh, eighth, ninth, eleventh, or twelfth embodiment, or a
pharmaceutically acceptable salt thereof, wherein R is
--(C.sub.1-C.sub.4)alkyl optionally substituted with methoxy or
--SO.sub.2CH.sub.3; --(CH.sub.2)tetrahydrofuranyl;
--(CH.sub.2)oxetanyl optionally substituted with hydroxy;
pyrrolidinyl; piperidinyl; or tetrahydropyranyl; wherein the
pyrrolidinyl or piperidinyl is optionally substituted with
--(C.sub.1-C.sub.4)alkyl, wherein the remainder of the variables
are as defined in the first, eighth, ninth, tenth, eleventh, or
twelfth embodiment. In a preferred embodiment, the pyrrolidinyl or
piperidinyl is optionally substituted with --CH.sub.3.
[0056] In a fourteenth embodiment, the invention provides a
compound according to the first, second, third, fourth, fifth,
sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, or
thirteenth embodiment, or a pharmaceutically acceptable salt
thereof, wherein R.sub.1 is --COOH, --C(.dbd.O)CF.sub.3,
--CH(CF.sub.3)(NH.sub.2), --C(.dbd.NOH)CF.sub.3, or
--C(.dbd.O)NHR.sub.3, wherein the remainder of the variables are as
defined in the first, eighth, ninth, tenth, eleventh, twelfth, or
thirteenth embodiment.
[0057] In a fifteenth embodiment, the invention provides a compound
according to the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or
fourteenth embodiment, or a pharmaceutically acceptable salt
thereof, wherein R.sub.3 is (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, (CH.sub.2).sub.p13-6 membered monocyclic
heterocyclyl, or
(CH.sub.2).sub.p2NHC(.dbd.O)(C.sub.1-C.sub.4)alkyl, wherein the
alkyl, alkoxy, or heterocyclyl represented by R.sub.3 or in the
group represented by R.sub.3 is optionally substituted with one or
more groups selected from the group consisting of halo, --OH,
--(C.sub.1-C.sub.4)alkyl, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)hydroxyalkyl, --(C.sub.1-C.sub.4)alkoxy,
--(C.sub.1-C.sub.4)haloalkoxy, --S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)hydroxyalkoxy, and --NR.sup.aR.sup.a, wherein
the remainder of the variables are as defined in the first, eighth,
ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth
embodiment.
[0058] In a sixteenth embodiment, the invention provides a compound
according to the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth,
fourteenth, or fifteenth embodiment, or a pharmaceutically
acceptable salt thereof, wherein R.sub.2 is H; halogen; CN;
--(C.sub.1-C.sub.4)alkyl optionally substituted with halo;
--(C.sub.1-C.sub.4)alkoxy optionally substituted with halo,
hydroxy, methoxy, or ethoxy; --C(.dbd.O)(C.sub.1-C.sub.4)alkyl;
cyclopropyl; O-tetrahydropyranyl; N-pyrolidinyl; or thiazolyl,
wherein the remainder of the variables are as defined in the first,
eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, or
fifteenth embodiment.
[0059] In a seventeenth embodiment, the invention provides a
compound according to the fifth embodiment, wherein the compound is
represented by structural formula (III-B):
##STR00010##
or a pharmaceutically acceptable salt thereof, wherein the
remainder of the variables are as defined in the first
embodiment.
[0060] In an eighteenth embodiment, the invention provides a
compound according to the first, second, third, fourth, fifth,
sixth, seventh, eighth, ninth, tenth, eleventh, twelfth,
thirteenth, fourteenth, fifteenth, sixteenth, or seventeenth
embodiment, or a pharmaceutically acceptable salt thereof, wherein
R.sub.1 is --COOH or --C(.dbd.O)NHR.sub.3; R.sub.3 is
--(C.sub.1-C.sub.4)alkyl, -hydroxy(C.sub.1-C.sub.4)alkyl,
-methoxy(C.sub.1-C.sub.4)alkyl, -amino(C.sub.1-C.sub.4)alkyl,
--(C.sub.1-C.sub.4)hydroxyalkoxy(C.sub.1-C.sub.4)alkyl, or
--(CH.sub.2).sub.p2NHC(.dbd.O)(dimethylamino(C.sub.1-C.sub.4)alkyl),
wherein the remainder of the variables are as defined in the first,
eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth,
fifteenth, sixteenth, or seventeenth embodiment.
[0061] In a nineteenth embodiment, the invention provides a
compound according to the first, second, third, fourth, fifth,
sixth, seventh, eighth, ninth, tenth, eleventh, twelfth,
thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, or
eighteenth embodiment, or a pharmaceutically acceptable salt
thereof, wherein R.sub.2 is H, halo, --(C.sub.1-C.sub.4)haloalkyl,
--(C.sub.1-C.sub.4)haloalkoxy, --(C.sub.1-C.sub.4)alkoxy optionally
substituted with methoxy, or --N-pyrrolidinyl, wherein the
remainder of the variables are as defined in the first, eighth,
ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth,
sixteenth, seventeenth, or eighteenth embodiment. In a preferred
embodiment, R.sub.2 is H, F, CF.sub.3, OCHF.sub.2, OCF.sub.3,
OCH.sub.2CH.sub.2OCH.sub.3, or --N-pyrrolidinyl.
[0062] In a twentieth embodiment, the invention provides a compound
according to the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth,
fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, or
nineteenth embodiment, or a pharmaceutically acceptable salt
thereof, wherein
[0063] R.sub.2 is H, R.sub.1 is --C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl
optionally substituted with --OH, NH.sub.2, oxetanyl, or
--(C.sub.1-C.sub.4)hydroxyalkoxy; or
--C(.dbd.O)NH(CH.sub.2).sub.p2NHC(.dbd.O)(dimethylamino(C.sub.1-C.sub.4)a-
lkyl); or
[0064] R.sub.2 is F, R.sub.1 is
--C(.dbd.O)NH(methoxy(C.sub.1-C.sub.4)alkyl); or
[0065] R.sub.2 is --N-pyrrolidinyl, R.sub.1 is
--C(.dbd.O)NH((C.sub.1-C.sub.4)hydroxyalkoxy(C.sub.1-C.sub.4)alkyl),
[0066] R.sub.2 is CF.sub.3, OCHF.sub.2, or OCF.sub.3, R.sub.1 is
--COOH; or
[0067] R.sub.2 is OCH.sub.2CH.sub.2OCH.sub.3, R.sub.1 is
--C(.dbd.O)NH((C.sub.1-C.sub.4)hydroxyalkoxy(C.sub.1-C.sub.4)alkyl),
--C(.dbd.O)NH(hydroxy(C.sub.1-C.sub.4)alkyl),
--C(.dbd.O)NH(methoxy(C.sub.1-C.sub.4)alkyl), or
--C(.dbd.O)NH(hydroxy(C.sub.1-C.sub.4)alkoxy);
[0068] wherein the remainder of the variables are as defined in the
first, eighth, ninth, tenth, eleventh, twelfth, thirteenth,
fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, or
nineteenth embodiment.
[0069] In a twentyfirst embodiment, the invention provides a
compound according to the seventeenth embodiment, or a
pharmaceutically acceptable salt thereof, wherein
[0070] R.sub.1 is --C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl optionally
substituted with --OH, NH.sub.2, --(C.sub.1-C.sub.4)alkoxy, or
--(C.sub.1-C.sub.4)hydroxyalkoxy, and
[0071] R.sub.2 is H, or OCH.sub.2CH.sub.2OCH.sub.3.
[0072] In a twentysecond embodiment, the invention provides a
compound according to the twentyfirst embodiment, or a
pharmaceutically acceptable salt thereof, wherein R.sub.2 is H,
wherein the remainder of the variables are as defined in the
twentyfirst embodiment.
[0073] In a twentythird embodiment, the invention provides a
compound according to the twentysecond embodiment, or a
pharmaceutically acceptable salt thereof, wherein R.sub.1 is
--C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl substituted with
--(C.sub.1-C.sub.4)hydroxyalkoxy, wherein the remainder of the
variables are as defined in the twentysecond embodiment.
[0074] In a twentyfourth embodiment, the invention provides a
compound according to the twentyfirst embodiment, or a
pharmaceutically acceptable salt thereof, wherein
[0075] R.sub.1 is --C(.dbd.O)NH(C.sub.1-C.sub.4)alkyl substituted
with --(C.sub.1-C.sub.4)alkoxy, and
[0076] R.sub.2 is OCH.sub.2CH.sub.2OCH.sub.3.
[0077] In one embodiment, the compound or a pharmaceutically
acceptable salt thereof is selected from the compounds disclosed in
examples and Table 1.
Definitions
[0078] The term "pharmaceutically-acceptable salt" refers to a
pharmaceutical salt that is, within the scope of sound medical
judgment, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, and allergic
response, and is commensurate with a reasonable benefit/risk ratio.
Pharmaceutically-acceptable salts are well known in the art. For
example, S. M. Berge et al. describes pharmacologically acceptable
salts in J. Pharm. Sci., 1977, 66, 1-19.
[0079] Included in the present teachings are pharmaceutically
acceptable salts of the compounds disclosed herein. Compounds
having basic groups can form pharmaceutically acceptable salts with
pharmaceutically acceptable acid(s). Suitable pharmaceutically
acceptable acid addition salts of the compounds described herein
include salts of inorganic acids (such as hydrochloric,
hydrobromic, phosphoric, metaphosphoric, nitric, and sulfuric
acids) and of organic acids (such as acetic, benzenesulfonic,
benzoic, ethanesulfonic, methanesulfonic, and succinic acids).
Compounds of the present teachings with acidic groups such as
carboxylic acids can form pharmaceutically acceptable salts with
pharmaceutically acceptable base(s). Suitable pharmaceutically
acceptable basic salts include ammonium salts, alkali metal salts
(such as sodium and potassium salts) and alkaline earth metal salts
(such as magnesium and calcium salts).
[0080] The term "halo" as used herein means halogen and includes
chloro, fluoro, bromo and iodo.
[0081] The term "alkyl" used alone or as part of a larger moiety,
such as "alkoxy" or "haloalkyl" and the like, means saturated
aliphatic straight-chain or branched monovalent hydrocarbon
radical. Unless otherwise specified, an alkyl group typically has
1-5 carbon atoms, i.e. (C.sub.1-C.sub.5)alkyl. As used herein, a
"(C.sub.1-C.sub.4)alkyl" group means a radical having from 1 to 4
carbon atoms in a linear or branched arrangement. Examples include
methyl, ethyl, n-propyl, iso-propyl, and the like.
[0082] The term "alkoxy" means an alkyl radical attached through an
oxygen linking atom, represented by --O-alkyl. For example,
"(C.sub.1-C.sub.4)alkoxy" includes methoxy, ethoxy, propoxy, and
butoxy.
[0083] The terms "haloalkyl" and "haloalkoxy" means alkyl or
alkoxy, as the case may be, substituted with one or more halogen
atoms.
[0084] The term "cycloalkyl" refers to a monocyclic saturated
hydrocarbon ring system. Unless otherwise specified, cycloalkyl has
from 3-7 carbon atoms. For example, a C.sub.3-C.sub.6 cycloalkyl
includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
Unless otherwise described, a "cycloalkyl" has from three to six
carbon atoms.
[0085] The term "heteroaryl", "heteroaromatic", "heteroaryl ring",
"heteroaryl group", "heteroaromatic ring", or "heteroaromatic
group", used alone or as part of a larger moiety as in
"heteroaralkyl" or "heteroarylalkoxy", refers to monocyclic
aromatic ring groups having five or six ring atoms (i.e., "5-6
membered") selected from carbon and at least one (typically 1 to 4,
more typically 1 or 2) heteroatoms (e.g., oxygen, nitrogen, or
sulfur).
[0086] Examples of monocyclic heteroaryl groups include furanyl
(e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g., N-imidazolyl,
2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl (e.g.,
3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g.,
2-oxadiazolyl, 5-oxadiazolyl), oxazolyl (e.g., 2-oxazolyl,
4-oxazolyl, 5-oxazolyl), pyrazolyl (e.g., 3-pyrazolyl,
4-pyrazolyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl),
pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (e.g.,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g.,
3-pyridazinyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl,
5-thiazolyl), triazolyl (e.g., 2-triazolyl, 5-triazolyl),
tetrazolyl (e.g., tetrazolyl), thienyl (e.g., 2-thienyl,
3-thienyl), pyrimidinyl, pyridinyl and pyridazinyl.
[0087] The term "heterocyclyl" refers to a monocyclic non-aromatic
ring radical containing from 3-7 ring atoms (i.e., "3-7 membered")
selected from carbon atom and 1 or 2 heteroatoms. Each heteroatom
is independently selected from nitrogen, quaternary nitrogen,
oxidized nitrogen (e.g., NO); oxygen; and sulfur, including
sulfoxide and sulfone.
[0088] Representative heterocyclyl groups include morpholinyl,
thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl,
and the like. A "substituted heterocylyl group" is substituted at
any one or more substitutable ring atom, which is a ring carbon or
ring nitrogen atom bonded to a hydrogen.
[0089] As used herein, many moieties (e.g., alkyl, alkylene,
cycloalkyl, cycloalkylene, aryl, arylene, heteroaryl,
heteroarylene, heterocyclyl or heterocyclylene) are referred to as
being either "substituted" or "optionally substituted". When a
moiety is modified by one of these terms, unless otherwise noted,
it denotes that any portion of the moiety that is known to one
skilled in the art as being available for substitution can be
substituted, which includes one or more substituents. Where if more
than one substituent is present, then each substituent may be
independently selected. Such means for substitution are well-known
in the art and/or taught by the instant disclosure. The optional
substituents can be any substituents that are suitable to attach to
the moiety.
[0090] Suitable substituents are those which do not have a
significant adverse effect on the ability of the compound to induce
HMOX1. Where suitable substituents are not specifically enumerated,
exemplary substituents include, but are not limited to:
(C.sub.1-C.sub.5)alkyl, (C.sub.1-C.sub.5)hydroxyalkyl,
(C.sub.1-C.sub.5)haloalkyl, (C.sub.1-C.sub.5) alkoxy,
(C.sub.1-C.sub.5) haloalkoxy, halogen, hydroxyl, --CN, --NH.sub.2,
--NO.sub.2, --OR.sup.c1, --NR.sup.a1R.sup.b1,
--S(O).sub.iiR.sup.a1, --NR.sup.a1S(O).sub.iiR.sup.b1,
--S(O).sub.iiNR.sup.a1R.sup.b1, --C(.dbd.O)OR.sup.a1,
--OC(.dbd.O)OR.sup.a1, --C(.dbd.S)OR.sup.a1, --O(C.dbd.S)R.sup.a1,
--C(.dbd.O)NR.sup.a1R.sup.b1, --NR.sup.a1C(.dbd.O)R.sup.b1,
--C(.dbd.S)NR.sup.a1R.sup.b1, NR.sup.a1C(.dbd.S)R.sup.b1,
--NR.sup.a1(C.dbd.O)OR.sup.b1, --O(C.dbd.O)NR.sup.a1R.sup.b1,
--NR.sup.a1(C.dbd.S)OR.sup.b1, --O(C.dbd.S)NR.sup.a1R.sup.b1,
--NR.sup.a1(C.dbd.O)NR.sup.a1R.sup.b1,
--NR.sup.a1(C.dbd.S)NR.sup.a1R.sup.b1, --C(.dbd.S)R.sup.a1,
--C(.dbd.O)R.sup.a1, phenyl, or 5-6 membered heteroaryl. Each
R.sup.a1 and each R.sup.b1 are independently selected from --H and
(C.sub.1-C.sub.5)alkyl, optionally substituted with hydroxyl or
(C.sub.1-C.sub.3)alkoxy; R.sup.c1 is --H,
(C.sub.1-C.sub.5)haloalkyl or (C.sub.1-C.sub.5)alkyl, wherein the
(C.sub.1-C.sub.5)alkyl is optionally substituted with hydroxyl or
(C.sub.1-C.sub.3)alkoxy; and ii is 1 or 2.
Pharmaceutical Compositions
[0091] The compounds disclosed herein are HMOX1 inducers. The
pharmaceutical composition of the present invention comprises one
or more HMOX1 inducers, or a pharmaceutically acceptable salt
thereof, and a pharmaceutically acceptable carrier or diluent.
[0092] "Pharmaceutically acceptable carrier" and "pharmaceutically
acceptable diluent" refer to a substance that aids the formulation
and/or administration of an active agent to and/or absorption by a
subject and can be included in the compositions of the present
disclosure without causing a significant adverse toxicological
effect on the subject. Non-limiting examples of pharmaceutically
acceptable carriers and/or diluents include water, NaCl, normal
saline solutions, lactated Ringer's, normal sucrose, normal
glucose, binders, fillers, disintegrants, lubricants, coatings,
sweeteners, flavors, salt solutions (such as Ringer's solution),
alcohols, oils, gelatins, carbohydrates such as lactose, amylose or
starch, hydroxymethycellulose, fatty acid esters, polyvinyl
pyrrolidine, and colors, and the like. Such preparations can be
sterilized and, if desired, mixed with auxiliary agents such as
lubricants, preservatives, stabilizers, wetting agents,
emulsifiers, salts for influencing osmotic pressure, buffers,
coloring, and/or aromatic substances and the like that do not
deleteriously react with or interfere with the activity of the
compounds provided herein. One of ordinary skill in the art will
recognize that other pharmaceutical excipients are suitable for use
with disclosed compounds.
[0093] The pharmaceutical compositions of the present invention
optionally include one or more pharmaceutically acceptable carriers
and/or diluents therefor, such as lactose, starch, cellulose and
dextrose. Other excipients, such as flavoring agents, sweeteners,
and preservatives, such as methyl, ethyl, propyl and butyl
parabens, can also be included. More complete listings of suitable
excipients can be found in the Handbook of Pharmaceutical
Excipients (5.sup.th Ed., Pharmaceutical Press (2005)). A person
skilled in the art would know how to prepare formulations suitable
for various types of administration routes. Conventional procedures
and ingredients for the selection and preparation of suitable
formulations are described, for example, in Remington's
Pharmaceutical Sciences (2003--20th edition) and in The United
States Pharmacopeia: The National Formulary (USP 24 NF19) published
in 1999. The carriers, diluents and/or excipients are "acceptable"
in the sense of being compatible with the other ingredients of the
pharmaceutical composition and not deleterious to the recipient
thereof.
Methods of Treatment
[0094] In certain embodiments, the invention provides methods of
increasing the activity of or the amount of HMOX1 in a human
subject comprising: administering to a human subject an effective
amount of the compounds of the invention, or a pharmaceutically
acceptable salt thereof, or an effective amount of the
pharmaceutical composition thereof.
[0095] In certain embodiments, the invention provides methods of
activating transcription factor Nrf2 in a human subject comprising:
administering to a human subject an effective amount of the
compounds of the invention, or a pharmaceutically acceptable salt
thereof, or an effective amount of the pharmaceutical composition
thereof.
[0096] In certain embodiments, the invention provides methods of
reducing the amount of ROS in a human subject comprising:
administering to a human subject an effective amount of the
compounds of the invention, or a pharmaceutically acceptable salt
thereof, or an effective amount of the pharmaceutical composition
thereof.
[0097] In certain embodiments, the invention provides methods for
using an effective amount of the compounds of the invention, or a
pharmaceutically acceptable salt thereof, or an effective amount of
the pharmaceutical composition thereof. The compounds of the
invention and pharmaceutical compositions thereof may be useful for
a variety of therapeutic applications including, for example,
treating and/or reducing a wide variety of diseases and disorders
including, for example, fibrotic diseases, neurodegenerative
disease, cardiovascular disease, renal disease, inflammatory
disease, liver disease, eye disease, thyroid disease, viral
infection, osteoporosis, pregnancy disorders, endometriosis,
diabetes, cancers, skin diseases, mitochondrial diseases,
hematological disorders, and muscle diseases. The methods comprise
administering to a subject in need thereof a pharmaceutically
effective amount of one or more compounds of the invention, a
pharmaceutically acceptable salt thereof, and/or pharmaceutical
compositions thereof.
[0098] Compounds that increase levels or activity of HMOX1 are
potentially useful in treating diseases or conditions that may be
associated at least in part with oxidative stress such as, but not
limited to, fibrotic diseases, neurodegenerative disease,
cardiovascular disease, renal disease, inflammatory disease, liver
disease, eye disease, thyroid disease, viral infection,
osteoporosis, pregnancy disorders, endometriosis, diabetes,
cancers, skin diseases, mitochondrial diseases, hematological
disorders, and muscle diseases. As used herein, the diseases or
conditions associated with oxidative stress also include chronic
effects (e.g., tissue damage, chronic inflammation) associated with
persistent or long-term increases in oxidative stress due to the
diseases or conditions described herein.
[0099] Fibrotic diseases associated with oxidative stress include,
but are not limited to, fibrotic diseases of the lung such as
chronic obstructive pulmonary disease (COPD), idiopathic pulmonary
fibrosis, and sarcoidosis; fibrotic diseases of the liver including
those caused by alcoholic cirrhosis, steatosis, cholestasis, drug
side effect, and viral infection; and fibrotic diseases of the skin
including autoimmune diseases such as scleroderma and
psoriasis.
[0100] Neurodegenerative diseases associated with oxidative stress
include, but are not limited to, Friedreich's ataxia, Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis,
multiple sclerosis, cerebral nerve degenerative disease, and
Charcot-Marie-Tooth syndrome.
[0101] Cardiovascular diseases associated with oxidative stress
include, but are not limited to, hypertension, heart failure,
hypercholesterolaemia, atherosclerosis, arteriosclerosis,
thrombosis, acute coronary thrombosis, deep vein thrombosis,
peripheral vascular disease, congestive heart failure, acute
coronary syndrome, failure of arterial fistula for dialysis,
ischemia reperfusion injury, primary pulmonary hypertension,
primary pulmonary arterial hypertension, and secondary pulmonary
arterial hypertension.
[0102] Renal diseases associated with oxidative stress include, but
are not limited to, acute kidney injury, polycystic kidney disease,
Alport syndrome, diabetic nephropathy, glomerular nephritis, lupus
nephritis, sickle cell nephropathy, and acute tubular necrosis.
[0103] Inflammatory diseases associated with oxidative stress
include, but are not limited to, asthma, chronic obstructive
pulmonary disease, idiopathic pulmonary fibrosis, inflammatory
bowel syndrome, Crohn's disease, celiac disease, ulcerative
colitis, chronic inflammatory bowel disease, scleroderma,
dermatitis, systemic lupus erythematosus, esophagitis, vasculitis,
pancreatitis, tendonitis, osteoarthritis, rheumatoid arthritis,
ankylosing spondylitis, and chronic inflammation of the brain.
[0104] Liver diseases associated with oxidative stress include, but
are not limited to, drug induced liver toxicity, nonalcoholic
steatohepatitis, and hepatitis, e.g., hepatitis B infection and
hepatitis C infection.
[0105] Eye diseases and conditions associated with oxidative stress
include, but are not limited to, conjunctivitis, glaucoma, uveitis,
wound healing (e.g., after surgery such as LASIK), eye trauma,
corneal grafts, Fuchs' endothelial corneal dystrophy, macular
degeneration, cataracts, light retinopathy, retinitis pigmentosa,
diabetic retinopathy, and retinopathy of prematurity, as well as
inflammation and tissue damage associated with these diseases.
[0106] Thyroid diseases associated with oxidative stress include,
but are not limited to, Graves' disease, follicular adenoma, and
papillary and follicular carcinomas.
[0107] Lung diseases associated with oxidative stress include, but
are not limited to, bronchitis, asthma, chronic obstructive
pulmonary disease, idiopathic pulmonary fibrosis, pulmonary
bronchitis, bronchiectasis, pulmonary edema, and emphysema.
[0108] Skin diseases associated with oxidative stress include, but
are not limited to, dermatitis, scleroderma, and psoriasis.
[0109] Viral infections associated with oxidative stress include
both viral replication of viruses, as well as tissue damage (e.g.,
fibrosis) due to oxidative stress resulting from chronic viral
infection, for viruses including but are not limited to human
immunodeficiency virus, hepatitis B, hepatitis C, and
herpesvirus.
[0110] Diabetic conditions include, but are not limited to, type 1
diabetes mellitus, type 2 diabetes mellitus, gestational diabetes,
pre-diabetes, hyperglycemia, and metabolic syndrome as well as
secondary conditions resulting from diabetic conditions (e.g.,
congestive heart failure and nephropathy).
[0111] Mitochondrial disease associated with oxidative stress
include, but are not limited to, mitochondrial myopathies, Leber's
hereditary optic neuropathy (LHON), myoclonic epilepsy with ragged
red fibers (MERFF), mitochondrial encephalomyopathy, lactic
acidosis and stroke-like episodes (MELAS) or Leigh's Syndrome.
[0112] Hematological disorders associated with oxidative stress
include, but are not limited to, Diamond Blackfan anemia,
myelodysplastic syndrome, sickle cell disease and
beta-thalessemia.
[0113] Muscle diseases associated with oxidative stress include,
but are not limited to, Duchenne muscular dystrophy, limb girdle
muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy
and rhabdomyolysis.
[0114] Cancers associated with oxidative stress include, but are
not limited to, breast cancer, colorectal cancer, lung cancer,
ovarian cancer, uterine cancer, prostate cancer, leukemias,
lymphomas, brain cancer (including glioblastoma multiforme and
neuroblastoma), head and neck cancer, pancreatic cancer, melanoma,
hepatocellular carcinoma, renal cancer, and soft tissue sarcomas.
In one embodiment, the cancer is breast cancer, colon cancer, and
ovarian cancer. In one embodiment, the cancer is selected from
leukemia, acute myeloid leukemia, chronic myelogenous leukemia,
breast cancer, brain cancer, colon cancer, colorectal cancer, head
and neck cancer, hepatocellular carcinoma, lung adenocarcinoma,
metastatic melanoma, pancreatic cancer, prostate cancer, ovarian
cancer and renal cancer. In one embodiment, the cancer is lung
cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer,
melanoma, glioblastoma multiforme or ovarian cancer. In another
embodiment, the cancer is lung cancer, breast cancer, colon cancer,
brain cancer, neuroblastoma, prostate cancer, melanoma,
glioblastoma multiforme or ovarian cancer. In yet another
embodiment, the cancer is breast cancer, colon cancer and lung
cancer. In another embodiment, the cancer is a breast cancer. In
yet another embodiment, the cancer is a basal sub-type breast
cancer or a luminal B sub-type breast cancer. In yet another
embodiment, the cancer is a basal sub-type breast cancer. In yet
another embodiment, the basal sub-type breast cancer is ER
(estrogen receptor), HER2 and PR (progesterone receptor) negative
breast cancer. In yet another embodiment, the cancer is a soft
tissue cancer. A "soft tissue cancer" is an art-recognized term
that encompasses tumors derived from any soft tissue of the body.
Such soft tissue connects, supports, or surrounds various
structures and organs of the body, including, but not limited to,
smooth muscle, skeletal muscle, tendons, fibrous tissues, fatty
tissue, blood and lymph vessels, perivascular tissue, nerves,
mesenchymal cells and synovial tissues. Thus, soft tissue cancers
can be of fat tissue, muscle tissue, nerve tissue, joint tissue,
blood vessels, lymph vessels, and fibrous tissues. Soft tissue
cancers can be benign or malignant. Generally, malignant soft
tissue cancers are referred to as sarcomas, or soft tissue
sarcomas. There are many types of soft tissue tumors, including
lipoma, lipoblastoma, hibernoma, liposarcoma, leiomyoma,
leiomyosarcoma, rhabdomyoma, rhabdomyosarcoma, neurofibroma,
schwannoma (neurilemoma), neuroma, malignant schwannoma,
neurofibrosarcoma, neurogenic sarcoma, nodular tenosynovitis,
synovial sarcoma, hemangioma, glomus tumor, hemangiopericytoma,
hemangioendothelioma, angiosarcoma, Kaposi sarcoma, lymphangioma,
fibroma, elastofibroma, superficial fibromatosis, fibrous
histiocytoma, fibrosarcoma, fibromatosis, dermatofibrosarcoma
protuberans (DFSP), malignant fibrous histiocytoma (MFH), myxoma,
granular cell tumor, malignant mesenchymomas, alveolar soft-part
sarcoma, epithelioid sarcoma, clear cell sarcoma, and desmoplastic
small cell tumor. In a particular embodiment, the soft tissue
cancer is a sarcoma selected from the group consisting of a
fibrosarcoma, a gastrointestinal sarcoma, a leiomyosarcoma, a
dedifferentiated liposarcoma, a pleomorphic liposarcoma, a
malignant fibrous histiocytoma, a round cell sarcoma, and a
synovial sarcoma.
[0115] Thus the present invention provides a method of treatment
comprising administering to a subject a compound of Formula (I) or
a pharmaceutically acceptable salt thereof so as to treat at least
one of the diseases or conditions listed above.
[0116] A "subject" is a mammal, preferably a human, but can also be
an animal in need of veterinary treatment, e.g., companion animals
(e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep,
pigs, horses, and the like) and laboratory animals (e.g., rats,
mice, guinea pigs, and the like).
Methods of Administration and Dosage Forms
[0117] The precise amount of compound administered to provide an
"effective amount" to the subject will depend on the mode of
administration, the type, and severity of the disease or condition,
and on the characteristics of the subject, such as general health,
age, sex, body weight, and tolerance to drugs. The skilled artisan
will be able to determine appropriate dosages depending on these
and other factors. When administered in combination with other
therapeutic agents, e.g., when administered in combination with an
anti-cancer agent, an "effective amount" of any additional
therapeutic agent(s) will depend on the type of drug used. Suitable
dosages are known for approved therapeutic agents and can be
adjusted by the skilled artisan according to the condition of the
subject, the type of condition(s) being treated and the amount of a
compound of the invention being used by following, for example,
dosages reported in the literature and recommended in the
Physician's Desk Reference (57th Ed., 2003).
[0118] The term "effective amount" means an amount when
administered to the subject which results in beneficial or desired
results, including clinical results, e.g., inhibits, suppresses or
reduces the symptoms of the condition being treated in the subject
as compared to a control. For example, a therapeutically effective
amount can be given in unit dosage form (e.g., 0.1 mg to about 50 g
per day, alternatively from 1 mg to about 5 grams per day; and in
another alternatively from 10 mg to 1 gram per day).
[0119] The terms "administer", "administering", "administration",
and the like, as used herein, refer to methods that may be used to
enable delivery of compositions to the desired site of biological
action. These methods include, but are not limited to,
intraarticular (in the joints), intravenous, intramuscular,
intratumoral, intradermal, intraperitoneal, subcutaneous, orally,
topically, intrathecally, inhalationally, transdermally, rectally,
and the like. Administration techniques that can be employed with
the agents and methods described herein are found in e.g., Goodman
and Gilman, The Pharmacological Basis of Therapeutics, current ed.;
Pergamon; and Remington's, Pharmaceutical Sciences (current
edition), Mack Publishing Co., Easton, Pa.
[0120] In addition, the disclosed HMOX1 inducers can be
co-administered with other therapeutic agents. As used herein, the
terms "co-administration", "administered in combination with", and
their grammatical equivalents, are meant to encompass
administration of two or more therapeutic agents to a single
subject, and are intended to include treatment regimens in which
the agents are administered by the same or different route of
administration or at the same or different times. In some
embodiments the one or more compounds described herein will be
co-administered with other agents. These terms encompass
administration of two or more agents to the subject so that both
agents and/or their metabolites are present in the subject at the
same time. They include simultaneous administration in separate
compositions, administration at different times in separate
compositions, and/or administration in a composition in which both
agents are present. Thus, in some embodiments, the compounds
described herein and the other agent(s) are administered in a
single composition. In some embodiments, the compounds described
herein and the other agent(s) are admixed in the composition.
[0121] The particular mode of administration and the dosage regimen
will be selected by the attending clinician, taking into account
the particulars of the case (e.g. the subject, the disease, the
disease state involved, the particular treatment). Treatment can
involve daily or multi-daily or less than daily (such as weekly or
monthly etc.) doses over a period of a few days to months, or even
years. However, a person of ordinary skill in the art would
immediately recognize appropriate and/or equivalent doses looking
at dosages of approved compositions for treating a disease using
the disclosed HMOX1 inducers for guidance.
[0122] The compounds or the corresponding pharmaceutical
compositions taught herein can be administered to a patient in a
variety of forms depending on the selected route of administration,
as will be understood by those skilled in the art. The compounds of
the present teachings may be administered, for example, by oral,
parenteral, buccal, sublingual, nasal, rectal, patch, pump or
transdermal administration and the pharmaceutical compositions
formulated accordingly. Parenteral administration includes
intravenous, intraperitoneal, subcutaneous, intramuscular,
transepithelial, nasal, intrapulmonary, intrathecal, rectal and
topical modes of administration. Parenteral administration can be
by continuous infusion over a selected period of time.
[0123] The pharmaceutical composition of the invention is
formulated to be compatible with its intended route of
administration. In an embodiment, the composition is formulated in
accordance with routine procedures as a pharmaceutical composition
adapted for intravenous, subcutaneous, intramuscular, oral,
intranasal, or topical administration to human beings. In preferred
embodiments, the pharmaceutical composition is formulated for
intravenous administration.
[0124] Typically, for oral therapeutic administration, a compound
of the present teachings may be incorporated with excipient and
used in the form of ingestible tablets, buccal tablets, troches,
capsules, elixirs, suspensions, syrups, wafers, and the like.
[0125] Typically for parenteral administration, solutions of a
compound of the present teachings can generally be prepared in
water suitably mixed with a surfactant such as
hydroxypropylcellulose. Dispersions can also be prepared in
glycerol, liquid polyethylene glycols, DMSO and mixtures thereof
with or without alcohol, and in oils. Under ordinary conditions of
storage and use, these preparations contain a preservative to
prevent the growth of microorganisms.
[0126] Typically, for injectable use, sterile aqueous solutions or
dispersion of, and sterile powders of, a compound described herein
for the extemporaneous preparation of sterile injectable solutions
or dispersions are appropriate.
EXEMPLIFICATION
[0127] The abbreviations used in the entire specification may be
summarized herein below with their particular meaning:
ACN--Acetonitrile;
[0128] AcOH--Acetic acid; Ac.sub.2O--Acetic anhydride;
AlCl.sub.3--Aluminum chloride;
anh.--Anhydrous;
Aq.--Aqueous;
[0129] BOC--tert-Butyloxycarbonyl; bs--Broad singlet;
Conc.--Concentrated;
[0130] .degree. C.--degree Celsius;
CDI--Carbonyldiimidazole;
[0131] CH.sub.3MgBr--Methylmagnesium bromide; CS.sub.2--Carbon
disulfide; d--Doublet;
.delta.--Delta;
DCM--Dichloromethane;
DIPEA--N,N-Diisopropylethylamine
DMFA--N, N-Dimethylformamide;
DMSO--Dimethylsulfoxide;
[0132] DMSO-d.sub.6--Deuterated dimethylsulfoxide;
D.sub.2O--Deuterated water; DPPA--Diphenylphosphoryl azide;
EDC.HCl--1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride; EtOH--ethanol; EtOAc--Ethyl acetate; g--Gram;
h--Hour;
.sup.1H--Proton;
H.sub.2--Hydrogen;
[0133]
HATU--N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethy-
lene]-N-methylmethanaminium hexafluorophosphate N-oxide;
HBTU--N,N,N',N'-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium
hexafluorophosphate; .sup.1HNMR--Proton nuclear magnetic resonance;
HNO.sub.3--Nitric acid;
H.sub.2O--Water;
[0134] HCl--Hydrochloric acid;
Hz--Hertz;
[0135] H.sub.2SO.sub.4--Sulfuric acid; J--Coupling constant;
K.sub.2CO.sub.3--Potassium carbonate; KOH--Potassium hydroxide;
K.sub.3PO.sub.4--Potassium phosphate; LC--Liquid chromatography;
LiOH. H.sub.2O--Lithium hydroxide monohydrate; M.sup.+--Molecular
ion; m--Multiplet;
M--Molar;
[0136] m-CPBA--meta-Chloroperbenzoic acid; Mel--Methyl iodide;
MeOH--Methanol;
[0137] mg--Milligrams; min--Minutes; MHz--Mega Hertz (frequency);
mL--Milliters; mM--Millimolar; mmol--Millimoles; MS--Mass
spectroscopy; m/z--Mass to charge ratio;
N--Normality;
[0138] NaBH.sub.4--Sodium borohydride; NaH--Sodium hydride;
NaHCO.sub.3--sodium hydrogencarbonate; NaNO.sub.2--Sodium nitrite;
NaNO.sub.3--Sodium nitrate; NaOEt--Sodium ethoxide; NaOH--Sodium
hydroxide; NaOMe--Sodium methoxide;
NBS--N-Bromosuccinimide
Pd/C--Palladium on Carbon;
[0139] Pd(OAc).sub.2--Palladium (II) acetate;
POCl.sub.3--Phosphorus Oxychloride;
[0140] P.sub.2S.sub.5--Phosphorus pentasulfide; PtO.sub.2--Platinum
dioxide:
%--Percentage;
[0141] pH--potential of Hydrogen; psi--Pounds per square inch;
q--Quartet; RT--Room temperature; s--Singlet; SOCl.sub.2--Thionyl
chloride; t--Triplet; TBAF--Tetra-n-butylammonium fluoride;
TBDMSCl--tert-Butyldimethylchlorosilane; TEA--Triethyl amine;
TFA--Trifluoroacetic acid;
THF--Tetrahydrofuran;
[0142] TLC--Thin layer chromatography.
Examples 1h and 1i. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid and Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imida-
zole-5-carboxamide
##STR00011## ##STR00012##
[0143] Step-a: Synthesis of benzo[d]oxazole-2-thiol (1a)
[0144] To a solution of 2-aminophenol (4.0 g, 36.7 mmol) in ethanol
(80 mL) at RT was added powdered potassium hydroxide (3.59 g, 64.2
mmol) and carbon disulfide (20 mL, 330.3 mmol) and the reaction
mixture was refluxed for 16 h. The reaction mixture was
concentrated, diluted with water (100 mL) and acidified with 1 N
HCl. The solid obtained was filtered and dried under vacuum to
afford the title compound (4.0 g, 72%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 13.85 (bs, 1H), 7.51-7.49 (m, 1H), 7.32-7.23
(m, 3H); LC-MS: m/z 152.0 (M+1).sup.+.
Step-b: Synthesis of 2-(methylthio)benzo[d]oxazole (1b)
[0145] To a solution of benzo[d]oxazole-2-thiol (3.0 g, 19.9 mmol)
in acetonitrile (50 mL) at 0.degree. C. was added potassium
carbonate (3.01 g, 21.9 mmol) and methyl iodide (1.36 mL, 21.9
mmol) and the reaction mixture was stirred at RT for 5 h. The
reaction mixture was diluted with water (60 mL), extracted with
EtOAc (2.times.100 mL). The combined organic layer was washed with
water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum to afford the product which was used
in the next step without any further purification (2.5 g, 76%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.65-7.62 (m, 2H),
7.34-7.30 (m, 2H), 2.76 (s, 3H); LC-MS: m/z 166.0 (M+1).sup.+.
Step-c: Synthesis of 2-(methylsulfonyl)benzo[d]oxazole (1c)
[0146] To a solution of 2-(methylthio)benzo[d]oxazole (500 mg, 3.0
mmol) in DCM (20 mL) at 0.degree. C. was added
meta-chloroperbenzoic acid (938 mg, 9.1 mmol) and the reaction
mixture was stirred at RT for 4 h. The reaction mixture was diluted
with water (40 mL) and aqueous layer was extracted with DCM
(2.times.100 mL). The combined organic layer was washed with
saturated sodium bicarbonate solution (6.times.150 mL), water (50
mL), brine (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the product which was
immediately used in the next step without any further purification
(300 mg); LC-MS: m/z 198.0 (M+1).sup.+.
Step-d: Synthesis of ethyl 4-(methylamino)-3-nitrobenzoate (1d)
[0147] To a solution of ethyl 4-chloro-3-nitrobenzoate (30.0 g, 131
mmol) in DMFA (100 mL) at RT was added methyl amine (26.8 mL (40%
aqueous solution), 262 mmol) and the reaction mixture was stirred
at 60.degree. C. for 16 h. The reaction mixture was cooled to RT,
diluted with cold water (1000 mL) and stirred at RT for 1 h. The
solid obtained was filtered and dried under vacuum to afford the
product as a yellow solid (26.0 g, 89%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.62 (d, J=2.0 Hz, 1H), 8.59 (bs, 1H), 7.99
(dd, J=2.0 Hz, J=8.8 Hz, 1H), 7.07 (d, J=8.8 Hz, 1H), 4.29 (q,
J=6.8 Hz, 2H), 3.01 (d, J=5.2 Hz, 3H), 1.31 (t, J=6.8 Hz, 3H);
LC-MS: m/z 225.0 (M+1).sup.+.
Step-e: Synthesis of ethyl 3-amino-4-(methylamino)benzoate (1e)
[0148] To a solution of ethyl 4-(methylamino)-3-nitrobenzoate (13.0
g, 58 mmol) in methanol (180 mL) was added slurry of 10% Pd/C (1.3
g in 10 mL of ethanol) under nitrogen atmosphere. The flask was
kept in a Parr shaker at RT under hydrogen pressure (60 psi) for 5
h. The reaction mixture was filtered through celite bed and
concentrated under vacuum to afford the title compound (10.0 g,
88%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.23 (dd, J=1.6
Hz, J=8.4 Hz 1H), 7.16 (d, J=1.6 Hz, 1H), 6.39 (d, J=8.4 Hz, 1H),
5.38-5.37 (m, 1H), 4.66 (s, 2H), 4.18 (q, J=7.2 Hz, 2H), 2.77 (d,
J=5.2 Hz, 3H), 1.26 (t, J=7.2 Hz, 3H); LC-MS: m/z 195.1
(M+1).sup.+.
Step-f: Synthesis of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (1f)
[0149] To a solution of ethyl 3-amino-4-(methylamino) benzoate (5.6
g, 28.8 mmol) in THF (23 mL) and water (56 mL) at RT was added
cyanogen bromide (3.7 g, 34.6 mmol) and the reaction mixture was
stirred at 50.degree. C. for 16 h. The reaction mixture was cooled
to RT, diluted with water (50 mL) and ethyl acetate (50 mL). The
aqueous layer was basified with saturated sodium bicarbonate
solution and extracted with EtOAc (2.times.250 mL). Combined
organic layer was washed with water (100 mL), brine (100 mL), dried
over anhydrous sodium sulfate and concentrated under vacuum to give
the product which was used in the next step without further
purification (5.2 g, 82%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.70 (d, J=1.2 Hz, 1H), 7.59 (dd, J=1.2 Hz, J=8.4 Hz, 1H),
7.20 (d, J=8.4 Hz, 1H), 6.64 (s, 2H), 4.27 (q, J=6.8 Hz, 2H), 3.53
(s, 3H), 1.32 (t, J=6.8 Hz, 3H).
Step-g: Synthesis of ethyl
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate
(1g)
[0150] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (150 mg, 0.68
mmol) in 1,4-dioxane (4 mL) at RT was added sodium hydride (96 mg,
2.4 mmol) and the reaction mixture was stirred for 15 min followed
by the addition of 2-(methylsulfonyl)benzo[d]oxazole (202 mg, 1.0
mmol). The reaction mixture was stirred at RT for 16 h and
concentrated, diluted with water (20 mL) and acidified (pH.about.6)
with 1 N HCl. The solid obtained was filtered, dried under vacuum
and purified by combiflash column chromatography using 100% DCM as
an eluent to afford the title compound (50 mg, 22%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.24 (s, 1H), 7.88
(d, J=8.4 Hz, 1H), 7.53-7.43 (m, 3H), 7.22 (t, J=7.2 Hz, 1H), 7.13
(t, J=7.6 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.64 (s, 3H), 1.35 (t,
J=7.2 Hz, 3H); LC-MS: m/z 337.0 (M+1).sup.+.
Step-h: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (1h)
[0151] To a stirred solution of ethyl
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate
(50 mg, 0.15 mmol) in a mixture of solvent of THF (1 mL), ethanol
(1 mL) and water (0.5 mL), was added lithium hydroxide monohydrate
(19 mg, 0.45 mmol). The reaction mixture was heated at 60.degree.
C. for 16 h. The reaction mixture was cooled to RT and concentrated
under reduced pressure. The residue was dissolved in water,
acidified with 1 N HCl to obtain the solid which was filtered and
dried under vacuum to afford the title compound (35 mg, 76%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.60 (bs, 2H), 8.20
(d, J=1.6 Hz, 1H), 7.87 (dd, J=1.6 Hz, J=8.0 Hz, 1H), 7.51-7.48 (m,
2H), 7.44 (d, J=7.2 Hz, 1H), 7.23-7.20 (m, 1H), 7.15-7.11 (m, 1H),
3.64 (s, 3H); LC-MS: m/z 308.6 (M+1).sup.+.
Step-i: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imida-
zole-5-carboxamide (1i)
[0152] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (30 mg, 0.1 mmol) in DMFA (1.0 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (0.02 mL, 0.1 mmol) and diphenylphosphoryl
azide (0.02 mL, 0.1 mmol). The reaction mixture was stirred for 30
min, followed by the addition of 2-methoxyethylamine (8 mg, 0.1
mmol). The reaction mixture was then stirred at RT for 16 h. Once
the reaction was completed (monitored by TLC), the reaction mixture
was diluted with cold water (15 mL) and stirred for 15 min. The
solid obtained was filtered, washed with diethyl ether and dried
under vacuum to afford the title compound (22 mg, 53%) as white
solid; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 1H),
8.45 (t, J=4.9 Hz, 1H), 8.08 (s, 1H), 7.76 (dd, J=1.5 Hz, J=8.3 Hz,
1H), 7.47 (d, J=8.3 Hz, 1H), 7.44-7.39 (m, 2H), 7.25-7.19 (m, 1H),
7.13-7.10 (m, 1H), 3.63 (s, 3H), 3.48-3.44 (m, 4H), 3.29 (s, 3H);
LC-MS: m/z 364.0 (M-1).
Examples 2d and 2e. Synthesis of
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)b-
enzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00013## ##STR00014##
[0153] Step-a: Synthesis of ethyl
3-nitro-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate (2a)
[0154] To a stirred solution of ethyl 4-chloro-3-nitrobenzoate (1.0
g, 4.4 mmol) in DMSO (10 mL) was added potassium carbonate (1.2 g,
8.7 mmol) and tetrahydro-2H-pyran-4-amine (0.53 g, 5.2 mmol) at RT.
Then the reaction mixture was heated to 70.degree. C. and stirred
for 16 h and then cooled to RT. The reaction mixture was diluted
with cold water and the solid obtained was filtered and dried under
vacuum to afford the title compound (1.1 g, 86%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 8.62 (d, J=2.0 Hz, 1H), 8.23 (d, J=7.8
Hz, 1H), 7.97 (dd, J=1.9 Hz, J=8.8 Hz, 1H), 7.29 (d, J=9.3 Hz, 1H),
4.29 (q, J=7.3 Hz, 2H), 3.96-3.94 (m, 1H), 3.90-3.83 (m, 2H),
3.51-3.45 (m, 2H), 1.96-1.93 (m, 2H), 1.66-1.61 (m, 2H), 1.31 (t,
J=7.3 Hz, 3H); LC-MS: m/z 294.8 (M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate (2b)
[0155] The title compound was synthesized using the same procedure
which was followed for intermediate 1e using ethyl
3-nitro-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate as starting
material (Yield: 100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.19 (d, J=8.0 Hz, 1H), 7.17 (s, 1H), 6.52 (d, J=8.3 Hz,
1H), 4.99 (d, J=7.3 Hz, 1H), 4.97 (s, 2H), 4.18 (q, J=7.3 Hz, 2H),
3.89-3.87 (m, 2H), 3.57-3.53 (m, 1H), 3.45-3.40 (m, 2H), 1.92-1.89
(m, 2H), 1.48-1.38 (m, 2H), 1.25 (t, J=7.4 Hz, 3H); LC-MS: m/z
264.8 (M+1).sup.+.
Step-c: Synthesis of ethyl
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxylate (2c)
[0156] To a stirred solution of
2-amino-6-(trifluoromethoxy)benzothiazole (177 mg, 0.76 mmol) in
DMFA (55 mL) was added 1,1'-thiocarbonyldiimidazole (270 mg, 1.5
mmol) and the solution was heated at 100.degree. C. for 4 h. The
reaction mixture was cooled to RT. EDC.HCl (291 mg, 1.5 mmol) was
added and the reaction mixture was heated at 60.degree. C. for 10
min, followed by the addition of ethyl
3-amino-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate (200 mg, 0.76
mmol). Then the reaction mixture was heated at 100.degree. C. for
16 h. It was cooled to RT, diluted with water (50 mL) and extracted
with EtOAc (2.times.50 mL). The combined organic layers were washed
with water (30 mL), brine (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
combiflash column chromatography using 100% DCM as an eluent to
afford the title compound (120 mg, 31%); LC-MS: m/z 505.0
(M-1).
Step-d: Synthesis of
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxylic acid (2d)
[0157] The title compound was synthesized using the same procedure
which was followed for intermediate 1h, using ethyl
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 53%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.91
(bs, 1H), 12.57 (bs, 1H), 8.24 (s, 1H), 8.02-7.64 (m, 4H), 7.37 (s,
1H), 4.96-4.94 (m, 1H), 4.20-4.05 (m, 2H), 3.59-3.52 (m, 2H),
2.60-2.44 (m, 2H), 1.79-1.76 (m, 2H); LC-MS: m/z 477.0 (M-1).
Step-e: Synthesis of
N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)b-
enzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
(2e)
[0158] The title compound was synthesized using the same procedure
which was followed for intermediate 1i using
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting material
(Yield: 18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.25 (t,
J=5.4 Hz, 1H), 7.90 (d, J=1.5 Hz, 1H), 7.71-7.64 (m, 2H), 7.33 (d,
J=0.9 Hz, 1H), 7.16-7.13 (m, 1H), 6.87 (d, J=8.8 Hz, 1H), 5.23-5.17
(m, 1H), 4.11-4.10 (m, 2H), 3.65 (t, J=11.2 Hz, 2H), 3.35-3.32 (m,
4H), 3.28 (s, 3H), 2.66-2.60 (m, 2H), 1.92-1.90 (m, 2H); LC-MS: m/z
536.0 (M+1).sup.+.
Example 3d and 3e. Synthesis of
1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)ben-
zo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00015## ##STR00016##
[0159] Step-a: Synthesis of ethyl
4-((1-methylpiperidin-4-yl)amino)-3-nitrobenzoate (3a)
[0160] To a stirred solution of ethyl 4-chloro-3-nitrobenzoate (500
mg, 2.2 mmol) in DMFA (5 mL) was added 1-methylpiperidin-4-amine
(0.30 mL, 2.6 mmol) and N-ethyldiisopropyl amine (0.8 mL, 5.0
mmol). The reaction mixture was heated to 70.degree. C. and
continued stirring for 16 h at the same temperature. Reaction
mixture was cooled to RT, diluted with water (50 mL) and extracted
with EtOAc (2.times.100 mL). The combined organic layer was washed
with water (50 mL), brine (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to afford the title compound
(620 mg, 92%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.62
(s, 1H), 8.25 (d, J=8.0 Hz, 1H), 7.97 (d, J=9.2 Hz, 1H), 7.23 (d,
J=9.2 Hz, 1H), 4.30 (q, J=7.6 Hz, 2H), 3.71 (bs, 1H), 2.69-2.66 (m,
2H), 2.18 (s, 3H), 2.16-2.13 (m, 2H), 1.96-1.93 (m, 2H), 1.67-1.58
(m, 2H), 1.33 (t, J=7.6 Hz, 3H); LC-MS: m/z 307.7 (M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-((1-methylpiperidin-4-yl)amino)benzoate (3b)
[0161] The title compound was synthesized using the same procedure
which was followed for intermediate 1e using ethyl
4-((1-methylpiperidin-4-yl)amino)-3-nitrobenzoate as the starting
material and stirring for 2 h (Yield: 100%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.19-7.16 (m, 2H), 6.47 (d, J=8.4 Hz, 1H),
4.96 (d, J=7.2 Hz, 1H), 4.78 (bs, 2H), 4.18 (q, J=7.2 Hz, 2H),
3.37-3.31 (m, 1H), 2.86-2.83 (m, 2H), 2.25 (s, 3H), 2.19-2.13 (m,
2H), 1.94-1.91 (m, 2H), 1.54-1.45 (m, 2H), 1.26 (t, J=6.8 Hz, 3H);
LC-MS: m/z 278.2 (M+1).sup.+.
Step-c: Synthesis of ethyl
1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylate (3c)
[0162] The title compound was synthesized using the same procedure
which was followed for intermediate 2c using ethyl
3-amino-4-((1-methylpiperidin-4-yl)amino)benzoate as starting
material (Yield: 15%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
12.6 (bs, 1H), 8.14 (s, 1H), 7.91 (s, 1H), 7.79 (d, J=8.3 Hz, 1H),
7.62 (d, J=8.3 Hz, 1H), 7.55 (s, 1H), 7.35 (d, J=8.8 Hz, 1H),
4.74-4.68 (m 1H), 4.34 (q, J=6.8 Hz, 2H), 3.01-2.98 (m, 2H),
2.67-2.56 (m, 2H), 2.30 (s, 3H), 2.20-2.15 (m, 2H), 1.79-1.76 (m,
2H), 1.35 (t, J=6.9 Hz, 3H); LC-MS: m/z 520.1 (M+1).sup.+.
Step-d: Synthesis of
1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylic acid (3d)
[0163] The title compound was synthesized using the same procedure
which was followed for intermediate 1h using ethyl
1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 56%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.40
(bs, 1H), 8.12 (s, 1H), 7.91 (s, 1H), 7.78 (d, J=8.3 Hz, 1H), 7.60
(d, J=8.3 Hz, 1H), 7.58 (bs, 1H), 7.34 (d, J=8.9 Hz, 1H), 4.79-4.68
(m 1H), 3.02-2.99 (m, 2H), 2.57-2.54 (m, 2H), 2.30 (s, 3H),
2.21-2.15 (m, 2H), 1.79-1.77 (m, 2H); LC-MS: m/z 491.6
(M+1).sup.+.
Step-e: Synthesis of
N-(2-methoxyethyl)-1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)ben-
zo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
(3e)
[0164] The title compound was synthesized using the same procedure
which was followed for intermediate 1i using
1-(1-methylpiperidin-4-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylic acid as starting material
(Yield: 40%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.40
(bs, 1H), 8.44 (s, 1H), 8.09 (s, 1H), 7.91 (s, 1H), 7.70-7.58 (m,
3H), 7.35 (d, J=6.8 Hz, 1H), 4.75-4.65 (m, 1H), 3.50-3.43 (m, 4H),
3.28 (s, 3H), 3.02-2.99 (m, 2H), 2.60-2.54 (m, 2H), 2.31 (s, 3H),
2.20-2.15 (m, 2H), 1.79-1.76 (m, 2H); LC-MS: m/z 549.2
(M+1).sup.+.
Example 4d and 4e. Synthesis of
1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)be-
nzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00017## ##STR00018##
[0165] Step-a: Synthesis of ethyl
4-((1-methylpyrrolidin-3-yl)amino)-3-nitrobenzoate (4a)
[0166] The title compound was synthesized using the same procedure
which was followed for intermediate 3a using ethyl
4-chloro-3-nitrobenzoate and 1-methylpyrrolidin-3-amine as starting
materials (Yield: 79%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.62 (d, J=1.9 Hz, 1H), 8.39 (d, J=6.8 Hz, 1H), 7.98 (dd,
J=2.0 Hz, J=8.8 Hz, 1H), 7.15 (d, J=9.3 Hz, 1H), 4.32-4.36 (m, 3H),
2.80-2.75 (m, 1H), 2.70-2.59 (m, 2H), 2.42-2.30 (m, 2H), 2.29 (s,
3H), 1.73-1.65 (m, 1H), 1.31 (t, J=7.4 Hz, 3H); LC-MS: m/z 294.1
(M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-((1-methylpyrrolidin-3-yl)amino)benzoate (4b)
[0167] The title compound was synthesized using the same procedure
which was followed for intermediate 1e using ethyl
4-((1-methylpyrrolidin-3-yl)amino)-3-nitrobenzoate as starting
material and stirring for 2 h (Yield: 78%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.19-7.15 (m, 2H), 6.38 (d, J=8.3 Hz, 1H),
5.16 (d, J=6.9 Hz, 1H), 4.81 (s, 2H), 4.18 (q, J=7.3 Hz, 2H), 3.95
(bs, 1H), 2.74-2.70 (m, 1H), 2.44-2.34 (m, 2H), 2.28-2.22 (m, 1H),
2.25 (s, 3H), 1.67-1.63 (m, 1H), 1.25 (t, J=7.3 Hz, 3H); LC-MS: m/z
264.1 (M+1).sup.+.
Step-c: Synthesis of ethyl
1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylate (4c)
[0168] The title compound was synthesized using the same procedure
which was followed for intermediate 2c using ethyl
3-amino-4-((1-methylpyrrolidin-3-yl)amino)benzoate as starting
material. Product obtained was used in the next step without
further purification; LC-MS: m/z 506.1 (M+1).sup.+.
Step-d: Synthesis of
1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylic acid (4d)
[0169] The title compound was synthesized using the same procedure
which was followed for intermediate 1h using ethyl
1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylate as starting material,
using THF, MeOH and water (2:2:1) as solvent (Yield: 13%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6+D.sub.2O): .delta. 8.03 (s, 1H), 7.83
(s, 1H), 7.78 (d, J=8.3 Hz, 1H), 7.59-7.54 (m, 2H), 7.32 (d, J=8.8
Hz, 1H), 5.50 (bs, 1H), 3.86-3.75 (m, 2H), 3.35 (bs, 1H), 3.07-3.05
(m, 1H). 2.91 (s. 3H). 2.28-2.0 (m. 2H): LC-MS: m/z 478.1
(M+1).sup.+.
Step-e: Synthesis of
N-(2-methoxyethyl)-1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)be-
nzo[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
(4e)
[0170] The title compound was synthesized using the same procedure
which was followed for intermediate 1i using
1-(1-methylpyrrolidin-3-yl)-2-((6-(trifluoromethoxy)benzo[d]thiazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylic acid as starting material
(Yield: 30%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.10
(bs, 1H), 8.04 (s, 1H), 7.85 (s, 1H), 7.76 (bs, 1H), 7.68 (d, J=8.3
Hz, 1H), 7.62 (bs, 1H), 7.30 (d, J=8.8 Hz, 1H), 5.50 (bs, 1H),
3.52-3.44 (m, 4H), 3.30 (s, 3H), 2.76-2.65 (m, 2H), 2.50 (s, 3H,
merged with DMSO peak), 2.31-2.30 (m, 2H), 2.15-2.13 (m, 2H);
LC-MS: m/z 535.0 (M+1).sup.+.
Example 5. Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide
##STR00019##
[0171] Step-a: Synthesis of methyl
1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate (5a)
[0172] To a stirred solution of
4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (216 mg, 1.4 mmol) in
DMFA (5 mL) was added 1,1'-thiocarbonyldiimidazole (494 mg, 2.8
mmol) and the solution was heated at 100.degree. C. for 2 h. The
reaction mixture was cooled to RT. EDC.HCl (533 mg, 2.8 mmol) was
added and the reaction mixture was heated at 60.degree. C. for 10
min, followed by the addition of methyl
3-amino-4-(methylamino)benzoate (250 mg, 1.4 mmol). The reaction
mixture was heated at 100.degree. C. for 16 h. It was cooled to RT,
diluted with water (50 mL) and extracted with EtOAc (2.times.50
mL). The combined organic layers were washed with water (30 mL),
brine (30 mL), dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was purified by combi flash column
chromatography using 100% DCM as an eluent to afford the title
compound (110 mg, 23%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.01 (bs, 1H), 7.97 (s, 1H), 7.73 (dd, J=1.6 Hz, J=8.4 Hz,
1H), 7.37 (d, J=8.4 Hz, 1H), 3.84 (s, 3H), 3.61 (s, 3H), 2.50 (bs,
4H, merged with DMSO peak), 1.78 (bs, 4H); LC-MS: m/z 341.0
(M-1).
Step-b: Synthesis of
1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid (5b)
[0173] The title compound was synthesized using the same procedure
which was followed for intermediate 1h using methyl
1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate as starting material, using THF, MeOH and
water (2:2:1) as solvent (Yield: 83%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.20 (bs, 2H), 7.95 (s, 1H), 7.73 (dd,
J=0.8 Hz, J=8.4 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 3.61 (s, 3H), 2.50
(bs, 4H, merged with DMSO peak), 1.78 (bs, 4H); LC-MS: m/z 327.0
(M-1).
Step-c: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide (5c)
[0174] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-((4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting material (Yield: 30%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.0 (bs, 1H), 8.34 (bs, 1H),
7.95 (s, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 3.60
(s, 3H), 3.48-3.42 (m, 4H), 3.28 (s, 3H), 2.50 (bs, 4H, merged with
DMSO peak), 1.78 (bs, 4H); LC-MS: m/z 384.0 (M-1).
Example 6. Synthesis of
2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-N-(2-(2-hy-
droxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00020##
[0175] Step-a: Synthesis of
((4,4-dimethylcyclohex-1-en-1-yl)oxy)trimethylsilane
[0176] To a solution of 4,4-dimethylcyclohexan-1-one (3.0 g, 23.8
mmol) in DCM (180 mL) at 0.degree. C. was added triethylamine (9.95
mL, 71.42 mmol). The reaction mixture was stirred for 5 min
followed by the addition of trimethylsilyl
trifluoromethanesulfonate (6.5 g, 29.28 mmol in 54 mL of DCM). The
reaction mixture was stirred at 0.degree. C. for 1.5 h and then
quenched with saturated sodium bicarbonate solution (30 mL) and
water (100 mL). The organic layer was separated and washed with
water (2.times.50 mL), brine solution (50 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum to afford the titled
compound (3.8 g, 81%) which was used in the next step without
further purification; .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
4.74 (t, J=4.0 Hz, 1H), 1.99-1.97 (m, 2H), 1.80 (d, J=2.0 Hz, 2H),
1.39 (t, J=6.8 Hz, 2H), 1.16 (s, 6H), 0.15 (s, 9H).
Step-b: Synthesis of
6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine
[0177] To a solution of
((4,4-dimethylcyclohex-1-en-1-yl)oxy)trimethylsilane (3.8 g, 19.16
mmol) in THF (40 mL) and water (40 mL) at RT was added
N-bromosuccinimide (4.09 g, 23.0 mmol) and sodium acetate (0.22 g,
2.7 mmol). The reaction mixture was then stirred for 2 h. Thiourea
(1.43 g, 18.8 mmol) was added and the reaction mixture was heated
at 80.degree. C. for 6 h with stirring. Then it was cooled to RT
and continued stirring for 16 h. The reaction mixture was quenched
with water (30 mL) and extracted with DCM (2.times.50 mL). The
aqueous layer was basified (pH.about.9) with 2 M sodium hydroxide
and stirred for 2 h at RT. The solid precipitated was filtered and
dried under vacuum to afford the titled compound (1.3 g, 37%) which
was used in the next step without further purification; .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 6.55 (bs, 2H), 2.35 (t, J=6.4 Hz,
2H), 2.26 (s, 2H), 1.46 (t, J=6.0 Hz, 2H), 0.95 (s, 6H); LC-MS: m/z
183.1 (M+1).sup.+.
Step-c: Synthesis of ethyl
2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1-
H-benzo[d]imidazole-5-carboxylate
[0178] To a stirred solution of
6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (809 mg,
4.44 mmol) in DMFA (10 mL) was added 1,1'-thiocarbonyldiimidazole
(1.58 g, 8.88 mmol) and the solution was heated at 100.degree. C.
for 2 h. The reaction mixture was cooled to RT and EDC.HCl (1.70 g,
8.88 mmol) was added. The reaction mixture was heated at 50.degree.
C. for 10 min, followed by the addition of ethyl
3-amino-4-(methylamino) benzoate (800 mg, 4.44 mmol). It was then
heated at 100.degree. C. for 16 h and cooled to RT. The reaction
mixture was diluted with water (50 mL) and extracted with EtOAc
(2.times.100 mL). The combined organic layers were washed with
water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was purified by combi
flash column chromatography using 100% DCM as an eluent to afford
the titled compound (500 mg, 32%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.10 (bs, 1H), 7.98 (s, 1H), 7.74 (d, J=8.4
Hz, 1H), 7.37 (d, J=8.4 Hz, 1H), 4.30 (q, J=7.2 Hz, 2H), 3.61 (s,
3H), 2.50 (2H merged with DMSO peak), 2.33 (s, 2H), 1.56 (t, J=6.0
Hz, 2H), 1.33 (t, J=7.2 Hz, 3H), 1.00 (s, 6H); LC-MS: m/z 385.1
(M+1).sup.+.
Step-d: Synthesis of
2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1-
H-benzo[d]imidazole-5-carboxylic acid
[0179] To a stirred solution of ethyl
2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1-
H-benzo[d]imidazole-5-carboxylate (500 mg, 1.30 mmol) in a mixture
of THF (4 mL), ethanol (4 mL) and water (2 mL) was added lithium
hydroxide monohydrate (136 mg, 3.25 mmol). The reaction mixture was
heated at 80.degree. C. for 16 h and then cooled to RT and
concentrated under reduced pressure. The residue was dissolved in
water, acidified with 1 N HCl to obtain the solid which was
filtered and dried under vacuum to afford the titled compound (300
mg, 65%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.00 (s,
1H), 7.86 (d, J=8.4 Hz, 1H), 7.54 (d, J=8.4 Hz, 1H), 3.64 (s, 3H),
2.50 (2H merged with DMSO peak), 2.38 (s, 2H), 1.58 (t, J=6.0 Hz,
2H), 1.01 (s, 6H); LC-MS: m/z 357.1 (M+1).sup.+.
Step-e: Synthesis of
2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-N-(2-(2-hy-
droxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0180] To a stirred solution of
2-((6,6-dimethyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1-methyl-1-
H-benzo[d]imidazole-5-carboxylic acid (100 mg, 0.28 mmol) in DMFA
(2 mL) at 0.degree. C. was added N-ethyldiisopropyl amine (0.04 mL,
0.28 mmol) and HBTU (106 mg, 0.28 mmol). The reaction mixture was
stirred for 30 min, followed by the addition of
2-(2-aminoethoxy)ethan-1-ol (0.02 mL, 0.28 mmol) and stirring was
continued at RT for 16 h. Once the reaction was completed
(monitored by TLC), the reaction mixture was diluted with cold
water (20 mL) and stirred for 15 min. The solid obtained was
filtered and dried under vacuum. The residue was purified by combi
flash column chromatography using 2% MeOH in DCM as an eluent to
afford the titled compound (50 mg, 40%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.0 (bs, 1H), 8.34 (s, 1H), 7.95 (s, 1H),
7.64 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 4.60 (bs, 1H), 3.60
(s, 3H), 3.56-3.42 (m, 8H), 2.50 (2H merged with DMSO peak), 2.32
(m, 2H), 1.55 (t, J=6.0 Hz, 2H), 1.00 (s, 6H); LC-MS: m/z 444.1
(M+1).sup.+.
Example 7. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenz-
o[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00021##
[0181] Step-a: Synthesis of
trimethyl((4-methylcyclohex-1-en-1-yl)oxy)silane
[0182] To a solution of 4-methylcyclohexan-1-one (2.0 g, 17.8 mmol)
in DCM (50 mL) at 0.degree. C. was added triethylamine (7.5 mL,
53.4 mmol) and stirred for 5 min followed by the addition of
trimethylsilyl trifluoromethanesulfonate (4.95 g, 22.3 mmol in 30
mL of DCM). The reaction mixture was stirred at 0.degree. C. for
1.5 h and then quenched with saturated sodium hydrogen carbonate
solution (20 mL) and water (100 mL). The organic layer was
separated and washed with water (2.times.100 mL), brine solution
(50 mL), dried over anhydrous sodium sulfate and concentrated under
vacuum to afford the titled compound (3.4 g, 100%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 4.74-4.71 (m, 1H), 2.66-2.49 (m,
1H), 2.16-1.99 (m, 2H), 1.89-1.88 (m, 1H), 1.62-1.57 (m, 2H),
1.25-1.22 (m, 1H), 0.89 (d, J=2.4 Hz, 3H), 0.27 (s, 9H).
Step-b: Synthesis of
6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine
[0183] To a solution of
trimethyl((4-methylcyclohex-1-en-1-yl)oxy)silane (3.3 g, 17.9 mmol)
in THF (25 mL) and water (25 mL) at RT was added N-bromosuccinimide
(3.83 g, 21.5 mmol) and sodium acetate (0.20 g, 2.5 mmol) and then
stirred for 2 h. Thiourea (1.43 g, 18.8 mmol) was added and the
reaction mixture was heated at 80.degree. C. for 6 h with stirring.
The reaction mixture was then cooled to RT and continued stirring
for 16 h. The reaction mixture was quenched with water (30 mL) and
extracted with DCM (2.times.100 mL). The aqueous layer was basified
(pH.about.9) with 2 M sodium hydroxide and extracted with DCM
(3.times.100 mL). The combined organic layers were washed with
brine solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the titled compound (1.9 g,
63%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 6.55 (bs, 2H),
2.57-2.51 (m, 1H), 2.40-2.36 (m, 2H), 2.12-2.05 (m, 1H), 1.79-1.74
(m, 2H), 1.35-1.34 (m, 1H), 1.00 (d, J=6.4 Hz, 3H); LC-MS: m/z
169.2 (M+1).sup.+.
Step-c: Synthesis of ethyl
1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-be-
nzo[d]imidazole-5-carboxylate
[0184] To a stirred solution of
6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-amine (400 mg, 2.38
mmol) in DMFA (10 mL) was added 1,1'-thiocarbonyldiimidazole (848
mg, 4.76 mmol) and the solution was heated at 100.degree. C. for 2
h. The reaction mixture was cooled to RT and EDC.HCl (914 mg, 4.76
mmol) was added. The reaction mixture was heated at 50.degree. C.
for 10 min, followed by the addition of ethyl
3-amino-4-(methylamino)benzoate (462 mg, 2.38 mmol). The reaction
mixture was heated at 100.degree. C. for 16 h. It was cooled to RT,
diluted with water (50 mL) and extracted with EtOAc (2.times.50
mL). The combined organic layers were washed with water (30 mL),
brine (30 mL), dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was purified by combi flash column
chromatography using 100% DCM as an eluent to afford the title
compound (400 mg, 45%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.03 (bs, 1H), 7.98 (s, 1H), 7.73 (dd, J=1.0 Hz, J=8.3 Hz,
1H), 7.37 (d, J=8.3 Hz, 1H), 4.30 (q, J=7.2 Hz, 2H), 3.62 (s, 3H),
2.67-2.60 (m, 1H), 2.50 (2H merged with DMSO peak), 2.18-2.11 (m,
1H), 1.87-1.84 (m, 2H), 1.46-1.42 (m, 1H), 1.34 (t, J=7.1 Hz, 3H),
1.05 (d, J=6.3 Hz, 3H); LC-MS: m/z 371.05 (M+1).sup.+.
Step-d: Synthesis of
1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-be-
nzo[d]imidazole-5-carboxylic acid
[0185] The title compound was synthesized using the same procedure
which was followed for compound 1h, using ethyl
1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-be-
nzo[d]imidazole-5-carboxylate as starting material (Yield: 100%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.01 (bs, 1H), 12.83
(bs, 1H), 8.01 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz,
1H), 3.67 (s, 3H), 2.67-2.66 (m, 1H), 2.52 (2H merged with DMSO
peak), 2.33-2.21 (m, 1H), 1.91-1.86 (m, 2H), 1.48-1.43 (m, 1H),
1.06 (d, J=6.4 Hz, 3H); LC-MS: m/z 343.05 (M+1).sup.+.
Step-e: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenz-
o[d]thiazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0186] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-be-
nzo[d]imidazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol
as starting materials (Yield: 48%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.99 (bs, 1H), 8.35 (t, J=5.6 Hz, 1H), 7.95
(s, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 4.62 (t,
J=5.0 Hz, 1H), 3.61 (s, 3H), 3.55-3.50 (m, 4H), 3.47-3.42 (m, 4H),
2.67-2.66 (m, 1H), 2.52 (2H merged with DMSO peak), 2.17-2.16 (m,
1H), 1.90-1.88 (m, 2H), 1.45-1.40 (m, 1H), 1.05 (d, J=6.4 Hz, 3H);
LC-MS: m/z 430.10 (M+1).sup.+.
Example 8. Synthesis of
2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1--
methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00022##
[0187] Step-a: Synthesis of
5,6-dihydro-4H-cyclopenta[d]thiazol-2-amine
[0188] A mixture of cyclopentanone (1.0 g, 11.9 mmol), thiourea
(1.8 g, 23.8 mmol) and iodine (3.0 g, 11.9 mmol) was stirred in a
sealed tube at 110.degree. C. for 12 h. The reaction mixture was
cooled to RT and hot water (30 mL) was added and stirred for 30
min. The reaction mixture was extracted with diethyl ether
(2.times.20 mL), aqueous layer was basified (pH.about.8) with solid
sodium bicarbonate and extracted with DCM (3.times.30 mL). The
combined organic layer was washed with brine (20 mL), dried over
anhydrous sodium sulfate and concentrated under vacuum. The
resulted residue was purified by combiflash chromatography using
10% methanol in DCM and 0.1% of aqueous ammonia as eluent to afford
the title compound (160 mg, 10%); .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 4.77 (bs, 2H), 2.79-2.74 (m, 2H), 2.68-2.64
(m, 2H), 2.41-2.34 (m, 2H); LC-MS: m/z 141.1 (M+1).sup.+.
Step-b: Synthesis of ethyl
2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylate
[0189] The title compound was synthesized using the same procedure
which was followed for compound 5a using ethyl
3-amino-4-(methylamino)benzoate and
5,6-dihydro-4H-cyclopenta[d]thiazol-2-amine as starting materials
(Yield: 23%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.0
(bs, 1H), 8.05 (s, 1H), 7.77 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.4 Hz,
1H), 4.30 (q, J=6.8 Hz, 2H), 3.56 (s, 3H), 2.80-2.72 (m, 4H),
2.36-2.33 (m, 2H), 1.33 (t, J=6.8 Hz, 3H); LC-MS: m/z 343.0
(M+1).sup.+.
Step-c: Synthesis of
2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylic acid
[0190] The title compound was synthesized using the same procedure
which was followed for compound 1h, using ethyl
2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylate as starting material (Yield: 55%); LC-MS:
m/z 315.1 (M+1).sup.+.
Step-d: Synthesis of
2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1--
methyl-1H-benzo[d]imidazole-5-carboxamide
[0191] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((5,6-dihydro-4H-cyclopenta[d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylic acid as starting material (Yield: 13%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.0 (bs, 1H), 8.36
(bs, 1H), 7.95 (s, 1H), 7.67 (d, J=7.6 Hz, 1H), 7.33 (d, J=8.4 Hz,
1H), 3.56 (s, 3H), 3.47-3.42 (m, 4H), 3.28 (s, 3H), 2.77-2.67 (m,
4H), 2.36-2.33 (m, 2H); LC-MS: m/z 372.0 (M+1).sup.+.
Example 9. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((4,5,6,7-tetrahydrothiazolo[5,4--
c]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
hydrochloride
##STR00023##
[0192] Step-a: Synthesis of tert-butyl
2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate
[0193] To a stirred solution of tert-butyl
4-oxopiperidine-1-carboxylate (3.0 g, 15.07 mmol) in THF (70 mL) at
RT was added pyrrolidone hydrobromide (7.47 g, 15.07 mmol) and the
reaction mixture was refluxed for 10 min. The reaction mixture was
cooled to RT, the precipitated solid was removed by filtration and
the filtrate was concentrated. The residue obtained was dissolved
in ethanol (80 mL) followed by the addition of thiourea (1.53 g,
20.14 mmol) and the reaction mixture was refluxed for 3 h. The
reaction mixture was cooled to RT, concentrated under vacuum. The
residue was purified by combiflash chromatography using 5% methanol
in DCM as an eluent to afford the title compound (450 mg, 12%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 6.80 (s, 2H), 4.29 (s,
2H), 3.56 (t, J=5.6 Hz, 2H), 2.43 (bs, 2H), 1.41 (s, 9H); LC-MS:
m/z 256.2 (M+1).sup.+.
Step-b: Synthesis of tert-butyl
2-((5-(ethoxycarbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihyd-
rothiazolo[5,4-c]pyridine-5(4H)-carboxylate
[0194] To a stirred solution of tert-butyl
2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (424
mg, 1.66 mmol) in DMFA (6 mL) was added
1,1'-thiocarbonyldiimidazole (593 mg, 3.33 mmol) and the solution
was heated at 100.degree. C. for 2 h. The reaction mixture was
cooled to RT and EDC.HCl (639 mg, 3.33 mmol) was added. The
reaction mixture was heated at 50.degree. C. for 10 min, followed
by the addition of ethyl 3-amino-4-(methylamino)benzoate (300 mg,
1.66 mmol). The reaction mixture was heated at 100.degree. C. for
16 h. It was cooled to RT, diluted with water (50 mL) and extracted
with EtOAc (2.times.50 mL). The combined organic layers were washed
with water (30 mL), brine (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
combiflash chromatography using 0.4% methanol in DCM as an eluent
to afford the titled compound (130 mg, 18%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.10 (bs, 1H), 8.03 (bs, 1H), 7.77 (d,
J=8.4 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 4.39 (bs, 2H), 4.30 (q,
J=6.8 Hz, 2H), 3.67-3.59 (m, 5H), 2.50 (2H merged with DMSO peak),
1.43 (s, 9H), 1.34 (t, J=6.8 Hz, 3H); LC-MS: m/z 458.2
(M+1).sup.+.
Step-c: Synthesis of
2-((5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl-
)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid
[0195] The title compound was synthesized using the same procedure
which was followed for compound 1h using tert-butyl
2-((5-(ethoxycarbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihyd-
rothiazolo[5,4-c]pyridine-5(4H)-carboxylate as starting material
and THF, methanol, water (2:2:1) as solvent. (Yield: 70%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.50 (bs, 1H), 8.00 (s, 1H),
7.78 (d, J=8.4 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 4.40 (s, 2H), 3.66
(t, J=4.8 Hz, 2H), 3.60 (s, 3H), 2.66-2.63 (m, 2H), 1.43 (s, 9H);
LC-MS: m/z 430.1 (M+1).sup.+.
Step-d: Synthesis of tert-butyl
2-((5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)carbamoyl)-1-meth-
yl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H-
)-carboxylate
[0196] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl-
)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid and
2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-amine as starting
materials (Yield: 40%); LC-MS: m/z 631.2 (M+1).sup.+.
Step-e: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((4,5,6,7-tetrahydrothiazolo-[5,4-
-c]pyridin-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
hydrochloride
[0197] To a stirred solution of tert-butyl
2-((5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)carbamoyl)-1-meth-
yl-1H-benzo[d]imidazol-2-yl)amino)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H-
)-carboxylate (50 mg, 0.08 mmol) in 1,4-dioxane (0.8 mL) at
0.degree. C. was added 4 M HCl in 1,4-dioxane (0.3 mL) and stirred
at RT for 16 h. The reaction mixture was concentrated under reduced
pressure. The residue was triturated with diethyl ether and solvent
was decanted. The solid obtained was dried under vacuum to afford
the title compound (12 mg, 33%); .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.01 (s, 1H), 7.87 (d, J=8.0 Hz, 1H), 7.55 (d, J=8.4 Hz,
1H), 4.35 (s, 2H), 3.74 (s, 3H), 3.71-3.53 (m, 10H), 3.05 (t, J=6.0
Hz, 2H); LC-MS: m/z 417.1 (M+1).sup.+.
Example 10. Synthesis of
2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-N-(2-(2-
-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00024##
[0198] Step-a: Synthesis of
1-methyl-2-((4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid trifluoroacetic acid salt
[0199] To a stirred solution of
2-((5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl-
)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (170 mg,
0.39 mmol) in DCM (5 mL) at 0.degree. C. was added TFA (0.1 mL,
1.19 mmol) and stirred at RT for 16 h. The reaction mixture was
concentrated under reduced pressure and the residue obtained was
triturated with diethyl ether and solvent was decanted. The residue
was dried under vacuum to afford the title compound (180 mg, 100%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 9.22 (s, 2H), 8.04 (s,
1H), 7.81 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.42 (d, J=8.4 Hz, 1H),
4.23 (s, 2H), 3.60 (s, 3H), 3.48-3.46 (m, 2H), 2.89 (bs, 2H);
LC-MS: m/z 330.1 (M+1).sup.+.
Step-b: Synthesis of
2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methy-
l-1H-benzo[d]imidazole-5-carboxylic acid
[0200] To a stirred solution of
1-methyl-2-((4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid trifluoroacetic acid salt (180 mg,
0.55 mmol) in pyridine (2 mL) at 0.degree. C. was added acetic
anhydride (0.06 mL, 0.6 mmol) and stirred at RT for 16 h. The
reaction mixture was diluted with water (15 mL), and extracted with
EtOAc (2.times.50 mL). The combined organic layers were washed with
1 N HCl (30 mL), water (20 mL), brine (20 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum and the residue
obtained was triturated with diethyl ether and solvent was
decanted. The obtained solid was dried under vacuum to afford the
title compound (70 mg, 46%); LC-MS: m/z 372.1 (M+1).sup.+.
Step-c: Synthesis of
2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-N-(2-(2-
-hydroxyethoxy)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0201] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((5-acetyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-1-methy-
l-1H-benzo[d]imidazole-5-carboxylic acid and
2-(2-aminoethoxy)ethan-1-ol as starting materials (Yield: 29%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.0 (bs, 1H), 8.38
(s, 1H), 7.96 (d, J=3.6 Hz, 1H), 7.67 (d, J=7.6 Hz, 1H), 7.35 (d,
J=8.4 Hz, 1H), 4.62-4.49 (m, 3H), 3.78-3.73 (m, 2H), 3.60-3.41 (m,
10H), 3.30 (2H merged with DMSO moisture peak), 2.09 (s, 3H);
LC-MS: m/z 459.1 (M+1).sup.+.
Example 11. Synthesis of
2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1--
methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00025##
[0202] Step-a: Synthesis of methyl
2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylate
[0203] The title compound was synthesized using the same procedure
which was followed for compound 5a using methyl
3-amino-4-(methylamino)benzoate and
6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-amine as starting materials
and stirring 16 h (Yield: 20%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.20 (bs, 1H), 8.02 (s, 1H), 7.77 (d, J=8.0
Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 4.58 (s, 2H), 3.93 (t, J=5.6 Hz,
2H), 3.84 (s, 3H), 3.60 (s, 3H), 2.50 (2H, merged with DMSO peak);
LC-MS: m/z 343.0 (M-1).
Step-b: Synthesis of
2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylic acid
[0204] The title compound was synthesized using the same procedure
which was followed for compound 1h using methyl
2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylate as starting material and using THF, methanol
and water (2:2:1) as solvent (Yield: 52%); S 12.40 (bs, 2H), 7.98
(s, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 4.58 (s,
2H), 3.92 (t, J=4.8 Hz, 2H), 3.59 (s, 3H), 2.50 (2H, merged with
DMSO peak); LC-MS: m/z 330.7 (M+1).sup.+.
Step-c: Synthesis of
2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-N-(2-methoxyethyl)-1--
methyl-1H-benzo[d]imidazole-5-carboxamide
[0205] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl)amino)-1-methyl-1H-benzo[d]i-
midazole-5-carboxylic acid and 2-methoxyethylamine as starting
materials. The crude product was purified by combiflash
chromatography using 1.2% methanol in DCM as an eluent (Yield:
34%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 1H),
8.40 (bs, 1H), 7.96 (s, 1H), 7.66 (bs, 1H), 7.35 (d, J=8.4 Hz, 1H),
4.58 (bs, 2H), 3.93 (s, 2H), 3.58 (s, 3H), 3.48-3.42 (m, 4H), 3.27
(s, 3H), 2.50 (2H, merged with DMSO peak); LC-MS: m/z 387.6
(M+1).sup.+.
Example 12. Synthesis of
2-((1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[-
d]imidazole-5-carboxamide
##STR00026##
[0206] Step-a: Synthesis of
N-(1H-benzo[d]imidazol-2-yl)-1H-imidazole-1-carbothioamide
[0207] To a solution of 1H-benzo[d]imidazol-2-amine (1.0 g, 7.5
mmol) in acetonitrile (10 mL) at RT was added
1,1'-thiocarbonyldiimidazole (1.34 g, 7.5 mmol) and it was stirred
at RT for 16 h. The reaction mixture was filtered and the solid
obtained was dried under vacuum to afford the title compound (1.1
g, 60%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.18 (bs,
2H), 8.55 (s, 1H), 7.93 (d, J=1.2 Hz, 1H), 7.63-7.59 (m, 2H),
7.36-7.32 (m, 2H), 6.99 (d, J=1.2 Hz, 1H).
Step-b: Synthesis of methyl
2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carbo-
xylate
[0208] To a stirred solution of
N-(1H-benzo[d]imidazol-2-yl)-1H-imidazole-1-carbothioamide (188 mg,
0.77 mmol) in DMFA (5 mL) was added EDC.HCl (297 mg, 1.5 mmol) and
heated to 60.degree. C. for 10 min. The reaction mixture was cooled
to RT, followed by the addition of methyl
3-amino-4-(methylamino)benzoate (150 mg, 0.77 mmol) and it was
heated at 100.degree. C. for 16 h. The reaction mixture was cooled
to RT, diluted with water (30 mL) and extracted with EtOAc
(2.times.50 mL). The combined organic layer was washed with water
(30 mL), brine (30 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combi flash
column chromatography using 2% methanol in DCM as eluent to afford
the title compound (40 mg, 16%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.12 (bs, 2H), 8.05 (d, J=1.6 Hz, 1H), 7.73
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.37-7.34 (m, 3H), 7.12-7.08 (m, 2H),
3.85 (s, 3H), 3.65 (s, 3H); LC-MS: m/z 322.0 (M+1).sup.+.
Step-c: Synthesis of
2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carbo-
xylic acid
[0209] The title compound was synthesized using the same procedure
which was followed for intermediate 1h, using methyl
2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carbo-
xylate as starting material and methanol, THF and water as solvent
(Yield: 92%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.0
(bs, 3H), 7.92 (s, 1H), 7.89 (d, J=1.6 Hz, 1H), 7.60 (d, J=8.4 Hz,
1H), 7.45-7.41 (m, 2H), 7.29-7.26 (m, 2H), 3.68 (s, 3H); LC-MS: m/z
308.1 (M+1).sup.+.
Step-d: Synthesis of
2-((1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-benzo[-
d]imidazole-5-carboxamide
[0210] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carbo-
xylic acid as starting material (Yield: 14%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.10 (bs, 2H), 8.33 (t, J=4.8 Hz, 1H), 7.98
(d, J=0.8 Hz, 1H), 7.62 (dd, J=1.2 Hz, J=8.0 Hz, 1H), 7.35-7.30 (m,
3H), 7.11-7.07 (m, 2H), 3.64 (s, 3H), 3.50-3.42 (m, 4H), 3.29 (s,
3H); LC-MS: m/z 365.0 (M+1).sup.+.
Example 13 and 14. Synthesis of
1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00027##
[0211] Step-a: Synthesis of
4-(trifluoromethoxy)benzene-1,2-diamine
[0212] To a solution of methyl 2-nitro-5-(trifluoromethoxy)aniline
(2.0 g, 9.0 mmol) in methanol (40 mL) was added 10% Pd/C (1.0 g)
under nitrogen atmosphere. Then the reaction mixture was stirred
under hydrogen gas for 16 h. The reaction mixture was filtered
through a bed of celite and concentrated under vacuum to afford the
title compound (1.6 g, 93%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 6.48 (d, J=8.0 Hz, 1H), 6.45 (d, J=1.6 Hz, 1H), 6.29 (dd,
J=2.0 Hz, J=8.0 Hz, 1H), 4.80 (s, 2H), 4.58 (s, 2H); LC-MS: m/z
193.0 (M+1).sup.+.
Step-b: Synthesis of ethyl
2-(1H-imidazole-1-carbothioamido)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late
[0213] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (500 mg, 2.28
mmol) in acetonitrile (10 mL) at RT was added
1,1'-thiocarbonyldiimidazole (529 mg, 2.97 mmol) and reaction
mixture was stirred at 60.degree. C. for 16 h. It was cooled to RT
and stirred for 30 min. The solid obtained was filtered and dried
under vacuum to afford the title compound (500 mg, 66%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 13.40 (bs, 1H), 8.68 (s, 1H),
8.40 (d, J=1.2 Hz, 1H), 8.03 (s, 1H), 7.99 (dd, J=1.2 Hz, J=8.4 Hz,
1H), 7.75 (d, J=8.4 Hz, 1H), 7.01 (s, 1H), 4.35 (q, J=7.2 Hz, 2H),
3.79 (s, 3H), 1.36 (t, J=7.2 Hz, 3H); LC-MS: m/z 328.2 (M-1).
Step-c: Synthesis of ethyl
1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylate
[0214] The title compound was synthesized using the same procedure
which was followed for Example 12 Step-b, using ethyl
2-(1H-imidazole-1-carbothioamido)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late and 4-(trifluoromethoxy)benzene-1,2-diamine as starting
materials (Yield: 27%); .sup.1H NMR-VT at 90.degree. C. (400 MHz,
DMSO-d.sub.6): .delta. 12.0 (bs, 2H), 8.09 (s, 1H), 7.77 (d, J=8.4
Hz, 1H), 7.35 (d, J=8.4 Hz, 2H), 7.28 (s, 1H), 7.0 (d, J=8.4 Hz,
1H), 4.35 (q, J=6.8 Hz, 2H), 3.63 (s, 3H), 1.35 (t, J=6.8 Hz, 3H);
LC-MS: m/z 420.0 (M+1).sup.+.
Step-d: Synthesis of
1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid
[0215] The title compound was synthesized using the same procedure
which was followed for intermediate 1h, using ethyl
1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylate (Yield: 77%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.60 (bs, 3H), 8.05 (d, J=1.6 Hz, 1H), 7.82
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.40 (d,
J=8.8 Hz, 1H), 7.34 (s, 1H), 7.09 (dd, J=1.2 Hz, J=8.8 Hz, 1H),
3.65 (s, 3H); LC-MS: m/z 392.0 (M+1).sup.+.
Step-e: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0216] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid as starting material (Yield: 43%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 2H), 8.37
(bs, 1H), 8.0 (d, J=1.2 Hz, 1H), 7.68 (dd, J=1.2 Hz, J=8.4 Hz, 1H),
7.36 (d, J=8.4 Hz, 2H), 7.30 (s, 1H), 7.01 (d, J=8.4 Hz, 1H), 3.63
(s, 3H), 3.59-3.43 (m, 4H), 3.29 (s, 3H); LC-MS: m/z 449.0
(M+1).sup.+.
Example 15. Synthesis of
1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino-
)-1H-benzo[d]imidazole-5-carboxylic acid
##STR00028##
[0217] Step-a: Synthesis of
N-methyl-2-nitro-4-(trifluoromethoxy)aniline
[0218] To a stirred solution of 2-nitro-4-(trifluoromethoxy)aniline
(2.0 mg, 9.0 mmol) in DMFA (20 mL) at 0.degree. C. was added sodium
hydride (60% dispersion in mineral oil) (0.4 g, 10.0 mmol) and the
reaction mixture was stirred for 10 min. Methyl iodide (0.56 mL,
9.0 mmol) was added to the reaction mixture and stirred at RT for 1
h. The reaction mixture was quenched with saturated ammonium
chloride solution and extracted with ethyl acetate (2.times.100
mL). The combined organic layer was washed with water (50 mL),
brine (50 mL), dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was purified by combiflash chromatography
using 5% ethyl acetate in hexane as an eluent to afford the title
compound (1.8 g, 85%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
8.28 (d, J=4.0 Hz, 1H), 8.00 (d, J=2.4 Hz, 1H), 7.61 (dd, J=2.4 Hz,
J=9.2 Hz, 1H), 7.10 (d, J=9.2 Hz, 1H), 2.98 (d, J=5.2 Hz, 3H);
LC-MS: m/z 237.0 (M+1).sup.+.
Step-b: Synthesis of
N.sup.1-methyl-4-(trifluoromethoxy)benzene-1,2-diamine
[0219] The title compound was synthesized using the same procedure
which was followed for compound 1e using
N-methyl-2-nitro-4-(trifluoromethoxy)aniline as starting material
and stirring for 6 h (Yield: 92%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 6.44 (s, 1H), 6.42 (d, J=10.4 Hz, 1H), 6.33
(d, J=8.4 Hz, 1H), 4.84 (bs, 2H), 2.70 (s, 3H); LC-MS: m/z 207.0
(M+1).sup.+.
Step-c: Synthesis of ethyl
1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino-
)-1H-benzo[d]imidazole-5-carboxylate
[0220] The title compound was synthesized using the same procedure
which was followed for Example 12 Step-b using ethyl
2-(1H-imidazole-1-carbothioamido)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late and N1-methyl-4-(trifluoromethoxy)benzene-1,2-diamine as
starting materials (Yield: 37%); LC-MS: m/z 434.2 (M+1).sup.+.
Step-d: Synthesis of
1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino-
)-1H-benzo[d]imidazole-5-carboxylic acid
[0221] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((1-methyl-5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amino-
)-1H-benzo[d]imidazole-5-carboxylate as starting material (Yield:
53%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.5 (bs, 2H),
8.10 (d, J=1.2 Hz, 1H), 7.79 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.44 (s,
1H), 7.41-7.37 (m, 2H), 7.08 (d, J=8.8 Hz, 1H), 3.70 (s, 3H), 3.68
(s, 3H); LC-MS: m/z 406.1 (M+1).sup.+.
Example 16. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imida-
zole-5-carboxamide
##STR00029##
[0223] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (50 mg, 0.16 mmol) in DMFA (1.0 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (0.03 mL, 0.16 mmol) and HBTU (62 mg, 0.16
mmol). The reaction mixture was stirred for 30 min, followed by the
addition of 2-aminoethan-1-ol (10 mg, 0.16 mmol) and stirring was
continued at RT for 16 h. Once the reaction was completed
(monitored by TLC), the reaction mixture was diluted with cold
water (20 mL) and stirred for 15 min. The solid obtained was
filtered, washed with diethyl ether and dried under vacuum to
afford the title compound (25 mg, 44%) as white solid; .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.36 (t, J=5.4 Hz,
1H), 8.08 (d, J=0.9 Hz, 1H), 7.78-7.76 (m, 1H), 7.48 (d, J=8.3 Hz,
2H), 7.43 (d, J=7.8 Hz, 1H), 7.21 (t, J=7.3 Hz, 1H), 7.12 (t, J=7.3
Hz, 1H), 4.72 (bs, 1H), 3.63 (s, 3H), 3.54 (t, J=6.4 Hz, 2H),
3.37-3.34 (m, 2H); LC-MS: m/z 352.2 (M+1).sup.+.
Example 17. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
##STR00030##
[0224] Step-a: Synthesis of ethyl
4-(methylamino)-3-nitrobenzoate
[0225] To a solution of ethyl 4-chloro-3-nitrobenzoate (30.0 g, 131
mmol) in DMFA (100 mL) at RT was added methyl amine (26.8 mL (40%
aqueous solution), 262 mmol) and the reaction mixture was stirred
at 60.degree. C. for 16 h. The reaction mixture was cooled to RT,
diluted with cold water (1000 mL) and stirred for 1 h. The solid
obtained was filtered and dried under vacuum to afford the product
as a yellow solid (28.0 g, 96%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.62 (d, J=2.0 Hz, 1H), 8.59 (bs, 1H), 7.99
(dd, J=2.0 Hz, J=8.8 Hz, 1H), 7.07 (d, J=8.8 Hz, 1H), 4.29 (q,
J=6.8 Hz, 2H), 3.01 (d, J=5.2 Hz, 3H), 1.31 (t, J=6.8 Hz, 3H);
LC-MS: m/z 225.0 (M+1).sup.+.
Step-b: Synthesis of ethyl 3-amino-4-(methylamino)benzoate
[0226] To a solution of ethyl 4-(methylamino)-3-nitrobenzoate (27.0
g, 120 mmol) in methanol (300 mL) was added slurry of 10% Pd/C (2.8
g in 15 mL of ethanol) under nitrogen atmosphere. The flask was
kept in a Parr shaker at RT under hydrogen (60 psi) for 3 h. The
reaction mixture was filtered through celite bed and concentrated
under vacuum to afford the title compound (19.0 g, 82%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 7.23 (dd, J=1.6 Hz, J=8.4 Hz
1H), 7.16 (d, J=1.6 Hz, 1H), 6.39 (d, J=8.4 Hz, 1H), 5.38-5.37 (m,
1H), 4.66 (s, 2H), 4.18 (q, J=7.2 Hz, 2H), 2.77 (d, J=5.2 Hz, 3H),
1.26 (t, J=7.2 Hz, 3H); LC-MS: m/z 195.1 (M+1).sup.+.
Step-c: Synthesis of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate
[0227] To a solution of ethyl 3-amino-4-(methylamino)benzoate (17.0
g, 87.6 mmol) in THF (68 mL) and water (170 mL) at RT was added
cyanogen bromide (11.13 g, 105.2 mmol) and the reaction mixture was
stirred at 60.degree. C. for 16 h. The reaction mixture was cooled
to RT and basified with saturated sodium bicarbonate solution. The
solid obtained was filtered and dried under vacuum to afford the
title compound which was used in the next step without further
purification (18.0 g, 94%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.70 (d, J=1.2 Hz, 1H), 7.59 (dd, J=1.2 Hz, J=8.4 Hz, 1H),
7.20 (d, J=8.4 Hz, 1H), 6.64 (s, 2H), 4.27 (q, J=6.8 Hz, 2H), 3.53
(s, 3H), 1.32 (t, J=6.8 Hz, 3H); LC-MS: m/z 220.1 (M+1).sup.+.
Step-d: Synthesis of ethyl
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate
[0228] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (4.0 g, 18.3
mmol) in 1,4-dioxane (40 mL) at 0.degree. C. was added sodium
hydride (60% dispersion in mineral oil) (1.09 g, 27.4 mmol) portion
wise and stirred for 10 min. 2-chlorobenzo[d]oxazole (2.79 g, 18.3
mmol) was added to the reaction mixture and stirred at RT for 16 h.
The reaction mixture was poured over cold water (100 mL) and
stirred at RT for 5 to 10 min. The obtained solid was filtered,
dried under vacuum and purified by combiflash column chromatography
using 100% DCM as an eluent to afford the title compound (4.0 g,
60%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H),
8.24 (s, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.53-7.43 (m, 3H), 7.22 (t,
J=7.2 Hz, 1H), 7.13 (t, J=7.6 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.64
(s, 3H), 1.35 (t, J=7.2 Hz, 3H); LC-MS: m/z 337.0 (M+1).sup.+.
Step-e: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid
[0229] To a stirred solution of ethyl
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylate
(4.0 g, 11.90 mmol) in a mixture of solvent of THF (20 mL), ethanol
(20 mL) and water (10 mL) was added lithium hydroxide monohydrate
(1.25 g, 29.76 mmol). The reaction mixture was heated at 60.degree.
C. with stirring for 16 h. The reaction mixture was cooled to RT
and concentrated under reduced pressure. The residue was dissolved
in water (60 mL), acidified with 1 N HCl to obtain the solid which
was filtered and dried under vacuum to afford the title compound
(3.4 g, 93%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.60
(bs, 2H), 8.20 (d, J=1.6 Hz, 1H), 7.87 (dd, J=1.6 Hz, J=8.0 Hz,
1H), 7.51-7.48 (m, 2H), 7.44 (d, J=7.2 Hz, 1H), 7.23-7.20 (m, 1H),
7.15-7.11 (m, 1H), 3.64 (s, 3H); LC-MS: m/z 309.1 (M+1).sup.+.
Step-f: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
[0230] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (3.0 g, 9.74 mmol) in DMFA (30 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (4.36 mL, 24.25 mmol) and HBTU (4.06 g,
10.71 mmol). The reaction mixture was stirred for 30 min, followed
by the addition of 2-(2-aminoethoxy)ethan-1-ol (1.02 g, 9.74 mmol)
and stirring was continued at RT for 16 h. Once the reaction was
completed (monitored by TLC), the reaction mixture was diluted with
cold water (300 mL) and stirred for 30 min. The solid obtained was
filtered, dried under vacuum and purified by combiflash column
chromatography using 5% methanol in DCM as an eluent to afford the
title compound (2.9 g, 75%) as white solid; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.20 (bs, 1H), 8.43 (t, J=5.3 Hz, 1H), 8.07
(s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.48 (d, J=7.9 Hz, 2H), 7.43 (d,
J=7.8 Hz, 1H), 7.21 (t, J=7.3 Hz, 1H), 7.11 (t, J=7.3 Hz, 1H), 4.60
(bs, 1H), 3.63 (s, 3H), 3.57-3.42 (m, 8H); LC-MS: m/z 396.2
(M+1).sup.+.
Example 18. Synthesis of
N-(2-aminoethyl)-2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazo-
le-5-carboxamide hydrochloride
##STR00031##
[0231] Step-a: Synthesis of tert-butyl
(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxam-
ido)ethyl)carbamate
[0232] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid and tert-butyl (2-aminoethyl)carbamate as starting materials
(Yield: 51%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20
(bs, 1H), 8.41 (t, J=5.1 Hz, 1H), 8.08 (s, 1H), 7.75 (d, J=8.3 Hz,
1H), 7.48 (d, J=8.4 Hz, 2H), 7.43 (d, J=7.8 Hz, 1H), 7.23-7.19 (m,
1H), 7.14-7.09 (m, 1H), 6.92 (d, J=5.4 Hz, 1H), 3.64 (s, 3H),
3.34-3.33 (m, 2H merged with DMSO moisture peak), 3.15-3.10 (m,
2H), 1.38 (s, 9H); LC-MS: m/z 451.55 (M+1).sup.+.
Step-b: Synthesis of
N-(2-aminoethyl)-2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazo-
le-5-carboxamide hydrochloride
[0233] To a solution of tert-butyl
(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxam-
ido)ethyl)carbamate (50 mg, 0.11 mmol) in THF (2 mL) at 0.degree.
C. was added 4 N HCl in 1,4-dioxane (0.5 mL) and reaction mixture
was stirred at RT for 3 h. The reaction mixture was concentrated on
rotary evaporator and stirred in diethyl ether (10 mL). The solid
obtained was filtered and dried under vacuum to afford the titled
compound (35 mg, 81%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
12.40 (bs, 1H), 8.70 (s, 1H), 8.13 (s, 1H), 7.96 (bs, 3H), 7.86 (d,
J=8.3 Hz, 1H), 7.56 (d, J=8.3 Hz, 1H), 7.48 (d, J=7.9 Hz, 2H), 7.25
(t, J=7.6 Hz, 1H), 7.17 (t, J=7.8 Hz, 1H), 3.67 (s, 3H), 3.55 (q,
J=5.7 Hz, 2H), 3.03-2.99 (m, 2H); LC-MS: m/z 351.10
(M+1).sup.+.
Example 19. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-(dimethylamino)acetamido)ethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
##STR00032##
[0234] Step-a: Synthesis of tert-butyl
(2-(2-(dimethylamino)acetamido)ethyl)carbamate
[0235] To a stirred solution of dimethylglycine (1.0 g, 9.71 mmol)
in DMFA (10 mL) at 0.degree. C. was added N-ethyldiisopropyl amine
(1.69 mL, 9.71 mmol) and HBTU (3.68 g, 9.71 mmol). The reaction
mixture was stirred for 30 min, followed by the addition of
tert-butyl (2-aminoethyl)carbamate (1.55 g, 9.71 mmol). The
reaction mixture was stirred at RT for 16 h. Once the reaction was
completed (monitored by TLC), the reaction mixture was diluted with
cold water (50 mL) and extracted with EtOAc (2.times.100 mL). The
combined organic layers were washed with water (3.times.30 mL),
brine solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The solid obtained was stirred in
diethyl ether (20 mL) for 5 min, filtered and dried under vacuum to
afford the title compound (600 mg, 25%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.77 (t, J=5.6 Hz, 1H), 6.83 (t, J=5.2 Hz,
1H), 3.11 (q, J=6.2 Hz, 2H), 2.99 (q, J=6.1 Hz, 2H), 2.82 (s, 2H),
2.18 (s, 6H), 1.37 (s, 9H); LC-MS: m/z 246.15 (M+1).sup.+.
Step-b: Synthesis of N-(2-aminoethyl)-2-(dimethylamino)acetamide
trifluoroacetate
[0236] To a solution of tert-butyl
(2-(2-(dimethylamino)acetamido)ethyl)carbamate (600 mg, 2.45 mmol)
in DCM (15 mL) at 0.degree. C. was added TFA (0.56 mL, 7.34 mmol)
and reaction mixture was stirred at RT for 16 h. The reaction
mixture was concentrated on rotary evaporator and dried under
vacuum to afford the titled compound (600 mg, 100%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 9.75 (bs, 1H), 8.75 (t, J=5.6 Hz,
1H), 7.90 (bs, 2H), 3.88 (s, 2H), 3.38 (q, J=6.2 Hz, 2H), 2.91 (q,
J=5.9 Hz, 2H), 2.82 (s, 6H); LC-MS: m/z 146.20 (M+1).sup.+.
Step-c: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-(dimethylamino)acetamido)ethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
[0237] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (100 mg, 0.32 mmol) in DMFA (4 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (0.17 mL, 0.97 mmol) and HBTU (123 mg,
0.32 mmol). The reaction mixture was stirred for 30 min, followed
by the addition of N-(2-aminoethyl)-2-(dimethylamino)acetamide
trifluoroacetate (145 mg, 0.39 mmol). The reaction mixture was then
stirred at RT for 16 h. Once the reaction was completed (monitored
by TLC), the reaction mixture was diluted with cold water (15 mL).
The solid obtained was filtered, washed with diethyl ether and
dried under vacuum to afford the title compound (40 mg, 28%) as a
white solid; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20
(bs, 1H), 8.44 (t, J=4.9 Hz, 1H), 8.07 (s, 1H), 7.92 (bs, 1H), 7.74
(d, J=7.8 Hz, 1H), 7.49-7.47 (m, 2H), 7.43 (d, J=7.8 Hz, 1H), 7.21
(t, J=7.6 Hz, 1H), 7.12 (t, J=7.6 Hz, 1H), 3.63 (s, 3H), 3.37 (t,
J=5.2 Hz, 2H), 3.35 (2H merged with DMSO moisture peak), 2.86 (s,
2H), 2.19 (s, 6H); LC-MS: m/z 436.0 (M+1).sup.+.
Example 20. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-N-(2-morpholinoethyl)-1H-benzo[d]im-
idazole-5-carboxamide
[0238] The title compound was synthesized using the same procedure
which was followed for compound 1i using 2-morpholinoethan-1-amine
and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.21 (bs, 1H), 8.33 (s, 1H), 8.06 (s, 1H), 7.73 (d, J=8.4
Hz, 1H), 7.48 (d, J=8.4 Hz, 1H), 7.43 (d, J=8.0 Hz, 2H), 7.21 (t,
J=7.2 Hz, 1H), 7.11 (t, J=8.0 Hz, 1H), 3.63 (s, 3H), 3.58 (t, J=3.6
Hz, 4H), 3.41 (q, J=6.4 Hz, 2H), 3.30 (2H merged with DMSO moisture
peak), 2.43 (bs, 4H); LC-MS: m/z 421.2 (M+1).sup.+.
Example 21. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(dimethylamino)ethyl)-1-methyl-1H-benzo-
[d]imidazole-5-carboxamide
[0239] The title compound was synthesized using the same procedure
which was followed for compound 1i using
N,N-dimethylethane-1,2-diamine and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.21 (bs, 1H), 8.29 (t, J=5.2 Hz, 1H), 8.07 (s, 1H), 7.74
(d, J=8.4 Hz, 1H), 7.48-7.42 (m, 3H), 7.21 (t, J=7.6 Hz, 1H), 7.11
(t, J=8.0 Hz, 1H), 3.63 (s, 3H), 3.39-3.35 (m, 2H), 2.50-2.42 (m,
2H), 2.19 (s, 6H); LC-MS: m/z 379.2 (M+1).sup.+.
Example 22. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-((4,5-dihydro-1H-imidazol-2-yl)amino)et-
hyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0240] The title compound was synthesized using the same procedure
which was followed for compound 1i using
N.sup.1-(4,5-dihydro-1H-imidazol-2-yl)ethane-1,2-diamine and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 2H), 8.52 (bs, 1H), 8.20 (bs, 1H), 8.09 (s, 1H),
7.75 (d, J=8.4 Hz, 1H), 7.52-7.43 (m, 3H), 7.21 (t, J=7.2 Hz, 1H),
7.12 (t, J=8.0 Hz, 1H), 3.64 (s, 3H), 3.59 (s, 2H), 3.45-3.43 (m,
2H), 3.36-3.34 (m, 4H); LC-MS: m/z 417.05 (M-1).sup.-.
Example 23. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-hydroxypropyl)-1-methyl-1H-benzo[d]imid-
azole-5-carboxamide
[0241] The title compound was synthesized using the same procedure
which was followed for compound 1i using 1-aminopropan-2-ol and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 1H), 8.36 (t, J=5.6 Hz, 1H), 8.19 (d, J=1.2 Hz,
1H), 7.78 (dd, J=1.2 Hz, J=8.4 Hz, 1H), 7.52-7.36 (m, 3H),
7.21-7.19 (m, 1H), 7.14-7.09 (m, 1H), 4.87-4.78 (m, 1H), 3.81 (q,
J=6.0 Hz, 1H), 3.64 (s, 3H), 3.24-3.20 (m, 2H), 1.14 (d, J=6.8 Hz,
3H); LC-MS: m/z 366.2 (M+1).sup.+.
Example 24. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2,3-dihydroxypropyl)-1-methyl-1H-benzo[d]-
imidazole-5-carboxamide
[0242] The title compound was synthesized using the same procedure
which was followed for compound 1i using 3-aminopropane-1,2-diol
and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 1H), 8.31 (t, J=5.2 Hz, 1H), 8.08 (s, 1H), 7.77
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.49-7.42 (m, 3H), 7.21 (t, J=8.0 Hz,
1H), 7.11 (t, J=7.2 Hz, 1H), 4.82 (d, J=4.4 Hz, 1H), 4.58 (bs, 1H),
3.64 (s, 3H), 3.45-3.37 (m, 3H), 3.26-3.19 (m, 2H); LC-MS: m/z
382.1 (M+1).sup.+.
Example 25. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxypropoxy)ethyl)-1,6-dimethyl-1-
H-benzo[d]imidazole-5-carboxamide
[0243] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-aminoethoxy)propan-2-ol and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 1H), 8.42 (t, J=5.2 Hz, 1H), 8.07 (s, 1H), 7.75
(dd, J=1.2 Hz, J=8.4 Hz, 1H), 7.49-7.42 (m, 3H), 7.21 (t, J=7.6 Hz,
1H), 7.11 (t, J=8.0 Hz, 1H), 4.57 (bs, 1H), 3.75 (q, J=5.6 Hz, 1H),
3.63 (s, 3H), 3.57-3.54 (m, 2H), 3.46-3.43 (m, 2H), 3.29-3.23 (m,
2H), 1.03 (d, J=6.4 Hz, 3H); LC-MS: m/z 410.2 (M+1).sup.+.
Example 26. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-((3-hydroxyoxetan-3-yl)methyl)-1-methyl-1H-
-benzo[d]imidazole-5-carboxamide
[0244] The title compound was synthesized using the same procedure
which was followed for compound 1i using 3-(aminomethyl)oxetan-3-ol
and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 1H), 8.55 (t, J=5.2 Hz, 1H), 8.10 (d, J=1.2 Hz,
1H), 7.79 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.51-7.42 (m, 3H), 7.21 (t,
J=7.6 Hz, 1H), 7.14 (t, J=7.6 Hz, 1H), 5.90 (s, 1H), 4.52 (d, J=6.8
Hz, 2H), 4.41 (d, J=6.4 Hz, 2H), 3.64 (s, 3H), 3.59 (d, J=6.0 Hz,
2H); LC-MS: m/z 394.2 (M+1).sup.+.
Example 27. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxy-2-methylpropoxy)ethyl)-1-met-
hyl-1H-benzo[d]imidazole-5-carboxamide
[0245] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-aminoethoxy)-2-methylpropan-2-ol and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxyl-
ic acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 1H), 8.43 (t, J=5.2 Hz, 1H), 8.07 (d, J=1.2 Hz,
1H), 7.75 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 7.49-7.42 (m, 3H), 7.21
(dd, J=1.2 Hz, J=7.6 Hz, 1H), 7.12 (dd, J=1.2 Hz, J=7.6 Hz, 1H),
4.34 (bs, 1H), 3.63 (s, 3H), 3.57 (t, J=6.4 Hz, 2H), 3.47-3.43 (m,
2H), 3.20 (s, 2H), 1.09 (s, 6H); LC-MS: m/z 424.2 (M+1).sup.+.
Example 28. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-1H-ben-
zo[d]imidazole-5-carboxamide
[0246] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-(pyrrolidin-1-yl)ethan-1-amine and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.24 (bs, 1H), 8.38 (t, J=5.6 Hz, 1H), 8.07 (s, 1H), 7.74
(d, J=8.4 Hz, 1H), 7.49-7.42 (m, 3H), 7.21 (t, J=6.8 Hz, 1H), 7.11
(t, J=7.2 Hz, 1H) 3.69 (s, 3H), 3.48-3.37 (m, 2H), 2.64-2.57 (m,
2H), 2.50 (4H merged in DMSO peak), 1.66 (bs, 4H); LC-MS: m/z 405.2
(M+1).sup.+.
Example 29. Synthesis of
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)acetic acid
##STR00033##
[0247] Step-a: Synthesis of ethyl
2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate
[0248] To a solution of tert-butyl (2-hydroxyethyl)carbamate (1.0
g, 6.21 mmol) in THF (10 mL) at 0.degree. C. was added sodium
hydride (60% dispersion in mineral oil) (397 mg, 9.93 mmol) by
portions followed by the addition of potassium iodide (164 mg, 0.99
mmol) and ethylbromo acetate (2.07 g, 12.42 mmol). The reaction
mixture was stirred at RT for 2 h. The reaction mixture was diluted
with cold water (60 mL) and extracted with ethyl acetate
(3.times.60 mL). The combined organic layers were washed with water
(30 mL), brine solution (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
combiflash column chromatography using 1% methanol in
dichloromethane as an eluent to afford the titled compound (1.0 g,
65%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 6.74 (bs, 1H),
4.14-4.08 (m, 4H), 3.45 (t, J=5.6 Hz, 2H), 3.08 (q, J=6.2 Hz, 2H),
1.37 (s, 9H), 1.19 (t, J=6.8 Hz, 3H); LC-MS: m/z 148.1
(M-Boc).sup.+.
Step-b: Synthesis of ethyl 2-(2-aminoethoxy)acetate trifluoroacetic
acid salt
[0249] To a stirred solution of ethyl
2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetate (1.0 g, 4.05 mmol)
in DCM (5 mL) at RT was added trifluoroacetic acid (1 mL) and
stirred at RT for 5 h. The reaction mixture was concentrated under
reduced pressure to afford the titled compound (1.1 g, 100%) which
was used in the next step without any further purification; .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 7.88 (bs, 3H), 4.17 (s, 2H),
4.14 (q, J=6.8 Hz, 2H), 3.68 (t, J=5.0 Hz, 2H), 3.01 (q, J=5.2 Hz,
2H), 1.21 (t, J=7.0 Hz, 3H); LC-MS: m/z 148.2 (M+1).sup.+.
Step-c: Synthesis of ethyl
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)acetate
[0250] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (150 mg, 0.48 mmol) in DMFA (2 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (0.26 mL, 1.46 mmol) and HBTU (184 mg,
0.48 mmol). The reaction mixture was stirred for 30 min, followed
by the addition of ethyl 2-(2-aminoethoxy)acetate trifluoroacetate
(129 mg, 0.53 mmol). The reaction mixture was then stirred at RT
for 16 h. Once the reaction was completed (monitored by TLC), the
reaction mixture was diluted with cold water (6 mL) and stirred for
5 min. The solid precipitated was filtered and dried under vacuum
to afford the titled compound (125 mg, 59%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.46 (bs, 1H), 8.08 (s, 1H),
7.76 (d, J=8.4 Hz, 1H), 7.49-7.47 (m, 2H), 7.43 (d, J=7.6 Hz, 1H),
7.21 (t, J=8.0 Hz, 1H), 7.14 (t, J=7.6 Hz, 1H), 4.15 (s, 2H), 4.12
(q, J=7.0 Hz, 2H), 3.65-3.62 (m, 5H), 3.47 (q, J=5.8 Hz, 2H), 1.19
(t, J=7.0 Hz, 3H); LC-MS: m/z 438.1 (M+1).sup.+.
Step-d: Synthesis of
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)acetic acid
[0251] To a solution of ethyl
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)acetate (110 mg, 0.25 mmol) in a mixture of solvents
of THF (1 mL), ethanol (1 mL) and water (0.5 mL) was added lithium
hydroxide monohydrate (26 mg, 0.63 mmol). The reaction mixture was
stirred at RT for 3 h. The reaction mixture was concentrated under
reduced pressure, the residue was dissolved in water (5 mL) and
acidified with 1 N HCl to obtain the solid which was filtered and
dried under vacuum to afford the titled compound (80 mg, 78%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.60 (bs, 1H), 8.47
(s, 1H), 8.08 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.50-7.43 (m, 3H),
7.22 (t, J=7.6 Hz, 1H), 7.13 (t, J=7.2 Hz, 1H), 4.06 (s, 2H), 3.64
(bs, 5H), 3.45 (q, J=5.2 Hz, 2H); LC-MS: m/z 410.4 (M+1).sup.+.
Example 30.
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)ethyl DL-valinate hydrochloride
##STR00034##
[0252] Step-a: Synthesis of (tert-butoxycarbonyl)-DL-valine
[0253] To a stirred solution of DL-valine (2.0 g, 17.07 mmol) in
THF (25 mL) and water (20 mL) at RT was added sodium hydroxide
(0.82 g, 20.5 mmol) and di-tert-butyl dicarbonate (4.09 g, 18.77
mmol) and the reaction mixture was stirred for 16 h. The mixture
was cooled to 0.degree. C., acidified with 1 N HCl and extracted
with EtOAc (2.times.50 mL). The combined organic layers were washed
with brine solution (30 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum. Crude product (1.8 g) was used in
the next step without any further purification,
Step-b: Synthesis of
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)ethyl (tert-butoxycarbonyl) -DL-valinate
[0254] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide (70 mg, 0.18 mmol) and
(tert-butoxycarbonyl) -DL-valine (42 mg, 0.19 mmol) in DMFA (5 mL)
at 0.degree. C. was added N-ethyldiisopropyl amine (0.04 mL, 0.21
mmol) and HATU (80 mg, 0.21 mmol). The reaction mixture was stirred
at RT for 16 h. Once the reaction was completed (monitored by TLC),
the reaction mixture was diluted with cold water (20 mL) and
extracted with ethyl acetate (2.times.30 mL). The combined organic
layers were washed with water (20 mL), brine solution (20 mL),
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was purified by combiflash column chromatography using
4.1% methanol in dichloromethane as an eluent to afford the titled
compound (40 mg, 38%); LC-MS: m/z 595.7 (M+1).sup.+.
Step-c: Synthesis of
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)ethyl DL-valinate hydrochloride
[0255] To a stirred solution of
2-(2-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carbox-
amido)ethoxy)ethyl (tert-butoxycarbonyl) -DL-valinate (40 mg, 0.07
mmol) in 1,4-dioxane (5 mL) at 10.degree. C. was added 4 N HCl in
1,4-dioxane (0.03 mL, 0.13 mmol) and the reaction mixture was
stirred at RT for 16 h. Once the reaction was completed (monitored
by TLC), the reaction mixture was concentrated under reduced
pressure and lyophilized for 18 h to afford the titled compound (19
mg, 53%) as hydrochloride salt; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.50 (s, 1H), 8.52 (bs, 1H), 8.40 (bs, 3H),
8.09 (s, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.48
(d, J=7.6 Hz, 2H), 7.25 (t, J=7.2 Hz, 1H), 7.17 (t, J=8.0 Hz, 1H),
4.43-4.40 (m, 2H), 4.28-4.25 (m, 2H), 3.95 (bs, 1H), 3.70-3.67 (s,
3H), 3.61-3.57 (m, 2H), 3.45-3.44 (m, 2H), 2.15-2.11 (m, 1H), 0.97
(d, J=6.8 Hz, 3H), 0.92 (d, J=6.8 Hz, 3H); LC-MS: m/z 495.1
(M+1).sup.+.
Examples 31 and 32. Synthesis of
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide
##STR00035## ##STR00036##
[0256] Step-a: Synthesis of 2-nitro-5-(trifluoromethyl)phenol
[0257] To a solution of 3-(trifluoromethyl)phenol (5.0 g, 30.86
mmol) in acetic acid (50 mL) was added 60% aqueous nitric acid (3.5
mL) dropwise at 0.degree. C. Then the mixture was stirred at this
temperature for 1.5 h and stirring was continued at RT for 16 h.
The mixture was poured into ice water (80 mL) and extracted with
EtOAc (2.times.100 mL). The combined organic layers were washed
with brine solution (50 mL), dried over anhydrous sodium sulfate
and concentrated in vacuum. The residue was purified by combiflash
column chromatography using 5% ethyl acetate in hexane as eluent to
afford the titled compound (1.0 g, 16%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.75 (bs, 1H), 8.06 (d, J=8.3 Hz, 1H), 7.41
(d, J=1.4 Hz, 1H), 7.32 (dd, J=1.4 Hz, J=8.3 Hz, 1H); LC-MS: m/z
206.0 (M-1).sup.-.
Step-b: Synthesis of 2-amino-5-(trifluoromethyl)phenol
[0258] To a solution of 2-nitro-5-(trifluoromethyl)phenol (1.0 g,
4.83 mmol) in methanol (15 mL) was added 10% Pd/C (100 mg) under
nitrogen atmosphere. The reaction mixture was stirred under
hydrogen balloon for 16 h. The reaction mixture was filtered
through a celite bed and the filtrate was concentrated under vacuum
to afford the title compound (850 mg, 99%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 9.58 (bs, 1H), 6.88 (s, 1H), 6.86 (s, 1H),
6.66 (d, J=7.8 Hz, 1H), 5.18 (s, 2H); LC-MS: m/z 178.0
(M+1).sup.+.
Step-c: Synthesis of 6-(trifluoromethyl)benzo[d]oxazole-2-thiol
[0259] To a solution of 2-amino-5-(trifluoromethyl)phenol (850 mg,
4.8 mmol) in ethanol (10 mL) at RT was added potassium
ethyl-xanthate (1.69 g, 10.56 mmol) and the reaction mixture was
refluxed for 16 h. The reaction mixture was concentrated under
vacuum and diluted with cold water (50 mL), acidified with 1 N HCl.
The solid obtained was filtered and dried under vacuum to afford
the title compound (1.0 g, 95%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 14.2 (bs, 1H), 7.98 (s, 1H), 7.66 (d, J=8.4
Hz, 1H), 7.41 (d, J=7.8 Hz, 1H); LC-MS: m/z 217.9 (M-1).sup.-.
Step-d: Synthesis of
2-chloro-6-(trifluoromethyl)benzo[d]oxazole
[0260] To a solution of 6-(trifluoromethyl)benzo[d]oxazole-2-thiol
(500 mg, 2.28 mmol) in thionyl chloride (4 mL) at RT was added
dimethyl formamide (catalytic amount) and the reaction mixture was
refluxed for 3 h. The reaction mixture concentrated, diluted with
cold water (30 mL) and extracted with EtOAc (2.times.30 mL). The
combined organic layers were washed with brine solution (20 mL),
dried over anhydrous sodium sulfate and concentrated under vacuum
to afford the title compound (290 mg, 57%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.31 (s, 1H), 7.97 (d, J=8.3 Hz, 1H), 7.80
(d, J=8.3 Hz, 1H).
Step-e: Synthesis of ethyl
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate
[0261] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (240 mg, 1.09
mmol) in 1,4-dioxane (8 mL) at 0.degree. C. was added sodium
hydride (60% dispersion in mineral oil) (109 mg, 2.74 mmol)
followed by the addition of
2-chloro-6-(trifluoromethyl)benzo[d]oxazole (290 mg, 1.31 mmol).
The reaction mixture was stirred at RT for 16 h. The reaction
mixture was concentrated, diluted with cold water (15 mL) and
stirred at RT for 30 min. The solid obtained was filtered, dried
under vacuum and purified by combiflash column chromatography using
100% DCM as an eluent to afford the title compound (150 mg, 34%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.25
(d, J=1.5 Hz, 1H), 7.89 (dd, J=1.5 Hz, J=8.3 Hz, 1H), 7.83 (s, 1H),
7.61-7.51 (m, 3H), 4.33 (q, J=6.9 Hz, 2H), 3.66 (s, 3H), 1.36 (t,
J=6.9 Hz, 3H); LC-MS: m/z 405.30 (M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid (Example 31)
[0262] To a stirred solution of ethyl
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate (80 mg, 0.20 mmol) in a mixture of solvent of
THF (0.5 mL), ethanol (0.5 mL) and water (0.25 mL) was added
lithium hydroxide monohydrate (20 mg, 0.50 mmol). The reaction
mixture was heated at 60.degree. C. for 16 h. The reaction mixture
was cooled to RT and concentrated under reduced pressure. The
residue was dissolved in water, acidified with 1 N HCl to obtain
the solid which was filtered and dried under vacuum to afford the
title compound (55 mg, 81%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.80 (bs, 1H), 12.40 (bs, 1H), 8.22 (s, 1H), 7.89 (d,
J=8.3 Hz, 1H), 7.84 (s, 1H), 7.63-7.53 (m, 3H), 3.67 (s, 3H);
LC-MS: m/z 377.05 (M+1).sup.+.
Step-g: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide (Example 32)
[0263] To a stirred solution of
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid (50 mg, 0.13 mmol) in DMFA (1.5 mL) at
0.degree. C. was added N-ethyldiisopropyl amine (0.02 mL, 0.13
mmol) and diphenylphosphoryl azide (0.02 mL, 0.13 mmol). The
reaction mixture was stirred for 30 min, followed by the addition
of 2-methoxyethylamine (0.01 mL, 0.13 mmol) and the reaction
mixture was then stirred at RT for 16 h. Once the reaction was
completed (monitored by TLC), the reaction mixture was diluted with
cold water (15 mL) and stirred for 15 min. The solid obtained was
filtered, washed with diethyl ether and dried under vacuum to
afford the title compound (28 mg, 49%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.48 (s, 1H), 8.10 (s, 1H),
7.83 (s, 1H), 7.79 (d, J=8.4 Hz, 1H), 7.61-7.51 (m, 3H), 3.67 (s,
3H), 3.48-3.44 (m, 4H), 3.30 (s, 3H); LC-MS: m/z 434.1
(M+1).sup.+.
Example 33. Synthesis of
N-(2-hydroxyethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide
##STR00037##
[0265] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials (Yield: 34%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.39
(t, J=5.3 Hz, 1H), 8.10 (s, 1H), 7.82 (s, 1H), 7.80 (d, J=8.3 Hz,
1H), 7.61-7.51 (m, 3H), 4.72 (t, J=5.2 Hz, 1H), 3.67 (s, 3H),
3.54-3.51 (m, 2H), 3.37-3.34 (m, 2H); LC-MS: m/z 420.0
(M+1).sup.+.
Example 34. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00038##
[0267] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as
starting materials (Yield: 50%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.46 (bs, 1H), 8.10 (s, 1H),
7.83 (s, 1H), 7.79 (d, J=8.3 Hz, 1H), 7.62-7.52 (m, 3H), 4.60 (bs,
1H), 3.67 (s, 3H), 3.58-3.44 (m, 8H); LC-MS: m/z 464.20
(M+1).sup.+.
Example 35. Synthesis of
N-(2-hydroxypropyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxamide
[0268] The title compound was synthesized using the same procedure
which was followed for compound 1i using 1-aminopropan-2-ol and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.35 (t, J=1.2 Hz, 1H),
8.10 (d, J=1.2 Hz, 1H), 7.82-7.79 (m, 2H), 7.61-7.51 (m, 3H), 4.76
(d, J=4.0 Hz, 1H), 3.84-3.80 (m, 1H), 3.67 (s, 3H), 3.26-3.21 (m,
2H), 1.09 (d, J=6.4 Hz, 3H); LC-MS: m/z 434.2 (M+1).sup.+.
Example 36. Synthesis of
1-methyl-N-(2-(pyrrolidin-1-yl)ethyl)-2-((6-(trifluoromethyl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0269] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-(pyrrolidin-1-yl)ethan-1-amine and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.39 (t, J=5.2 Hz, 1H),
8.09 (s, 1H), 7.82 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.61-7.51 (m,
3H), 3.66 (s, 3H), 3.43-3.38 (m, 2H), 2.61 (t, J=7.2 Hz, 2H), 2.5
(m, 4H Merged in DMSO peak), 1.69 (bs, 4H); LC-MS: m/z 473.1
(M+1).sup.+.
Example 37. Synthesis of
1-methyl-N-(2-(piperidin-1-yl)ethyl)-2-((6-(trifluoromethyl)benzo[d]oxazo-
l-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0270] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-(piperidin-1-yl)ethan-1-amine and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.32 (t, J=5.6 Hz, 1H),
8.07 (s, 1H), 7.82 (s, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.61-7.51 (m,
3H), 3.66 (s, 3H), 3.41-3.36 (m, 2H), 2.43-2.32 (m, 6H), 1.53-1.38
(m, 6H); LC-MS: m/z 487.15 (M+1).sup.+.
Example 38. Synthesis of
N-(2-(2-hydroxypropoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxa-
zol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0271] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-aminoethoxy)propan-2-ol and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.46 (t, J=5.6 Hz, 1H),
8.09 (s, 1H), 7.83 (s, 1H), 7.78 (d, J=8.8 Hz, 1H), 7.62-7.52 (m,
3H), 4.58 (d, J=4.4 Hz, 1H), 3.77-3.73 (m, 1H), 3.66 (s, 3H), 3.56
(t, J=6.0 Hz, 2H), 3.45 (t, J=5.2 Hz, 2H), 2.29-2.23 (m, 2H), 1.04
(d, J=6.4 Hz, 3H); LC-MS: m/z 478.2 (M+1).sup.+.
Example 39. Synthesis of
N-(2,3-dihydroxypropyl)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2--
yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0272] The title compound was synthesized using the same procedure
which was followed for compound 1i using 3-aminopropane-1,2-diol
and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.39 (t, J=5.2 Hz, 1H),
8.10 (s, 1H), 7.84 (s, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.62-7.53 (m,
3H), 4.87 (d, J=4.4 Hz, 1H), 4.62 (bs, 1H), 3.67 (s, 4H), 3.45-3.40
(m, 1H), 3.30 (2H merged with DMSO moisture peak), 3.25-3.19 (m,
1H); LC-MS: m/z 450.15 (M+1).sup.+.
Example 40. Synthesis of
N-(2-(2-(dimethylamino)acetamido)ethyl)-1-methyl-2-((6-(trifluoromethyl)b-
enzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0273] The title compound was synthesized using the same procedure
which was followed for Example 19 Step-c using
N-(2-aminoethyl)-2-(dimethylamino)acetamide trifluoroacetate and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.47 (bs, 1H), 8.09 (s,
1H), 7.92 (bs, 1H), 7.83 (s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.61-7.52
(m, 3H), 3.66 (s, 3H), 3.38-3.35 (m, 4H), 2.86 (s, 2H), 2.19 (s,
6H); LC-MS: m/z 504.2 (M+1).sup.+.
Example 41. Synthesis of
2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxamido)ethoxy)acetic acid
##STR00039##
[0274] Step-a: Synthesis of ethyl
2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxamido)ethoxy)acetate
[0275] The title compound was synthesized using the same procedure
which was followed for Example 29 Step-c using
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and ethyl 2-(2-aminoethoxy)acetate
trifluoraro aetate as starting materials (Yield: 65%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.38 (bs, 1H), 8.49 (bs, 1H),
8.10 (s, 1H), 7.82 (s, 1H), 7.79 (d, J=8.8 Hz, 1H), 7.61-7.52 (m,
3H), 4.15-4.09 (m, 4H), 3.66-3.62 (m, 5H), 3.48-3.46 (m, 2H), 1.19
(t, J=7.0 Hz, 3H); LC-MS: m/z 506.1 (M+1).sup.+.
Step-b: Synthesis of
2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxamido)ethoxy)acetic acid
[0276] The title compound was synthesized using the same procedure
which was followed for Example 29 Step-d using ethyl
2-(2-(1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxamido)ethoxy)acetate as starting material
(Yield: 75%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.70
(bs, 1H), 12.30 (bs, 1H), 8.49 (bs, 1H), 8.10 (s, 1H), 7.82-7.78
(m, 2H), 7.61-7.51 (m, 3H), 4.06 (s, 2H), 3.66-3.62 (m, 5H),
3.48-3.41 (m, 2H); LC-MS: m/z 478.2 (M+1).sup.+.
Example 42. Synthesis of
N-(2-(2-hydroxy-2-methylpropoxy)ethyl)-1-methyl-2-((6-(trifluoromethyl)be-
nzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0277] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-aminoethoxy)-2-methylpropan-2-ol and
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d-
]imidazole-5-carboxylic acid as starting materials. .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.83 (s, 1H), 8.08
(s, 1H), 7.81 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.58-7.52 (m, 3H),
4.32 (bs, 1H), 3.66 (s, 3H), 3.58-3.56 (m, 2H), 3.46-3.44 (m, 2H),
3.21 (s, 2H), 1.08 (s, 6H); LC-MS: m/z 492.1 (M+1).sup.+.
Example 43. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((5-(trifluoromethyl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00040##
[0278] Step-a: Synthesis of 2-nitro-4-(trifluoromethyl)phenol
[0279] To a solution of 1-chloro-2-nitro-4-(trifluoromethyl)benzene
(10.0 g, 44.3 mmol) in DMSO (100 mL) at RT was added sodium
hydroxide (4.44 g, 110.7 mmol) and the mixture was stirred at
60.degree. C. for 16 h. The reaction mixture was cooled to RT,
diluted with water (250 mL) and extracted with EtOAc (200 mL). The
aqueous layer was acidified to pH.about.1 with 3 N HCl and
extracted with EtOAc (2.times.250 mL), organic layer was washed
with brine solution (50 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum to afford the titled compound (7.0 g,
81%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.99 (bs, 1H),
8.22 (d, J=1.6 Hz, 1H), 7.88 (dd, J=2.0 Hz, J=8.8 Hz, 1H), 7.30 (d,
J=8.8 Hz, 1H).
Step-b: Synthesis of 2-amino-4-(trifluoromethyl)phenol
[0280] To a solution of 2-nitro-4-(trifluoromethyl)phenol (5.0 g,
24.15 mmol) in methanol (50 mL) was added 10% Pd/C (2.5 g) under
nitrogen atmosphere. The reaction mixture was stirred under
hydrogen balloon for 16 h. The reaction mixture was filtered
through a celite bed and the filtrate was concentrated under vacuum
to afford the title compound (3.0 g, 70%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 9.85 (bs, 1H), 6.87 (d, J=2.0 Hz, 1H),
6.77-6.70 (m, 2H), 5.0 (bs, 2H); LC-MS: m/z 178.1 (M+1).sup.+.
Step-c: Synthesis of 5-(trifluoromethyl)benzo[d]oxazole-2-thiol
[0281] To a solution of 2-amino-4-(trifluoromethyl)phenol (3.0 g,
16.9 mmol) in ethanol (45 mL) at RT was added potassium
ethyl-xanthate (6.78 g, 42.4 mmol) and the reaction mixture was
refluxed for 16 h. The reaction mixture was concentrated under
vacuum and diluted with cold water (100 mL), acidified with 3 N
HCl. The precipitated solid was filtered and dried under vacuum to
afford the title compound (3.0 g, 81%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 14.2 (bs, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.64
(d, J=8.4 Hz, 1H), 7.51 (s, 1H); LC-MS: m/z 220.0 (M+1).sup.+.
Step-d: Synthesis of
2-chloro-5-(trifluoromethyl)benzo[d]oxazole
[0282] To a solution of 5-(trifluoromethyl)benzo[d]oxazole-2-thiol
(2.0 g, 9.1 mmol) in thionyl chloride (10 mL) at RT was added
N,N-dimethyl formamide (catalytic amount) and the reaction mixture
was refluxed for 1 h. The reaction mixture concentrated, diluted
with cold water (60 mL) and extracted with EtOAc (2.times.100 mL).
The combined organic layers were washed with brine solution (50
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum to afford the title compound (1.3 g, 65%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 8.23 (s, 1H), 8.02 (d, J=8.8 Hz, 1H),
7.85 (d, J=8.8 Hz, 1H).
Step-e: Synthesis of ethyl
1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate
[0283] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (200 mg, 0.91
mmol) in 1,4-dioxane (10 mL) at 0.degree. C. was added sodium
hydride (60% dispersion in mineral oil) (91 mg, 2.27 mmol) and
stirred for 15 min followed by the addition of
2-chloro-5-(trifluoromethyl)benzo[d]oxazole (222 mg, 1.0 mmol) and
stirring was continued at RT for 16 h. The reaction mixture was
concentrated, diluted with cold water (50 mL) and acidified with 3
N HCl and extracted with ethyl acetate (2.times.50 mL). The
combined organic layers were washed with water (30 mL), brine
solution (30 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combiflash
column chromatography using 100% dichloromethane as an eluent to
afford the titled compound (150 mg, 40%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.41 (bs, 1H), 8.25 (s, 1H), 7.90 (dd,
J=1.2 Hz, J=8.4 Hz, 1H), 7.67-7.64 (m, 2H), 7.57 (d, J=8.4 Hz, 1H),
7.49 (d, J=8.4 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.66 (s, 3H), 1.35
(t, J=7.2 Hz, 3H); LC-MS: m/z 405.00 (M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0284] To a stirred solution ethyl
1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate (150 mg, 0.37 mmol) in a mixture of solvents
of THF (2 mL), methanol (2 mL) and water (2 mL) was added lithium
hydroxide monohydrate (78 mg, 1.85 mmol). The reaction mixture was
heated at 50.degree. C. for 16 h. The reaction mixture was cooled
to RT and concentrated under reduced pressure. The residue was
dissolved in water (30 mL), acidified to pH.about.2 with 3 N HCl
and stirred for 1 h. The solid precipitated was filtered and dried
under vacuum to afford the title compound (140 mg, 100%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.85 (bs, 1H), 12.40 (bs,
1H), 8.18 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.67 (s, 1H), 7.63 (d,
J=8.4 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.46 (d, J=8.0 Hz, 1H), 3.64
(s, 3H); LC-MS: m/z 377.1 (M+1).sup.+.
Step-g: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((5-(trifluoromethyl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0285] To a stirred solution of
1-methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid (80 mg, 0.21 mmol) in DMFA (5 mL) at
0.degree. C. was added N-ethyldiisopropyl amine (0.04 mL, 0.21
mmol) and HBTU (81 mg, 0.21 mmol). The reaction mixture was stirred
for 15 min, followed by the addition of 2-(2-aminoethoxy)ethan-1-ol
(22 mg, 0.21 mmol). The reaction mixture was then stirred at RT for
16 h. Once the reaction was completed (monitored by TLC), the
reaction mixture was diluted with cold water (30 mL) and stirred
for 1 h. The solid precipitated was filtered and dried under
vacuum. The solid was stirred in diethyl ether (15 mL), filtered
and dried under vacuum to afford the titled compound (80 mg, 85%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.33 (bs, 1H), 8.46
(t, J=5.4 Hz, 1H), 8.09 (d, J=1.2 Hz, 1H), 7.78 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.68 (s, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.52 (d, J=8.0
Hz, 1H), 7.48 (d, J=8.4 Hz, 1H), 4.60 (t, J=5.2 Hz, 1H), 3.66 (s,
3H), 3.58-3.43 (m, 8H); LC-MS: m/z 464.2 (M+1).sup.+.
Examples 44 and 45. Synthesis of
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxamide
##STR00041##
[0286] Step-a: Synthesis of 2-nitro-5-(trifluoromethoxy)phenol
[0287] To a solution of 3-(trifluoromethoxy)phenol (1 g, 5.6 mmol)
in acetic acid (10 mL) was added 60% aqueous nitric acid (1 mL)
dropwise at 10.about.15.degree. C. The mixture was stirred at this
temperature for 1.5 h and continued to stir at RT for 16 h. The
mixture was poured into ice water (20 mL) and extracted with EtOAc
(2.times.25 mL). The combined organic layers were washed with brine
solution (25 mL), dried over anhydrous sodium sulfate and
concentrated in vacuum. The residue was purified by combiflash
chromatography using 5% EtOAc in hexanes as eluent to afford the
title compound (300 mg, 24%); .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 10.73 (s, 1H), 8.18 (d, J=9.6 Hz, 1H), 6.99 (s, 1H), 6.83
(d, J=9.2 Hz, 1H); LC-MS: m/z 222.0 (M-1).
Step-b: Synthesis of 2-amino-5-(trifluoromethoxy)phenol
[0288] To a solution of 2-nitro-5-(trifluoromethoxy)phenol (300 mg,
1.35 mmol) in methanol (6 mL) was added 10% Pd/C (60 mg) under
nitrogen atmosphere. The reaction mixture was stirred under
hydrogen gas for 5 h. The reaction mixture was filtered through a
bed of celite and concentrated under vacuum to afford the title
compound (250 mg, 96%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 9.60 (s, 1H), 6.59-6.57 (m, 2H), 6.53-6.50 (m, 1H), 4.68
(bs, 2H); LC-MS: m/z 194.0 (M+1).sup.+.
Step-c: Synthesis of
6-(trifluoromethoxy)benzo[d]oxazole-2-thiol
[0289] To a solution of 2-amino-5-(trifluoromethoxy)phenol (250 mg,
1.3 mmol) in ethanol (5 mL) at RT was added powdered potassium
hydroxide (127 mg, 2.3 mmol) and carbon disulfide (1 mL, 17.0
mmol). The reaction mixture was refluxed for 6 h. After cooling to
RT, the mixture was concentrated in vacuo. The residue was diluted
with cold water (100 mL), acidified with 1 N HCl. The solid
obtained was filtered and dried under vacuum to afford the title
compound (200 mg, 66%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 14.10 (bs, 1H), 7.73 (s, 1H), 7.32 (s, 2H); LC-MS: m/z
235.9 (M+1).sup.+.
Step-d: Synthesis of
2-(methylthio)-6-(trifluoromethoxy)benzo[d]oxazole
[0290] The title compound was synthesized using the same procedure
which was followed for compound 1b using
6-(trifluoromethoxy)benzo[d]oxazole-2-thiol as starting material
and stirring at RT for 16 h (Yield: 94%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.85 (d, J=1.6 Hz, 1H), 7.73 (d, J=8.0 Hz,
1H), 7.37-7.34 (m, 1H), 2.77 (s, 3H); LC-MS: m/z 250.1
(M+1).sup.+.
Step-e: Synthesis of
2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole
[0291] The title compound was synthesized using the same procedure
which was followed for compound 1c using
2-(methylthio)-6-(trifluoromethoxy)benzo[d]oxazole as starting
material and stirring at RT for 6 h (Yield: 94%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 8.22 (s, 1H), 8.15 (d, J=8.8 Hz, 1H),
7.62 (d, J=8.8 Hz, 1H), 3.67 (s, 3H).
Step-f: Synthesis of ethyl
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylate
[0292] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (100 mg, 0.46
mmol) in 1,4-dioxane (2 mL) at RT was added sodium hydride (60%
dispersion in mineral oil) (64 mg, 1.6 mmol) followed by the
addition of 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole
(167 mg, 0.6 mmol). The reaction mixture was stirred at RT for 16
h. It was then concentrated, diluted with cold water (15 mL) and
acidified with 1 N HCl. The solid obtained was filtered, dried
under vacuum and purified by combiflash column chromatography using
100% DCM as an eluent to afford the title compound (30 mg, 16%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.40 (bs, 1H), 8.24
(s, 1H), 7.89 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.58-7.50 (m, 3H), 7.22
(d, J=8.0 Hz, 1H), 4.33 (q, J=7.6 Hz, 2H), 3.65 (s, 3H), 1.35 (t,
J=7.2 Hz, 3H); LC-MS: m/z 421.0 (M+1).sup.+.
Step-g: Synthesis of
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid
[0293] The title compound was synthesized using the same procedure
which was followed for compound 1h, using ethyl
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylate as starting material (Yield: 72%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.80 (bs, 1H), 12.30 (bs,
1H), 8.20 (s, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.58 (s, 1H), 7.52 (d,
J=8.8 Hz, 2H), 7.22 (d, J=8.0 Hz, 1H), 3.65 (s, 3H); LC-MS: m/z
393.0 (M+1).sup.+.
Step-h: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)
benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0294] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting material (Yield: 23%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.47
(t, J=5.2 Hz, 1H), 8.08 (s, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.57 (s,
1H), 7.52-7.49 (m, 2H), 7.21 (d, J=8.4 Hz, 1H), 3.64 (s, 3H),
3.48-3.44 (m, 4H), 3.28 (s, 3H); LC-MS: m/z 450.0 (M+1).sup.+.
Example 46. Synthesis of
1-methyl-N-(1H-pyrazol-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxamide
[0295] The title compound was synthesized using the same procedure
which was followed for compound 1i using 1H-pyrazol-4-amine and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.65 (bs, 1H), 12.30 (bs, 1H), 10.40
(s, 1H), 8.17 (d, J=1.2 Hz, 1H), 8.02 (bs, 1H), 7.89 (dd, J=1.2 Hz,
J=8.4 Hz, 1H), 7.69 (bs, 1H), 7.58-7.49 (m, 3H), 7.21 (d, J=8.4 Hz,
1H), 3.67 (s, 3H); LC-MS: m/z 458.0 (M+1).sup.+.
Example 47. Synthesis of
N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-1-methyl-2-((6-(trifluorom-
ethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0296] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-amino-2-(hydroxymethyl)propane-1,3-diol and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.05 (s, 1H), 7.43 (d,
J=8.4 Hz, 1H), 7.57 (s, 1H), 7.50 (d, J=5.8 Hz, 2H), 7.26 (s, 1H),
7.21 (d, J=8.4 Hz, 1H), 4.83 (bs, 3H), 3.71 (bs, 6H), 3.65 (s, 3H);
LC-MS: m/z 496.3 (M+1).sup.+.
Example 48. Synthesis of
N-(1,3-dihydroxypropan-2-yl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxa-
zol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0297] The title compound was synthesized using the same procedure
which was followed for compound 1i using 2-amino-propane-1,3-diol
and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.09 (s, 1H), 7.88 (d,
J=7.6 Hz, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.57 (d, J=1.2 Hz, 1H), 7.51
(d, J=8.0 Hz, 2H), 7.21 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 4.66 (t,
J=6.0 Hz, 2H), 4.00-3.95 (m, 1H), 3.65 (s, 3H), 3.54 (t, J=6.0 Hz,
4H); LC-MS: m/z 466.0 (M+1).sup.+.
Example 49. Synthesis of
N-(2-(2-(dimethylamino)acetamido)ethyl)-1-methyl-2-((6-(trifluoromethoxy)-
benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0298] The title compound was synthesized using the same procedure
which was followed for Example 19 Step-c using
N-(2-aminoethyl)-2-(dimethylamino)acetamide trifluoroacetate and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.0 (bs, 1H), 8.45 (t, J=4.4 Hz, 1H),
8.07 (s, 1H), 7.91 (t, J=5.6 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.56
(s, 1H), 7.50 (d, J=8.4 Hz, 2H), 7.21 (d, J=8.0 Hz, 1H), 3.64 (s,
3H), 3.36 (t, J=5.6 Hz, 2H), 3.30 (2H merged with DMSO moisture
peak), 2.85 (s, 2H), 2.18 (s, 6H); LC-MS: m/z 520.5
(M+1).sup.+.
Example 50. Synthesis of
1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxa-
zol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0299] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-1H-pyrazol-4-amine and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 10.40 (s, 1H), 8.17 (s,
1H), 8.03 (s, 1H), 7.88 (d, J=8.0 Hz, 1H), 7.58-7.51 (m, 4H), 7.22
(d, J=7.6 Hz, 1H), 3.83 (s, 3H), 3.66 (s, 3H); LC-MS: m/z 472.0
(M+1).sup.+.
Example 51. Synthesis of
1-methyl-N-(oxetan-3-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amin-
o)-1H-benzo[d]imidazole-5-carboxamide
[0300] The title compound was synthesized using the same procedure
which was followed for compound 1i using oxetan-3-amine and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 9.07 (d, J=6.0 Hz, 1H),
8.10 (s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.57 (s, 1H), 7.52 (t, J=8.8
Hz, 2H), 7.21 (d, J=8.4 Hz, 1H), 5.05-5.00 (m, 1H), 4.78 (t, J=6.4
Hz, 2H), 4.62 (t, J=6.4 Hz, 2H), 3.65 (s, 3H); LC-MS: m/z 448.0
(M+1).sup.+.
Example 52. Synthesis of
N-((3-hydroxyoxetan-3-yl)methyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d-
]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0301] The title compound was synthesized using the same procedure
which was followed for compound 1i using 3-(aminomethyl)oxetan-3-ol
and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.54 (t, J=6.0 Hz, 1H),
8.10 (d, J=1.2 Hz, 1H), 7.80 (dd, J=1.2 Hz, J=8.8 Hz, 1H), 7.57 (d,
J=1.6 Hz, 1H), 7.53-7.49 (m, 2H), 7.21 (dd, J=1.6 Hz, J=8.8 Hz,
1H), 5.88 (s, 1H), 4.52 (d, J=6.4 Hz, 2H), 4.41 (d, J=6.4 Hz, 2H),
3.65 (s, 3H), 3.59 (d, J=6.0 Hz, 2H); LC-MS: m/z 478.2
(M+1).sup.+.
Example 53. Synthesis of
N-(2-hydroxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxamide
[0302] The title compound was synthesized using the same procedure
which was followed for compound 1i using 2-aminoethan-1-ol and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.38 (t, J=5.2 Hz, 1H),
8.09 (d, J=1.2 Hz, 1H), 7.78 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 7.57 (s,
1H), 7.52-7.49 (m, 2H), 7.22 (d, J=8.0 Hz, 1H), 4.72 (t, J=5.2 Hz,
1H), 3.64 (s, 3H), 3.54 (q, J=6.0 Hz, 2H), 3.37-3.30 (m, 2H);
LC-MS: m/z 436.0 (M+1).sup.+.
Example 54. Synthesis of
1-methyl-N-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0303] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-(methylsulfonyl)ethan-1-amine hydrochloride and
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.68 (t, J=5.2 Hz, 1H),
8.09 (d, J=1.6 Hz, 1H), 7.76 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.57 (s,
1H), 7.53-7.50 (m, 2H), 7.27-7.20 (m, 1H), 3.70 (q, J=6.0 Hz, 2H),
3.65 (s, 3H), 3.40 (t, J=6.8 Hz, 2H), 3.05 (s, 3H); LC-MS: m/z
497.9 (M+1).sup.+.
Examples 55 and 56. Synthesis of
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and Synthesis of
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
##STR00042##
[0304] Step-a: Synthesis of 5-(2-methoxyethoxy)-2-nitrophenol
[0305] To a stirred 2-methoxyethan-1-ol (50 mL) at 0.degree. C. was
added sodium metal (2.29 g, 95.46 mmol) and the reaction mixture
was allowed to stir at RT for 30 min, followed by the addition of
5-fluoro-2-nitrophenol (5.0 g, 31.82 mmol). The reaction mixture
was heat to 100.degree. C. for 16 h. Once the reaction was
completed (monitored by TLC), the reaction mixture was cooled to
0.degree. C., diluted with cold water (200 mL) and acidified with 1
N HCl. The solid obtained was filtered and dried under vacuum to
afford the title compound (4.0 g, 59%) as a yellow solid; .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 10.93 (s, 1H), 7.96 (d, J=9.3
Hz, 1H), 6.64-6.58 (m, 2H), 4.19-4.17 (m, 2H), 3.67-3.65 (m, 2H),
3.30 (s, 3H).
Step-b: Synthesis of 2-amino-5-(2-methoxyethoxy)phenol
[0306] The title compound was synthesized using the same procedure
which was followed for compound 1e using
5-(2-methoxyethoxy)-2-nitrophenol as starting material (Yield:
96%); LC-MS: m/z 184.1 (M+1).sup.+.
Step-c: Synthesis of 6-(2-methoxyethoxy)benzo[d]oxazole-2-thiol
[0307] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-(2-methoxyethoxy)phenol as starting material (Yield:
76%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.78 (s, 1H),
7.29 (d, J=2.4 Hz, 1H), 7.19 (d, J=8.8 Hz, 1H), 6.96 (dd, J=2.4 Hz,
J=8.8 Hz, 1H), 4.18-4.16 (m, 2H), 3.73-3.71 (m, 2H), 3.36 (s, 3H);
LC-MS: m/z 226.0 (M+1).sup.+.
Step-d: Synthesis of
2-chloro-6-(2-methoxyethoxy)benzo[d]oxazole
[0308] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-(2-methoxyethoxy)benzo[d]oxazole-2-thiol as starting material and
stirred for 2 h (Yield: 69%); LC-MS: m/z 228.05 (M+1).sup.+.
Step-e: Synthesis of ethyl
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylate
[0309] The title compound was synthesized using the same procedure
which was followed for compound Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-(2-methoxyethoxy)benzo[d]oxazole as starting materials
(Yield: 24%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20
(bs, 1H), 8.21 (d, J=1.5 Hz, 1H), 7.86 (dd, J=1.5 Hz, J=8.3 Hz,
1H), 7.49 (d, J=8.3 Hz, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.14 (d, J=2.4
Hz, 1H), 6.83 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H),
4.12 (t, J=4.6 Hz, 2H), 3.67 (t, J=4.6 Hz, 2H), 3.62 (s, 3H), 3.32
(s, 3H), 1.35 (t, J=7.1 Hz, 3H); LC-MS: m/z 411.0 (M+1).sup.+.
Step-f: Synthesis of
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0310] The title compound was synthesized using the same procedure
which was followed for compound 1h, using ethyl
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylate as starting material (Yield: 77%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.15 (bs, 2H), 8.17 (d, J=1.5 Hz,
1H), 7.85 (dd, J=2.0 Hz, J=8.8 Hz, 1H), 7.47 (d, J=8.3 Hz, 1H),
7.36 (d, J=8.3 Hz, 1H), 7.13 (d, J=2.4 Hz, 1H), 6.82 (dd, J=2.4 Hz,
J=8.3 Hz, 1H), 4.12 (t, J=4.6 Hz, 2H), 3.67 (t, J=4.6 Hz, 2H), 3.62
(s, 3H), 3.32 (s, 3H); LC-MS: m/z 383.0 (M+1).sup.+.
Step-g: Synthesis of
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
[0311] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting material (Yield: 29%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.15 (bs, 1H), 8.44 (t, J=5.4
Hz, 1H), 8.05 (d, J=1.5 Hz, 1H), 7.75 (dd, J=1.4 Hz, J=8.3 Hz, 1H),
7.45 (d, J=8.3 Hz, 1H), 7.35 (d, J=8.3 Hz, 1H), 7.13 (d, J=2.4 Hz,
1H), 6.82 (dd, J=2.4 Hz, J=8.3 Hz, 1H), 4.12-4.10 (m, 2H),
3.68-3.66 (m, 2H), 3.62 (s, 3H), 3.49-3.43 (m, 4H), 3.32 (s, 3H),
3.28 (s, 3H); LC-MS: m/z 440.60 (M+1).sup.+.
Example 57. Synthesis of
N-(2-hydroxyethyl)-2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
##STR00043##
[0313] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting material (Yield: 27%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.16 (bs, 1H), 8.35 (t, J=5.4
Hz, 1H), 8.05 (d, J=1.0 Hz, 1H), 7.75 (dd, J=1.5 Hz, J=8.3 Hz, 1H),
7.45 (d, J=8.3 Hz, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.12 (d, J=2.4 Hz,
1H), 6.81 (dd, J=2.5 Hz, J=8.4 Hz, 1H), 4.72 (bs, 1H), 4.11 (t,
J=4.6 Hz, 2H), 3.67 (t, J=4.6 Hz, 2H), 3.61 (s, 3H), 3.53 (t, J=5.3
Hz, 2H), 3.35 (t, J=6.0 Hz, 2H), 3.32 (s, 3H); LC-MS: m/z 426.45
(M+1).sup.+.
Example 58. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)a-
mino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00044##
[0315] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as
starting materials (Yield: 61%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.15 (bs, 1H), 8.41 (t, J=5.4 Hz, 1H), 8.05
(d, J=0.9 Hz, 1H), 7.74 (dd, J=1.5 Hz, J=8.3 Hz, 1H), 7.45 (d,
J=8.3 Hz, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.12 (d, J=1.9 Hz, 1H), 6.82
(dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.60 (bs, 1H), 4.13 (t, J=4.6 Hz,
2H), 3.67 (t, J=4.6 Hz, 2H), 3.62 (s, 3H), 3.57-3.42 (m, 8H), 3.32
(s, 3H); LC-MS: m/z 470.25 (M+1).sup.+.
Examples 59 and 60. Synthesis of
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-
-carboxylic acid and Synthesis of
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H--
benzo[d]imidazole-5-carboxamide
##STR00045##
[0316] Step-a: Synthesis of 5-isopropyl-2-nitrophenol
[0317] To a solution of 3-isopropylphenol (2.0 g, 14.7 mmol) in DCM
(30 mL) and 3 M sulfuric acid (25 mL) was added sodium nitrate
(1.37 g, 16.18 mmol) and sodium nitrite (10 mg, 0.14 mmol) at RT.
Then the mixture was stirred for 24 h. The mixture was poured into
ice water (100 mL) and extracted with DCM (2.times.50 mL). The
combined organic layers were washed with brine solution (50 mL),
dried over anhydrous sodium sulfate and concentrated in vacuum. The
residue was purified by combiflash chromatography using 5% ethyl
acetate in hexane as eluent to afford the titled compound (500 mg,
19%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.76 (s, 1H),
7.86 (d, J=8.8 Hz, 1H), 6.98 (d, J=1.5 Hz, 1H), 6.89 (dd, J=1.5 Hz,
J=8.3 Hz, 1H), 2.92-2.89 (m, 1H), 1.19 (d, J=6.9 Hz, 6H); LC-MS:
m/z 180.0 (M-1).
Step-b: Synthesis of 2-amino-5-isopropylphenol
[0318] The title compound was synthesized using the same procedure
which was followed for compound 1e using 5-isopropyl-2-nitrophenol
as starting material (Yield: 86%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.88 (bs, 1H), 6.50 (dd, J=1.9 Hz, J=10.7
Hz, 1H), 6.41 (d, J=2.0 Hz, 1H), 6.39 (d, J=2.0 Hz, 1H), 4.25 (s,
2H), 2.68-2.61 (m, 1H), 1.10 (d, J=6.8 Hz, 6H); LC-MS: m/z 152.15
(M+1).sup.+.
Step-c: Synthesis of 6-isopropylbenzo[d]oxazole-2-thiol
[0319] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-isopropylphenol as starting material (Yield: 68%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.74 (s, 1H), 7.41
(s, 1H), 7.20-7.13 (m, 2H), 3.0-2.93 (m, 1H), 1.21 (d, J=6.9 Hz,
6H); LC-MS: m/z 194.15 (M+1).sup.+.
Step-d: Synthesis of 2-chloro-6-isopropylbenzo[d]oxazole
[0320] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-isopropylbenzo[d]oxazole-2-thiol as starting material and stirred
for 2 h (Yield: 85%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.17 (s, 1H), 7.02-6.97 (m, 2H), 2.96-2.86 (m, 1H), 1.19 (d, J=6.8
Hz, 6H); LC-MS: m/z 196.0 (M+1).sup.+.
Step-e: Synthesis of ethyl
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-
-carboxylate
[0321] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-isopropylbenzo[d]oxazole as starting materials (Yield:
77%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.15 (bs, 1H),
8.22 (d, J=1.0 Hz, 1H), 7.86 (dd, J=1.0 Hz, J=8.3 Hz, 1H), 7.50 (d,
J=8.3 Hz, 1H), 7.38 (d, J=8.3 Hz, 1H), 7.33 (s, 1H), 7.11 (d, J=7.8
Hz, 1H), 4.33 (q, J=7.0 Hz, 2H), 3.63 (s, 3H), 3.01-2.95 (m, 1H),
1.35 (t, J=7.0 Hz, 3H), 1.25 (d, J=6.8 Hz, 6H); LC-MS: m/z 379.1
(M+1).sup.+.
Step-f: Synthesis of
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-
-carboxylic acid
[0322] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-
-carboxylate as starting material and stirring at 60.degree. C. for
5 h (Yield: 92%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
12.20 (bs, 2H), 8.18 (s, 1H), 7.86 (d, J=8.3 Hz, 1H), 7.49 (d,
J=8.3 Hz, 1H), 7.39 (d, J=7.8 Hz, 1H), 7.33 (s, 1H), 7.10 (d, J=7.8
Hz, 1H), 3.63 (s, 3H), 2.98-2.97 (m, 1H), 1.25 (d, J=6.8 Hz, 6H);
LC-MS: m/z 351.20 (M+1).sup.+.
Step-g: Synthesis of
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H--
benzo[d]imidazole-5-carboxamide
[0323] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-
-carboxylic acid as starting material (Yield: 69%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.15 (bs, 1H), 8.44 (s, 1H), 8.07
(s, 1H), 7.75 (d, J=8.3 Hz, 1H), 7.46 (d, J=8.3 Hz, 1H), 7.37 (d,
J=8.3 Hz, 1H), 7.32 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 3.63 (s, 3H),
3.48-3.44 (m, 4H), 3.28 (s, 3H), 2.98-2.97 (m, 1H), 1.25 (d, J=6.8
Hz, 6H); LC-MS: m/z 408.0 (M+1).sup.+.
Example 61. Synthesis of
N-(2-hydroxyethyl)-2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H--
benzo[d]imidazole-5-carboxamide
[0324] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-isopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-
-carboxylic acid and 2-aminoethan-1-ol as starting materials.
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.50 (bs, 1H), 8.43
(bs, 1H), 8.08 (s, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.55 (d, J=8.2 Hz,
1H), 7.38-7.36 (m, 2H), 7.16 (d, J=8.0 Hz, 1H), 3.67 (s, 3H), 3.54
(d, J=5.6 Hz, 2H), 3.36 (q, J=6.0 Hz, 2H), 3.02-2.99 (m, 1H), 1.25
(d, J=7.2 Hz, 6H); LC-MS: m/z 394.0 (M+1).sup.+.
Example 62. Synthesis of
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid
##STR00046##
[0325] Step-a: Synthesis of
2-(benzyloxy)-4-fluoro-1-nitrobenzene
[0326] To a stirred solution of 5-fluoro-2-nitrophenol (10 g, 63.7
mmol) in DMFA (100 mL) at RT was added potassium carbonate (10.54
g, 76.43 mmol) and benzyl bromide (7.56 mL, 63.7 mmol). The
reaction mixture was then stirred at RT for 16 h. Once the reaction
was completed (monitored by TLC), the reaction mixture was diluted
with water (300 mL) and extracted with ethylacetate (2.times.100
mL). The combined organic layers were washed with cold water
(2.times.200 mL), brine solution (100 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
purified by combiflash column chromatography using 5% EtOAc in
hexane as eluent to afford the titled compound (12.0 g, 76%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.04 (dd, J=5.8 Hz,
J=9.3 Hz, 1H), 7.48-7.34 (m, 6H), 7.02-6.97 (m, 1H), 5.33 (s,
2H).
Step-b: Synthesis of 3-(benzyloxy)-4-nitrophenol
[0327] To a stirred solution of KOH (7.93 g, 141.7 mmol) in water
(70 mL) at RT was added 2-(benzyloxy)-4-fluoro-1-nitrobenzene (7.0
g, 28.3 mmol) and the reaction mixture was stirred at 100.degree.
C. for 30 h. The reaction mixture was cooled to RT, diluted with
water (100 mL), acidified with 3N HCl and extracted with ethyl
acetate (3.times.50 mL). The combined organic layers were washed
with brine solution (50 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was purified by
combiflash column chromatography using 20% EtOAc in hexane as
eluent to afford the titled compound (2.0 g, 29%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 10.88 (s, 1H), 7.90 (d, J=8.8 Hz, 1H),
7.47 (t, J=7.4 Hz, 2H), 7.41-7.39 (m, 2H), 7.36-7.32 (m, 1H), 6.69
(d, J=2.0 Hz, 1H), 6.49 (dd, J=2.4 Hz, J=9.3 Hz, 1H), 5.25 (s, 2H);
LC-MS: m/z 244.0 (M-1).
Step-c: Synthesis of
2-(benzyloxy)-4-(difluoromethoxy)-1-nitrobenzene
[0328] To a stirred solution of 3-(benzyloxy)-4-nitrophenol (1.1 g,
4.49 mmol) in acetonitrile (6 mL) at 0.degree. C. was added
potassium hydroxide (5.02 g, 89.79 mmol) in water (6 mL) and
diethyl (bromodifluoromethyl) phosphonate (1.58 mL, 8.98 mmol). The
reaction mixture was stirred at RT for 1 h and diluted with water
(100 mL). The reaction mixture was extracted with ethyl acetate
(3.times.60 mL). The combined organic layers were washed with brine
solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combiflash
column chromatography using 10% EtOAc in hexane as eluent to afford
the titled compound (1.2 g, 91%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.04 (d, J=9.3 Hz, 1H), 7.64-7.27 (m, 6H),
7.26 (d, J=2.5 Hz, 1H), 6.93 (dd, J=2.5 Hz, J=8.8 Hz, 1H), 5.34 (s,
2H).
Step-d: Synthesis of 2-amino-5-(difluoromethoxy)phenol
[0329] To a solution of
2-(benzyloxy)-4-(difluoromethoxy)-1-nitrobenzene (1.2 g, 4.07 mmol)
in methanol (20 mL) was added 10% Pd/C (300 mg) under nitrogen
atmosphere. The reaction mixture was stirred under hydrogen balloon
for 16 h. The reaction mixture was filtered through a bed of celite
and concentrated under vacuum to afford the title compound (600 mg,
84%); LC-MS: m/z 176.0 (M+1).sup.+.
Step-e: Synthesis of 6-(difluoromethoxy)benzo[d]oxazole-2-thiol
[0330] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-(difluoromethoxy)phenol as starting material (Yield:
81%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.96 (bs, 1H),
7.49 (d, J=2.0 Hz, 1H), 7.26 (d, J=8.3 Hz, 1H), 7.21 (t, J=73.2 Hz,
1H), 7.13 (dd, J=2.4 Hz, J=8.8 Hz, 1H); LC-MS: m/z 218.0
(M+1).sup.+.
Step-f: Synthesis of
2-chloro-6-(difluoromethoxy)benzo[d]oxazole
[0331] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-(difluoromethoxy)benzo[d]oxazole-2-thiol as starting material and
stirred for 2 h (Yield: 82%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.80 (d, J=8.8 Hz, 1H), 7.74 (d, J=2.5 Hz, 1H), 7.29-7.27
(m, 2H).
Step-g: Synthesis of ethyl
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylate
[0332] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-(difluoromethoxy)benzo[d]oxazole as starting materials
(Yield: 27%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20
(bs, 1H), 8.23 (d, J=1.0 Hz, 1H), 7.88 (dd, J=1.5 Hz, J=8.4 Hz,
1H), 7.53 (d, J=8.3 Hz, 1H), 7.46 (d, J=8.3 Hz, 1H), 7.38-7.37 (m,
1H), 7.19 (s, 1H), 7.07-7.00 (m, 1H), 4.33 (q, J=7.0 Hz, 2H), 3.64
(s, 3H), 1.35 (t, J=7.1 Hz, 3H); LC-MS: m/z 403.0 (M+1).sup.+.
Step-h: Synthesis of
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0333] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylate as starting material (Yield: 93%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.80 (bs, 1H), 12.40 (bs, 1H),
8.19 (d, J=1.0 Hz, 1H), 7.87 (dd, J=1.4 Hz, J=8.3 Hz, 1H),
7.52-7.46 (m, 2H), 7.38-7.00 (m, 3H), 3.64 (s, 3H); LC-MS: m/z
375.0 (M+1).sup.+.
Example 63. Synthesis of
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
[0334] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-methoxyethan-1-amine as starting
materials; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.25 (bs,
1H), 8.45 (t, J=5.2 Hz, 1H), 8.07 (s, 1H), 7.77 (d, J=8.4 Hz, 1H),
7.49-7.45 (m, 2H), 7.37 (s, 1H), 7.18 (s, 1H), 7.06-7.00 (m, 1H),
3.63 (s, 3H), 3.48-3.44 (m, 4H), 3.28 (s, 3H); LC-MS: m/z 432.0
(M+1).sup.+.
Example 64. Synthesis of
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
[0335] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(difluoromethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-aminoethan-1-ol as starting
materials; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs,
1H), 8.38 (t, J=5.6 Hz, 1H), 8.08 (s, 1H), 7.78 (d, J=8.4 Hz, 1H),
7.50 (d, J=8.4 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.38-7.00 (m, 3H),
3.64 (s, 3H), 3.53 (t, J=6.4 Hz, 2H), 3.35 (q, J=6.0 Hz, 2H);
LC-MS: m/z 418.0 (M+1).sup.+.
Example 65. Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((5-methylbenzo[d]oxazol-2-yl)amino)-1H-ben-
zo[d]imidazole-5-carboxamide
##STR00047## ##STR00048##
[0336] Step-a: Synthesis of 2-amino-4-methylphenol
[0337] To a solution of 4-methyl-2-nitrophenol (1.75 g, 11.4 mmol)
in methanol (15 mL) was added a slurry of 10% Pd/C (500 mg in 5 mL
methanol) under nitrogen atmosphere. Then the reaction mixture was
stirred under hydrogen gas balloon for 16 h. The reaction mixture
was filtered through a bed of celite and concentrated under vacuum
to afford the title compound (1.3 g, 93%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.62 (bs, 1H), 6.49 (d, J=8.0 Hz, 1H), 6.38
(s, 1H), 6.17 (d, J=8.0 Hz, 1H), 4.36 (bs, 2H), 2.07 (s, 3H);
LC-MS: m/z 124.2 (M+1).sup.+.
Step-b: Synthesis of 5-methylbenzo[d]oxazole-2-thiol
[0338] To a solution of 2-amino-4-methylphenol (1.3 g, 10.5 mmol)
in ethanol (15 mL) at RT was added potassium ethyl-xanthate (3.7 g,
22.2 mmol) and the reaction mixture was refluxed for 16 h. The
reaction mixture was concentrated under vacuum and diluted with
cold water (30 mL), acidified with 1 N HCl. The solid obtained was
filtered and dried under vacuum to afford the title compound (1.3
g, 75%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.78 (s,
1H), 7.37 (d, J=8.0 Hz, 1H), 7.07-7.05 (m, 2H), 2.36 (s, 3H);
LC-MS: m/z 166.1 (M+1).sup.+.
Step-c: Synthesis of 5-methyl-2-(methylthio)benzo[d]oxazole
[0339] To a solution of 5-methylbenzo[d]oxazole-2-thiol (1.3 g, 7.9
mmol) in acetonitrile (15 mL) at 0.degree. C. was added potassium
carbonate (1.3 g, 9.4 mmol) and methyl iodide (0.53 mL, 8.7 mmol)
and the reaction mixture was stirred at RT for 3 h. The reaction
mixture was concentrated under vacuum and diluted with water (30
mL), acidified with 1 N HCl. The solid obtained was filtered and
dried under vacuum to afford the title compound (1.4 g, 99%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.50 (d, J=8.0 Hz,
1H), 7.43 (s, 1H), 7.11 (d, J=8.4 Hz, 1H), 2.74 (s, 3H), 2.40 (s,
3H); LC-MS: m/z 180.1 (M+1).sup.+.
Step-d: Synthesis of 5-methyl-2-(methylsulfonyl)benzo[d]oxazole
[0340] To a solution of 5-methyl-2-(methylthio)benzo[d]oxazole (350
mg, 1.95 mmol) in DCM (10 mL) at 0.degree. C. was added
meta-chloroperbenzoic acid (2.14 g, 6.8 mmol) and the reaction
mixture was stirred at RT for 3 h. The reaction mixture was diluted
with DCM (100 mL), washed with saturated sodium bicarbonate
solution (2.times.30 mL), aqueous 1N sodium hydroxide (30 mL),
water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum to afford the product which was
immediately used in the next step without any further purification
(340 mg); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.84-7.79
(m, 2H), 7.49 (d, J=8.4 Hz, 1H), 3.65 (s, 3H), 2.48 (s, 3H).
Step-e: Synthesis of 4-chloro-3-nitrobenzoyl chloride
[0341] To a solution of 4-chloro-3-nitrobenzoic acid (15.0 g, 74.6
mmol) in DCM (150 mL) at 10.degree. C. was added thionyl chloride
(15.9 mL, 223.8 mmol) and DMFA (1 mL) and the reaction mixture was
refluxed for 4 h. The reaction mixture was concentrated under
vacuum to afford the product which was immediately used in the next
step without any further purification (15.0 g).
Step-f: Synthesis of
4-chloro-N-(2-methoxyethyl)-3-nitrobenzamide
[0342] To a solution of 2-methoxyethan-1-amine (5.1 g, 68.2 mmol)
in DCM (60 mL) at 0.degree. C. was added triethylamine (20 mL,
138.6 mmol) and stirred for 10 min. Then a solution of
4-chloro-3-nitrobenzoyl chloride (15.0 g, 68.2 mmol) in DCM (50 mL)
was added to the reaction mixture and stirred the contents at RT
for 16 h. The reaction mixture was diluted with DCM (150 mL) and
water (100 mL). Organic layer was separated and washed with water
(150 mL), brine (100 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the title compound (18.5 g,
100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.88 (bs, 1H),
8.51 (d, J=2.0 Hz, 1H), 8.14 (dd, J=2.0 Hz, J=8.4 Hz, 1H), 7.90 (d,
J=8.4 Hz, 1H), 3.49-3.42 (m, 4H), 3.30 (s, 3H).
Step-g: Synthesis of
N-(2-methoxyethyl)-4-(methylamino)-3-nitrobenzamide
[0343] To a solution of
4-chloro-N-(2-methoxyethyl)-3-nitrobenzamide (18.0 g, 69.8 mmol) in
DMFA (180 mL) at 0.degree. C. was added DIPEA (12.5 mL, 69.8 mmol)
and 2 M methyl amine in THF (70 mL, 139.3 mmol). The reaction
mixture was stirred at 70.degree. C. for 24 h. The reaction mixture
was cooled to RT, diluted with water (200 mL) and extracted with
EtOAc (2.times.250 mL). The combined organic layers were washed
with water (100 mL), brine (100 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to give the product which was
used in the next step without further purification (17.0 g, 96%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.65 (d, J=2.0 Hz,
1H), 8.54 (t, J=5.2 Hz, 1H), 8.42 (d, J=4.8 Hz, 1H), 8.02 (dd,
J=1.6 Hz, J=9.2 Hz, 1H), 7.03 (d, J=9.2 Hz, 1H), 3.46-3.40 (m, 4H),
2.98 (d, J=3.2 Hz, 3H), 3.26 (s, 3H); LC-MS: m/z 254.1
(M+1).sup.+.
Step-h: Synthesis of
3-amino-N-(2-methoxyethyl)-4-(methylamino)benzamide
[0344] To a solution of
N-(2-methoxyethyl)-4-(methylamino)-3-nitrobenzamide (6.0 g, 23.7
mmol) in methanol (100 mL) was added a slurry of 10% Pd/C (1.2 g in
20 mL methanol) under nitrogen atmosphere. The reaction mixture was
stirred under hydrogen gas balloon for 16 h. The reaction mixture
was filtered through a bed of celite and concentrated under vacuum
to afford the title compound (4.0 g, 75%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.88 (t, J=5.2 Hz, 1H), 7.11-7.06 (m, 2H),
6.34 (d, J=8.0 Hz, 1H), 5.07 (bs, 1H), 4.54 (bs, 2H), 3.42-3.34 (m,
4H) 3.27 (s, 3H), 2.75 (d, J=2.8 Hz, 3H); LC-MS: m/z 224.2
(M+1).sup.+.
Step-i: Synthesis of
2-amino-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0345] To a solution of
3-amino-N-(2-methoxyethyl)-4-(methylamino)benzamide (2.0 g, 8.92
mmol) in THF (10 mL) and water (20 mL) at RT was added cyanogen
bromide (1.04 g, 9.82 mmol) and the reaction mixture was stirred at
50.degree. C. to 60.degree. C. for 16 h. The reaction mixture was
cooled to RT and basified with saturated sodium bicarbonate
solution, extracted with ethyl acetate (2.times.100 mL). The
combined organic layers were washed with water (50 mL), brine (50
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum to afford the crude product which was purified by combiflash
chromatography using 5% methanol in DCM as an eluent to afford the
title compound (1.3 g, 59%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.26 (bs, 1H), 7.66 (s, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.14
(d, J=8.0 Hz, 1H), 6.52 (bs, 2H), 3.51 (s, 3H), 3.45-3.41 (m, 4H),
3.26 (s, 3H); LC-MS: m/z 249.2 (M+1).sup.+.
Step-j: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((5-methylbenzo[d]oxazol-2-yl)amino)-1H-ben-
zo[d]imidazole-5-carboxamide
[0346] To a solution of
2-amino-N-(2-methoxyethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
(300 mg, 1.2 mmol) in 1,4-dioxane (5 mL) at 10.degree. C. was added
sodium hydride (60% dispersion in mineral oil) (96 mg, 2.4 mmol)
and stirred for 10 min followed by the addition of
5-methyl-2-(methylsulfonyl)benzo[d]oxazole (306 mg, 1.45 mmol) and
it was stirred at RT for 16 h. The reaction mixture was quenched
with cold water (20 mL) and extracted with ethyl acetate
(2.times.50 mL). The combined organic layers were washed with water
(30 mL), brine (30 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to obtain the crude product which was
purified by combiflash chromatography using 2% methanol in DCM as
an eluent to afford the title compound (6 mg, 1%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 1H), 8.45 (t, J=5.2 Hz, 1H),
8.08 (d, J=1.6 Hz, 1H), 7.76 (dd, J=1.2 Hz, J=8.0 Hz, 1H), 7.47 (d,
J=8.4 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.26 (s, 1H), 6.93 (d, J=7.6
Hz, 1H), 3.62 (s, 3H), 3.50-3.42 (m, 4H), 3.29 (s, 3H), 2.49 (s,
3H); LC-MS: m/z 380.2 (M+1).sup.+.
Examples 66 and 67. Synthesis of
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and Synthesis of
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
##STR00049##
[0347] Step-a: Synthesis of 2-amino-4-fluorophenol
[0348] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-b using
4-fluoro-2-nitrophenol as starting material (Yield: 91%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 8.88 (bs, 1H), 6.56-6.53 (m,
1H), 6.35 (dd, J=2.0 Hz, J=10.4 Hz, 1H), 6.13-6.08 (m, 1H), 4.78
(bs, 2H); LC-MS: m/z 128.1 (M+1).sup.+.
Step-b: Synthesis of 5-fluorobenzo[d]oxazole-2-thiol
[0349] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-4-fluorophenol as starting material (Yield: 86%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 14.01 (bs, 1H), 7.55-7.51 (m,
1H), 7.15-7.08 (m, 2H); LC-MS: m/z 170.0 (M+1).sup.+.
Step-c: Synthesis of 5-fluoro-2-(methylthio)benzo[d]oxazole
[0350] The title compound was synthesized using the same procedure
which was followed for Compound 1b using
5-fluorobenzo[d]oxazole-2-thiol as starting material (stirring for
16 h) (Yield: 92%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.69-7.65 (m, 1H), 7.53 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 7.19-7.11 (m,
1H), 2.76 (s, 3H); LC-MS: m/z 184.1 (M+1).sup.+.
Step-d: Synthesis of 5-fluoro-2-(methylsulfonyl)benzo[d]oxazole
[0351] The title compound was synthesized using the same procedure
which was followed for compound 1c using
5-fluoro-2-(methylthio)benzo[d]oxazole as starting material
(stirring for 4 h) (Yield: 99%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.05-8.01 (m, 1H), 7.94 (dd, J=2.4 Hz, J=8.0
Hz, 1H), 7.57-7.54 (m, 1H), 3.67 (s, 3H); LC-MS: m/z 216.0
(M+1).sup.+.
Step-e: Synthesis of ethyl
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate
[0352] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
5-fluoro-2-(methylsulfonyl)benzo[d]oxazole as starting materials
(Yield: 26%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.34
(bs, 1H), 8.23 (s, 1H), 7.88 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.49 (d,
J=8.0 Hz, 1H), 7.46-7.42 (m, 1H), 7.23 (dd, J=2.4 Hz, J=9.2 Hz,
1H), 6.97-6.91 (m, 1H), 4.34 (q, J=6.4 Hz, 2H), 3.64 (s, 3H), 1.36
(t, J=4.4 Hz, 3H); LC-MS: m/z 355.2 (M+1).sup.+.
Step-f: Synthesis of
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid
[0353] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate as starting material (Yield: 58%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (s, 1H),
7.87 (d, J=8.4 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.45-7.42 (m, 1H),
7.24 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 6.96-6.91 (m, 1H), 3.64 (s, 3H);
LC-MS: m/z 327.2 (M+1).sup.+.
Step-g: Synthesis of
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
[0354] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((5-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and 2-methoxyethylamine as starting materials (Yield:
62%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 1H),
8.20 (s, 1H), 8.06 (s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.44 (d, J=8.4
Hz, 1H), 7.40-7.37 (m, 1H), 7.20 (d, J=8.8 Hz, 1H), 6.89 (t, J=10.0
Hz, 1H), 3.63 (s, 3H), 3.50-3.45 (m, 4H), 3.09 (s, 3H); LC-MS: m/z
384.2 (M+1).sup.+.
Examples 68 and 69. Synthesis of
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and Synthesis of
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
##STR00050##
[0355] Step-a: Synthesis of 2-amino-5-fluorophenol
[0356] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-b using
5-fluoro-2-nitrophenol as starting material (Yield: 92%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 9.5 (bs, 1H), 6.54-6.51 (m,
1H), 6.46 (dd, J=2.8 Hz, J=10.0 Hz, 1H), 6.37-6.32 (m, 1H); LC-MS:
m/z 128.2 (M+1).sup.+.
Step-b: Synthesis of 6-fluorobenzo[d]oxazole-2-thiol
[0357] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-fluorophenol as starting material (Yield: 89%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 13.94 (bs, 1H), 7.57 (dd,
J=2.0 Hz, J=8.4 Hz, 1H), 7.25-7.22 (m, 1H), 7.19-7.14 (m, 1H);
LC-MS: m/z 170.0 (M+1).sup.+.
Step-c: Synthesis of 6-fluoro-2-(methylthio)benzo[d]oxazole
[0358] The title compound was synthesized using the same procedure
which was followed for compound 1b using
6-fluorobenzo[d]oxazole-2-thiol as starting material (stirring for
5 h) (Yield: 99%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.67-7.63 (m, 2H), 7.24-7.18 (m, 1H), 2.75 (s, 3H); LC-MS: m/z
184.0 (M+1).sup.+.
Step-d: Synthesis of 6-fluoro-2-(methylsulfonyl)benzo[d]oxazole
[0359] The title compound was synthesized using the same procedure
which was followed for compound 1c using
6-fluoro-2-(methylthio)benzo[d]oxazole as starting material
(stirring for 4 h) (Yield: 95%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.08-8.02 (m, 1H), 8.01-7.99 (m, 1H),
7.56-7.46 (m, 1H), 3.67 (s, 3H).
Step-e: Synthesis of ethyl
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate
[0360] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
6-fluoro-2-(methylsulfonyl)benzo[d]oxazole as starting materials
(Yield: 28%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3
(bs, 1H), 8.23 (d, J=1.6 Hz, 1H), 7.88 (dd, J=2.0 Hz, J=8.4 Hz,
1H), 7.52 (d, J=8.4 Hz, 1H), 7.45-7.41 (m, 2H), 7.10-7.04 (m, 1H),
4.33 (q, J=6.8 Hz, 2H), 3.64 (s, 3H), 1.35 (t, J=7.2 Hz, 3H);
LC-MS: m/z 355.1 (M+1).sup.+.
Step-f: Synthesis of
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid
[0361] To a stirred solution of ethyl
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate (45 mg, 0.13 mmol) in a mixture of solvent of THF (1 mL),
ethanol (1 mL) and water (0.5 mL) was added lithium hydroxide
monohydrate (10 mg, 0.25 mmol). The reaction mixture was heated at
60.degree. C. for 16 h with stirring. The reaction mixture was
cooled to RT and concentrated under reduced pressure. The residue
was dissolved in water (15 mL), acidified with 1 N HCl to obtain
the solid which was filtered and dried under vacuum to afford the
title compound (30 mg, 72%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.8 (bs, 1H), 12.3 (bs, 1H) 8.19 (d, J=1.6 Hz, 1H), 7.87
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.50 (d, J=8.8 Hz, 1H), 7.46-7.41 (m,
2H), 7.09-7.03 (m, 1H), 3.63 (s, 3H); LC-MS: m/z 327.05
(M+1).sup.+.
Step-g: Synthesis of
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
[0362] To a stirred solution of
2-((6-fluorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid (30 mg, 0.09 mmol) in DMFA (2 mL) at 0.degree. C. was
added N-ethyldiisopropyl amine (0.03 mL, 0.18 mmol) and
diphenylphosphoryl azide (0.02 mL, 0.09 mmol). The reaction mixture
was stirred for 30 min, followed by the addition of
2-methoxyethylamine (6 mg, 0.09 mmol) and the reaction mixture was
then stirred at RT for 16 h. Once the reaction was completed
(monitored by TLC), the reaction mixture was diluted with cold
water (6 mL) and stirred for 15 min. The solid obtained was
filtered, washed with diethyl ether and dried under vacuum to
afford the title compound (20 mg, 58%) as white solid; .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 1H), 8.45 (t, J=5.2 Hz,
1H), 8.07 (d, J=1.2 Hz, 1H), 7.75 (dd, J=1.6 Hz, J=8.8 Hz, 1H),
7.49-7.40 (m, 3H), 7.08-7.03 (m, 1H), 3.63 (s, 3H), 3.50-3.43 (m,
4H), 3.39 (s, 3H); LC-MS: m/z 384.1 (M+1).sup.+.
Examples 70 and 71. Synthesis of
6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-b-
enzo[d]imidazole-5-carboxylic acid and Synthesis of
6-fluoro-N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00051##
[0363] Step-a: Synthesis of methyl
2-amino-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate
[0364] The title compound was synthesized using the same procedure
which was followed for compound if using methyl
5-amino-2-fluoro-4-(methylamino)benzoate as starting material and
heating to 60.degree. C. for 16 h. (Yield: 89%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 7.54 (d, J=6.4 Hz, 1H), 7.16 (d, J=11.6
Hz, 1H), 6.69 (bs, 2H), 3.80 (s, 3H), 3.51 (s, 3H); LC-MS: m/z
224.1 (M+1).sup.+.
Step-b: Synthesis of methyl
6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-b-
enzo[d]imidazole-5-carboxylate
[0365] The title compound was synthesized using the same procedure
which was followed for compound 1g using methyl
2-amino-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole as starting
materials (Yield: 18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.3 (bs, 1H), 8.10 (d, J=6.0 Hz, 1H), 7.95-7.51 (m, 3H),
7.22 (d, J=8.4 Hz, 1H), 3.87 (s, 3H), 3.61 (s, 3H); LC-MS: m/z
425.1 (M+1).sup.+.
Step-c: Synthesis of
6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-b-
enzo[d]imidazole-5-carboxylic acid
[0366] The title compound was synthesized using the same procedure
which was followed for compound 1h using methyl
6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-b-
enzo[d]imidazole-5-carboxylate as starting material and THF,
methanol and water as solvents (2:2:1) (Yield: 66%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 13.0 (bs, 1H), 12.3 (bs, 1H), 8.08
(d, J=6.0 Hz, 1H), 7.59 (s, 1H), 7.53-7.49 (m, 2H), 7.22 (d, J=7.2
Hz, 1H), 3.61 (s, 3H); LC-MS: m/z 411.1 (M+1).sup.+.
Step-d: Synthesis of
6-fluoro-N-(2-methoxyethyl)-1-methyl-2-((6-(trifluoromethoxy)-benzo[d]oxa-
zol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0367] The title compound was synthesized using the same procedure
which was followed for compound 1i using
6-fluoro-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-b-
enzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as
starting materials (Yield: 48%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.18 (d, J=4.0 Hz, 1H), 7.86
(d, J=6.4 Hz, 1H), 7.58 (s, 1H), 7.52-7.49 (m, 2H), 7.21 (d, J=9.2
Hz, 1H), 3.61 (s, 3H), 3.47-3.44 (m, 4H), 3.29 (s, 3H); LC-MS: m/z
468.1 (M+1).sup.+.
Example 72. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-6-fluoro-N-(2-(2-hydroxyethoxy)ethyl)-1-meth-
yl-1H-benzo[d]imidazole-5-carboxamide
##STR00052##
[0368] Step-a: Synthesis of methyl
2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-car-
boxylate
[0369] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using methyl
2-amino-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chlorobenzo[d]oxazole as starting materials (Yield: 66%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 12.25 (bs, 1H), 8.09 (d, J=6.0
Hz, 1H), 7.55-7.44 (m, 3H), 7.24-7.22 (m, 1H), 7.17-7.12 (m, 1H),
3.86 (s, 3H), 3.60 (s, 3H); LC-MS: m/z 341.0 (M+1).sup.+.
Step-b: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-car-
boxylic acid
[0370] The title compound was synthesized using the same procedure
which was followed for compound 1h using methyl
2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-car-
boxylate as starting material and methanol, THF and water (2:2:1)
as solvent (Yield: 75%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.80 (bs, 2H), 8.07 (d, J=6.8 Hz, 1H), 7.50-7.44 (m, 3H),
7.22 (t, J=6.8 Hz, 1H), 7.15-7.11 (m, 1H), 3.60 (s, 3H); LC-MS: m/z
327.0 (M+1).sup.+.
Step-c: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-6-fluoro-N-(2-(2-hydroxyethoxy)ethyl)-1-meth-
yl-1H-benzo[d]imidazole-5-carboxamide
[0371] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-(benzo[d]oxazol-2-ylamino)-6-fluoro-1-methyl-1H-benzo[d]imidazole-5-car-
boxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials
(Yield: 49%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20
(bs, 1H), 8.15 (bs, 1H), 7.86 (d, J=6.4 Hz, 1H), 7.50-7.47 (m, 2H),
7.43 (d, J=8.0 Hz, 1H), 7.23-7.19 (m, 1H), 7.14-7.10 (m, 1H), 4.60
(bs, 1H), 3.60 (s, 3H), 3.57-3.51 (m, 4H), 3.48-3.31 (m, 4H);
LC-MS: m/z 414.05 (M+1).sup.+.
Example 73. Synthesis of
2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylic acid
##STR00053##
[0372] Step-a: Synthesis of ethyl
2-(1H-imidazole-1-carbothioamido)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late
[0373] To a solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (1.0 g, 4.5
mmol) in acetonitrile (20 mL) at RT was added
1,1'-thiocarbonyldiimidazole (1.06 g, 5.9 mmol) and stirred at
60.degree. C. for 16 h. The reaction mixture was cooled to RT and
stirred for 30 min. The solid obtained was filtered and dried under
vacuum to afford the titled compound which was used in the next
step without further purification (1.1 g, 73%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 13.4 (bs, 1H), 8.68 (s, 1H), 8.41 (d,
J=1.6 Hz, 1H), 8.03 (s, 1H), 7.99 (dd, J=1.2 Hz, J=8.8 Hz, 1H),
7.75 (d, J=8.4 Hz, 1H), 7.01 (d, J=1.2 Hz, 1H), 4.35 (q, J=7.2 Hz,
2H), 3.79 (s, 3H), 1.36 (t, J=6.8 Hz, 3H).
Step-b: Synthesis of ethyl
2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylate
[0374] To a stirred solution of ethyl
2-(1H-imidazole-1-carbothioamido)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late (900 mg, 2.74 mmol) in DMFA (15 mL) was added EDC.HCl (1.05 g,
5.47 mmol) and heated to 60.degree. C. for 10 min. The reaction
mixture was cooled to RT, followed by the addition of
4-fluorobenzene-1,2-diamine (345 mg, 2.74 mmol) and it was heated
at 100.degree. C. for 16 h. The reaction mixture was cooled to RT,
diluted with water (30 mL) and extracted with EtOAc (2.times.50
mL). The combined organic layer was washed with water (30 mL),
brine (30 mL), dried over anhydrous sodium sulfate and concentrated
under vacuum to afford a residue which was purified by combiflash
chromatography using 0.5% methanol in DCM as an eluent to afford
the title compound (200 mg, 21%); LC-MS: m/z 354.2 (M+1).sup.+.
Step-c: Synthesis of
2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylic acid
[0375] To a stirred solution of ethyl
2-((5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylate (200 mg, 0.57 mmol) in a mixture of solvent of THF
(5 mL), methanol (5 mL) and water (5 mL) was added lithium
hydroxide monohydrate (119 mg, 2.83 mmol). The reaction mixture was
heated at 60.degree. C. for 16 h with stirring. The reaction
mixture was cooled to RT and concentrated under reduced pressure.
The residue was dissolved in water (15 mL), acidified with 1 N HCl
to obtain the solid which was filtered and dried under vacuum to
afford the title compound (150 mg, 81%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.2 (bs, 2H), 8.04 (s, 1H), 7.75 (d, J=8.0
Hz, 1H), 7.32-7.26 (m, 2H), 7.13 (d, J=8.4 Hz, 1H), 6.88 (t, J=8.0
Hz, 1H), 3.62 (s, 3H); LC-MS: m/z 326.05 (M+1).sup.+.
Example 74. Synthesis of
1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxylic acid
##STR00054##
[0376] Step-a: Synthesis of ethyl
4-((2-(dimethylamino)ethyl)amino)-3-nitrobenzoate
[0377] To a solution of ethyl 4-chloro-3-nitrobenzoate (5.0 g, 21.8
mmol) in DMFA (40 mL) at RT was added DIPEA (9.5 mL, 54.4 mmol) and
N.sup.1,N.sup.1-dimethylethane-1,2-diamine (2.87 g, 32.7 mmol) and
the reaction mixture was stirred at 60.degree. C. for 16 h. The
reaction mixture was cooled to RT, diluted with cold water (250 mL)
and stirred for 10 min. The precipitated solid was filtered and
dried under vacuum to afford the title compound (4.8 g, 92%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.65 (t, J=4.4 Hz,
1H), 8.62 (d, J=2.0 Hz, 1H), 7.79 (dd, J=2.0 Hz, J=8.8 Hz, 1H),
7.13 (d, J=9.2 Hz, 1H), 4.32-4.26 (m, 2H), 3.47-3.43 (m, 2H),
2.57-2.52 (m, 2H), 2.22 (s, 6H), 1.33-1.28 (m, 3H); LC-MS: m/z
282.2 (M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-((2-(dimethylamino)ethyl)amino)benzoate
[0378] The title compound was synthesized using the same procedure
which was followed for compound 1e using ethyl
4-((2-(dimethylamino)ethyl)amino)-3-nitrobenzoate as starting
material and stirring for 16 h. (Yield: 67%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.23 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.18 (d,
J=2.0 Hz, 1H), 6.45 (d, J=8.4 Hz, 1H), 5.09 (bs, 1H), 4.68 (s, 2H),
4.18 (q, J=6.8 Hz, 2H), 3.19-3.15 (m, 2H), 2.49-2.46 (m, 2H), 2.18
(s, 6H), 1.26 (t, J=6.8 Hz, 3H); LC-MS: m/z 252.2 (M+1).sup.+.
Step-c: Synthesis of ethyl
2-amino-1-(2-(dimethylamino)ethyl)-1H-benzo[d]imidazole-5-carboxylate
[0379] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-((2-(dimethylamino)ethyl)amino)benzoate as starting
material and heating to 60.degree. C. for 16 h. (Yield: 26%);
LC-MS: m/z 277.2 (M+1).sup.+.
Step-d: Synthesis of ethyl
1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxylate
[0380] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-(2-(dimethylamino)ethyl)-1H-benzo[d]imidazole-5-carboxylate
and 2-(methylsulfonyl)-6-(trifluoromethoxy)benzo[d]oxazole as
starting materials (Yield: 26%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.4 (bs, 1H), 8.25 (d, J=1.2 Hz, 1H), 7.87
(dd, J=1.2 Hz, J=8.4 Hz, 1H), 7.59-7.57 (m, 2H), 7.51 (d, J=8.4 Hz,
1H), 7.22 (d, J=8.8 Hz, 1H), 4.36-4.26 (m, 4H), 2.68 (q, J=6.8 Hz,
2H), 2.22 (s, 6H), 1.35 (t, J=6.8 Hz, 3H); LC-MS: m/z 478.1
(M+1).sup.+.
Step-e: Synthesis of
1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxylic acid
[0381] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-(2-(dimethylamino)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.8
(bs, 1H), 12.3 (bs, 1H), 8.20 (d, J=1.6 Hz, 1H), 7.86 (dd, J=1.6
Hz, J=8.4 Hz, 1H), 7.59-7.51 (m, 3H), 7.21 (d, J=8.4 Hz, 1H), 4.27
(t, J=6.4 Hz, 2H), 2.79-2.66 (m, 2H), 2.21 (s, 6H); LC-MS: m/z
450.1 (M+1).sup.+.
Examples 75 and 76. Synthesis of
1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amin-
o)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
N,1-bis(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00055## ##STR00056##
[0382] Step-a: Synthesis of ethyl
4-((2-methoxyethyl)amino)-3-nitrobenzoate
[0383] To a solution of ethyl 4-chloro-3-nitrobenzoate (10 g, 43.7
mmol) in DMSO (100 mL) at RT was added 2-methoxyethan-1-amine (7.5
mL g, 87.3 mmol) and the reaction mixture was stirred at 60.degree.
C. for 16 h. The reaction mixture was cooled to RT, diluted with
cold water (250 mL) and stirred for 1 h. The precipitated solid was
filtered and dried under vacuum to afford the title compound (12 g,
100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.61 (d, J=2.4
Hz, 1H), 8.54 (s, 1H), 7.97 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 7.18 (d,
J=9.2 Hz, 1H), 4.29 (q, J=6.8 Hz, 2H), 3.60 (bs, 4H), 3.31 (s, 3H),
1.31 (t, J=6.8 Hz, 3H); LC-MS: m/z 269.1 (M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-((2-methoxyethyl)amino)benzoate
[0384] The title compound was synthesized using the same procedure
which was followed for compound 1e using ethyl
4-((2-methoxyethyl)amino)-3-nitrobenzoate as starting material
(Yield: 75%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.22-7.17 (m, 2H), 6.46 (d, J=8.4 Hz, 1H), 5.20 (t, J=7.6 Hz, 1H),
4.74 (bs, 2H), 4.18 (q, J=7.2 Hz, 2H), 3.53 (t, J=5.6 Hz, 2H),
3.30-3.26 (m, 5H), 1.26 (t, J=7.6 Hz, 3H); LC-MS: m/z 239.1
(M+1).sup.+.
Step-c: Synthesis of ethyl
2-amino-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate
[0385] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-((2-methoxyethyl)amino)benzoate as starting material and
heating to 60.degree. C. for 16 h. (Yield: 73%); LC-MS: m/z 264.1
(M+1).sup.+.
Step-d: Synthesis of ethyl
2-(1H-imidazole-1-carbothioamido)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-
-5-carboxylate
[0386] The title compound was synthesized using the same procedure
which was followed for compound 12a using ethyl
2-amino-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate and
1,1'-thiocarbonyldiimidazole as starting materials (Yield: 60%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.5 (bs, 1H), 8.66
(s, 1H), 8.42 (s, 1H), 8.01-7.97 (m, 2H), 7.78 (d, J=8.8 Hz, 1H),
7.01 (s, 1H), 4.54 (t, J=4.8 Hz, 2H), 4.35 (q, J=7.2 Hz, 2H), 3.74
(t, J=4.8 Hz, 2H), 3.20 (s, 3H), 1.35 (t, J=7.2 Hz, 3H).
Step-e: Synthesis of ethyl
1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amin-
o)-1H-benzo[d]imidazole-5-carboxylate
[0387] The title compound was synthesized using the same procedure
which was followed for compound 12b using ethyl
2-(1H-imidazole-1-carbothioamido)-1-(2-methoxyethyl)-1H-benzo[d]imidazole-
-5-carboxylate and 4-(trifluoromethoxy)benzene-1,2-diamine as
starting materials (Yield: 38%); LC-MS: m/z 464.0 (M+1).sup.+.
Step-f: Synthesis of
1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amin-
o)-1H-benzo[d]imidazole-5-carboxylic acid
[0388] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amin-
o)-1H-benzo[d]imidazole-5-carboxylate as starting material and THF,
methanol and water as solvents. (Yield: 65%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.3 (bs, 3H), 8.08 (d, J=1.2 Hz, 1H), 7.74
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.41 (d, J=8.4 Hz, 1H), 7.36-7.31 (m,
2H), 7.02 (d, J=8.0 Hz, 1H), 4.32 (t, J=5.2 Hz, 2H), 3.71 (t, J=6.0
Hz, 2H), 3.25 (s, 3H); LC-MS: m/z 436.0 (M+1).sup.+.
Step-g: Synthesis of
N,1-bis(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxamide
[0389] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-methoxyethyl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)amin-
o)-1H-benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine
as starting materials (Yield: 2%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.23 (bs, 1H), 8.26-8.23 (m, 1H), 7.58-7.53
(m, 1H), 7.43-7.38 (m, 1H), 7.30-6.37 (m, 5H), 4.50-4.48 (m, 2H),
3.86-3.80 (m, 2H), 3.32 (s, 3H), 3.27-3.25 (m, 4H), 3.16 (s, 3H);
LC-MS: m/z 493.1 (M+1).sup.+.
Examples 77 and 78. Synthesis of
1-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H--
benzo[d]imidazole-5-carboxylic acid and Synthesis of
N,1-bis(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino-
)-1H-benzo[d]imidazole-5-carboxamide
##STR00057##
[0390] Step-a: Synthesis of
1-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H--
benzo[d]imidazole-5-carboxylic acid
[0391] To a solution of ethyl
2-amino-1-(2-methoxyethyl)-1H-benzo[d]imidazole-5-carboxylate (200
mg, 0.76 mmol) in 1,4-dioxane (10 mL) at 0.degree. C. was added
sodium hydride (60% dispersion in mineral oil) (107 mg, 2.66 mmol)
and stirred for 10 min.
2-chloro-6-(trifluoromethoxy)benzo[d]oxazole (270 mg, 1.14 mmol)
was added to the reaction mixture and stirred at 90.degree. C. for
16 h. The reaction mixture was cooled to RT. Solvent was evaporated
and the residue was diluted with cold water (20 mL), acidified with
1N HCl. The reaction mixture was extracted with ethyl acetate
(2.times.50 mL). Combined organic layer was washed with water (30
mL), brine (30 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combiflash
chromatography using 2% methanol in DCM as an eluent to afford the
title compound (70 mg, 21%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.8 (bs, 1H), 12.3 (bs, 1H), 8.20 (d, J=1.6 Hz, 1H), 7.86
(dd, J=1.2 Hz, J=8.0 Hz, 1H), 7.58-7.52 (m, 3H), 7.22 (d, J=7.2 Hz,
1H), 4.36 (t, J=4.8 Hz, 2H), 3.74 (t, J=5.6 Hz, 2H), 3.24 (s, 3H);
LC-MS: m/z 437.05 (M+1).sup.+.
Step-b: Synthesis of
N,1-bis(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino-
)-1H-benzo[d]imidazole-5-carboxamide
[0392] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H--
benzo[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as
starting materials (Yield: 2%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.45 (bs, 1H), 8.08 (s, 1H),
7.75 (d, J=8.4 Hz, 1H), 7.56 (s, 1H), 7.53-7.50 (m, 2H), 7.21 (d,
J=8.4 Hz, 1H), 4.35 (t, J=4.8 Hz, 2H), 3.73 (t, J=5.2 Hz, 2H),
3.48-3.43 (m, 4H), 3.28 (s, 3H), 3.24 (s, 3H); LC-MS: m/z 494.15
(M+1).sup.+.
Example 79 and 80. Synthesis of
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)b-
enzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00058##
[0393] Step-a: Synthesis of ethyl
2-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate
[0394] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-((tetrahydro-2H-pyran-4-yl)amino)benzoate as starting
material and heating to 60.degree. C. (Yield: 92%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 7.71 (s, 1H), 7.55 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 6.65 (bs, 2H), 4.50-4.48 (m,
1H), 4.28 (q, J=7.2 Hz, 2H), 4.05-4.01 (m, 2H), 3.47 (t, J=11.2 Hz,
2H), 2.36-2.32 (m, 2H), 1.72 (d, J=10.4 Hz, 2H), 1.31 (t, J=6.8 Hz,
3H); LC-MS: m/z 290.1 (M+1).sup.+.
Step-b: Synthesis of ethyl
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)-benzo[d]oxazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxylate
[0395] To a solution of ethyl
2-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate
(100 mg, 0.35 mmol) in 1,4-dioxane (2 mL) at RT was added sodium
hydride (60% dispersion in mineral oil) (34 mg, 0.86 mmol) and
stirred for 10 min. 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole
(99 g, 0.41 mmol) was added to the reaction mixture and stirred at
RT for 16 h. The reaction mixture was concentrated and diluted with
cold water (30 mL) and stirred at RT for 5 to 10 min. The solid
obtained was filtered, dried under vacuum and purified by
combiflash chromatography using 100% DCM as an eluent to afford the
title compound (60 mg, 35%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.40 (bs, 1H), 8.29 (d, J=1.6 Hz, 1H), 7.86 (dd, J=1.2 Hz,
J=8.0 Hz, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.58 (d, J=1.6 Hz, 1H), 7.52
(d, J=8.4 Hz, 1H), 7.21 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 4.97-4.93 (m,
1H), 4.33 (q, J=7.6 Hz, 2H), 4.07-4.03 (m, 2H), 3.56 (t, J=9.2 Hz,
2H), 2.63-2.55 (m, 2H), 1.79 (d, J=9.2 Hz, 2H), 1.35 (t, J=6.8 Hz,
3H); LC-MS: m/z 491.1 (M+1).sup.+.
Step-e: Synthesis of
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylic acid
[0396] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 71%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.8
(bs, 1H), 12.50 (bs, 1H), 8.24 (d, J=1.6 Hz, 1H), 7.86 (dd, J=1.2
Hz, J=8.8 Hz, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.58 (d, J=1.2 Hz, 1H),
7.53 (d, J=8.8 Hz, 1H), 7.22 (d, J=10.4 Hz, 1H), 5.01-4.92 (m, 1H),
4.05 (dd, J=4.0 Hz, J=11.2 Hz, 2H), 3.58-3.53 (m, 2H), 2.67-2.57
(m, 2H), 1.78 (d, J=10.0 Hz, 2H); LC-MS: m/z 463.1 (M+1).sup.+.
Step-f: Synthesis of
N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)b-
enzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0397] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(tetrahydro-2H-pyran-4-yl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxylic acid and
2-methoxyethylamine as starting materials (Yield: 76%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.48 (t, J=5.2 Hz,
1H), 8.13 (d, J=1.2 Hz, 1H), 7.76 (dd, J=1.6 Hz, J=8.8 Hz, 1H),
7.68 (d, J=8.0 Hz, 1H), 7.57 (s, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.21
(d, J=8.8 Hz, 1H), 4.98-4.92 (m, 1H), 4.07-4.04 (m, 2H), 3.56 (t,
J=1.2 Hz, 2H), 3.49-3.44 (m, 4H), 3.28 (s, 3H), 2.67-2.58 (m, 2H),
1.78 (d, J=9.6 Hz, 2H); LC-MS: m/z 520.2 (M+1).sup.+.
Example 81. Synthesis of
N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)--
1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00059##
[0398] Step-a: Synthesis of ethyl
2-(1H-imidazole-1-carbothioamido)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d-
]imidazole-5-carboxylate
[0399] The title compound was synthesized using the same procedure
which was followed for compound 12a using ethyl
2-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazole-5-carboxylate
and 1,1'-thiocarbonyldiimidazole as starting materials (Yield:
72%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.50 (bs, 1H),
8.64 (s, 1H), 8.43 (s, 1H), 7.98 (d, J=4.4 Hz, 1H), 7.96-7.94 (m,
1H), 7.09 (s, 1H), 6.72 (bs, 1H), 5.05-5.00 (m, 1H), 4.36-4.26 (m,
2H), 4.06-4.02 (m, 2H), 3.60 (t, J=11.6 Hz, 2H), 2.54-2.50 (m, 2H),
1.86 (d, J=9.6 Hz, 2H), 1.37-1.33 (m, 3H).
Step-b: Synthesis of ethyl
1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-
-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate
[0400] The title compound was synthesized using the same procedure
which was followed for compound 12b using ethyl
2-(1H-imidazole-1-carbothioamido)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d-
]imidazole-5-carboxylate and
4-(trifluoromethoxy)benzene-1,2-diamine as starting materials
(Yield: 46%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3
(bs, 1H), 8.12 (d, J=6.4 Hz, 1H), 7.95 (s, 1H), 7.74 (dd, J=2.0 Hz,
J=8.4 Hz, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.37-7.32 (m, 2H), 7.06 (dd,
J=1.6 Hz, J=8.4 Hz, 1H), 4.97-4.90 (m, 1H), 4.32 (q, J=6.8 Hz, 2H),
4.08-4.05 (m, 2H), 3.51 (t, J=11.6 Hz, 2H), 2.67-2.55 (m, 2H), 1.75
(d, J=9.6 Hz, 2H), 1.07 (t, J=8.4 Hz, 3H); LC-MS: m/z 490.0
(M+1).sup.+.
Step-c: Synthesis of
1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-
-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid
[0401] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-
-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as starting
material (Yield: 55%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
12.7 (bs, 3H), 8.04 (s, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.65 (d, J=8.8
Hz, 1H), 7.42-7.35 (m, 2H), 7.12 (d, J=8.0 Hz, 1H), 4.93 (bs, 1H),
4.08-4.05 (m, 2H), 3.54-3.48 (m, 2H), 2.61-2.58 (m, 2H), 1.77 (d,
J=10.0 Hz, 2H); LC-MS: m/z 462.15 (M+1).sup.+.
Step-d: Synthesis of
N-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)--
1H-benzo[d]imidazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0402] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(tetrahydro-2H-pyran-4-yl)-2-((5-(trifluoromethoxy)-1H-benzo[d]imidazol-
-2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and
2-methoxyethylamine as starting materials (Yield: 42%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 2H), 8.37 (t, J=5.6 Hz,
1H), 8.02 (d, J=1.6 Hz, 1H), 7.64 (dd, J=1.2 Hz, J=8.0 Hz, 1H),
7.52 (d, J=8.8 Hz, 1H), 7.53-7.30 (m, 2H), 7.03 (d, J=8.0 Hz, 1H),
4.98-4.89 (m, 1H), 4.08-4.05 (m, 2H), 3.51-3.43 (m, 6H), 3.28 (s,
3H), 2.67-2.58 (m, 2H), 1.75-1.73 (m, 2H); LC-MS: m/z 519.1
(M+1).sup.+.
Examples 82 and 83. Synthesis of
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylic acid and Synthesis of
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl--
1H-benzo[d]imidazole-5-carboxamide
##STR00060##
[0403] Step-a: Synthesis of ethyl
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylate
[0404] The title compound was synthesized using the same procedure
which was followed for compound 12b using ethyl
2-(1H-imidazole-1-carbothioamido)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late and 4-chlorobenzene-1,2-diamine as starting materials (Yield:
24%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 2H),
8.10 (s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.40-7.29 (m, 3H), 7.09 (dd,
J=1.2 Hz, J=8.4 Hz, 1H), 4.31 (q, J=6.8 Hz, 2H), 3.64 (s, 3H), 1.35
(t, J=6.8 Hz, 3H); LC-MS: m/z 370.05 (M+1).sup.+.
Step-b: Synthesis of
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylic acid
[0405] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylate as starting material (Yield: 84%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 3H), 8.07 (s, 1H), 7.76 (d,
J=8.0 Hz, 1H), 7.37-7.29 (m, 3H), 7.07 (d, J=7.6 Hz, 1H), 3.63 (s,
3H); LC-MS: m/z 342.0 (M+1).sup.+.
Step-c: Synthesis of
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl--
1H-benzo[d]imidazole-5-carboxamide
[0406] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazol-
e-5-carboxylic acid and 2-methoxyethylamine as starting materials
(Yield: 49%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2
(bs, 2H), 8.36 (s, 1H), 7.99 (s, 1H), 7.66 (d, J=7.2 Hz, 1H), 7.35
(d, J=8.4 Hz, 1H), 7.30-7.28 (m, 2H), 7.06 (d, J=8.4 Hz, 1H), 3.62
(s, 3H), 3.48-3.43 (m, 4H), 3.17 (s, 3H); LC-MS: m/z 399.1
(M+1).sup.+.
Examples 84 and 85. Synthesis of
1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and Synthesis of
1-ethyl-N-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide
##STR00061##
[0407] Step-a: Synthesis of ethyl
4-(ethylamino)-3-nitrobenzoate
[0408] To a solution of ethyl 4-chloro-3-nitrobenzoate (4.0 g, 17.5
mmol) in DMFA (100 mL) at RT was added ethylamine (2.24 mL (70%
aqueous solution), 34.9 mmol) and the reaction mixture was stirred
at 60.degree. C. for 16 h. The reaction mixture was cooled to RT,
diluted with cold water (200 mL) and stirred for 15 min. The
precipitated solid was filtered and dried under vacuum to afford
the title product (3.0 g, 63%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.62 (d, J=2.0 Hz, 1H), 8.51 (t, J=5.2 Hz,
1H), 7.97 (dd, J=2.0 Hz, J=9.2 Hz, 1H), 7.14 (d, J=9.2 Hz, 1H),
4.29 (q, J=6.8 Hz, 2H), 3.49-3.42 (m, 2H), 1.33 (t, J=5.2 Hz, 3H),
1.23 (t, J=7.2 Hz, 3H); LC-MS: m/z 239.0 (M+1).sup.+.
Step-b: Synthesis of ethyl 3-amino-4-(ethylamino)benzoate
[0409] The title compound was synthesized using the same procedure
which was followed for compound 1e using ethyl
4-(ethylamino)-3-nitrobenzoate as starting material (Yield: 79%)
and the crude compound was used in the next step without any
purification.
Step-c: Synthesis of ethyl
2-amino-1-ethyl-1H-benzo[d]imidazole-5-carboxylate
[0410] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-(ethylamino)benzoate as starting material (Yield: 74%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.70 (s, 1H), 7.58
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.23 (d, J=8.4 Hz, 1H), 6.66 (bs,
2H), 4.27 (q, J=7.2 Hz, 2H), 4.05 (q, J=6.8 Hz, 2H), 1.31 (t, J=6.8
Hz, 3H), 1.20 (t, J=7.6 Hz, 3H); LC-MS: m/z 234.1 (M+1).sup.+.
Step-d: Synthesis of ethyl
1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate
[0411] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-ethyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting materials
(Yield: 54%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3
(bs, 1H), 8.25 (d, J=1.6 Hz, 1H), 7.88 (dd, J=2.0 Hz, J=8.8 Hz,
1H), 7.60-7.57 (m, 2H), 7.51 (d, J=8.8 Hz, 1H), 7.22 (dd, J=1.6 Hz,
J=8.8 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 4.22 (q, J=7.6 Hz, 2H),
1.37-1.31 (m, 6H); LC-MS: m/z 435.05 (M+1).sup.+.
Step-e: Synthesis of
1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0412] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate as starting material (Yield: 75%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.3 (bs, 1H), 8.21
(s, 1H), 7.88 (d, J=8.0 Hz, 1H), 7.58-7.57 (m, 2H), 7.52 (d, J=8.4
Hz, 1H), 7.20 (d, J=9.6 Hz, 1H), 4.22 (q, J=7.6 Hz, 2H), 1.33 (t,
J=6.8 Hz, 3H); LC-MS: m/z 407.0 (M+1).sup.+.
Step-f: Synthesis of
1-ethyl-N-(2-methoxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide
[0413] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-methoxyethylamine as starting
materials (Yield: 58%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.3 (bs, 1H), 8.46 (s, 1H), 8.09 (s, 1H), 7.77 (d, J=8.4
Hz, 1H), 7.56-7.50 (m, 3H), 7.21 (d, J=8.0 Hz, 1H), 4.22 (q, J=7.6
Hz, 2H), 3.48-3.44 (m, 4H), 3.28 (s, 3H), 1.32 (t, J=7.6 Hz, 3H);
LC-MS: m/z 464.1 (M+1).sup.+.
Example 86. Synthesis of
1-ethyl-N-(2-hydroxyethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)am-
ino)-1H-benzo[d]imidazole-5-carboxamide
##STR00062##
[0415] To a stirred solution of
1-ethyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid (60 mg, 0.14 mmol) in DMFA (1 mL) at
0.degree. C. was added N-ethyldiisopropyl amine (0.02 mL, 0.14
mmol) and HBTU (52 mg, 0.14 mmol). The reaction mixture was stirred
for 30 min, followed by the addition of 2-aminoethan-1-ol (8 mg,
0.14 mmol) and stirring was continued at RT for 16 h. Once the
reaction was completed (monitored by TLC), the reaction mixture was
diluted with cold water (15 mL) and stirred for 15 min. The solid
obtained was filtered, washed with diethyl ether and dried under
vacuum to afford the title compound (20 mg, 30%) as white solid;
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.37
(t, J=4.8 Hz, 1H), 8.09 (s, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.56-7.49
(m, 3H), 7.21 (d, J=8.0 Hz, 1H), 4.72 (t, J=5.6 Hz, 1H), 4.22 (q,
J=7.2 Hz, 2H), 3.53 (q, J=5.2 Hz, 2H), 3.39-3.37 (m, 2H), 1.32 (t,
J=8.0 Hz, 3H); LC-MS: m/z 450.1 (M+1).sup.+.
Examples 87 and 88. Synthesis of
1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)-benzo[d]oxazol--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid Synthesis of
N-(2-methoxyethyl)-1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluorometho-
xy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00063## ##STR00064##
[0416] Step-a: Synthesis of ethyl
3-nitro-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate
[0417] To a solution of ethyl 4-chloro-3-nitrobenzoate (2.0 g, 8.7
mmol) in THF (40 mL) at RT was added DIPEA (4.6 mL, 26.1 mmol) and
(tetrahydrofuran-3-yl)methanamine (1.06 g, 10.5 mmol) then the
reaction mixture was stirred at 60.degree. C. for 16 h. The
reaction mixture was cooled to RT, diluted with cold water (200 mL)
and stirred for 1 h. The solid precipitated was filtered and dried
under vacuum to afford the title compound (2.4 g, 94%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 8.62-8.59 (m, 2H), 7.97 (dd, J=2.0
Hz, J=9.2 Hz, 1H), 7.20 (d, J=8.8 Hz, 1H), 4.29 (q, J=7.6 Hz, 2H),
3.82-3.77 (m, 1H), 3.73-3.69 (m, 1H), 3.66-3.60 (m, 1H), 3.53-3.50
(m, 1H), 3.45-3.40 (m, 2H), 2.67-2.58 (m, 1H), 2.03-1.95 (m, 1H),
1.69-1.63 (m, 1H), 1.31 (t, J=7.2 Hz, 3H); LC-MS: m/z 295.0
(M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate
[0418] The title compound was synthesized using the same procedure
which was followed for compound 1e using ethyl
3-nitro-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate as starting
material (Yield: 86%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.20 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.16 (d, J=2.0 Hz, 1H), 6.46 (d,
J=8.0 Hz, 1H), 5.26 (bs, 1H), 4.75 (s, 2H), 4.18 (q, J=7.2 Hz, 2H),
3.77-3.73 (m, 2H), 3.64-3.62 (m, 1H), 3.49-3.47 (m, 1H), 3.07 (t,
J=6.4 Hz, 2H), 2.50-2.49 (m, 1H), 2.11-1.98 (m, 1H), 1.63-1.48 (m,
1H), 1.26 (t, J=7.2 Hz, 3H); LC-MS: m/z 265.1 (M+1).sup.+.
Step-c: Synthesis of ethyl
2-amino-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxyla-
te
[0419] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-(((tetrahydrofuran-3-yl)methyl)amino)benzoate as starting
material (Yield: 79%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.70 (s, 1H), 7.58 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.27 (d, J=8.4 Hz,
1H), 6.71 (s, 2H), 4.27 (q, J=6.8 Hz, 2H), 4.03 (d, J=8.0 Hz, 2H),
3.78-3.71 (m, 1H), 3.63-3.59 (m, 2H), 3.48-3.41 (m, 1H), 2.72-2.68
(m, 1H), 1.85-1.79 (m, 1H), 1.65-1.58 (m, 1H), 1.31 (t, J=7.2 Hz,
3H); LC-MS: m/z 290.1 (M+1).sup.+.
Step-d: Synthesis of ethyl
1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylate
[0420] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-ethyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting materials
(Yield: 44%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.4
(bs, 1H), 8.26 (d, J=1.6 Hz, 1H), 7.88 (dd, J=1.6 Hz, J=8.4 Hz,
1H), 7.63 (d, J=8.4 Hz, 1H), 7.59 (s, 1H), 7.52 (d, J=8.4 Hz, 1H),
7.22 (d, J=7.6 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 4.20-4.18 (m, 2H),
3.88-3.86 (m, 1H), 3.70-3.56 (m, 3H), 3.80-3.78 (m, 1H), 1.94-1.91
(m, 1H), 1.73-1.71 (m, 1H), 1.35 (t, J=7.2 Hz, 3H); LC-MS: m/z
491.15 (M+1).sup.+.
Step-e: Synthesis of
1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)-benzo[d]oxazol--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid
[0421] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 76%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.8
(bs, 1H), 12.3 (bs, 1H), 8.21 (s, 1H), 7.87 (d, J=8.0 Hz, 1H),
7.62-7.58 (m, 2H), 7.53 (d, J=8.8 Hz, 1H), 7.21 (d, J=8.4 Hz, 1H),
4.19 (d, J=7.6 Hz, 2H), 3.89-3.84 (m, 1H), 3.70-3.58 (m, 3H),
2.89-2.85 (m, 1H), 1.98-1.90 (m, 1H), 1.76-1.68 (m, 1H); LC-MS: m/z
463.1 (M+1).sup.+.
Step-f: Synthesis of
N-(2-methoxyethyl)-1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluorometho-
xy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0422] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-((tetrahydrofuran-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and
2-methoxyethylamine as starting materials (Yield: 18%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.47 (s, 1H), 8.09
(s, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.60-7.50 (m, 3H), 7.21 (d, J=8.0
Hz, 1H), 4.18 (bs, 2H), 3.87 (bs, 1H), 3.67-3.57 (m, 3H), 3.47 (bs,
4H), 3.28 (s, 3H), 2.88 (bs, 1H), 1.92 (bs, 1H), 1.73 (bs, 1H);
LC-MS: m/z 520.15 (M+1).sup.+.
Examples 89 and 90. Synthesis of
1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)be-
nzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00065## ##STR00066##
[0423] Step-a: Synthesis of ethyl
4-((2-(methylsulfonyl)ethyl)amino)-3-nitrobenzoate
[0424] The title compound was synthesized using the same procedure
which was followed for compound 3a using ethyl
4-chloro-3-nitrobenzoate and 2-(methylsulfonyl)ethan-1-amine
hydrochloride as starting materials and heating to 60.degree. C.
(Yield: 89%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.69 (t,
J=6.0 Hz, 1H), 8.63 (d, J=2.0 Hz, 1H), 8.02 (dd, J=2.0 Hz, J=8.8
Hz, 1H), 7.20 (d, J=9.2 Hz, 1H), 4.30 (q, J=6.8 Hz, 2H), 3.89 (q,
J=5.6 Hz, 2H), 3.52 (t, J=6.8 Hz, 2H), 3.08 (s, 3H), 1.30 (t, J=6.8
Hz, 3H); LC-MS: m/z 317.0 (M+1).sup.+.
Step-b: Synthesis of ethyl
3-amino-4-((2-(methylsulfonyl)ethyl)amino)benzoate
[0425] The title compound was synthesized using the same procedure
which was followed for compound 1e using ethyl
4-((2-(methylsulfonyl)ethyl)amino)-3-nitrobenzoate as starting
material (Yield: 86%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.24-7.20 (m, 2H), 6.52 (d, J=8.4 Hz, 1H), 5.45 (t, J=5.2 Hz, 1H),
4.72 (s, 2H), 4.19 (q, J=7.2 Hz, 2H), 3.58 (q, J=6.4 Hz, 2H), 3.38
(t, J=6.8 Hz, 2H), 3.03 (s, 3H), 1.26 (t, J=6.8 Hz, 3H); LC-MS: m/z
287.0 (M+1).sup.+.
Step-c: Synthesis of ethyl
2-amino-1-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazole-5-carboxylate
[0426] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-((2-(methylsulfonyl)ethyl)amino)benzoate as starting
material (Yield: 86%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.71 (d, J=1.2 Hz, 1H), 7.61 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.28 (d,
J=8.4 Hz, 1H), 6.75 (s, 2H), 4.47-4.40 (m, 2H), 4.30 (q, J=7.6 Hz,
2H), 3.55 (t, J=6.8 Hz, 2H), 3.03 (s, 3H), 1.31 (t, J=6.8 Hz,
3H).
Step-d: Synthesis of ethyl
1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylate
[0427] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-(2-(methylsulfonyl)ethyl)-1H-benzo[d]imidazole-5-carboxylate
and 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting
materials (Yield: 24%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 13.4 (bs, 1H), 8.25 (d, J=1.6 Hz, 1H), 7.89 (dd, J=1.2 Hz,
J=8.0 Hz, 1H), 7.63-7.61 (m, 2H), 7.54 (d, J=8.8 Hz, 1H), 7.56-7.51
(m, 1H), 4.61 (t, J=6.8 Hz, 2H), 4.34 (q, J=7.2 Hz, 2H), 3.73 (d),
J=6.8 Hz, 2H), 3.14 (s, 3H), 1.35 (t, J=7.6 Hz, 3H); LC-MS: m/z
513.05 (M+1).sup.+.
Step-e: Synthesis of
1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylic acid
[0428] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 17%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.8
(bs, 1H), 12.4 (bs, 1H), 8.20 (d, J=1.2 Hz, 1H), 7.88 (dd, J=1.2
Hz, J=8.0 Hz, 1H), 7.61-7.59 (m, 2H), 7.54 (d, J=8.4 Hz, 1H), 7.22
(d, J=8.8 Hz, 1H), 4.61 (t, J=6.8 Hz, 2H), 3.72 (t, J=6.8 Hz, 2H),
3.14 (s, 3H); LC-MS: m/z 484.9 (M+1).sup.+.
Step-f: Synthesis of
N-(2-methoxyethyl)-1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)be-
nzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0429] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-(2-(methylsulfonyl)ethyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxylic acid and
2-methoxyethylamine as starting materials (Yield: 32%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.48 (t, J=5.2 Hz,
1H), 8.08 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.67-7.54 (m, 3H), 7.21
(d, J=9.6 Hz, 1H), 4.60 (t, J=6.8 Hz, 2H), 3.74 (t, J=10.8 confirm
coupling constant Hz, 2H), 3.48-3.44 (m, 4H), 3.28 (s, 3H), 3.14
(s, 3H); LC-MS: m/z 542.0 (M+1).sup.+.
Example 91. Synthesis of
2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-car-
boxylic acid
##STR00067##
[0430] Step-a: Synthesis of 2-amino-5-bromophenol
[0431] To a solution of 5-bromo-2-nitrophenol (4.0 g, 18.35 mmol)
in ethanol (60 mL) at RT was added SnCl.sub.2.2H.sub.2O (20.6 g,
91.74 mmol) and the reaction mixture was refluxed for 4 h. The
reaction mixture was cooled to RT, concentrated under reduced
pressure. The residue was diluted with water (20 mL) and basified
with saturated aqueous sodium bicarbonate solution, extracted with
ethyl acetate (2.times.100 mL). The combined organic layer was
washed with water (50 mL), brine (30 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum to afford the title
compound (2.4 g, 70%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
9.44 (bs, 1H), 6.75 (d, J=2.4 Hz, 1H), 6.67 (dd, J=2.0 Hz, J=8.4
Hz, 1H), 6.51 (d, J=8.4 Hz, 1H), 4.65 (bs, 2H); LC-MS: m/z 190.0
(M+1).sup.+.
Step-b: Synthesis of 6-bromobenzo[d]oxazole-2-thiol
[0432] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-bromophenol as starting material (Yield: 98%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 14.0 (bs, 1H), 7.84 (d, J=1.6
Hz, 1H), 7.47 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H);
LC-MS: m/z 227.9 (M-1).sup.-.
Step-c: Synthesis of 6-bromo-2-chlorobenzo[d]oxazole
[0433] To a solution of 6-bromobenzo[d]oxazole-2-thiol (2.89 g,
12.56 mmol) in thionyl chloride (20 mL) at RT was added
N,N-dimethylformamide (0.2 mL) and the reaction mixture was
refluxed for 3 h. The reaction mixture was concentrated, diluted
with cold water (50 mL) and extracted with EtOAc (2.times.50 mL).
The combined organic layers were washed with saturated aqueous
sodium bicarbonate solution (50 mL), brine solution (40 mL), dried
over anhydrous sodium sulfate and concentrated under vacuum to
afford the title compound (2.8 g, 96%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.14 (s, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.62
(dd, J=2.0 Hz, J=8.8 Hz, 1H).
Step-d: Synthesis of ethyl
2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-car-
boxylate
[0434] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
6-bromo-2-chlorobenzo[d]oxazole as starting materials (Yield: 20%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.56 (bs, 1H), 8.23
(d, J=1.6 Hz, 1H), 7.88 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.72 (d,
J=1.6 Hz, 1H), 7.54 (d, J=8.8 Hz, 1H), 7.38-7.36 (m, 2H), 4.33 (q,
J=7.2 Hz, 2H), 3.64 (s, 3H), 1.35 (t, J=7.2 Hz, 3H); LC-MS: m/z
416.9 (M+1).sup.+.
Step-e: Synthesis of
2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-car-
boxylic acid
[0435] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-bromobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-car-
boxylate as starting material (Yield: 75%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (s, 1H),
7.87 (d, J=8.4 Hz, 1H), 7.71 (d, J=1.6 Hz, 1H), 7.51 (d, J=8.8 Hz,
1H), 7.42-7.35 (m, 2H), 3.64 (s, 3H); LC-MS: m/z 388.9
(M+1).sup.+.
Example 92. Synthesis of
N-(2-hydroxyethyl)-2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxamide
##STR00068##
[0436] Step-a: Synthesis of 5-methoxy-2-nitrophenol
[0437] To a stirred suspension of sodium methoxide (0.86 g, 18.35
mmol) in methanol (50 mL) at RT was added a solution of
5-fluoro-2-nitrophenol (3.0 g, 19.1 mmol) in methanol (40 mL)
through a syringe and the reaction mixture was heated at 60.degree.
C. for 40 h. The reaction mixture was cooled to RT, quenched with
cold water (50 mL), acidified with 1 N HCl and extracted with ethyl
acetate (2.times.100 mL). The combined organic layer was washed
with water (50 mL), brine (50 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
combiflash chromatography using 3% ethyl acetate in hexane as an
eluent to afford the title compound (2.0 g, 62%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 10.94 (s, 1H), 7.97 (d, J=9.6 Hz, 1H),
6.63 (d, J=2.4 Hz, 1H), 6.59 (dd, J=3.0 Hz, J=9.2 Hz, 1H), 3.83 (s,
3H); LC-MS: m/z 167.95 (M-1).sup.-.
Step-b: Synthesis of 2-amino-5-methoxyphenol
[0438] The title compound was synthesized using the same procedure
which was followed for compound 1e using 5-methoxy-2-nitrophenol as
starting material (Yield: 96%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.8 (bs, 1H), 6.49 (d, J=8.4 Hz, 1H), 6.30
(d, J=2.1 Hz, 1H), 6.18-6.14 (m, 1H), 3.58 (s, 3H); LC-MS: m/z
140.15 (M+1).sup.+.
Step-c: Synthesis of 6-methoxybenzo[d]oxazole-2-thiol
[0439] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-methoxyphenol as starting material (Yield: 72%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 13.7 (s, 1H), 7.21 (d, J=2.4
Hz, 1H), 7.13 (d, J=8.4 Hz, 1H), 6.88 (dd, J=2.0 Hz, J=8.4 Hz, 1H),
3.77 (s, 3H); LC-MS: m/z 182.0 (M+1).sup.+.
Step-d: Synthesis of 2-chloro-6-methoxybenzo[d]oxazole
[0440] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-methoxybenzo[d]oxazole-2-thiol as starting material and stirred
for 2 h (Yield: 91%); LC-MS: m/z 184.0 (M+1).sup.+.
Step-e: Synthesis of ethyl
2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-c-
arboxylate
[0441] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-methoxybenzo[d]oxazole as starting materials (Yield:
18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H),
8.21 (d, J=1.4 Hz, 1H), 7.87 (dd, J=1.2 Hz, J=8.4 Hz, 1H), 7.50 (d,
J=8.0 Hz, 1H), 7.36 (d, J=8.4 Hz, 1H), 7.13 (d, J=2.0 Hz, 1H), 6.83
(dd, J=2.4 Hz, J=8.4 Hz, 1H), 4.33 (q, J=6.8 Hz, 2H), 3.82 (s, 3H),
3.62 (s, 3H), 1.35 (t, J=7.2 Hz, 3H); LC-MS: m/z 367.0
(M+1).sup.+.
Step-f: Synthesis of
2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-c-
arboxylic acid
[0442] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-c-
arboxylate as starting material (Yield: 79%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.5 (bs, 2H), 8.17 (s, 1H), 7.85 (dd, J=1.6
Hz, J=8.4 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 7.37 (d, J=8.8 Hz, 1H),
7.12 (d, J=2.0 Hz, 1H), 6.82 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 3.79 (s,
3H), 3.62 (s, 3H); LC-MS: m/z 339.0 (M+1).sup.+.
Step-g: Synthesis of
N-(2-hydroxyethyl)-2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxamide
[0443] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-methoxybenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-c-
arboxylic acid and 2-aminoethan-1-ol as starting materials (Yield:
59%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.18 (bs, 1H),
8.35 (t, J=5.2 Hz, 1H), 8.05 (d, J=1.2 Hz, 1H), 7.75 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.11
(d, J=2.4 Hz, 1H), 6.81 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.72 (bs,
1H), 3.78 (s, 3H), 3.61 (s, 3H), 3.53 (t, J=6.0 Hz, 2H), 3.35-3.30
(m, 2H); LC-MS: m/z 382.0 (M+1).sup.+.
Examples 93 and 94. Synthesis of
1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and Synthesis of
1-((3-hydroxyoxetan-3-yl)methyl)-N-(2-methoxyethyl)-2-((6-(trifluorometho-
xy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00069## ##STR00070##
[0444] Step-a: Synthesis of 3-(nitromethyl)oxetan-3-ol
[0445] To a solution of oxetan-3-one (10.0 g, 138.9 mmol) in
nitromethane (25 mL) at 0.degree. C. was added triethylamine (5 mL,
347.2 mmol) and the reaction mixture was stirred at RT for 16 h.
The reaction mixture was concentrated under reduced pressure. The
residue was purified by combi flash column chromatography using 40%
ethyl acetate in hexane as an eluent to afford the title compound
(14.0 g, 77%) as pale yellow liquid; .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 4.82 (s, 2H), 4.71 (d, J=8.0 Hz, 2H), 4.61 (d,
J=8.0 Hz, 2H), 3.53 (s, 1H).
Step-b: Synthesis of 3-(aminomethyl)oxetan-3-ol
[0446] To a solution of 3-(nitromethyl)oxetan-3-ol (5.0 g, 37.6
mmol) in methanol (80 mL) was added a slurry of 10% Pd/C (2.0 g in
20 mL methanol) under nitrogen atmosphere. Then the reaction
mixture was stirred under hydrogen gas balloon for 3 h. The
reaction mixture was filtered through a bed of celite and
concentrated under vacuum to afford the title compound (3.8 g,
98%); LC-MS: m/z 104.2 (M+1).sup.+.
Step-c: Synthesis of ethyl
4-(((3-hydroxyoxetan-3-yl)methyl)amino)-3-nitrobenzoate
[0447] The title compound was synthesized using the same procedure
which was followed for compound 3a using ethyl
4-chloro-3-nitrobenzoate and 3-(aminomethyl)oxetan-3-ol as starting
materials heating to 60.degree. C. (Yield: 54%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 8.62 (d, J=1.6 Hz, 1H), 8.53 (bs, 1H),
7.99 (dd, J=2.0 Hz, J=9.2 Hz, 1H), 7.29 (d, J=9.2 Hz, 1H), 6.35 (s,
1H), 4.51 (d, J=6.8 Hz, 2H), 4.44 (d, J=6.8 Hz, 2H), 4.29 (q, J=7.2
Hz, 2H), 3.75 (d, J=5.2 Hz, 2H), 1.31 (t, J=6.8 Hz, 3H); LC-MS: m/z
297.1 (M+1).sup.+.
Step-d: Synthesis of ethyl
3-amino-4-(((3-hydroxyoxetan-3-yl)methyl)amino)benzoate
[0448] The title compound was synthesized using the same procedure
which was followed for compound 1e using ethyl
4-(((3-hydroxyoxetan-3-yl)methyl)amino)-3-nitrobenzoate as starting
material (Yield: 95%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.23-7.20 (m, 2H), 6.57 (d, J=8.4 Hz, 1H), 5.96 (bs, 1H), 5.04 (bs,
1H), 4.75 (s, 2H), 4.46-4.43 (m, 4H), 4.19 (q, J=7.2 Hz, 2H), 3.40
(d, J=5.6 Hz, 2H), 1.26 (t, J=6.8 Hz, 3H); LC-MS: m/z 267.1
(M+1).sup.+.
Step-e: Synthesis of ethyl
2-amino-1-((3-hydroxyoxetan-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxyla-
te
[0449] The title compound was synthesized using the same procedure
which was followed for compound if using ethyl
3-amino-4-(((3-hydroxyoxetan-3-yl)methyl)amino)benzoate as starting
material (Yield: 70%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.72 (s, 1H), 7.59 (dd, J=1.6 Hz, J=8.0 Hz, 1H), 7.35 (d, J=8.0 Hz,
1H), 6.56 (s, 2H), 6.45 (s, 1H), 4.55 (d, J=6.4 Hz, 2H), 4.43 (d,
J=6.0 Hz, 2H), 4.34 (s, 2H), 4.28 (q, J=6.8 Hz, 2H), 1.32 (t, J=5.2
Hz, 3H); LC-MS: m/z 292.1 (M+1).sup.+.
Step-f: Synthesis of ethyl
1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylate
[0450] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-((3-hydroxyoxetan-3-yl)methyl)-1H-benzo[d]imidazole-5-carboxyla-
te and 2-chloro-6-(trifluoromethoxy)benzo[d]oxazole as starting
materials (Yield: 18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.4 (bs, 1H), 8.24 (d, J=1.6 Hz, 1H), 7.85 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.60-7.58 (m, 2H), 7.53 (d, J=8.4 Hz, 1H), 7.23 (dd,
J=1.2 Hz, J=8.8 Hz, 1H), 6.18 (s, 1H), 4.79 (d, J=6.8 Hz, 2H), 4.50
(bs, 2H), 4.46 (d, J=6.8 Hz, 2H), 4.33 (q, J=6.8 Hz, 2H), 1.35 (t,
J=7.6 Hz, 3H); LC-MS: m/z 493.0 (M+1).sup.+.
Step-g: Synthesis of
1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid
[0451] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylate as starting material
(Yield: 49%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.8
(bs, 1H), 12.3 (bs, 1H), 8.19 (d, J=1.2 Hz, 1H), 7.84 (dd, J=1.2
Hz, J=8.0 Hz, 1H), 7.60-7.52 (m, 3H), 7.22 (dd, J=1.6 Hz, J=8.4 Hz,
1H), 6.18 (s, 1H), 4.79 (d, J=6.4 Hz, 2H), 4.51 (s, 2H), 4.46 (d,
J=6.4 Hz, 2H); LC-MS: m/z 465.1 (M+1).sup.+.
Step-h: Synthesis of
1-((3-hydroxyoxetan-3-yl)methyl)-N-(2-methoxyethyl)-2-((6-(trifluorometho-
xy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0452] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and
2-methoxyethylamine as starting materials. Crude product was
purified by combiflash chromatography using 2% methanol in DCM as
an eluent to afford the title compound (Yield: 28%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.43 (t, J=5.2 Hz,
1H), 8.07 (s, 1H), 7.73 (d, J=8.8 Hz, 1H), 7.58 (s, 1H), 7.55-7.51
(m, 2H), 7.21 (d, J=8.4 Hz, 1H), 6.17 (s, 1H), 4.79 (d, J=6.8 Hz,
2H), 4.50 (s, 2H), 4.46 (d, J=6.4 Hz, 2H), 3.49-3.43 (m, 4H), 3.28
(s, 3H); LC-MS: m/z 522.0 (M+1).sup.+.
Example 95. Synthesis of
N-(2-hydroxyethyl)-1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluorometho-
xy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00071##
[0454] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-((3-hydroxyoxetan-3-yl)methyl)-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxylic acid and
2-aminoethan-1-ol as starting materials. Crude product was purified
by combiflash chromatography using 3% methanol in DCM as an eluent
to afford the title compound (Yield: 15%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.35 (t, J=5.6 Hz, 1H), 8.07
(d, J=1.2 Hz, 1H), 7.73 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.58 (s, 1H),
7.58-7.51 (m, 2H), 7.22 (dd, J=1.2 Hz, J=10.0 Hz, 1H), 6.17 (s,
1H), 4.80 (d, J=6.8 Hz, 2H), 4.71 (t, J=5.2 Hz, 1H), 4.51 (s, 2H),
4.46 (d, J=6.4 Hz, 2H), 3.55-3.51 (m, 2H), 3.37-27 (m, 2H); LC-MS:
m/z 508.45 (M+1).sup.+.
Examples 96 and 97. Synthesis of
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and Synthesis of
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
##STR00072##
[0455] Step-a: Synthesis of 6-chlorobenzo[d]oxazole-2-thiol
[0456] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-chlorophenol as starting material (Yield: 69%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 14.0 (bs, 1H), 7.73 (d, J=2.0
Hz, 1H), 7.35 (dd, J=1.6 Hz, J=8.0 Hz, 1H), 7.23 (d, J=8.8 Hz, 1H);
LC-MS: m/z 184.0 (M-1).sup.-.
Step-b: Synthesis of 2,6-dichlorobenzo[d]oxazole
[0457] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-chlorobenzo[d]oxazole-2-thiol as starting material (Yield: 69%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.01 (d, J=1.6 Hz,
1H), 7.77 (d, J=8.4 Hz, 1H), 7.51 (dd, J=2.0 Hz, J=8.4 Hz, 1H).
Step-c: Synthesis of ethyl
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate
[0458] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2,6-dichlorobenzo[d]oxazole as starting materials (Yield: 24%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.23
(d, J=1.6 Hz, 1H), 7.88 (d, J=8.0 Hz, 1H), 7.60 (d, J=2.0 Hz, 1H),
7.53 (d, J=8.4 Hz, 1H), 7.44 (d, J=8.0 Hz, 1H), 7.25 (dd, J=2.0 Hz,
J=8.0 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.64 (s, 3H), 1.35 (t, J=7.2
Hz, 3H); LC-MS: m/z 369.0 (M-1).sup.-.
Step-d: Synthesis of
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid
[0459] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate as starting material (Yield: 81%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.3 (bs, 1H), 8.19 (d, J=1.2
Hz, 1H), 7.87 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.59 (d, J=2.0 Hz, 1H),
7.51 (d, J=8.4 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.24 (dd, J=2.0 Hz,
J=8.4 Hz, 1H), 3.64 (s, 3H); LC-MS: m/z 342.9 (M+1).sup.+.
Step-e: Synthesis of
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-methyl-1H-ben-
zo[d]imidazole-5-carboxamide
[0460] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-chlorobenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and 2-aminoethan-1-ol as starting materials (Yield:
53%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H),
8.37 (t, J=5.6 Hz, 1H), 8.08 (s, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.58
(d, J=2.0 Hz, 1H), 7.49 (d, J=8.8 Hz, 1H), 7.44 (d, J=8.4 Hz, 1H),
7.24 (dd, J=2.0 Hz, J=8.4 Hz, 1H), 4.72 (t, J=5.2 Hz, 1H), 3.64 (s,
3H), 3.55-3.51 (m, 2H), 3.37-3.33 (m, 2H); LC-MS: m/z 386.1
(M+1).sup.+.
Examples 98 and 99. Synthesis of
1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxylic acid and Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00073##
[0461] Step-a: Synthesis of
2-(benzyloxy)-4-fluoro-1-nitrobenzene
[0462] To a stirred solution of 5-fluoro-2-nitrophenol (8.0 g, 50.9
mmol) in DMFA (80 mL) at 0.degree. C. was added potassium carbonate
(14.0 g, 101.8 mmol) and benzyl bromide (5.4 mL, 45.8 mmol) and the
reaction mixture was stirred at RT for 16 h. The reaction mixture
was diluted with water (200 mL) and extracted with ethyl acetate
(2.times.200 mL). The combined organic layer was washed with water
(2.times.200 mL), brine (50 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
combiflash chromatography using 10% ethyl acetate in hexane as an
eluent to afford the title compound (8.0 g, 64%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 8.06-8.02 (m, 1H), 7.47-7.36 (m, 6H),
7.05-6.95 (m, 1H), 5.33 (s, 2H).
Step-b: Synthesis of
2-(benzyloxy)-1-nitro-4-(2,2,2-trifluoroethoxy)benzene
[0463] To a solution of trifluoroethanol (0.23 mL, 3.24 mmol) in
THF (10 mL) at 0.degree. C. was added sodium hydride (60%
dispersion in mineral oil) (194 mg, 4.86 mmol) by portions and
stirred for 1 h. Then a solution of
2-(benzyloxy)-4-fluoro-1-nitrobenzene (400 mg, 1.62 mmol) was added
to the reaction mixture and stirred at RT for 2 h. The reaction
mixture was concentrated and diluted with cold water (20 mL). Solid
precipitated was filtered and dried under vacuum to afford the
title compound (350 mg, 66%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.01 (d, J=9.2 Hz, 1H), 7.48-7.33 (m, 5H), 7.11 (d, J=2.8
Hz, 1H), 6.82 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 5.32 (s, 2H), 4.94 (q,
J=8.8 Hz, 2H).
Step-c: Synthesis of 2-amino-5-(2,2,2-trifluoroethoxy)phenol
[0464] To a solution of
2-(benzyloxy)-1-nitro-4-(2,2,2-trifluoroethoxy)benzene (350 mg,
1.07 mmol) in methanol (10 mL) was added 10% Pd/C (50 mg) under
nitrogen atmosphere. The reaction mixture was stirred under
hydrogen gas balloon for 16 h. The reaction mixture was filtered
through a bed of celite and concentrated under vacuum to afford the
title compound (210 mg, 95%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 6.51 (d, J=8.8 Hz, 1H), 6.38 (d, J=2.4 Hz, 1H), 6.28 (dd,
J=2.8 Hz, J=8.8 Hz, 1H), 4.48 (q, J=8.8 Hz, 2H); LC-MS: m/z 208.0
(M+1).sup.+.
Step-d: Synthesis of
6-(2,2,2-trifluoroethoxy)benzo[d]oxazole-2-thiol
[0465] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-(2,2,2-trifluoroethoxy)phenol as starting material
(Yield: 79%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.8
(bs, 1H), 7.38 (d, J=2.4 Hz, 1H), 7.18 (d, J=8.8 Hz, 1H), 7.01 (dd,
J=2.4 Hz, J=8.8 Hz, 1H), 4.79 (q, J=8.8 Hz, 2H); LC-MS: m/z 250.0
(M+1).sup.+.
Step-e: Synthesis of
2-chloro-6-(2,2,2-trifluoroethoxy)benzo[d]oxazole
[0466] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-(2,2,2-trifluoroethoxy)benzo[d]oxazole-2-thiol as starting
material and stirring for 2 h. (Yield: 87%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.69 (d, J=8.8 Hz, 1H), 7.60 (d, J=2.4 Hz,
1H), 6.15 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.85 (q, J=8.8 Hz, 2H).
Step-f: Synthesis of ethyl
1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxylate
[0467] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-(2,2,2-trifluoroethoxy)benzo[d]oxazole starting
materials (Yield: 21%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.3 (bs, 1H), 8.22 (d, J=1.6 Hz, 1H), 7.88 (dd, J=1.2 Hz,
J=8.0 Hz, 1H), 7.51 (d, J=8.4 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 7.29
(d, J=2.4 Hz, 1H), 6.94 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 4.77 (q,
J=8.8 Hz, 2H), 4.33 (q, J=7.2 Hz, 2H), 3.63 (s, 3H), 1.35 (t, J=7.2
Hz, 3H); LC-MS: m/z 435.35 (M+1).sup.+.
Step-g: Synthesis of
1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxylic acid
[0468] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxylate as starting material (Yield: 62%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.5 (bs, 2H), 8.18
(d, J=1.2 Hz, 1H), 7.86 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.48 (d,
J=8.8 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H), 7.29 (d, J=2.4 Hz, 1H), 6.93
(dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.77 (q, J=9.2 Hz, 2H), 3.62 (s, 3H);
LC-MS: m/z 407.0 (M+1).sup.+.
Step-h: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0469] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxylic acid and 2-methoxyethylamine as starting
materials (Yield: 70%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.2 (bs, 1H), 8.4 (t, J=5.6 Hz, 1H), 8.06 (s, 1H), 7.75
(d, J=8.0 Hz, 1H), 7.46 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H),
7.28 (d, J=1.6 Hz, 1H), 6.93 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 4.77 (q,
J=8.8 Hz, 2H), 3.62 (s, 3H), 3.48-3.43 (m, 4H), 3.28 (s, 3H);
LC-MS: m/z 464.0 (M+1).sup.+.
Example 100. Synthesis of
N-(2-hydroxyethyl)-1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-
-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00074##
[0471] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(2,2,2-trifluoroethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo-
[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting
materials (Yield: 63%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.5 (bs, 1H), 8.42 (t, J=5.2 Hz, 1H), 8.07 (s, 1H), 7.81
(d, J=8.4 Hz, 1H), 7.53 (d, J=8.4 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H),
7.32 (d, J=2.4 Hz, 1H), 6.98 (dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.80 (q,
J=8.8 Hz, 2H), 3.66 (s, 3H), 3.54 (t, J=6.4 Hz, 2H), 3.36 (q, J=6.0
Hz, 2H); LC-MS: m/z 450.0 (M+1).sup.+.
Examples 101 and 102. Synthesis of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and Synthesis of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
##STR00075##
[0472] Step-a: Synthesis of 3-(benzyloxy)-4-nitrophenol
[0473] To a stirred suspension of
2-(benzyloxy)-4-fluoro-1-nitrobenzene (4.0 g, 16.2 mmol) in water
(70 mL) at RT was added potassium hydroxide (4.53 g, 80.9 mmol) and
the reaction mixture was stirred at 100.degree. C. for 30 h. The
reaction mixture was cooled to RT, diluted with water (50 mL) and
acidified with 1 N HCl and extracted with ethyl acetate
(3.times.100 mL). The combined organic layer was washed with water
(50 mL), brine (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to obtain the residue which was purified
by combiflash chromatography using 20% ethyl acetate in hexane as
an eluent to afford the title compound (1.5 g, 38%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 10.88 (s, 1H), 7.90 (d, J=8.8 Hz,
1H), 7.49-7.47 (m, 2H), 7.43-7.40 (m, 2H), 7.35 (d, J=6.8 Hz, 1H),
6.69 (d, J=2.4 Hz, 1H), 6.49 (dd, J=2.4 Hz, J=9.2 Hz, 1H), 5.25 (s,
2H).
Step-b: Synthesis of
(2-(3-(benzyloxy)-4-nitrophenoxy)ethoxy)(tert-butyl)dimethylsilane
[0474] To a stirred solution of 3-(benzyloxy)-4-nitrophenol (1.5 g,
6.1 mmol) in DMFA (15 mL) at RT was added potassium carbonate (2.1
g, 15.3 mmol) and (2-bromoethoxy)(tert-butyl)dimethylsilane (1.75
g, 7.3 mmol) in a seal tube and heated at 130.degree. C. for 4 h.
The reaction mixture was cooled to RT, diluted with water (50 mL)
and extracted with ethyl acetate (2.times.50 mL). The combined
organic layer was washed with water (2.times.500 mL), brine (30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum to obtain the residue which was purified by combiflash
chromatography using 5% ethyl acetate in hexane as an eluent to
afford the title compound (8.0 g, 64%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.96 (d, J=8.8 Hz, 1H), 7.49-7.47 (m, 2H),
7.43-7.39 (m, 2H), 7.36-7.34 (m, 1H), 6.89 (d, J=2.4 Hz, 1H), 6.67
(dd, J=2.4 Hz, J=9.2 Hz, 1H), 5.32 (s, 2H), 4.17 (t, J=4.4 Hz, 2H),
3.92 (t, J=4.8 Hz, 2H), 0.86 (s, 9H), 0.02 (s, 6H).
Step-c: Synthesis of
2-amino-5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenol
[0475] The title compound was synthesized using the same procedure
which was followed for compound 1e using
(2-(3-(benzyloxy)-4-nitrophenoxy)ethoxy)(tert-butyl)dimethylsilane
as starting material (Yield: 87%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 6.47 (d, J=8.0 Hz, 1H), 6.30 (d, J=2.8 Hz,
1H), 6.15 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 3.84-3.80 (m, 4H), 0.87 (s,
9H), 0.02 (s, 6H); LC-MS: m/z 284.1 (M+1).sup.+.
Step-d: Synthesis of
6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazole-2-thiol
[0476] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenol as
starting material (Yield: 77%). The crude compound was used in the
next step without any analytical data.
Step-e: Synthesis of
6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylthio)benzo[d]oxazole
[0477] The title compound was synthesized using the same procedure
which was followed for compound 1b using
6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazole-2-thiol
as starting material and stirring for 16 h. (Yield: 80%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 7.50 (d, J=8.8 Hz, 1H), 7.28
(d, J=2.4 Hz, 1H), 6.91 (dd, J=2.8 Hz, J=8.8 Hz, 1H), 4.06 (t,
J=4.4 Hz, 2H), 3.92 (t, J=5.2 Hz, 2H), 2.27 (s, 3H), 0.86 (s, 9H),
0.2 (s, 6H); LC-MS: m/z 340.0 (M+1).sup.+.
Step-f: Synthesis of
6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylsulfonyl)-benzo[d]oxa-
zole
[0478] The title compound was synthesized using the same procedure
which was followed for compound 1c using
6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylthio)benzo[d]oxazole
as starting material and stirring for 4 h (Yield: 100%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 7.90-7.89 (m, 1H), 7.55 (d,
J=8.0 Hz, 1H), 6.99-6.97 (m, 1H), 4.10 (t, J=4.8 Hz, 2H), 3.95 (t,
J=5.2 Hz, 2H), 3.62 (s, 3H), 0.85 (s, 9H), 0.2 (s, 6H).
Step-g: Synthesis of ethyl
2-((6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazol-2-yl)amino)--
1-methyl-1H-benzo[d]imidazole-5-carboxylate
[0479] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-(methylsulfonyl)benzo[d]oxaz-
ole as starting materials (Yield: 17%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.2 (bs, 1H), 8.21 (d, J=1.6 Hz, 1H), 7.86
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H), 7.35 (d,
J=8.4 Hz, 1H), 7.12 (d, J=2.4 Hz, 1H), 6.81 (dd, J=1.6 Hz, J=8.0
Hz, 1H), 4.32 (q, J=7.6 Hz, 2H), 4.06-4.04 (m, 2H), 3.94-3.92 (m,
2H), 3.62 (s, 3H), 1.35 (t, J=6.8 Hz, 3H), 0.88 (s, 9H), 0.2 (s,
6H); LC-MS: m/z 511.1 (M+1).sup.+.
Step-h: Synthesis of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0480] To a stirred solution of ethyl
2-((6-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzo[d]oxazol-2-yl)amino)--
1-methyl-1H-benzo[d]imidazole-5-carboxylate (80 mg, 0.15 mmol) in a
mixture of solvent of THF (2 mL), ethanol (2 mL) and water (1 mL)
was added lithium hydroxide monohydrate (32 mg, 0.78 mmol). The
reaction mixture was heated at 60.degree. C. for 16 h with
stirring. The reaction mixture was cooled to RT and concentrated
under reduced pressure. The residue was dissolved in water (20 mL)
and acidified with 1 N HCl. The solid obtained was filtered and
dried under vacuum to afford the title compound (50 mg, 87%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.3
(bs, 1H), 8.16 (d, J=1.6 Hz, 1H), 7.85 (dd, J=1.6 Hz, J=8.4 Hz,
1H), 7.46 (d, J=8.4 Hz, 1H), 7.36 (d, J=8.4 Hz, 1H), 7.12 (d, J=2.4
Hz, 1H), 6.82 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 4.85 (bs, 1H), 4.01 (t,
J=4.8 Hz, 2H), 3.75-3.73 (m, 2H), 3.66 (s, 3H); LC-MS: m/z 369.0
(M+1).sup.+.
Step-i: Synthesis of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
[0481] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-methoxyethylamine as starting
materials. The crude product was purified by combiflash
chromatography using 4% methanol in DCM as an eluent (Yield: 17%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 1H), 8.43
(t, J=5.2 Hz, 1H), 8.05 (d, J=1.2 Hz, 1H), 7.75 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.12
(d, J=2.4 Hz, 1H), 6.82 (dd, J=2.8 Hz, J=8.8 Hz, 1H), 4.11 (t,
J=4.4 Hz, 2H), 3.66 (t, J=4.4 Hz, 2H), 3.61 (s, 3H), 3.49-3.41 (m,
4H), 3.28 (bs, 1H), 3.24 (s, 3H); LC-MS: m/z 426.4 (M+1).sup.+.
Example 103. Synthesis of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyethyl)-1-me-
thyl-1H-benzo[d]imidazole-5-carboxamide
##STR00076##
[0483] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-aminoethan-1-ol as starting
materials. The crude product was purified by combiflash
chromatography using 6% methanol in DCM as an eluent to afford the
title compound (Yield: 18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.05 (bs, 1H), 8.35 (t, J=5.2 Hz, 1H), 8.05 (s, 1H), 7.75
(d, J=8.0 Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H),
7.11 (d, J=2.4 Hz, 1H), 6.82 (dd, J=2.8 Hz, J=8.8 Hz, 1H), 4.85
(bs, 1H), 4.72 (t, J=4.8 Hz, 1H), 4.01 (t, J=4.8 Hz, 2H), 3.72 (q,
J=4.4 Hz, 2H), 3.61 (s, 3H), 3.53 (q, J=5.6 Hz, 2H), 3.37-3.33 (m,
2H); LC-MS: m/z 412.0 (M+1).sup.+.
Example 104. Synthesis of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-N-(2-(2-hydroxyethoxy)e-
thyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00077##
[0485] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as
starting materials. The crude product was purified by combiflash
chromatography using 10% methanol in DCM as an eluent to afford the
title compound (Yield: 18%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.05 (bs, 1H), 8.41 (bs, 1H), 8.04 (s, 1H), 7.74 (d, J=8.4
Hz, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.11 (s,
1H), 6.82 (d, J=6.8 Hz, 1H), 4.61 (bs, 2H), 4.01 (t, J=4.4 Hz, 2H),
3.72 (t, J=4.8 Hz, 2H), 3.66 (s, 3H), 3.57-3.43 (m, 8H); LC-MS: m/z
456.3 (M+1).sup.+.
Example 105. Synthesis of
N-(2-aminoethyl)-2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-meth-
yl-1H-benzo[d]imidazole-5-carboxamide hydrochloride
##STR00078##
[0486] Step-a: Synthesis of tert-butyl
(2-(2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d-
]imidazole-5-carboxamido)ethyl)carbamate
[0487] To a stirred solution of
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid (100 mg, 0.27 mmol) in DMFA (2 mL) at
0.degree. C. was added N-ethyldiisopropyl amine (0.09 mL, 0.54
mmol) and HBTU (102 mg, 0.27 mmol). The reaction mixture was
stirred for 30 min, followed by the addition of tert-butyl
(2-aminoethyl)carbamate (48 mg, 0.30 mmol) and stirring was
continued at RT for 16 h. Once the reaction was complete, the
reaction mixture was diluted with water (15 mL) and stirred for 15
min. The obtained solid was filtered, dried under vacuum to get the
crude product which was purified by combiflash chromatography using
3% methanol in DCM as an eluent to afford the title compound (70
mg, 50%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs,
1H), 8.39 (bs, 1H), 8.05 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.45 (d,
J=8.4 Hz, 1H), 7.35 (d, J=8.0 Hz, 1H), 7.11 (d, J=2.0 Hz, 1H), 6.91
(bs, 1H), 6.82 (dd, J=2.0 Hz, J=8.4 Hz, 1H), 4.85 (bs, 1H), 4.01
(t, J=4.8 Hz, 2H), 3.72 (bs, 2H), 3.61 (s, 3H), 3.30 (2H merged
with DMSO moisture peak), 3.12 (d, J=6.0 Hz, 2H), 1.38 (s, 9H);
LC-MS: m/z 511.3 (M+1).sup.+.
Step-b: Synthesis of
N-(2-aminoethyl)-2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-meth-
yl-1H-benzo[d]imidazole-5-carboxamide hydrochloride
[0488] To a stirred solution of tert-butyl
(2-(2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d-
]imidazole-5-carboxamido)ethyl)carbamate (70 mg, 0.14 mmol) in
1,4-dioxane (3 mL) at 0.degree. C. was added 4 M HCl in 1,4-dioxane
(1 mL) and stirred at RT 3 h. The reaction mixture was concentrated
under reduced pressure and the residue was triturated with diethyl
ether and solvent was decanted. The obtained solid was dried under
vacuum to afford the title compound (35 mg, 57%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.5 (bs, 1H), 8.78 (s, 1H), 8.12-8.07
(m, 4H), 7.90 (d, J=8.0 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.36 (d,
J=8.4 Hz, 1H), 7.18 (s, 1H), 6.88 (d, J=8.0 Hz, 1H), 4.02 (bs, 2H),
3.73 (bs, 2H), 3.66 (s, 3H), 3.56 (q, J=5.2 Hz, 2H), 3.02 (q, J=5.6
Hz, 2H); LC-MS: m/z 411.2 (M+1).sup.+.
Example 106. Synthesis of
N-(2-((4,5-dihydro-1H-imidazol-2-yl)amino)ethyl)-2-((6-(2-hydroxyethoxy)b-
enzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00079##
[0490] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and
N1-(4,5-dihydro-1H-imidazol-2-yl)ethane-1,2-diamine as starting
materials (Yield: 58%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.73 (bs, 1H), 8.49 (s, 1H), 8.05 (s, 1H), 7.75 (d, J=8.4
Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.31 (d, J=8.4 Hz, 1H), 7.08 (d,
J=2.0 Hz, 1H), 6.79 (dd, J=1.6 Hz, J=8.0 Hz, 1H), 4.86 (bs, 1H),
4.00 (t, J=4.8 Hz, 2H), 3.72 (bs, 2H), 3.60-3.55 (m, 7H), 3.43 (bs,
2H), 3.30 (2H merged with DMSO moisture peak); LC-MS: m/z 479.2
(M+1).sup.+.
Examples 107 and 108. Synthesis of
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxylic acid and Synthesis of
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyet-
hyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00080##
[0491] Step-a: Synthesis of
4-fluoro-2-nitro-5-(trifluoromethyl)phenol
[0492] To a solution of 4-fluoro-3-(trifluoromethyl)phenol (1 g,
5.6 mmol) in acetic acid (20 mL) was added 60% aqueous nitric acid
(3 mL) in acetic acid (5 mL) dropwise at 10.about.15.degree. C. The
reaction mixture was stirred at room temperature for 2 h. Then the
mixture was poured into ice water (50 mL) and extracted with EtOAc
(3.times.50 mL). The combined organic layers were washed with water
(2.times.50 mL), brine solution (30 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum to obtain the crude
product which was purified by combiflash chromatography using 5%
EtOAc in hexanes as eluent to afford the title compound (700 mg,
22%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.71 (bs, 1H),
8.14 (d, J=10.4 Hz, 1H), 7.44 (d, J=5.6 Hz, 1H); LC-MS: m/z 224.0
(M-1).sup.-.
Step-b: Synthesis of 2-amino-4-fluoro-5-(trifluoromethyl)phenol
[0493] The title compound was synthesized using the same procedure
which was followed for compound 1e using
4-fluoro-2-nitro-5-(trifluoromethyl)phenol as starting material
(Yield: 82%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 9.54 (s,
1H), 6.78 (d, J=7.2 Hz, 1H), 6.48 (d, J=13.2 Hz, 1H), 5.5 (bs,
2H).
Step-c: Synthesis of
5-fluoro-6-(trifluoromethyl)benzo[d]oxazole-2-thiol
[0494] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-4-fluoro-5-(trifluoromethyl)phenol as starting material
(Yield: 82%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 14.4
(bs, 1H), 8.10 (d, J=5.6 Hz, 1H), 7.43 (d, J=9.6 Hz, 1H); LC-MS:
m/z 236.0 (M-1).sup.-.
Step-d: Synthesis of
2-chloro-5-fluoro-6-(trifluoromethyl)benzo[d]oxazole
[0495] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
5-fluoro-6-(trifluoromethyl)benzo[d]oxazole-2-thiol as starting
material and stirring for 2 h (Yield: 99%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.74 (d, J=6.0 Hz, 1H), 7.30 (d, J=10.0 Hz,
1H).
Step-e: Synthesis of ethyl
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxylate
[0496] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-5-fluoro-6-(trifluoromethyl)benzo[d]oxazole as starting
materials (Yield: 52%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.43 (bs, 1H), 8.22 (d, J=1.6 Hz, 1H), 7.88 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.83 (d, J=6.0 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.41
(d, J=11.2 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.66 (s, 3H), 1.35 (t,
J=7.2 Hz, 3H); LC-MS: m/z 423.0 (M+1).sup.+.
Step-f: Synthesis of
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxylic acid
[0497] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxylate as starting material (Yield: 86%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.4 (bs, 2H), 8.20
(s, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.84 (d, J=6.4 Hz, 1H), 7.55 (d,
J=8.8 Hz, 1H), 7.44 (d, J=11.2 Hz, 1H), 3.67 (s, 3H); LC-MS: m/z
395.1 (M+1).sup.+.
Step-g: Synthesis of
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyet-
hyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0498] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting
materials (Yield: 72%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.35 (bs, 1H), 8.40 (bs, 1H), 8.09 (s, 1H), 7.84-7.79 (m,
2H), 7.54 (d, J=8.4 Hz, 1H), 7.44 (d, J=11.6 Hz, 1H), 4.50 (bs,
1H), 3.67 (s, 3H), 3.54 (t, J=6.4 Hz, 2H), 3.38-3.33 (m, 2H);
LC-MS: m/z 438.0 (M+1).sup.+.
Example 109. Synthesis of
N-(2-methoxyethyl)-1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[-
d]imidazole-5-carboxamide
##STR00081##
[0499] Step-a: Synthesis of 3-aminopyridin-2-ol
[0500] The title compound was synthesized using the same procedure
which was followed for compound 1e using 3-nitropyridin-2-ol as
starting material (Yield: 85%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.3 (bs, 1H), 6.59 (dd, J=2.0 Hz, J=6.8 Hz,
1H), 6.43 (dd, J=2.4 Hz, J=6.8 Hz, 1H), 5.98 (t, J=6.0 Hz, 1H),
4.97 (bs, 2H); LC-MS: m/z 111.25 (M+1).sup.+.
Step-b: Synthesis of oxazolo[5,4-b]pyridine-2-thiol
[0501] To a solution of 3-aminopyridin-2-ol (500 mg, 4.5 mmol) in
THF (15 mL) at RT was added thiophosgene (0.41 mL, 5.4 mmol) slowly
over a period of 15 min and stirred at RT for 16 h. The reaction
mixture was quenched with saturated aqueous ammonium chloride
solution (9 mL) and concentrated. Aqueous layer was basified with
10 N sodium hydroxide solution (5 mL) and extracted with ethyl
acetate (2.times.30 mL), aqueous layer was acidified with 1 N HCl
and extracted with ethyl acetate (2.times.100 mL). The organic
layer was dried over anhydrous sodium sulfate and concentrated
under vacuum to get the residue which was purified by combiflash
chromatography using 2% methanol in DCM as an eluent to afford the
title compound (200 mg, 29%); LC-MS: m/z 153.15 (M+1).sup.+.
Step-c: Synthesis of 2-chlorooxazolo[5,4-b]pyridine
[0502] To a solution of oxazolo[5,4-b]pyridine-2-thiol (200 mg,
1.31 mmol) in thionyl chloride (5 mL) at RT was added
N,N-dimethylformamide (1 drop) and the reaction mixture was
refluxed for 2 h. The reaction mixture was concentrated under
reduced pressure and the crude compound was used in the next step
without any further purification (220 mg); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.40 (dd, J=1.6 Hz, J=4.8 Hz, 1H), 8.26 (dd,
J=1.2 Hz, J=7.6 Hz, 1H), 7.56-7.53 (m, 1H); LC-MS: m/z 155.1
(M+1).sup.+.
Step-d: Synthesis of ethyl
1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylate
[0503] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chlorooxazolo[5,4-b]pyridine as starting materials (Yield: 20%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.24 (s, 1H), 8.02 (d,
J=5.2 Hz, 1H), 7.89 (dd, J=1.6 Hz, J=8.8 Hz, 1H), 7.79 (d, J=7.2
Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.29-7.26 (m, 1H), 4.33 (q, J=7.2
Hz, 2H), 3.67 (s, 3H), 1.35 (t, J=6.8 Hz, 3H); LC-MS: m/z 338.15
(M+1).sup.+.
Step-e: Synthesis of
1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylic acid
[0504] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylate as starting material (Yield: 54%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.4 (bs, 1H), 8.20 (s, 1H),
8.01 (d, J=5.2 Hz, 1H), 7.89 (d, J=8.0 Hz, 1H), 7.79 (d, J=7.2 Hz,
1H), 7.54 (d, J=8.0 Hz, 1H), 7.28-7.25 (m, 1H), 3.67 (s, 3H);
LC-MS: m/z 310.1 (M+1).sup.+.
Step-f: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[-
d]imidazole-5-carboxamide
[0505] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylic acid and 2-methoxyethylamine as starting materials (Yield:
38%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.38 (bs, 1H),
8.47 (s, 1H), 8.09 (s, 1H), 8.0 (d, J=3.6 Hz, 1H), 7.79-7.77 (m,
2H), 7.52 (d, J=8.4 Hz, 1H), 7.27-7.24 (m, 1H), 3.66 (s, 3H),
3.48-3.44 (m, 4H), 3.28 (s, 3H); LC-MS: m/z 367.2 (M+1).sup.+.
Example 110. Synthesis of
N-(2-hydroxyethyl)-1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[-
d]imidazole-5-carboxamide
##STR00082##
[0507] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-(oxazolo[5,4-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylic acid and 2-aminoethan-1-ol as starting materials (Yield:
51%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H),
8.38 (bs, 1H), 8.09 (s, 1H), 8.01 (d, J=4.4 Hz, 1H), 7.80-7.76 (m,
2H), 7.52 (d, J=8.4 Hz, 1H), 7.25 (t, J=6.8 Hz, 1H), 4.72 (bs, 1H),
3.66 (s, 3H), 3.53 (bs, 2H), 3.35 (q, J=6.0 Hz, 2H); LC-MS: m/z
353.0 (M+1).sup.+.
Examples 111 and 112. Synthesis of
1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylic acid and Synthesis of
N-(2-methoxyethyl)-1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[-
d]imidazole-5-carboxamide
##STR00083##
[0508] Step-a: Synthesis of oxazolo[4,5-b]pyridine-2-thiol
[0509] To a solution of 2-aminopyridin-3-ol (2.2 g, 20 mmol) in
ethanol (40 mL) at RT was added potassium hydroxide (1.68 g, 30
mmol) and carbondisulfide (15 mL). The reaction mixture was
refluxed for 12 h, then cooled to RT, diluted with water (75 mL)
and neutralized with glacial acetic acid. A solid precipitated and
was filtered and dried under vacuum to afford the title compound
(1.8 g, 59%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 14.5 (s,
1H), 8.23 (dd, J=1.2 Hz, J=5.2 Hz, 1H), 7.88 (dd, J=1.6 Hz, J=8.4
Hz, 1H), 7.29-7.26 (m, 1H); LC-MS: m/z 153.1 (M+1).sup.+.
Step-b: Synthesis of 2-chlorooxazolo[4,5-b]pyridine
[0510] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
oxazolo[4,5-b]pyridine-2-thiol as starting material and heating for
2 h. (Yield: 100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
8.01 (dd, J=1.6 Hz, J=5.6 Hz, 1H), 7.61 (dd, J=1.2 Hz, J=8.0 Hz,
1H), 7.10-7.06 (m, 1H); LC-MS: m/z 155.01 (M+1).sup.+.
Step-c: Synthesis of ethyl
1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylate
[0511] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chlorooxazolo[4,5-b]pyridine as starting materials (Yield: 32%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.98 (s, 1H), 7.94 (d,
J=4.4 Hz, 1H), 7.62 (d, J=9.2 Hz, 1H), 7.36 (d, J=7.2 Hz, 1H),
7.21-7.18 (m, 1H), 6.77-6.74 (m, 1H), 4.32-4.26 (m, 2H), 3.57 (s,
3H), 1.38 (t, J=6.8 Hz, 3H); LC-MS: m/z 338.15 (M+1).sup.+.
Step-d: Synthesis of
1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylic acid
[0512] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylate as starting material (Yield: 73%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.83 (bs, 1H), 12.44 (bs, 1H), 8.26-8.23
(m, 2H), 7.89 (d, J=8.4 Hz, 1H), 7.78 (d, J=7.6 Hz, 1H), 7.75 (d,
J=8.4 Hz, 1H), 7.12-7.09 (m, 1H), 3.72 (s, 3H); LC-MS: m/z 310.15
(M+1).sup.+.
Step-e: Synthesis of
N-(2-methoxyethyl)-1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[-
d]imidazole-5-carboxamide
[0513] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-(oxazolo[4,5-b]pyridin-2-ylamino)-1H-benzo[d]imidazole-5-carbo-
xylic acid and 2-methoxyethylamine as starting materials (Yield:
53%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.4 (bs, 1H),
8.48 (bs, 1H), 8.23 (d, J=4.4 Hz, 1H), 8.13 (s, 1H), 7.79-7.75 (s,
2H), 7.53 (d, J=8.4 Hz, 1H), 7.11-7.08 (m, 1H), 3.67 (s, 3H),
3.48-3.44 (m, 4H), 3.29 (s, 3H); LC-MS: m/z 367.2 (M+1).sup.+.
Example 113. Synthesis of
N-(2-hydroxyethyl)-1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00084##
[0514] Step-a: Synthesis of
3-nitro-6-(trifluoromethyl)pyridin-2-ol
[0515] To a solution of 2-nitroacetamide (5.0 g, 47.8 mmol) in
ethanol (25 mL) at RT was added ethyl
(E)-5,5,5-trifluoro-4-oxopent-2-enoate (11.24 g, 57.3 mmol) and 25%
sodium ethoxide in ethanol (25.9 mL, 95.3 mmol). The reaction
mixture was stirred at 90.degree. C. for 2 h. Reaction mixture was
cooled to RT, diluted with water (50 mL), acidified with 1N HCl and
extracted with EtOAc (2.times.150 mL). The combined organic layers
were washed brine solution (50 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to get the residue which was
purified by combiflash chromatography using 50% EtOAc in hexanes as
eluent to afford the title compound (1.5 g); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.58 (d, J=8.4 Hz, 1H), 7.84 (bs, 1H), 7.51
(d, J=7.6 Hz, 1H).
Step-b: Synthesis of 3-amino-6-(trifluoromethyl)pyridin-2-ol
[0516] The title compound was synthesized using the same procedure
which was followed for compound 1e using
3-nitro-6-(trifluoromethyl)pyridin-2-ol as starting material
(Yield: 82%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.7
(bs, 1H), 6.88 (bs, 1H), 6.69 (bs, 1H), 5.60 (s, 2H); LC-MS: m/z
179.1 (M+1).sup.+.
Step-c: Synthesis of
5-(trifluoromethyl)oxazolo[5,4-b]pyridine-2-thiol
[0517] The title compound was synthesized using the same procedure
which was followed for Example 109 Step-b using
3-amino-6-(trifluoromethyl)pyridin-2-ol as starting material
(Yield: 65%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.81-7.75 (m, 2H); LC-MS: m/z 219.0 (M-1).
Step-d: Synthesis of
2-chloro-5-(trifluoromethyl)oxazolo[5,4-b]pyridine
[0518] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
5-(trifluoromethyl)oxazolo[5,4-b]pyridine-2-thiol as starting
material (Yield: 74%). The crude compound was used in the next step
without further purification.
Step-e: Synthesis of ethyl
1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylate
[0519] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-5-(trifluoromethyl)oxazolo[5,4-b]pyridine as starting
materials (Yield: 43%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.5 (bs, 1H), 8.27 (s, 1H), 7.93-7.89 (m, 2H), 7.75 (d,
J=12.4 Hz, 1H), 7.62 (d, J=8.4 Hz, 1H), 4.34 (q, J=6.8 Hz, 2H),
3.71 (s, 3H), 1.35 (t, J=7.2 Hz, 3H); LC-MS: m/z 406.1
(M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid
[0520] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylate as starting material (Yield: 75%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.20 (bs, 1H),
7.74-7.70 (m, 2H), 7.55 (d, J=6.8 Hz, 1H), 7.09 (d, J=8.4 Hz, 1H),
3.62 (s, 3H); LC-MS: m/z 378.1 (M+1).sup.+.
Step-g: Synthesis of
N-(2-hydroxyethyl)-1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0521] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((5-(trifluoromethyl)oxazolo[5,4-b]pyridin-2-yl)amino)-1H-benz-
o[d]imidazole-5-carboxylic acid and 2-aminoethan-1-ol as starting
materials (Yield: 28%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.22 (bs, 1H), 7.78 (bs, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.51
(bs, 1H), 7.31 (d, J=8.4 Hz, 2H), 4.70 (t, J=5.2 Hz, 1H), 3.67 (s,
3H), 3.50 (q, J=5.2 Hz, 2H), 3.36 (q, J=6.0 Hz, 2H); LC-MS: m/z
421.1 (M+1).sup.+.
Example 114. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-(thiazolo[4,5-b]pyrazin-2-ylamino-
)-1H-benzo[d]imidazole-5-carboxamide
##STR00085##
[0522] Step-a: Synthesis of 114a
[0523] To a stirred solution of pyrazin-2-amine (2.0 mg, 21.0 mmol)
in 1,4-dioxane (20 mL) at RT was added O-ethyl
carbonisothiocyanatidate (3.03 g, 23.1 mmol) and stirred at RT for
16 h. The reaction mixture was concentrated under vacuum. To the
residue ethyl acetate was added and the precipitated solid was
filtered and dried under vacuum to afford the title compound (2.0
g, 42%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.07 (s,
1H), 11.76 (s, 1H), 9.67 (s, 1H), 8.50 (s, 2H), 4.24 (q, J=7.2 Hz,
2H), 1.27 (t, J=7.2 Hz, 3H); LC-MS: m/z 227.0 (M+1).sup.+.
Step-b: Synthesis of ethyl thiazolo[4,5-b]pyrazin-2-ylcarbamate
[0524] To a stirred solution of 114a (1.8 g, 7.96 mmol) in
1,4-dioxane (9 mL) was added 6 M HCl (18 mL) and stirred at
50.degree. C. for 4 h. The reaction mixture was cooled to RT and
solid obtained was filtered and dried under vacuum to afford the
title compound (1.5 g, 84%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.60 (bs, 1H), 8.58 (d, J=3.2 Hz, 1H), 8.44 (d, J=2.4 Hz,
1H), 4.29 (q, J=6.8 Hz, 2H), 1.30 (t, J=7.6 Hz, 3H); LC-MS: m/z
225.0 (M+1).sup.+.
Step-c: Synthesis of thiazolo[4,5-b]pyrazin-2-amine
[0525] To a solution of ethyl thiazolo[4,5-b]pyrazin-2-ylcarbamate
(500 mg, 2.23 mmol) in water (5 mL) was added sodium hydroxide (267
mg, 6.69 mmol) and heated at 120.degree. C. for 16 h. The reaction
mixture was cooled to RT, acidified with 1 N HCl. The obtained
solid was filtered and dried under vacuum to afford the title
compound (300 mg, 88%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.42 (s, 2H), 8.23 (d, J=2.8 Hz, 1H), 8.03 (d, J=2.8 Hz,
1H); LC-MS: m/z 153.1 (M+1).sup.+.
Step-d: Synthesis of ethyl
1-methyl-2-(thiazolo[4,5-b]pyrazin-2-ylamino)-1H-benzo[d]imidazole-5-carb-
oxylate
[0526] The title compound was synthesized using the same procedure
which was followed for compound 2c using ethyl
3-amino-4-(methylamino)benzoate and thiazolo[4,5-b]pyrazin-2-amine
as starting materials (Yield: 9%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.63 (bs, 1H), 8.44 (d, J=2.4 Hz, 1H), 8.33
(s, 1H), 8.23 (d, J=2.8 Hz, 1H), 7.91 (dd, J=1.2 Hz, J=8.4 Hz, 1H),
7.60 (d, J=8.4 Hz, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.67 (s, 3H), 1.35
(d, J=7.2 Hz, 3H); LC-MS: m/z 355.0 (M+1).sup.+.
Step-e: Synthesis of
1-methyl-2-(thiazolo[4,5-b]pyrazin-2-ylamino)-1H-benzo[d]imidazole-5-carb-
oxylic acid
[0527] To a stirred solution of ethyl
1-methyl-2-(thiazolo[4,5-b]pyrazin-2-ylamino)-1H-benzo[d]imidazole-5-carb-
oxylate (60 mg, 0.17 mmol) in a mixture of solvent of THF (1 mL),
ethanol (1 mL) and water (0.5 mL) was added lithium hydroxide
monohydrate (35 mg, 0.85 mmol). The reaction mixture was heated at
60.degree. C. for 16 h with stirring. The reaction mixture was
cooled to RT and concentrated under reduced pressure. The crude
material was directly used in the next step (40 mg); LC-MS: m/z
326.95 (M+1).sup.+.
Step-f: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-(thiazolo[4,5-b]pyrazin-2-ylamino-
)-1H-benzo[d]imidazole-5-carboxamide
[0528] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-(thiazolo[4,5-b]pyrazin-2-ylamino)-1H-benzo[d]imidazole-5-carb-
oxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials
(Yield: 59%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.60
(bs, 1H), 8.46-8.41 (m, 2H), 8.20-8.14 (m, 2H), 7.78 (s, 1H), 7.56
(s, 1H), 4.60 (t, J=4.8 Hz, 1H), 3.70 (s, 3H), 3.59-3.43 (m, 8H);
LC-MS: m/z 414.05 (M+1).sup.+.
Examples 115 and 116. Synthesis of
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-
-5-carboxylic acid and Synthesis of
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1-
H-benzo[d]imidazole-5-carboxamide
##STR00086##
[0529] Step-a: Synthesis of 5-cyclopropyl-2-nitrophenol
[0530] To a stirred solution of 5-bromo-2-nitrophenol (2.0 g, 9.17
mmol) and cyclopropyl boronic acid (1.02 g, 11.92 mmol) in toluene
(40 mL) was added potassium phosphate (6.81 g, 32.1 mmol),
tricyclohexyl phosphine (0.25 g, 0.91 mmol) and water (2 mL). The
reaction mixture was purged with nitrogen gas for 10 min and then
palladium diacetate (0.1 g, 0.45 mmol) was added to the reaction
mixture and it was heated at 100.degree. C. for 16 h. The reaction
mixture was cooled to RT, filtered through a celite bed and washed
with ethyl acetate (150 mL). The organic layer was washed brine
solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to get the residue which was purified by
combiflash chromatography using 100% hexane as an eluent to afford
the title compound (0.9 g, 55%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 10.72 (bs, 1H), 7.82 (d, J=8.8 Hz, 1H), 6.82
(d, J=2.0 Hz, 1H), 6.68 (dd, J=2.0 Hz, J=8.8 Hz, 1H), 1.99-1.94 (m,
1H), 1.08-1.03 (m, 2H), 0.78-0.74 (m, 2H).
Step-b: Synthesis of 2-amino-5-cyclopropylphenol
[0531] To a solution of 5-cyclopropyl-2-nitrophenol (1.75 g, 11.4
mmol) in ethanol (4 mL) and THF (4 mL) was added a PtO.sub.2 (12
mg). The reaction mixture was stirred under hydrogen gas balloon
for 4 h. It was filtered through a celite bed and concentrated
under vacuum to afford the title compound (250 mg, 100%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 8.99 (bs, 1H), 6.61-6.59 (m,
1H), 6.45 (d, J=2.0 Hz, 1H), 6.43-6.34 (m, 1H), 5.35 (bs, 2H),
1.74-1.65 (m, 1H), 0.80-0.75 (m, 2H), 0.48-0.44 (m, 2H).
Step-c: Synthesis of 6-cyclopropylbenzo[d]oxazole-2-thiol
[0532] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-cyclopropylphenol as starting material (Yield: 90%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.72 (bs, 1H), 7.22
(s, 1H), 7.11-7.04 (m, 2H), 2.02-1.98 (m, 1H), 0.98-0.94 (m, 2H),
0.71-0.67 (m, 2H); LC-MS: m/z 190.05 (M-1).
Step-d: Synthesis of 2-chloro-6-cyclopropylbenzo[d]oxazole
[0533] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-cyclopropylbenzo[d]oxazole-2-thiol as starting material (Yield:
98%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.59 (d, J=8.0
Hz, 1H), 7.46 (s, 1H), 7.18 (d, J=8.4 Hz, 1H), 2.09-2.01 (m, 1H),
1.02-0.99 (m, 2H), 0.75-0.74 (m, 2H); LC-MS: m/z 194.0
(M+1).sup.+.
Step-e: Synthesis of ethyl
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-
-5-carboxylate
[0534] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-cyclopropylbenzo[d]oxazole as starting materials (Yield:
27%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H),
8.22 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.50 (d, J=8.4 Hz, 1H), 7.33
(d, J=8.4 Hz, 1H), 7.15 (s, 1H), 6.97 (d, J=6.8 Hz, 1H), 4.35-4.27
(m, 2H), 3.62 (s, 3H), 2.02-1.98 (m, 1H), 1.36-1.30 (m, 3H),
0.97-0.92 (m, 2H), 0.71-0.67 (m, 2H); LC-MS: m/z 377.2
(M+1).sup.+.
Step-f: Synthesis of
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-
-5-carboxylic acid
[0535] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-
-5-carboxylate as starting material (Yield: 81%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 13.5-11.2 (bs, 2H), 8.18 (s, 1H), 7.91
(d, J=8.4 Hz, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H),
7.22 (s, 1H), 7.04 (d, J=8.4 Hz, 1H), 3.67 (s, 3H), 2.06-2.02 (m,
1H), 1.00-0.95 (m, 2H), 0.72-0.68 (m, 2H); LC-MS: m/z 349.0
(M+1).sup.+.
Step-g: Synthesis of
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethyl)-1-methyl-1-
H-benzo[d]imidazole-5-carboxamide
[0536] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-((6-cyclopropylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-
-5-carboxylic acid and 2-methoxyethylamine as starting materials
(Yield: 46%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2
(bs, 1H), 8.44 (t, J=5.2 Hz, 1H), 8.06 (d, J=1.6 Hz, 1H), 7.75 (d,
J=8.4 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.33 (d, J=8.0 Hz, 1H), 7.14
(s, 1H), 6.96 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 3.62 (s, 3H), 3.48-3.43
(m, 4H), 3.28 (s, 3H), 2.02-1.98 (m, 1H), 0.96-0.92 (m, 2H),
0.70-0.66 (m, 2H); LC-MS: m/z 406.2 (M+1).sup.+.
Example 117. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((7-(trifluoromethyl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00087##
[0537] Step-a: Synthesis of 2-nitro-6-(trifluoromethyl)phenol
[0538] To 3 M sulfuric acid (25 mL) stirring at RT was added sodium
nitrate (1.73 g, 20.37 mmol) and sodium nitrite (100 mg) followed
by the addition of a solution of 2-(trifluoromethyl)phenol (3.0 g,
18.52 mmol) in DCM (40 mL) and stirred for 16 h. The mixture was
poured into ice water (50 mL) and extracted with DCM (2.times.100
mL). The combined organic layers were washed with water (50 mL),
brine solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combiflash
chromatography using 5% ethyl acetate in hexane as eluent to afford
the titled compound (1.3 g, 40%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.34 (bs, 1H), 8.27 (dd, J=1.6 Hz, J=8.4
Hz, 1H), 8.00 (dd, J=1.2 Hz, J=7.6 Hz, 1H), 7.21-7.17 (m, 1H).
Step-b: Synthesis of 2-amino-6-(trifluoromethyl)phenol
[0539] The title compound was synthesized using the same procedure
which was followed for compound 1e using
2-nitro-6-(trifluoromethyl)phenol as starting material and stirring
for 4 h (Yield: 90%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
6.88-6.84 (m, 1H), 6.75-6.70 (m, 2H), 6.50 (bs, 2H); LC-MS: m/z
178.05 (M+1).sup.+.
Step-c: Synthesis of
7-(trifluoromethyl)benzo[d]oxazole-2(3H)-thione
[0540] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-6-(trifluoromethyl)phenol as starting material (Yield:
65%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 14.28 (bs, 1H),
7.59-7.53 (m, 2H), 7.49-7.45 (m, 1H); LC-MS: m/z 218.1
(M-1).sup.-.
Step-d: Synthesis of
2-chloro-7-(trifluoromethyl)benzo[d]oxazole
[0541] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
7-(trifluoromethyl)benzo[d]oxazole-2(3H)-thione as starting
material and stirring for 2 h (Yield: 84%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.11 (d, J=8.0 Hz, 1H), 7.84 (d, J=7.6 Hz,
1H), 7.64 (t, J=7.2 Hz, 1H).
Step-e: Synthesis of ethyl
1-methyl-2-((7-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate
[0542] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-7-(trifluoromethyl)benzo[d]oxazole as starting materials
(Yield: 36%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.41
(s, 1H), 8.26 (d, J=1.6 Hz, 1H), 7.90 (dd, J=1.6 Hz, J=8.4 Hz, 1H),
7.75 (d, J=6.4 Hz, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.44-7.38 (m, 2H),
4.33 (q, J=6.8 Hz, 2H), 3.67 (s, 3H), 1.35 (d, J=6.8 Hz, 3H);
LC-MS: m/z 405.0 (M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((7-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0543] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((7-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate as starting material (Yield: 75%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.83 (bs, 1H), 12.40 (bs, 1H),
8.22 (d, J=1.6 Hz, 1H), 7.89 (dd, J=1.2 Hz, J=8.4 Hz, 1H), 7.75 (d,
J=8.4 Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.43-7.37 (m, 2H), 3.67 (s,
3H); LC-MS: m/z 377.0 (M+1).sup.+.
Step-g: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((7-(trifluoromethyl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0544] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((7-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as
starting materials (Yield: 61%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.46 (t, J=5.2 Hz, 1H), 8.10
(d, J=1.2 Hz, 1H), 7.80-7.73 (m, 2H), 7.53 (d, J=8.4 Hz, 1H),
7.42-7.38 (m, 2H), 4.60 (bs, 1H), 3.67 (s, 3H), 3.58-3.43 (m, 8H);
LC-MS: m/z 464.1 (M+1).sup.+.
Example 118. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-2-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)-
benzo[d]oxazole-5-carboxamide
##STR00088##
[0545] Step-a: Synthesis of N-methyl-2-nitroaniline
[0546] To a solution of 1-fluoro-2-nitrobenzene (1.0 g, 7.08 mmol)
in DMFA (3 mL) at RT was added methyl amine (1 mL, 40% aqueous
solution, 35.4 mmol) and the reaction mixture was stirred at
60.degree. C. for 16 h. The reaction mixture was cooled to RT,
diluted with cold water (50 mL) and stirred for 2 h. The solid
obtained was filtered and dried under vacuum to afford the product
as a yellow solid (700 mg, 75%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.14 (bs, 1H), 8.06 (dd, J=1.2 Hz, J=8.8 Hz,
1H), 7.57-7.53 (m, 1H), 6.98 (d, J=8.8 Hz, 1H), 6.69-6.66 (m, 1H),
2.96 (d, J=4.8 Hz, 3H); LC-MS: m/z 153.0 (M+1).sup.+.
Step-b: Synthesis of N.sup.1-methylbenzene-1,2-diamine
[0547] The title compound was synthesized using the same procedure
which was followed for compound 1e using N-methyl-2-nitroaniline as
starting material (Yield: 98%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 6.52-6.48 (m, 2H), 6.41-6.34 (m, 2H), 4.45
(bs, 2H), 2.68 (s, 3H); LC-MS: m/z 123.2 (M+1).sup.+.
Step-c: Synthesis of 1-methyl-1H-benzo[d]imidazol-2-amine
[0548] The title compound was synthesized using the same procedure
which was followed for compound if using
N.sup.1-methylbenzene-1,2-diamine as starting material (Yield:
83%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.11-7.09 (m,
2H), 6.94-6.87 (m, 2H), 6.37 (s, 2H), 3.78 (s, 3H).
Step-d: Synthesis of ethyl
2-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)benzo[d]oxazole-5-carboxylate
[0549] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using
1-methyl-1H-benzo[d]imidazol-2-amine and ethyl
2-chlorobenzo[d]oxazole-5-carboxylate as starting materials (Yield:
31%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 1H),
7.99 (d, J=1.6 Hz, 1H), 7.76-7.74 (m, 1H), 7.64-7.62 (m, 1H), 7.52
(d, J=8.0 Hz, 1H), 7.45-7.43 (m, 1H), 7.26-7.23 (m, 2H), 4.32 (q,
J=7.6 Hz, 2H), 3.63 (s, 3H), 1.35 (t, J=6.8 Hz, 3H); LC-MS: m/z
336.95 (M+1).sup.+.
Step-e: Synthesis of
2-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)benzo[d]oxazole-5-carboxylic
acid
[0550] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)benzo[d]oxazole-5-carboxylate
as starting material (Yield: 78%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.80 (bs, 1H), 12.22 (bs, 1H), 7.98 (d,
J=1.6 Hz, 1H), 7.76 (dd, J=2.0 Hz, J=8.4 Hz, 1H), 7.67-7.63 (m,
1H), 7.52 (d, J=8.4 Hz, 1H), 7.47-7.45 (m, 1H), 7.28-7.21 (m, 2H),
3.68 (s, 3H); LC-MS: m/z 309.1 (M+1).sup.+.
Step-f: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-2-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)-
benzo[d]oxazole-5-carboxamide
[0551] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)benzo[d]oxazole-5-carboxylic
acid and 2-(2-aminoethoxy)ethan-1-ol as starting materials. The
crude product was purified by combiflash chromatography using 9%
methanol in DCM as an eluent (Yield: 64%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 8.48 (t, J=5.2 Hz, 1H), 7.92
(s, 1H), 7.65-7.62 (m, 2H), 7.48-7.45 (m, 2H), 7.28-7.22 (m, 2H),
3.63 (s, 3H), 3.57-3.35 (m, 8H); LC-MS: m/z 396.2 (M+1).sup.+.
Example 119. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-methoxyethoxy)-1-methyl-1H-benzo[d]imid-
azole-5-carboxamide
##STR00089##
[0552] Step-a: Synthesis of
2-(2-methoxyethoxy)isoindoline-1,3-dione
[0553] To a stirred solution of N-hydroxyphthalimide (4.6 g, 28.2
mmol) in DMFA (15 mL) at RT was added triethyl amine (8.0 mL, 56.4
mmol) and 1-bromo-2-methoxyethane (4.0 mL, 42.3 mmol). The reaction
mixture was then stirred at 60.degree. C. for 16 h. Once the
reaction was completed (monitored by TLC), the reaction mixture was
cooled to RT, diluted with cold water (100 mL) and extracted with
ethyl acetate (2.times.100 mL). The combined organic layers were
washed with cold water (2.times.200 mL), brine solution (50 mL),
dried over anhydrous sodium sulfate and concentrated under vacuum
to afford the titled compound (2.8 g, 45%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.86 (s, 4H), 4.26 (t, J=4.4 Hz, 2H),
3.65-3.63 (m, 2H), 3.25 (s, 3H); LC-MS: m/z 222.20 (M+1).sup.+.
Step-b: Synthesis of O-(2-methoxyethyl)hydroxylamine
[0554] To a stirred solution of
2-(2-methoxyethoxy)isoindoline-1,3-dione (2.8 g, 12.6 mmol) in
methanol (75 mL) at RT was added hydrazine hydrate (0.95 g, 19.0
mmol) and refluxed for 4 h. Then the reaction mixture was cooled to
RT, filtered and the filtrate was concentrated. The residue
obtained was stirred in diethyl ether (30 mL) and filtered. The
filtrate was concentrated under vacuum to afford the titled
compound (550 mg, 48%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 5.50 (s, 2H), 3.84-3.82 (m, 2H), 3.58-3.56 (m, 2H), 3.39
(s, 3H).
Step-c: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-methoxyethoxy)-1-methyl-1H-benzo[d]imid-
azole-5-carboxamide
[0555] The title compound was synthesized using the same procedure
which was followed for compound 1i using
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid and O-(2-methoxyethyl)hydroxylamine as starting materials
(Yield: 20%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.28
(s, 1H), 11.73 (s, 1H), 8.01 (s, 1H), 7.64 (d, J=8.3 Hz, 1H), 7.48
(d, J=7.8 Hz, 2H), 7.44 (d, J=7.8 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H),
7.12 (t, J=7.9 Hz, 1H), 4.04 (t, J=4.2 Hz, 2H), 3.63 (s, 3H), 3.59
(t, J=4.2 Hz, 2H), 3.31 (s, 3H); LC-MS: m/z 382.0 (M+1).sup.+.
Example 120. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-hydroxypropoxy)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxamide
##STR00090##
[0556] Step-a: Synthesis of
2-(2-hydroxypropoxy)isoindoline-1,3-dione
[0557] To a stirred solution of 2-hydroxyisoindoline-1,3-dione (5.0
g, 30.65 mmol) and 2-methyloxirane (4.1 mL, 61.3 mmol) in toluene
(50 mL) at RT was added DIPEA (0.6 mL, 3.1 mmol) and
tetrabutylammonium bromide (0.99 g, 3.1 mmol). The reaction mixture
was then refluxed for 5 h. The mixture was cooled to RT,
concentrated under reduced pressure and extracted with EtOAc
(2.times.100 mL) and water (50 mL). The combined organic layers
were washed with water (30 mL), brine solution (30 mL), dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was purified by combiflash column chromatography using 100%
dichloromethane as an eluent to afford the titled compound (4.0 g,
59%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.85 (s, 4H),
4.80 (d, J=4.8 Hz, 1H), 4.03-4.00 (m, 1H), 3.96-3.93 (m, 2H), 1.14
(d, J=6.0 Hz, 3H); LC-MS: m/z 222.1 (M+1).sup.+.
Step-b: Synthesis of 1-(aminooxy)propan-2-ol hydrochloride
[0558] A solution of 2-(2-hydroxypropoxy)isoindoline-1,3-dione (2.0
g, 9.0 mmol) in 6 N aqueous hydrochloric acid (15 mL) was stirred
at RT for 16 h. The solid precipitated in the reaction mixture was
removed by filtration and filtrate was concentrated under reduced
pressure to afford the titled compound as hydrochloride salt (1.0
g), crude compound was used in the next step without further
purification.
Step-c: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-hydroxypropoxy)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxamide
[0559] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (100 mg, 0.32 mmol) in DMFA (5 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (0.06 mL, 0.32 mmol) and HBTU (122 mg,
0.32 mmol). The reaction mixture was stirred for 30 min, followed
by the addition of 1-(aminooxy)propan-2-ol hydrochloride (41 mg,
0.32 mmol) and stirring was continued at RT for 16 h. Once the
reaction was completed (monitored by TLC), the reaction mixture was
diluted with cold water (20 mL) and extracted with ethyl acetate
(2.times.50 mL). The combined organic layers were washed with water
(30 mL), brine solution (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was purified by
preparative HPLC method to afford the titled compound (35 mg,
28%).
[0560] Preparative HPLC Purification Method Details:
TABLE-US-00001 DILUTION: THF:ACN:WATER MOBILE PHASE A: 100% Water
MOBILE PHASE B: 100% ACETONITRILE GRADIENT: 0/10, 6/20, 10/80 FLOW:
15 ml/min COLUMN: Luna (250 .times. 21.1 .times. 5 .mu.m)
[0561] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H),
11.7 (bs, 1H), 8.01 (d, J=1.2 Hz, 1H), 7.63 (dd, J=1.2 Hz, J=8.0
Hz, 1H), 7.48 (d, J=8.8 Hz, 2H), 7.43 (d, J=7.6 Hz, 1H), 7.21 (t,
J=7.6 Hz, 1H), 7.12 (t, J=7.6 Hz, 1H), 4.90 (bs, 1H), 3.92-3.89 (m,
1H), 3.78-3.74 (m, 2H), 3.63 (s, 3H), 1.10 (d, J=6.4 Hz, 3H);
LC-MS: m/z 382.05 (M+1).sup.+.
Example 121. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-(dimethylamino)acetamido)ethoxy)-1-m-
ethyl-1H-benzo[d]imidazole-5-carboxamide
##STR00091##
[0562] Step-a: Synthesis of tert-butyl
(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)carbamate
[0563] To a stirred solution of 2-hydroxyisoindoline-1,3-dione (5.0
g, 30.67 mmol) in THF (150 mL) at 0.degree. C. was added tert-butyl
(2-hydroxyethyl)carbamate (4.93 g, 30.67 mmol) and
triphenylphosphine (8.03 g, 30.67 mmol). The reaction mixture was
stirred for 10 min followed by the addition of diisopropyl
azodicarboxylate (6.19 g, 30.67 mmol) and continued stirring at RT
for 16 h. The reaction mixture was diluted with water (50 mL) and
extracted with ethyl acetate (2.times.100 mL). The combined organic
layers were washed with water (50 mL), brine solution (50 mL),
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was purified by combiflash column chromatography using
10% ethyl acetate in hexane as an eluent to afford the titled
compound (12.0 g, semi pure) which was used in the next step
without any further purification; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.86 (s, 4H), 6.82 (bs, 1H), 4.13 (t, J=5.6
Hz, 2H), 3.28-3.27 (m, 2H), 1.37 (s, 9H); LC-MS: m/z 207.0
(M-Boc).sup.+.
Step-b: Synthesis of 2-(2-aminoethoxy)isoindoline-1,3-dione
trifluoroacetic acid salt
[0564] To a stirred solution of tert-butyl
(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)carbamate (12.0 g, 39.08
mmol) in DCM (150 mL) at 0.degree. C. was added trifluoroacetic
acid (20 mL) and stirred at RT for 3 h. The reaction mixture was
concentrated under vacuum, the residue was stirred in diethyl ether
(50 mL) and the solid precipitated was filtered and dried under
vacuum to afford the titled compound (3.8 g, 32%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 8.05 (bs, 3H), 7.90 (s, 4H), 4.34 (t,
J=5.2 Hz, 2H), 3.38 (q, J=7.2 Hz, 2H).
Step-c: Synthesis of
2-(dimethylamino)-N-(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)acetamide
[0565] To a stirred solution of
2-(2-aminoethoxy)isoindoline-1,3-dione trifluoroacetate (1.0 g,
4.85 mmol) in DMFA (15 mL) at 0.degree. C. was added
dimethylglycine (499 mg, 4.85 mmol), N-ethyldiisopropyl amine (1.69
mL, 9.7 mmol) and HATU (2.02 g, 5.34 mmol) and the reaction mixture
was stirred at RT for 16 h. Once the reaction was completed
(monitored by TLC), the reaction mixture was diluted with water (50
mL) and extracted with ethyl acetate (2.times.50 mL). The combined
organic layers were washed with water (30 mL), brine solution (30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified by combiflash column
chromatography using 2% methanol in dichloromethane as an eluent to
afford the titled compound (280 mg, 29%); LC-MS: m/z 292.1
(M+1).sup.+.
Step-d: Synthesis of
N-(2-(aminooxy)ethyl)-2-(dimethylamino)acetamide
[0566] To a stirred solution of
2-(dimethylamino)-N-(2-((1,3-dioxoisoindolin-2-yl)oxy)ethyl)acetamide
(280 mg, 0.96 mmol) in methanol (5 mL) at RT was added hydrazine
hydrate (0.3 mL) and refluxed for 4 h. The reaction mixture was
cooled to RT and concentrated on rotary evaporator. The residue
obtained was stirred in diethyl ether (30 mL) and filtered. The
filtrate was concentrated under vacuum to afford the titled
compound (120 mg, 77%); .sup.1H NMR (400 MHz, CDCl.sub.3): .delta.
7.39 (bs, 1H), 5.50 (bs, 2H), 3.73 (t, J=5.2 Hz, 2H), 3.57-3.47 (m,
2H), 2.96 (s, 2H), 2.29 (s, 6H).
Step-e: Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(2-(dimethylamino)acetamido)ethoxy)-1-m-
ethyl-1H-benzo[d]imidazole-5-carboxamide
[0567] To a stirred solution of
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid (80 mg, 0.26 mmol) in DMFA (2 mL) at 0.degree. C. was added
N-ethyldiisopropyl amine (0.04 mL, 0.26 mmol) and HBTU (98 mg, 0.26
mmol). The reaction mixture was stirred for 30 min, followed by the
addition of N-(2-(aminooxy)ethyl)-2-(dimethylamino)acetamide (41
mg, 0.26 mmol). The reaction mixture was then stirred at RT for 16
h. Once the reaction was completed (monitored by TLC), the reaction
mixture was diluted with cold water (15 mL) and extracted with
ethyl acetate (2.times.20 mL). The aqueous layer was concentrated
under vacuum. The residue obtained was purified by preparative HPLC
method to afford the titled compound (10 mg, 9%).
[0568] Preparative HPLC Purification Method Details:
TABLE-US-00002 DILUTION: THF:ACN:WATER MOBILE PHASE A: 10 mM
aqueous ammonium acetatae MOBILE PHASE B: 100% ACETONITRILE
GRADIENT: T/% B: 0/10, 10/50, 17/65, 19/90 FLOW: 15 ml/min COLUMN:
Phenomenex Luna (250 .times. 21.2 .times. 5 .mu.m)
[0569] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H),
11.60 (bs, 1H), 8.01 (bs, 2H), 7.64 (d, J=8.8 Hz, 1H), 7.49-7.42
(m, 3H), 7.20 (t, J=8.0 Hz, 1H), 7.12 (t, J=8.0 Hz, 1H), 3.90 (s,
2H), 3.63 (s, 3H), 3.41 (q, J=6.0 Hz, 2H), 2.89 (s, 2H), 2.32 (s,
6H); LC-MS: m/z 452.2 (M+1).sup.+.
Example 122. Synthesis of
N-(2-(dimethylamino)ethoxy)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazo-
l-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00092##
[0570] Step-a: Synthesis of
2-(2-(dimethylamino)ethoxy)isoindoline-1,3-dione
[0571] The title compound was synthesized using the same procedure
which was followed for Example 119 Step-a using
N-hydroxyphthalimide and 1-chloro-2-dimethylaminoethane
hydrochloride as starting materials and 4 equivalents of triethyl
amine (Yield: 17%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.86 (s, 4H), 4.21 (t, J=5.4 Hz, 2H), 2.61 (t, J=5.4 Hz, 2H), 2.18
(s, 6H); LC-MS: m/z 235.1 (M+1).sup.+.
Step-b: Synthesis of 2-(aminooxy)-N,N-dimethylethan-1-amine
[0572] The title compound was synthesized using the same procedure
which was followed for Example 119 Step-b using
2-(2-(dimethylamino)ethoxy)isoindoline-1,3-dione as starting
material (Yield: 34%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
5.88 (bs, 2H), 3.58 (t, J=5.9 Hz, 2H), 2.38 (t, J=5.9 Hz, 2H), 2.13
(s, 6H); LC-MS: m/z 105.20 (M+1).sup.+.
Step-c: Synthesis of
N-(2-(dimethylamino)ethoxy)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazo-
l-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0573] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(aminooxy)-N,N-dimethylethan-1-amine
as starting materials (Yield: 15%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.40 (bs, 2H), 8.01 (s, 1H), 7.82 (s, 1H),
7.66 (d, J=1.5 Hz, 1H), 7.64 (d, J=1.5 Hz, 1H), 7.61-7.51 (m, 2H),
3.99 (t, J=5.4 Hz, 2H), 3.66 (s, 3H), 2.55 (t, J=5.3 Hz, 2H), 2.22
(s, 6H); LC-MS: m/z 463.50 (M+1).sup.+.
Example 123. Synthesis of
2-(benzo[d]oxazol-2-ylamino)-N-(2-(dimethylamino)ethoxy)-1-methyl-1H-benz-
o[d]imidazole-5-carboxamide
[0574] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-(aminooxy)-N,N-dimethylethan-1-amine and
2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid as starting materials.
[0575] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.30 (bs, 1H),
8.00 (s, 1H), 7.63 (d, J=8.4 Hz, 1H), 7.48 (d, J=8.4 Hz, 2H), 7.43
(d, J=8.0 Hz, 1H), 7.21 (t, J=7.2 Hz, 1H), 7.12 (t, J=7.6 Hz, 1H),
3.99 (t, J=6.0 Hz, 2H), 3.82 (s, 3H), 2.56 (t, J=5.2 Hz, 2H), 2.32
(s, 6H); LC-MS: m/z 395.1 (M+1).sup.+.
Example 124. Synthesis of
N-(2-methoxyethoxy)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxamide
##STR00093##
[0577] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and O-(2-methoxyethyl)hydroxylamine as
starting materials (Yield: 28%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.39 (bs, 1H), 11.72 (s, 1H), 8.03 (s, 1H),
7.83 (s, 1H), 7.67 (d, J=8.3 Hz, 1H), 7.61 (d, J=8.3 Hz, 1H),
7.57-7.52 (m, 2H), 4.04 (t, J=4.4 Hz, 2H), 3.66 (s, 3H), 3.59 (t,
J=4.4 Hz, 2H), 3.30 (s, 3H merged in DMSO); LC-MS: m/z 450.15
(M+1).sup.+.
Example 125. Synthesis of
N-(2-hydroxyethoxy)-1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)a-
mino)-1H-benzo[d]imidazole-5-carboxamide
##STR00094##
[0579] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(aminooxy)ethan-1-ol as starting
materials (Yield: 51%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.39 (bs, 1H), 11.73 (s, 1H), 8.04 (s, 1H), 7.84 (s, 1H),
7.68 (d, J=8.3 Hz, 1H), 7.61 (d, J=8.3 Hz, 1H), 7.57-7.53 (m, 2H),
4.78 (s, 1H), 3.94 (t, J=4.9 Hz, 2H), 3.67 (s, 3H), 3.66-3.63 (m,
2H); LC-MS: m/z 436.15 (M+1).sup.+.
Example 126. Synthesis of
N-(2-hydroxyethoxy)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00095##
[0581] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid and 2-(aminooxy)ethan-1-ol as starting
materials (Yield: 58%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.30 (bs, 1H), 11.72 (s, 1H), 8.02 (d, J=1.0 Hz, 1H), 7.66
(d, J=6.9 Hz, 1H), 7.58 (s, 1H), 7.53-7.51 (m, 2H), 7.22 (d, J=8.3
Hz, 1H), 4.78 (t, J=5.6 Hz, 1H), 3.94 (t, J=4.7 Hz, 2H), 3.64-3.62
(m, 5H); LC-MS: m/z 451.9 (M+1).sup.+.
Example 127. Synthesis of
N-(2-methoxyethoxy)-1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00096##
[0583] The title compound was synthesized using the same procedure
which was followed for compound 1i using
1-methyl-2-((6-(trifluoromethoxy)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]im-
idazole-5-carboxylic acid and O-(2-methoxyethyl)hydroxylamine as
starting materials (Yield: 28%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 11.70 (s, 1H), 8.01 (d,
J=1.4 Hz, 1H), 7.65 (dd, J=1.5 Hz, J=8.3 Hz, 1H), 7.58 (d, J=1.5
Hz, 1H), 7.53-7.49 (m, 2H), 7.22 (dd, J=1.5 Hz, J=8.3 Hz, 1H),
4.05-4.02 (m, 2H), 3.64 (s, 3H), 3.61-3.58 (m, 2H), 3.31 (s, 3H);
LC-MS: m/z 466.0 (M+1).sup.+.
Example 128. Synthesis of
N-(2-hydroxyethoxy)-2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-m-
ethyl-1H-benzo[d]imidazole-5-carboxamide
[0584] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-(aminooxy)ethan-1-ol and
2-((6-(2-methoxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid as starting materials. .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 1H), 11.68 (s, 1H), 7.98 (s,
1H), 7.63 (d, J=8.0 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.35 (d, J=8.8
Hz, 1H), 7.12 (s, 1H), 6.82 (d, J=8.8 Hz, 1H), 4.78 (s, 1H), 4.11
(bs, 2H), 3.93 (bs, 2H), 3.67-3.61 (m, 7H), 3.32 (s, 3H merged with
DMSO moisture peak); LC-MS: m/z 442.2 (M+1).sup.+.
Example 129. Synthesis of
N-(2-hydroxyethoxy)-2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-m-
ethyl-1H-benzo[d]imidazole-5-carboxamide
##STR00097##
[0586] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-(2-hydroxyethoxy)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imi-
dazole-5-carboxylic acid and 2-(aminooxy)ethan-1-ol as starting
materials. The crude product was purified by combiflash
chromatography using 10% methanol in DCM as an eluent to afford the
title compound (Yield: 14%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.15 (bs, 1H), 11.67 (s, 1H), 7.98 (s, 1H), 7.63 (d, J=7.6
Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 7.35 (d, J=8.4 Hz, 1H), 7.11 (s,
1H), 6.82 (d, J=8.8 Hz, 1H), 4.83 (bs, 1H), 4.77 (bs, 1H), 4.01 (t,
J=4.4 Hz, 2H), 3.93 (t, J=4.4 Hz, 2H), 3.72 (bs, 2H), 3.61 (bs,
5H); LC-MS: m/z 428.2 (M+1).sup.+.
Example 130. Synthesis of
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-N-(2-hydroxyet-
hoxy)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00098##
[0588] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((5-fluoro-6-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxylic acid and 2-(aminooxy)ethan-1-ol as
starting materials (Yield: 61%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.45 (bs, 1H), 11.74 (s, 1H), 8.03 (s, 1H),
7.85 (d, J=5.6 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.55 (d, J=8.0 Hz,
1H), 7.45 (d, J=11.2 Hz, 1H), 4.50 (bs, 1H), 3.94 (t, J=4.4 Hz,
2H), 3.66 (s, 3H), 3.64-3.63 (m, 2H); LC-MS: m/z 454.1
(M+1).sup.+.
Example 131 Synthesis of
N-(2-hydroxyethoxy)-1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00099##
[0590] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-methyl-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)amino)-1H-be-
nzo[d]imidazole-5-carboxylic acid and 2-(aminooxy)ethan-1-ol as
starting materials (Yield: 43%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.05 (bs, 1H), 11.56 (s, 1H), 7.83 (s, 1H),
7.55 (dd, J=1.0 Hz, J=8.3 Hz, 1H), 7.35 (d, J=8.3 Hz, 1H), 4.78
(bs, 1H), 3.92 (t, J=4.9 Hz, 2H), 3.63-3.61 (m, 5H), 2.67-2.59 (m,
1H), 2.50 (2H merged with DMSO peak), 2.18-2.11 (m, 1H), 1.87-1.84
(m, 2H), 1.46-1.43 (m, 1H), 1.05 (d, J=6.3 Hz, 3H); LC-MS: m/z
402.2 (M+1).sup.+.
Example 132. Synthesis of
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethoxy)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxamide
##STR00100## ##STR00101##
[0591] Step-a: Synthesis of
1-(4-amino-3-hydroxyphenyl)ethan-1-one
[0592] A mixture of 6-acetylbenzo[d]oxazol-2(3H)-one (5.0 g, 28.2
mmol) in 10% aqueous sodium hydroxide (50 mL) was refluxed for 4 h.
The reaction mixture was cooled to RT, acidified with 3 N HCl
followed by basification to pH.about.8 with saturated sodium
carbonate solution. The precipitated solid was filtered and dried
under vacuum afford the title compound (4.1 g, 98%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 9.34 (s, 1H), 7.28 (dd, J=2.0 Hz,
J=8.4 Hz, 1H), 7.22 (d, J=2.0 Hz, 1H), 6.58 (d, J=8.4 Hz, 1H), 5.44
(s, 2H), 2.36 (s, 3H).
Step-b: Synthesis of
1-(2-mercaptobenzo[d]oxazol-6-yl)ethan-1-one
[0593] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
1-(4-amino-3-hydroxyphenyl)ethan-1-one (Yield: 100%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 14.2 (bs, 1H), 8.04 (s, 1H), 7.94
(d, J=8.0 Hz, 1H), 7.33 (d, J=8.0 Hz, 1H), 2.60 (s, 3H); LC-MS: m/z
192.02 (M-1).sup.-.
Step-c: Synthesis of
1-(2-(methylthio)benzo[d]oxazol-6-yl)ethan-1-one
[0594] The title compound was synthesized using the same procedure
which was followed for compound 1b using
1-(2-mercaptobenzo[d]oxazol-6-yl)ethan-1-one as starting material
(Yield: 78%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.22 (s,
1H), 7.98 (d, J=8.4 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 2.80 (s, 3H),
2.67 (s, 3H).
Step-d: Synthesis of
1-(2-(methylthio)benzo[d]oxazol-6-yl)ethan-1-ol
[0595] To a stirred solution of
1-(2-(methylthio)benzo[d]oxazol-6-yl)ethan-1-one (4.1 g, 19.8 mmol)
in methanol (80 mL) at 0.degree. C. was added sodium borohydride
(1.12 g, 29.7 mmol) and the reaction mixture was stirred for 1 h.
The reaction mixture was quenched with cold water (100 mL) and
extracted with EtOAc (2.times.150 mL). The combined organic layers
were washed with water (50 mL), brine (50 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum to afford the titled
compound (4.1 g, 100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.57-7.53 (m, 2H), 7.31 (dd, J=1.2 Hz, J=8.0 Hz, 1H), 5.28
(d, J=3.6 Hz, 1H), 4.85-4.80 (m, 1H), 2.74 (s, 3H), 1.35 (d, J=6.4
Hz, 3H).
Step-e: Synthesis of
6-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(methylthio)benzo[d]oxazole
[0596] To a stirred solution of
1-(2-(methylthio)benzo[d]oxazol-6-yl)ethan-1-ol (4.1 g, 19.6 mmol)
in DCM (80 mL) at 0.degree. C. was added imidazole (2.0 g, 29.4
mmol) and stirred for 5 min followed by the addition of TBDMSCl
(3.5 g, 23.5 mmol) and it was stirred at RT for 2 h. The reaction
mixture was diluted with water (100 mL) and extracted with DCM
(2.times.150 mL). The combined organic layers were washed with
water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum to afford the titled compound (6.6 g,
100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.63-7.61 (m,
2H), 7.36 (d, J=8.0 Hz, 1H), 5.08 (q, J=6.4 Hz, 1H), 2.80 (s, 3H),
1.42 (d, J=6.0 Hz, 3H), 0.91 (s, 9H), 0.2 (s, 6H); LC-MS: m/z 324.1
(M+1).sup.+.
Step-f: Synthesis of
6-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(methylsulfonyl)-benzo[d]oxaz-
ole
[0597] The title compound was synthesized using the same procedure
which was followed for compound 1c using
6-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(methylthio)benzo[d]oxazole
as starting material and stirred for 4 h (Yield: 100%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 7.96-7.49 (m, 3H), 5.14-5.11 (m,
1H), 3.66 (s, 3H), 1.40 (d, J=6.0 Hz, 3H), 0.88 (s, 9H), 0.2 (s,
3H), -0.2 (s, 3H).
Step-g: Synthesis of ethyl
2-((6-(1-((tert-butyldimethylsilyl)oxy)ethyl)benzo[d]oxazol-2-yl)amino)-1-
-methyl-1H-benzo[d]imidazole-5-carboxylate
[0598] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
6-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(methylsulfonyl)benzo[d]oxazo-
le as starting materials (Yield: 31%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 8.23 (d, J=1.6 Hz, 1H), 7.87
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.42-7.39 (m,
2H), 7.20 (d, J=8.0 Hz, 1H), 5.0 (d, J=6.4 Hz, 1H), 4.32 (q, J=7.6
Hz, 2H), 3.63 (s, 3H), 1.40-1.33 (m, 6H), 0.87 (s, 9H), 0.001 (s,
3H), -0.036 (s, 3H).
Step-h: Synthesis of ethyl
2-((6-(1-hydroxyethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imid-
azole-5-carboxylate
[0599] To a stirred solution of ethyl
2-((6-(1-((tert-butyldimethylsilyl)oxy)ethyl)benzo[d]oxazol-2-yl)amino)-1-
-methyl-1H-benzo[d]imidazole-5-carboxylate (1.4 g, 2.8 mmol) in THF
(30 mL) at 0.degree. C. was added 1 M TBAF in THF (5.7 mL, 5.7
mmol) and the reaction mixture was stirred at RT for 16 h. The
reaction mixture was quenched with saturated ammonium chloride
solution (50 mL) and extracted with EtOAc (2.times.100 mL). The
combined organic layers were washed with water (30 mL), brine (30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was stirred in pentane for 15 min and solid
obtained was filtered and dried under vacuum to afford the titled
compound (1.1 g, 100%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.3 (bs, 1H), 8.23 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.51
(d, J=8.4 Hz, 1H), 7.41-7.39 (m, 2H), 7.19 (d, J=7.6 Hz, 1H), 5.16
(bs, 1H), 4.80 (bs, 1H), 4.33 (q, J=7.2 Hz, 2H), 3.63 (s, 3H),
1.40-1.35 (m, 6H); LC-MS: m/z 381.15 (M+1).sup.+.
Step-i: Synthesis of ethyl
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate
[0600] To a stirred solution of ethyl
2-((6-(1-hydroxyethyl)benzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imid-
azole-5-carboxylate (1.1 g, 2.9 mmol) in DCM (30 mL) at 0.degree.
C. was added Dess-martin periodinane (1.47 g, 3.5 mmol) and the
reaction mixture was stirred for 1 h. The reaction mixture was
diluted with DCM (100 mL), water (50 mL). The organic layer was
washed with saturated sodium bicarbonate solution (2.times.50 mL),
water (50), brine (30 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the titled compound (540 mg,
49%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.4 (bs, 1H),
8.26 (s, 1H), 8.00 (s, 1H), 7.91-7.89 (m, 2H), 7.58-7.51 (m, 2H),
4.34 (q, J=6.8 Hz, 2H), 3.87 (s, 3H), 2.66 (s, 3H), 1.35 (t, J=6.8
Hz, 3H); LC-MS: m/z 379.15 (M+1).sup.+.
Step-j: Synthesis of
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]-imidazole-5-c-
arboxylic acid
[0601] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylate as starting material (Yield: 68%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.8 (bs, 1H), 12.4 (s, 1H), 8.21 (s, 1H),
7.99 (s, 1H), 7.82-7.79 (m, 2H), 7.59-7.52 (m, 2H), 3.67 (s, 3H),
2.66 (s, 3H); LC-MS: m/z 351.1 (M+1).sup.+.
Step-k: Synthesis of
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-N-(2-methoxyethoxy)-1-methyl-1H-be-
nzo[d]imidazole-5-carboxamide
[0602] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and O-(2-methoxyethyl)hydroxylamine as starting
materials (Yield: 42%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.4 (bs, 1H), 11.7 (s, 1H), 8.02-7.99 (s, 2H), 7.99 (dd,
J=1.6 Hz, J=8.4 Hz, 1H), 7.68-7.63 (m, 1H), 7.54-7.51 (m, 2H), 4.04
(t, J=4.4 Hz, 2H), 3.66 (s, 3H), 3.60 (t, J=4.4 Hz, 2H), 3.22 (s,
3H), 2.60 (s, 3H); LC-MS: m/z 424.15 (M+1).sup.+.
Example 133. Synthesis of
N-(2-hydroxyethyl)-2-((6-(2-hydroxypropan-2-yl)benzo[d]oxazol-2-yl)amino)-
-1-methyl-1H-benzo[d]imidazole-5-carboxamide
##STR00102##
[0603] Step-a: Synthesis of
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-N-(2-((tert-butyldimethylsilyl)oxy-
)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0604] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-ca-
rboxylic acid and 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine as
starting materials (Yield: 48%); LC-MS: m/z 508.25 (M+1).sup.+.
Step-b: Synthesis of
N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-((6-(2-hydroxypropan-2-yl)ben-
zo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0605] To a stirred solution of
2-((6-acetylbenzo[d]oxazol-2-yl)amino)-N-(2-((tert-butyldimethylsilyl)oxy-
)ethyl)-1-methyl-1H-benzo[d]imidazole-5-carboxamide (200 mg, 0.39
mmol) in THF (5 mL) at 0.degree. C. was added 3 M methyl magnesium
bromide in diethyl ether (0.13 mL, 0.39 mmol) and the reaction
mixture was stirred for 30 min. The reaction mixture was quenched
with saturated aqueous ammonium chloride solution (20 mL) and
extracted with ethyl acetate (2.times.50 mL). The combined organic
layers were washed with brine (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to afford the titled compound
(100 mg, crude); LC-MS: m/z 524.3 (M+1).sup.+.
Step-c: Synthesis of
N-(2-hydroxyethyl)-2-((6-(2-hydroxypropan-2-yl)benzo[d]oxazol-2-yl)amino)-
-1-methyl-1H-benzo[d]imidazole-5-carboxamide
[0606] The title compound was synthesized using the same procedure
which was followed for Example 132 Step-h using
N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-((6-(2-hydroxypropan-2-yl)ben-
zo[d]oxazol-2-yl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxamide
as starting material and stirring for 4 h. Crude product was
purified by preparative HPLC method (Yield: 6%).
[0607] Preparative HPLC Purification Method Details:
TABLE-US-00003 DILUTION: ACN:WATER MOBILE PHASE A: 0.1% formic acid
in Water MOBILE PHASE B: 100% ACETONITRILE GRADIENT: 0/10, 2/10,
6/100, 10/100, 11/10, 12/10 FLOW: 1.0 ml/min COLUMN: Kinetex C-18
(250 .times. 21.1 .times. 5 .mu.m)
[0608] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.23 (bs, 1H),
8.35 (bs, 1H), 8.06 (s, 1H), 7.76 (d, J=6.8 Hz, 1H), 7.51 (s, 1H),
7.46 (d, J=8.4 Hz, 1H), 7.37 (d, J=8.4 Hz, 1H), 7.30 (d, J=8.4 Hz,
1H), 5.03 (bs, 1H), 4.73 (bs, 1H), 3.62 (s, 3H), 3.53 (bs, 2H),
3.35-3.34 (m, 2H), 1.47 (s, 6H); LC-MS: m/z 410.2 (M+1).sup.+.
Example 134. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(thiazol-4-yl)benzo[d]oxazol--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00103## ##STR00104##
[0609] Step-a: Synthesis of
6-(2-bromoacetyl)benzo[d]oxazol-2(3H)-one
[0610] DMFA (5.75 mL, 74 mmol) was added to dropwise to AlCl.sub.3
(34.5 g, 259.3 mmol) and the mixture was stirred at 45.degree. C.
for 30 min. Then benzo[d]oxazol-2(3H)-one (5.0 g, 37 mmol) and
2-bromoacetyl chloride (4.6 mL, 55.5 mmol) was added to the
reaction mixture and stirred at 75.degree. C. for 2 h. The reaction
mixture was cooled to RT and poured over ice and stirred for 10
min. The precipitated solid was filtered and dried under vacuum to
afford the titled compound (4.0 g, 42%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.13 (bs, 1H), 7.90-7.87 (m, 2H), 7.23 (d,
J=7.6 Hz, 1H), 4.89 (s, 2H); LC-MS: m/z 253.9 (M-1).sup.-.
Step-b: Synthesis of 6-(thiazol-4-yl)benzo[d]oxazol-2(3H)-one
[0611] To a stirred solution of formamide (5.49 mL, 137.7 mmol) in
1,4-dioxane (100 mL) at RT was added phosphorus pentasulfide (6.1
g, 27.5 mmol) and heated at 100.degree. C. for 2 h. The solid
precipitated was removed by filtration and the filtrate was added
to 6-(2-bromoacetyl)benzo[d]oxazol-2(3H)-one (13.5, 13.7 mmol). The
reaction mixture was stirred at 100.degree. C. for 16 h and
concentrated on rotary evaporator to remove 1,4-dioxane. The
residue was diluted with ethyl acetate (150 mL), water (100 mL) and
extracted. Organic layer was washed with water (50 mL), brine (50
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified by combiflash chromatography using
30% ethyl acetate in hexane as an eluent to afford the title
compound (1.2 g, 40%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
11.72 (s, 1H), 9.18 (d, J=1.6 Hz, 1H), 8.12 (d, J=1.2 Hz, 1H), 7.88
(s, 1H), 7.83 (d, J=8.0 Hz, 1H), 7.15 (d, J=8.0 Hz, 1H); LC-MS: m/z
219.0 (M+1).sup.+.
Step-c: Synthesis of 2-amino-5-(thiazol-4-yl)phenol
[0612] To a stirred solution of
6-(thiazol-4-yl)benzo[d]oxazol-2(3H)-one (600 mg, 2.75 mmol) in
water (6 mL) at RT was added sodium hydroxide (1.09 g, 27.5 mmol)
and heated at 100.degree. C. for 16 h. The reaction mixture was
cooled to RT, quenched with saturated ammonium chloride solution
and extracted with ethyl acetate (100 mL). Organic layer was washed
with water brine (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the title compound (400 mg,
76%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 9.13 (bs, 1H),
9.06 (d, J=1.2 Hz, 1H), 7.65 (d, J=1.6 Hz, 1H), 7.31 (d, J=1.2 Hz,
1H), 7.19 (d, J=7.6 Hz, 1H), 6.61 (d, J=8.4 Hz, 1H), 4.71 (bs, 2H);
LC-MS: m/z 193.0 (M+1).sup.+.
Step-d: Synthesis of
6-(thiazol-4-yl)benzo[d]oxazole-2(3H)-thione
[0613] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-(thiazol-4-yl)phenol (Yield: 92%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 13.99 (s, 1H), 9.22 (d, J=1.6 Hz, 1H), 8.23
(d, J=1.6 Hz, 1H), 8.10 (d, J=1.2 Hz, 1H), 7.99 (dd, J=1.6 Hz,
J=8.4 Hz, 1H), 7.31 (d, J=8.4 Hz, 1H); LC-MS: m/z 234.95
(M+1).sup.+.
Step-e: Synthesis of
2-(methylthio)-6-(thiazol-4-yl)benzo[d]oxazole
[0614] The title compound was synthesized using the same procedure
which was followed for compound 1b using
6-(thiazol-4-yl)benzo[d]oxazole-2(3H)-thione as starting material
stirring for 4 hours (Yield: 84%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 9.21 (bs, 1H), 8.24-8.23 (m, 2H), 8.01 (d,
J=8.4 Hz, 1H), 8.69 (d, J=8.4 Hz, 1H), 2.78 (s, 3H); LC-MS: m/z
249.0 (M+1).sup.+.
Step-f: Synthesis of
2-(methylsulfonyl)-6-(thiazol-4-yl)benzo[d]oxazole
[0615] The title compound was synthesized using the same procedure
which was followed for compound 1c using
2-(methylthio)-6-(thiazol-4-yl)benzo[d]oxazole as starting material
and stirring for 4 h. Crude compound was used in the next step
without any analytical data.
Step-g: Synthesis of ethyl
1-methyl-2-((6-(thiazol-4-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidaz-
ole-5-carboxylate
[0616] The title compound was synthesized using the same procedure
which was followed for compound 1g using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-(methylsulfonyl)-6-(thiazol-4-yl)benzo[d]oxazole as starting
materials (Yield: 26%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.4 (bs, 1H), 9.20 (d, J=4.4 Hz, 1H), 8.25 (s, 1H), 8.22
(s, 1H), 8.08 (s, 1H), 7.92-7.87 (m, 2H), 7.54-7.50 (m, 2H), 4.33
(q, J=7.6 Hz, 2H), 3.66 (s, 3H), 1.35 (t, J=6.8 Hz, 3H); LC-MS: m/z
420.05 (M+1).sup.+.
Step-h: Synthesis of
1-methyl-2-((6-(thiazol-4-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidaz-
ole-5-carboxylic acid
[0617] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((6-(thiazol-4-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidaz-
ole-5-carboxylate as starting material and stirring for 5 h (Yield:
71%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 9.16 (s, 1H),
8.00 (s, 1H), 7.95 (s, 1H), 7.81 (s, 1H), 7.77 (d, J=8.0 Hz, 1H),
7.66 (d, J=8.4 Hz, 1H), 7.20 (d, J=7.6 Hz, 1H), 7.06 (d, J=8.4 Hz,
1H), 3.59 (s, 3H); LC-MS: m/z 392.1 (M+1).sup.+.
Step-i: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(thiazol-4-yl)benzo[d]oxazol--
2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0618] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-(thiazol-4-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidaz-
ole-5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting
materials. Crude product was purified by combiflash chromatography
using 20% Methanol in DCM as an eluent (Yield: 28%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 12.3 (bs, 1H), 9.19 (s, 1H), 8.45
(bs, 1H), 8.13-8.04 (m, 3H), 7.91 (d, J=7.6 Hz, 1H), 7.77 (d, J=8.4
Hz, 1H), 7.51 (d, J=8.0 Hz, 2H), 3.66 (s, 3H), 3.56-3.44 (m, 8H);
LC-MS: m/z 479.05 (M+1).sup.+.
Example 135. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(3-methyl-2-oxooxazolidin-5-y-
l)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00105## ##STR00106##
[0619] Step-a: Synthesis of
6-(2-bromo-1-hydroxyethyl)benzo[d]oxazol-2(3H)-one
[0620] To a stirred solution of
6-(2-bromoacetyl)benzo[d]oxazol-2(3H)-one (4.0 g, 15.62 mmol) in
methanol (50 mL) at 0.degree. C. was added sodium borohydride (587
mg, 15.62 mmol) portion wise and the reaction mixture was stirred
for 1 h. The reaction mixture was quenched with water (100 mL) and
concentrated under reduced pressure to remove methanol. The aqueous
layer was extracted with EtOAc (3.times.100 mL). Combined organic
layers were washed with brine (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to afford the titled compound
(4.0 g, 99%); LC-MS: m/z 257.9 (M+1).sup.+.
Step-b: Synthesis of
6-(1-hydroxy-2-(methylamino)ethyl)benzo[d]oxazol-2(3H)-one
[0621] A mixture of
6-(2-bromo-1-hydroxyethyl)benzo[d]oxazol-2(3H)-one (4.0 g, 15.5
mmol) in 40% aqueous methylamine (20 mL) was stirred at RT for 30
min. The reaction mixture was concentrated under vacuum and the
residue was purified by combiflash chromatography using 5% methanol
in DCM as an eluent to afford the title compound (1.8 g, 56%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.8 (bs, 1H), 8.9
(bs, 1H), 7.47 (d, J=1.2 Hz, 1H), 7.28 (dd, J=1.2 Hz, J=8.0 Hz,
1H), 7.17 (d, J=8.0 Hz, 1H), 5.68 (t, J=4.8 Hz, 1H), 4.29 (t, J=6.4
Hz, 1H), 3.81-3.74 (m, 2H), 1.24 (s, 3H); LC-MS: m/z 209.05
(M+1).sup.+.
Step-c: Synthesis of
6-(3-methyl-2-oxooxazolidin-5-yl)benzo[d]oxazol-2(3H)-one
[0622] To a stirred solution of
6-(1-hydroxy-2-(methylamino)ethyl)benzo[d]oxazol-2(3H)-one (1.8 g,
8.65 mmol) in DMFA (20 mL) at RT was added 1,1'-carbonyldiimidazole
(1.54 g, 9.52 mmol). The reaction mixture was heated to 100.degree.
C. with stirring for 16 h. The reaction mixture was cooled to RT,
diluted with water (100 mL) and extracted with ethyl acetate
(3.times.100 mL). The combined organic layer was washed brine
solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combiflash
chromatography using 1% methanol in DCM as an eluent to afford the
title compound (500 mg, 25%); .sup.1H NMR (400 MHz, DMSO-d6):
.delta. 7.22 (s, 1H), 7.09 (d, J=8.0 Hz, 1H), 7.01 (d, J=8.0 Hz,
1H), 3.57-3.54 (m, 1H), 3.45-3.41 (m, 1H), 3.34-3.30 (m, 1H), 2.16
(s, 3H).
Step-d: Synthesis of
5-(2-chlorobenzo[d]oxazol-6-yl)-3-methyloxazolidin-2-one
[0623] A 50 mL round bottom flask was charged with
6-(3-methyl-2-oxooxazolidin-5-yl)benzo[d]oxazol-2(3H)-one (500 mg,
2.14 mmol) and POCl.sub.3 (0.98 mL, 10.68 mmol) followed by slow
addition of triethyl amine (1.51 mL, 10.68 mmol) at 0.degree. C.
The reaction mixture was heated to reflux for 5 h. The reaction
mixture was cooled to RT, poured over ice and extracted with ethyl
acetate (2.times.50 mL). The combined organic layer was washed with
saturated sodium bicarbonate solution (2.times.50 mL), water (50
mL), brine solution (30 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was purified by
combiflash chromatography using 50% EtOAc in hexane as an eluent to
afford the title compound (120 mg, 22%); .sup.1H NMR (400 MHz,
DMSO-d6): .delta. 7.58 (s, 1H), 7.35 (dd, J=1.6 Hz, J=8.0 Hz, 1H),
7.19 (d, J=7.6 Hz, 1H), 4.64 (bs, 1H), 4.23-4.19 (m, 1H), 4.16-4.11
(m, 1H), 2.46 (s, 3H).
Step-e: Synthesis of ethyl
2-(bis((benzyloxy)carbonyl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late
[0624] To a stirred solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (1.0 g, 3.24
mmol) in acetone (10 mL) and water (10 mL) at 0.degree. C. was
added sodium bicarbonate (722 mg, 6.88 mmol) and benzyl
chloroformate (1.2 mL, 4.22 mmol, 50% in toluene). The reaction
mixture was stirred at RT for 16 h. The reaction mixture was
diluted with water (100 mL) and extracted with ethyl acetate
(2.times.100 mL). The combined organic layer was washed brine
solution (50 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude compound was used in the next
step without any further purification (2.2 g, 99%); LC-MS: m/z
488.2 (M+1).sup.+.
Step-f: Synthesis of
2-(((benzyloxy)carbonyl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid
[0625] To a stirred solution of ethyl
2-(bis((benzyloxy)carbonyl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxy-
late (2.2 g, 4.52 mmol) in a mixture of solvent of THF (15 mL),
ethanol (15 mL) and water (10 mL) was added lithium hydroxide
monohydrate (948 mg, 22.6 mmol). The reaction mixture was heated at
80.degree. C. for 16 h with stirring. The reaction mixture was
cooled to RT and concentrated under reduced pressure. The residue
was dissolved in water (30 mL), acidified with 1 N HCl and
extracted with ethyl acetate (2.times.150 mL). The combined organic
layer was washed brine solution (50 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum to give the crude
compound which was used in the next step without any further
purification (1.4 g, 95%); LC-MS: m/z 326.1 (M+1).sup.+.
Step-g: Synthesis of benzyl
(5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)carbamoyl)-1-methyl--
1H-benzo[d]imidazol-2-yl)carbamate
[0626] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
2-(((benzyloxy)carbonyl)amino)-1-methyl-1H-benzo[d]imidazole-5-carboxylic
acid and 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-amine as
starting materials (Yield: 66%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.20 (bs, 1H), 8.42 (t, J=5.2 Hz, 1H), 7.85
(s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.41-7.33 (m, 6H), 5.08 (s, 2H),
3.66 (t, J=5.2 Hz, 2H), 3.54-3.38 (m, 9H), 0.81 (s, 9H), 0.03 (s,
6H); LC-MS: m/z 527.25 (M+1).sup.+.
Step-h: Synthesis of
2-amino-N-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)-1-methyl-1H-b-
enzo[d]imidazole-5-carboxamide
[0627] To a solution of benzyl
(5-((2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)carbamoyl)-1-methyl--
1H-benzo[d]imidazol-2-yl)carbamate (320 mg, 0.61 mmol) in methanol
(8 mL) was added 10% Pd/C (40 mg) under nitrogen atmosphere. Then
the reaction mixture was stirred under hydrogen gas balloon for 6
h. The reaction mixture was filtered through a bed of celite and
concentrated under vacuum to afford the title compound (170 mg,
71%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.22 (t, J=4.8
Hz, 1H), 7.65 (s, 1H)), 7.45 (d, J=8.0 Hz, 1H), 7.14 (d, J=8.0 Hz,
1H), 6.52 (s, 2H), 3.69 (t, J=4.8 Hz, 2H), 3.55-3.46 (m, 7H),
3.41-3.37 (m, 2H), 0.84 (s, 9H), 0.01 (s, 6H); LC-MS: m/z 393.65
(M+1).sup.+.
Step-i: Synthesis of
N-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)-1-methyl-2-((6-(3-met-
hyl-2-oxooxazolidin-5-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-
-carboxamide
[0628] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using
2-amino-N-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)-1-methyl-1H-b-
enzo[d]imidazole-5-carboxamide and
5-(2-chlorobenzo[d]oxazol-6-yl)-3-methyloxazolidin-2-one as
starting materials stirring for 3 h (Yield: 74%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 11.74 (bs, 1H), 8.43 (t, J=5.2 Hz, 1H),
8.05 (d, J=1.2 Hz, 1H), 7.77 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.56 (d,
J=8.4 Hz, 1H), 7.42 (d, J=1.2 Hz, 1H), 7.25 (dd, J=1.6 Hz, J=8.4
Hz, 1H), 7.15 (d, J=8.0 Hz, 1H), 4.87 (t, J=7.2 Hz, 1H), 4.35 (t,
J=9.2 Hz, 1H), 3.82-3.76 (m, 5H), 3.68 (t, J=5.2 Hz, 2H), 3.54-3.52
(m, 2H), 3.48-3.31 (m, 2H), 2.62 (s, 3H), 0.84 (s, 9H), -0.01 (s,
3H), -0.02 (s, 3H); LC-MS: m/z 609.3 (M+1).sup.+.
Step-j: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(3-methyl-2-oxooxazolidin-5-y-
l)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0629] To a stirred solution of
N-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)-1-methyl-2-((6-(3-met-
hyl-2-oxooxazolidin-5-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-
-carboxamide (30 mg, 0.05 mmol) in THF (2 mL) at 0.degree. C. was
added 1 M TBAF in THF (0.1 mL) and the reaction mixture was stirred
at RT for 16 h. The reaction mixture was quenched with saturated
ammonium chloride solution (10 mL) and extracted with EtOAc
(2.times.30 mL). The combined organic layers were washed with water
(20 mL), brine (20 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to obtain a residue which was purified by
combiflash chromatography using 5% methanol in DCM as an eluent to
afford the title compound (14 mg, 58%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.8 (bs, 1H), 8.43 (t, J=5.2 Hz, 1H), 8.06
(s, 1H), 7.78 (d, J=8.8 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.38 (s,
1H), 7.21 (d, J=8.0 Hz, 1H), 7.13 (d, J=7.6 Hz, 1H), 4.87 (t, J=8.0
Hz, 1H), 4.59 (s, 1H), 4.35 (t, J=9.2 Hz, 1H), 3.82 (t, J=9.2 Hz,
1H), 3.78 (s, 3H), 3.56-3.41 (m, 8H), 2.63 (s, 3H); LC-MS: m/z
495.2 (M+1).sup.+.
Example 136. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-morpholinobenzo[d]oxazol-2-yl-
)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00107##
[0630] Step-a: Synthesis of 5-morpholino-2-nitrophenol
[0631] To a stirred solution of 5-fluoro-2-nitrophenol (5.0 g,
31.84 mmol) in acetonitrile (50 mL) at RT was added morpholine
(8.31 g, 95.54 mmol) and the reaction mixture was heated at
60.degree. C. for 2 h. The reaction mixture was cooled to RT,
diluted with cold water (300 mL) and the precipitated solid was
filtered and dried under vacuum to afford the title compound (5.0
g, 70%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.9 (bs,
1H), 7.88 (d, J=9.2 Hz, 1H), 6.65 (dd, J=2.4 Hz, J=9.6 Hz, 1H),
6.44 (d, J=2.8 Hz, 1H), 3.70 (t, J=5.2 Hz, 4H), 3.41 (t, J=4.8 Hz,
4H); LC-MS: m/z 225.1 (M+1).sup.+.
Step-b: Synthesis of 2-amino-5-morpholinophenol
[0632] The title compound was synthesized using the same procedure
which was followed for compound 1e using 5-morpholino-2-nitrophenol
as starting material and stirred for 3 h (Yield: 81%); .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 8.8 (bs, 1H), 6.48 (d, J=8.0 Hz,
1H), 6.33 (d, J=2.4 Hz, 1H), 6.19 (dd, J=2.8 Hz, J=8.8 Hz, 1H),
3.68 (t, J=5.2 Hz, 4H), 2.84 (t, J=4.8 Hz, 4H); LC-MS: m/z 195.1
(M+1).sup.+.
Step-c: Synthesis of 6-morpholinobenzo[d]oxazole-2(3H)-thione
[0633] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-morpholinophenol as starting material (Yield: 75%);
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 13.6 (s, 1H), 7.14 (d,
J=2.4 Hz, 1H), 7.09 (d, J=8.8 Hz, 1H), 6.91 (dd, J=2.4 Hz, J=8.8
Hz, 1H), 3.73 (t, J=4.4 Hz, 4H), 3.10 (t, J=4.8 Hz, 4H); LC-MS: m/z
237.1 (M+1).sup.+.
Step-d: Synthesis of 2-chloro-6-morpholinobenzo[d]oxazole
[0634] To a solution of 6-morpholinobenzo[d]oxazole-2(3H)-thione
(500 mg, 1.12 mmol) in DCM (10 mL) at RT was added thionyl chloride
(0.79 mL, 10.6 mmol) and dimethylformamide (0.2 mL) and the
reaction mixture was stirred at RT for 1 h. The reaction mixture
was poured on cold water (50 mL), basified with saturated sodium
bicarbonate solution and extracted with DCM (2.times.50 mL). The
combined organic layers were washed with brine solution (30 mL),
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was purified by combiflash chromatography using 30%
EtOAc in hexane as eluent to afford the title compound (300 mg,
60%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.56 (d, J=8.8
Hz, 1H), 7.29 (d, J=2.4 Hz, 1H), 7.09 (dd, J=2.4 Hz, J=8.8 Hz, 1H),
3.75 (t, J=4.8 Hz, 4H), 3.16 (t, J=4.8 Hz, 4H); LC-MS: m/z 239.0
(M+1).sup.+.
Step-e: Synthesis of ethyl
1-methyl-2-((6-morpholinobenzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole--
5-carboxylate
[0635] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-morpholinobenzo[d]oxazole as starting materials (Yield:
37%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.2 (bs, 1H),
8.20 (d, J=1.2 Hz, 1H), 7.86 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.49 (d,
J=8.4 Hz, 1H), 7.33 (d, J=8.4 Hz, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.87
(dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.32 (q, J=8.4 Hz, 2H), 3.76 (t,
J=4.4 Hz, 4H), 3.61 (s, 3H), 3.09 (t, J=4.8 Hz, 4H), 1.35 (t, J=7.2
Hz, 3H); LC-MS: m/z 422.1 (M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((6-morpholinobenzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole--
5-carboxylic acid
[0636] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((6-morpholinobenzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole--
5-carboxylate as starting material (Yield: 71%); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.5 (bs, 1H), 8.16 (d, J=1.2 Hz, 1H),
7.85 (d, J=8.4 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.34 (d, J=8.8 Hz,
1H), 7.08 (d, J=2.0 Hz, 1H), 6.86 (dd, J=2.0 Hz, J=8.8 Hz, 1H),
3.76 (t, J=4.4 Hz, 4H), 3.61 (s, 3H), 3.09 (t, J=4.4 Hz, 4H);
LC-MS: m/z 394.0 (M+1).sup.+.
Step-g: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-morpholinobenzo[d]-oxazol-2-y-
l)amino)-1H-benzo[d]imidazole-5-carboxamide
[0637] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-morpholinobenzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole--
5-carboxylic acid and 2-(2-aminoethoxy)ethan-1-ol as starting
materials (Yield: 98%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.4 (bs, 1H), 8.49 (t, J=4.8 Hz, 1H), 8.05 (d, J=1.2 Hz,
1H), 7.78 (d, J=7.2 Hz, 1H), 7.52 (d, J=7.2 Hz, 1H), 7.34 (d, J=8.4
Hz, 1H), 7.15 (s, 1H), 6.94 (d, J=7.2 Hz, 1H), 3.86 (bs, 4H), 3.64
(s, 3H), 3.56-3.54 (m, 4H), 3.47-3.45 (m, 4H), 3.14 (bs, 4H);
LC-MS: m/z 481.2 (M+1).sup.+.
Example 137. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(pyrrolidin-1-yl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00108##
[0638] Step-a: Synthesis of 2-nitro-5-(pyrrolidin-1-yl)phenol
[0639] To a solution of 5-fluoro-2-nitrophenol (2.0 g, 12.73 mmol)
in acetonitrile 20 mL) at RT was added pyrrolidine (3.15 mL, 38.21
mmol) and stirred at 100.degree. C. for 12 h. The reaction mixture
was concentrated under vacuum and the residue was purified by
combi-flash column chromatography using 30% ethyl acetate in hexane
as an eluent to afford the titled compound (1.5 g, 57%); .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 7.85 (d, J=9.2 Hz, 1H), 6.28
(dd, J=2.4 Hz, J=9.2 Hz, 1H), 6.02 (d, J=2.4 Hz, 1H), 3.39-3.36 (m,
4H), 1.98-1.94 (m, 4H).
Step-b: Synthesis of 2-amino-5-(pyrrolidin-1-yl)phenol
[0640] To a solution of 2-nitro-5-(pyrrolidin-1-yl)phenol (1.5 g,
7.20 mmol) in methanol (300 mL) was added 10% Pd/C (300 mg) under
nitrogen atmosphere. The reaction mixture was stirred under
hydrogen balloon for 4 h. The reaction mixture was filtered through
a celite bed and the filtrate was concentrated under vacuum to
afford the crude compound (1.3 g) which was used in the next step
without any further purification and structural confirmation by
analytical technique.
Step-c: Synthesis of
6-(pyrrolidin-1-yl)benzo[d]oxazole-2(3H)-thione
[0641] To a solution of 2-amino-5-(pyrrolidin-1-yl)phenol (1.3 g,
7.30 mmol) in ethanol (13 mL) at RT was added potassium
ethyl-xanthate (2.3 g, 14.6 mmol) and the reaction mixture was
refluxed for 16 h. The reaction mixture was concentrated under
vacuum and diluted with cold water (50 mL), acidified with 1 N HCl.
The solid obtained was filtered and dried under vacuum to afford
the titled compound (0.8 g, 50%) which was used in the next step
without further purification; .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 13.50 (bs, 1H), 7.03 (d, J=8.4 Hz, 1H), 6.65 (d, J=2.0 Hz,
1H), 6.46 (dd, J=2.0 Hz, J=8.4 Hz, 1H), 3.22-3.19 (m, 4H),
1.97-1.94 (m, 4H); LC-MS: m/z 220.9 (M+1).sup.+.
Step-d: Synthesis of
2-chloro-6-(pyrrolidin-1-yl)benzo[d]oxazole
[0642] To a solution of
6-(pyrrolidin-1-yl)benzo[d]oxazole-2(3H)-thione (400 mg, 1.82 mmol)
in DCM (10 mL) at 0.degree. C. was added thionyl chloride (0.66 mL,
9.09 mmol) and the reaction mixture was stirred at 0.degree. C. for
1 h. The reaction mixture was quenched with water (20 mL),
extracted with EtOAc (2.times.50 mL). The combined organic layers
were washed with saturated sodium bicarbonate solution (30 mL),
brine solution (30 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum to afford the titled compound (300 mg,
74%) which was used in the next step without further purification;
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 6.91 (d, J=8.4 Hz, 1H),
6.48 (d, J=2.0 Hz, 1H), 6.42 (dd, J=2.4 Hz, J=8.8 Hz, 1H),
3.21-3.16 (m, 4H), 1.96-1.91 (m, 4H).
Step-e: Synthesis of ethyl
1-methyl-2-((6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate
[0643] To a stirred solution of ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate (200 mg, 0.91
mmol) in 1,4-dioxane (5 mL) at 0.degree. C. was added sodium
hydride (60% dispersion in mineral oil) (73 mg, 1.82 mmol) and
stirred for 30 min followed by the addition of
2-chloro-6-(pyrrolidin-1-yl)benzo[d]oxazole (243 mg, 1.09 mmol).
The reaction mixture was stirred at RT for 4 h and then quenched
with cold water (20 mL) and extracted with EtOAc (2.times.50 mL).
Combined organic layers were washed with water (30 mL), brine (30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified by combi-flash column
chromatography using 3% methanol in DCM as an eluent to afford the
titled compound (150 mg, 40%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.10 (bs, 1H), 8.18 (d, J=1.6 Hz, 1H), 7.85 (dd, J=1.2 Hz,
J=8.4 Hz, 1H), 7.46 (d, J=8.4 Hz, 1H), 7.29 (d, J=8.8 Hz, 1H), 6.64
(d, J=2.0 Hz, 1H), 6.46 (dd, J=2.0 Hz, J=8.4 Hz, 1H), 4.32 (q,
J=6.8 Hz, 2H), 3.60 (s, 3H), 3.26-3.23 (m, 4H), 1.99-1.95 (m, 4H),
1.35 (t, J=6.8 Hz, 3H); LC-MS: m/z 406.2 (M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid
[0644] To a stirred solution of ethyl
1-methyl-2-((6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylate (150 mg, 0.37 mmol) in a mixture of solvent of
[THF (2 mL), ethanol (2 mL) and water (1 mL)] was added lithium
hydroxide monohydrate (77 mg, 1.85 mmol). The reaction mixture was
heated at 60.degree. C. for 16 h. The reaction mixture was cooled
to RT and concentrated under reduced pressure. The residue was
dissolved in water, acidified with 1 N HCl to obtain the solid
which was filtered and dried under vacuum to afford the titled
compound (120 mg, 86%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.87 (s, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.00 (d, J=8.4 Hz,
1H), 6.95 (d, J=7.6 Hz, 1H), 6.50 (s, 1H), 6.31 (d, J=7.2 Hz, 1H),
3.52 (s, 3H), 3.25-3.21 (m, 4H), 1.97-1.93 (m, 4H); LC-MS: m/z
376.0 (M-1).
Step-g: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-(pyrrolidin-1-yl)benzo[d]oxaz-
ol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0645] To a stirred solution of
1-methyl-2-((6-(pyrrolidin-1-yl)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imi-
dazole-5-carboxylic acid (120 mg, 0.32 mmol) in DMFA (5 mL) at
0.degree. C. was added N-ethyldiisopropyl amine (0.08 mL, 0.48
mmol) and HBTU (180 mg, 0.48 mmol). The reaction mixture was
stirred for 30 min, followed by the addition of
2-(2-aminoethoxy)ethan-1-ol (80 mg, 0.48 mmol) and stirring was
continued at RT for 16 h. Once the reaction was completed
(monitored by TLC), the reaction mixture was diluted with cold
water (20 mL) and extracted with EtOAc (2.times.50 mL). Combined
organic layers were washed with water (25 mL), brine (25 mL), dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was purified by preparative HPLC purification method to
afford the titled compound (15 mg, 10%);
[0646] Preparative HPLC Purification Method Details:
TABLE-US-00004 DILUTION: THF + Acetonitrile:Water (50:50) MOBILE
PHASE A: 0.1% Formic acid in water MOBILE PHASE B: Acetonitrile
(100%) GRADIENT: T/% B: 0/15, 10/35 FLOW RATE: 15 mL/min COLUMN:
Agilent ZORBAX XDB C18 (150 .times. 21.2 .times. 5 .mu.m)
[0647] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.0 (bs, 1H),
8.40 (t, J=5.2 Hz, 1H), 8.03 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.43
(d, J=8.4 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 6.63 (bs, 1H), 6.46 (bs,
1H), 4.63 (s, 1H), 3.59 (s, 3H), 3.57-3.39 (m, 8H), 3.24 (bs, 4H),
1.97 (bs, 4H); LC-MS: m/z 465.20 (M+1).sup.+.
Example 138. Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-((tetrahydro-2H-pyran-4-yl)ox-
y)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
##STR00109##
[0648] Step-a: Synthesis of
2-nitro-5-((tetrahydro-2H-pyran-4-yl)oxy)phenol
[0649] To a solution of tetrahydro-2H-pyran-4-ol (2.27 mL, 22.29
mmol) in DMFA (15 mL) at 10.degree. C. was added sodium hydride
(60% dispersion in mineral oil) (1.27 g, 31.84 mmol) and stirred
for 5 min, followed by the addition of 5-fluoro-2-nitrophenol (1.0
g, 6.37 mmol) to the reaction mixture and it was stirred at
60.degree. C. for 16 h. The reaction mixture was cooled to RT,
quenched with cold water (100 mL) and neutralized with 1 N HCl. The
precipitated solid was filtered and dried under vacuum to afford
the title compound (1.0 g, 33%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 10.90 (bs, 1H), 7.95 (d, J=9.2 Hz, 1H), 6.68
(d, J=2.0 Hz, 1H), 6.63 (dd, J=2.4 Hz, J=9.2 Hz, 1H), 4.71-4.68 (m,
1H), 3.86-3.82 (m, 2H), 3.52-3.49 (m, 2H), 1.99-1.97 (m, 2H),
1.64-1.56 (m, 2H).
Step-b: Synthesis of
2-amino-5-((tetrahydro-2H-pyran-4-yl)oxy)phenol
[0650] The title compound was synthesized using the same procedure
which was followed for compound 1e using
2-nitro-5-((tetrahydro-2H-pyran-4-yl)oxy)phenol as starting
material and stirring for 6 h (Yield: 87%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 9.0 (bs, 1H), 6.47 (d, J=8.4 Hz, 1H), 6.32
(d, J=2.8 Hz, 1H), 6.21 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 4.22-4.17 (m,
1H), 3.83-3.78 (m, 2H), 3.44-3.40 (m, 2H), 1.89-1.85 (m, 2H),
1.54-1.45 (m, 2H); LC-MS: m/z 209.95 (M+1).sup.+.
Step-c: Synthesis of
6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazole-2(3H)-thione
[0651] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-c using
2-amino-5-((tetrahydro-2H-pyran-4-yl)oxy)phenol as starting
material (Yield: 75%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
13.74 (bs, 1H), 7.30 (d, J=2.4 Hz, 1H), 7.12 (d, J=8.8 Hz, 1H),
6.92 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 4.59-4.53 (m, 1H), 3.87-3.82 (m,
2H), 3.47-3.40 (m, 2H), 1.98-1.93 (m, 2H), 1.61-1.52 (m, 2H);
LC-MS: m/z 252.1 (M+1).sup.+.
Step-d: Synthesis of
2-chloro-6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazole
[0652] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-d using
6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazole-2(3H)-thione as
starting material (Yield: 25%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.59 (d, J=8.8 Hz, 1H), 7.47 (d, J=2.0 Hz,
1H), 7.02 (dd, J=2.0 Hz, J=8.8 Hz, 1H), 4.62-4.59 (m, 1H),
3.85-3.77 (m, 2H), 3.49-3.43 (m, 2H), 1.97-1.94 (m, 2H), 1.61-1.52
(m, 2H); LC-MS: m/z 254.1 (M+1).sup.+.
Step-e: Synthesis of ethyl
1-methyl-2-((6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazol-2-yl)amino)--
1H-benzo[d]imidazole-5-carboxylate
[0653] The title compound was synthesized using the same procedure
which was followed for Example 32 Step-e using ethyl
2-amino-1-methyl-1H-benzo[d]imidazole-5-carboxylate and
2-chloro-6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazole as
starting materials (Yield: 23%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.20 (bs, 1H), 8.21 (d, J=1.2 Hz, 1H), 7.85
(dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.35 (d,
J=8.8 Hz, 1H), 7.19 (d, J=2.4 Hz, 1H), 6.85 (dd, J=2.0 Hz, J=8.8
Hz, 1H), 4.56-4.54 (m, 1H), 4.32 (q, J=7.2 Hz, 2H), 3.88-3.85 (m,
2H), 3.62 (s, 3H), 3.51-3.44 (m, 2H), 2.00-1.98 (m, 2H), 1.61-1.58
(m, 2H), 1.35 (q, J=6.8 Hz, 3H); LC-MS: m/z 437.2 (M+1).sup.+.
Step-f: Synthesis of
1-methyl-2-((6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazol-2-yl)amino)--
1H-benzo[d]imidazole-5-carboxylic acid
[0654] The title compound was synthesized using the same procedure
which was followed for compound 1h using ethyl
1-methyl-2-((6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazol-2-yl)amino)--
1H-benzo[d]imidazole-5-carboxylate as starting material (Yield:
67%); .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.40 (bs, 1H),
8.17 (d, J=1.2 Hz, 1H), 7.86 (dd, J=1.2 Hz, J=8.4 Hz, 1H), 7.49 (d,
J=8.4 Hz, 1H), 7.36 (d, J=5.6 Hz, 1H), 7.20 (d, J=2.4 Hz, 1H), 6.86
(dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.57-4.53 (m, 1H), 3.88-3.84 (m, 2H),
3.62 (s, 3H), 3.51-3.44 (m, 2H), 2.00-1.95 (m, 2H), 1.61-1.58 (m,
2H); LC-MS: m/z 409.1 (M+1).sup.+.
Step-g: Synthesis of
N-(2-(2-hydroxyethoxy)ethyl)-1-methyl-2-((6-((tetrahydro-2H-pyran-4-yl)ox-
y)benzo[d]oxazol-2-yl)amino)-1H-benzo[d]imidazole-5-carboxamide
[0655] The title compound was synthesized using the same procedure
which was followed for Example 6 Step-e using
1-methyl-2-((6-((tetrahydro-2H-pyran-4-yl)oxy)benzo[d]oxazol-2-yl)amino)--
1H-benzo[d]imidazole-5-carboxylic acid and
2-(2-aminoethoxy)ethan-1-ol as starting materials. The crude
product was purified by combiflash chromatography using 4% methanol
in DCM as an eluent (Yield: 40%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.17 (bs, 1H), 8.44 (d, J=5.6 Hz, 1H), 8.05
(d, J=1.2 Hz, 1H), 7.74 (dd, J=1.6 Hz, J=8.4 Hz, 1H), 7.46 (d,
J=8.4 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.18 (d, J=2.0 Hz, 1H), 6.84
(dd, J=2.4 Hz, J=8.8 Hz, 1H), 4.62 (bs, 1H), 4.57-4.51 (m, 1H),
3.89-3.84 (m, 2H), 3.61 (s, 3H), 3.55-3.33 (m, 10H), 1.98-1.95 (m,
2H), 1.61-1.57 (m, 2H); LC-MS: m/z 496.2 (M+1).sup.+
Examples 139, 140 and 141. Synthesis of
1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2--
trifluoroethan-1-one, Synthesis of
(Z)-1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,-
2,2-trifluoroethan-1-one oxime and Synthesis of
N-(5-(1-amino-2,2,2-trifluoroethyl)-1-methyl-1H-benzo[d]imidazol-2-yl)ben-
zo[d]oxazol-2-amine
##STR00110##
[0656] Step-a: Synthesis of
2,2,2-trifluoro-1-(4-fluoro-3-nitrophenyl)ethan-1-one
[0657] To a solution of
2,2,2-trifluoro-1-(4-fluorophenyl)ethan-1-one (3.0 g, 15.62 mmol)
in conc. sulfuric acid (12 mL) at 0.degree. C. was added fuming
nitric acid (0.9 mL) and stirred at RT for 2 h. The reaction
mixture was quenched with cold water (100 mL) and extracted with
ethyl acetate (200 mL). Organic layer was washed with cold water
(2.times.50 mL), brine solution (50 mL), dried over anhydrous
sodium sulfate and concentrated under vacuum to afford the titled
compound (3.5 g, 94%) which was used in the next step without
further purification; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
8.80 (d, J=6.8 Hz, 1H), 8.37 (d, J=8.8 Hz, 1H), 7.54 (t, J=9.4 Hz,
1H).
Step-b: Synthesis of
2,2,2-trifluoro-1-(4-(methylamino)-3-nitrophenyl)ethan-1-one
[0658] To a stirred solution of
2,2,2-trifluoro-1-(4-fluoro-3-nitrophenyl)ethan-1-one (3.5 g, 14.7
mmol) in DMFA (17.5 mL) at 0.degree. C. was added 40% aqueous
methyl amine (3.5 mL) and the reaction mixture was stirred at RT
for 2 h. The reaction mixture was diluted with cold water (100 mL)
and extracted with ethyl acetate (2.times.100 mL). Combined organic
layers were washed with water (2.times.50 mL), brine solution (50
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum to afford the titled compound (3.3 g, 89%) which was used in
the next step without further purification; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.99 (bs, 1H), 8.69 (s, 1H), 8.05 (d, J=9.2
Hz, 1H), 7.19 (d, J=9.2 Hz, 1H), 3.06 (d, J=4.8 Hz, 3H); LC-MS: m/z
247.1 (M-1).
Step-c: Synthesis of
1-(3-amino-4-(methylamino)phenyl)-2,2,2-trifluoroethan-1-one
[0659] To a stirred solution of
2,2,2-trifluoro-1-(4-(methylamino)-3-nitrophenyl)ethan-1-one (2.0
g, 8.1 mmol) in methanol (20 mL) at 0.degree. C. was added iron
(2.25 g, 40.3 mmol) and conc. hydrochloric acid (5.0 mL, 40.3
mmol). The reaction mixture was stirred at RT for 1 h and then
heated at 60.degree. C. with stirring for another 1 h. The reaction
mixture was cooled to RT, diluted with methanol (30 mL) and
filtered through a celite pad. The filtrate was concentrated and
diluted with water (50 mL), basified with saturated sodium
bicarbonate solution and extracted with EtOAc (2.times.50 mL). The
combined organic layers were washed with water (30 mL), brine (30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum to afford the titled compound (1.5 g, 84%) which was used in
the next step without further purification; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.35 (d, J=8.4 Hz, 1H), 7.21 (s, 1H), 6.50
(d, J=8.8 Hz, 1H), 6.30 (bs, 1H), 4.96 (s, 2H), 2.85 (d, J=4.8 Hz,
3H); LC-MS: m/z 218.90 (M+1).sup.+.
Step-d: Synthesis of
1-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2-trifluoroethan-1-one
[0660] To a stirred solution of
1-(3-amino-4-(methylamino)phenyl)-2,2,2-trifluoroethan-1-one (1.0
g, 4.6 mmol) in THF (10 mL) and water (10 mL) at RT was added
cyanogen bromide (0.58 g, 5.5 mmol) and the reaction mixture was
stirred at 60.degree. C. for 16 h. The reaction mixture was
concentrated under reduced pressure and the residue was diluted
with water (50 mL), basified with saturated sodium bicarbonate
solution and extracted with EtOAc (2.times.100 mL). Combined
organic layers were washed with water (50 mL), brine (500 mL),
dried over anhydrous sodium sulfate and concentrated under vacuum
to afford the titled compound which was used in the next step
without further purification (900 mg, 81%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.75 (s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.38
(d, J=8.4 Hz, 1H), 6.96 (s, 2H), 3.58 (s, 3H); LC-MS: m/z 244.1
(M+1).sup.+.
Step-e: Synthesis of
1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2--
trifluoroethan-1-one
[0661] To a stirred solution of
1-(2-amino-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2-trifluoroethan-1-one
(900 mg, 3.70 mmol) in 1,4-dioxane (20 mL) at 0.degree. C. was
added sodium hydride (60% dispersion in mineral oil) (518 mg, 12.96
mmol) and stirred for 15 min followed by the addition of
2-chlorobenzoxazole (567 mg, 3.70 mmol). The reaction mixture was
stirred at RT for 16 h. The reaction mixture was then quenched with
cold water (30 mL) and extracted with EtOAc (2.times.50 mL).
Combined organic layers were washed with water (30 mL), brine (30
mL), dried over anhydrous sodium sulfate and concentrated under
vacuum. The residue was purified by combi flash column
chromatography using 100% DCM as an eluent to afford the titled
compound (700 mg, 52%); .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 12.50 (bs, 1H), 8.35 (s, 1H), 7.97 (d, J=8.8 Hz, 1H), 7.67
(d, J=8.8 Hz, 1H), 7.52-7.46 (m, 2H), 7.25 (t, J=7.8 Hz, 1H), 7.16
(t, J=7.8 Hz, 1H), 3.67 (s, 3H); LC-MS: m/z 361.1 (M+1).sup.+.
Step-f: Synthesis of
(Z)-1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,-
2,2-trifluoroethan-1-one oxime
[0662] To a stirred solution of
1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2--
trifluoroethan-1-one (700 mg, 1.94 mmol) in ethanol (20 mL) at RT
was added hydroxylamine hydochloride (405 mg, 5.83 mmol) and
potassium acetate (572 mg, 5.83 mmol). The reaction mixture was
stirred at 80.degree. C. for 16 h. Once the reaction was completed
(monitored by TLC), the reaction mixture was concentrated under
reduced pressure and diluted with water (50 mL) and extracted with
EtOAc (2.times.100 mL). Combined organic layers were washed with
water (50 mL), brine (30 mL), dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was purified by combi
flash column chromatography using 2% methanol in DCM as an eluent
to afford the titled compound (500 mg, 68%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 13.05 (bs, 1H), 12.40 (bs, 1H), 7.81-7.76
(m, 1H), 7.59-7.53 (m, 1H), 7.48-7.46 (m, 2H), 7.41-7.37 (m, 1H),
7.24 (t, J=7.4 Hz, 1H), 7.15 (t, J=7.6 Hz, 1H), 3.65 (s, 3H);
LC-MS: m/z 376.1 (M+1).sup.+.
Step-g: Synthesis of
N-(5-(1-amino-2,2,2-trifluoroethyl)-1-methyl-1H-benzo[d]imidazol-2-yl)ben-
zo[d]oxazol-2-amine
[0663] To a stirred solution of
(Z)-1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,-
2,2-trifluoroethan-1-one oxime (300 mg, 0.80 mmol) in THF (5 mL) at
10.degree. C. was added 1 M solution of lithium aluminium hydride
(1.6 mL, 1.60 mmol). The reaction mixture was stirred at 10.degree.
C. for 4 h. Once the reaction was completed (monitored by TLC), the
reaction mixture was quenched with 1N sodium hydroxide solution (5
mL), diluted with water (10 mL) and extracted with EtOAc
(2.times.30 mL). Combined organic layers were washed with water (20
mL), brine (20 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by preparative
HPLC method to afford the titled compound (100 mg, 35%).
[0664] Preparative HPLC Purification Method Details
TABLE-US-00005 DILUTION: THF + ACN:WATER (50:50) MOBILE PHASE A:
0.1% formic acid in Water MOBILE PHASE B: 100% ACETONITRILE
GRADIENT: T/% B: 0/15, 10/40 FLOW RATE: 15 mL/min COLUMN: Kinetex
C-18 (250 .times. 21.1 .times. 5 .mu.m)
[0665] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 1H),
7.73 (s, 1H), 7.46-7.36 (m, 4H), 7.20 (t, J=7.2 Hz, 1H), 7.10 (t,
J=7.2 Hz, 1H), 4.59-4.57 (m, 1H), 3.61 (s, 3H); LC-MS: m/z 362.3
(M+1).sup.+.
[0666] Two isomers of this compound were separated by chiral HPLC
purification.
TABLE-US-00006 Chiral HPLC purification method details: DILUTION:
IPA:DCM (90:10) MOBILE PHASE A: 0.1% DEA in Hexane MOBILE PHASE B:
IPA:DCM (90:10) % ISOCRATIC: A:B (40:60) FLOW RATE: 15 mL/min
[0667] Peak-1 Analytical Data:
[0668] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 1H),
7.73 (s, 1H), 7.46-7.36 (m, 4H), 7.20 (t, J=7.2 Hz, 1H), 7.10 (t,
J=7.2 Hz, 1H), 4.59-4.57 (m, 1H), 3.61 (s, 3H); LC-MS: m/z 362.05
(M+1).sup.+.
[0669] Peak-2 Analytical Data:
[0670] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 12.20 (bs, 1H),
7.73 (s, 1H), 7.46-7.36 (m, 4H), 7.20 (t, J=7.2 Hz, 1H), 7.10 (t,
J=7.2 Hz, 1H), 4.60-4.58 (m, 1H), 3.61 (s, 3H); LC-MS: m/z 362.05
(M+1).sup.+.
Example 142. Synthesis of
1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2--
trifluoroethan-1-ol
##STR00111##
[0672] To a stirred solution of
1-(2-(benzo[d]oxazol-2-ylamino)-1-methyl-1H-benzo[d]imidazol-5-yl)-2,2,2--
trifluoroethan-1-one (50 mg, 0.14 mmol) in methanol (3 mL) at
0.degree. C. was added sodium borohydride (6 mg, 0.15 mmol) and the
reaction mixture was stirred at RT for 1 h. The reaction mixture
was quenched with cold water (10 mL) and extracted with EtOAc
(2.times.20 mL). The combined organic layers were washed with water
(15 mL), brine (15 mL), dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was purified by combi flash
column chromatography using 2% methanol in DCM as an eluent to
afford the titled compound (40 mg, 80%); .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 12.30 (bs, 1H), 7.77 (s, 1H), 7.46-7.34 (m,
4H), 7.20 (t, J=7.6 Hz, 1H), 7.10 (t, J=7.6 Hz, 1H), 6.90 (bs, 1H),
5.24-5.22 (m, 1H), 3.62 (s, 3H); LC-MS: m/z 363.30 (M+1).sup.+.
Example 143. ELISA Assay to Measure Human Heme Oxygenase-1 (HMOX-1)
in HepG2 Lysate
[0673] Reagents and Technical Notes:
[0674] ELISA capture antibody, standard HO-1, detection antibody
and streptavidin HRP were supplied in the DuoSet IC Human total
HO-1 ELISA from R&D systems (DYC3776-2). The substrate cocktail
was KPL LumiGLO reserve Chemiluminescent Substrate (54-71-00). PBS
was Corning Cellgro Cell Culture (21-040-CV). 10.times.PBS+0.05%
tween20 (PBST) was from KPL.
[0675] All incubations of the plate were at room temperature
(20.degree. C.) in a closed drawer.
[0676] The ELISA plate was processed manually. All loadings were
with a multichannel pipet. Plates were emptied by shaking into the
sink and tapping onto paper towels to remove any remaining reagent.
Plate washing was accomplished by loading all wells with PBS+0.05%
tween20 (PBST) using a squirt bottle, shaking the PBST out and
tapping the plate onto paper towels.
[0677] Preparation of the ELISA Plate: [0678] 1. anti-HO-1 capture
antibody was 1440 .mu.g/ml after reconstitution in PBS. This
antibody was diluted to 8 .mu.g/ml in PBS and 50 .mu.l per well was
added to a 384 well greiner "lumitrac 200" plate. Incubated
overnight. [0679] 2. The plate was emptied and 100 .mu.l PBS+1% BSA
added to all wells. Incubated 90 minutes at room temperature.
[0680] Preparation of HepG2 Lysate: [0681] 1. Cells were cultured
in a 96-well tissue culture plate washed with PBS and then the
plate frozen at -70.degree. C. overnight. Plates were allowed to
warm to ice temperature in an ice bucket. 20 .mu.l of PBS, 0.5%
Triton X100, 1 mM EDTA with 1.times. HALT.TM. protease inhibitors
was added to each well and the plates incubated on ice for 1 hour.
[0682] 2. The lysates were frozen at -20.degree. C. overnight.
[0683] Measurement of HMOX1 ("HO-1") [0684] 1. In a polypropylene
384 well plate, human HO-1 (after reconstitution in PBS+0.5%
Triton+1 mM EDTA) was serially diluted from 20 ng/ml 2-fold in
PBS+0.5% triton-X100, 1 mM EDTA to make a 12-point standard curve
including a zero point. [0685] 2. In a polypropylene 96 well plate,
HepG2 lysate was diluted 1 to 20 in Diluent #4 from DUOSET kit in
which the assay standard is also diluted. [0686] 3. The PBS+1% BSA
was emptied from the ELISA plate and 30 .mu.l of all samples and
standards were added (duplicates recommended). The plate was
incubated 90 minutes. [0687] 4. Emptied plate and washed 4 times
with PBST. [0688] 5. Diluted HO-1 detection antibody to 200 ng/ml
in PBS+1% BSA and added 30 .mu.l to all wells. Incubated 90
minutes. [0689] 6. Emptied plate and washed 4 times with PBST.
[0690] 7. Added 30 .mu.l streptavidin HRP at 1/200 in PBS+1% BSA
(stock streptavidin concentration not specified) to all wells.
Incubated 30 minutes. [0691] 8. Emptied plate and washed 4 times
with PBST. [0692] 9. Diluted Lumiglo reserve reagent two parts
buffer to one part lumiglo substrate. Added 30 .mu.l to all wells.
Incubated 5 minutes. [0693] 10. Measured chemiluminescence on
spectramax M5 using 150 ms integration.
[0694] Table 1 below lists EC.sub.50 and fold changes of human
HMOX1 protein levels relative to DMSO control upon treatment with
representative compounds.
Example 144. Kinetic Solubility
[0695] 10 .mu.L of 10 mM DMSO stock solution were aliquotted to 490
.mu.L of DMSO solution and separately 490 .mu.L of Dulbecco's
phosphate buffer saline, DPBS, pH 7.4 solution in 1.2 mL 96-well
plates in duplicate. Final concentration was 200 .mu.M of the test
compound. Samples were incubated at 25.degree. C. with shaking at
200 rpm for 16 h. Samples were centrifuged at 3500 rpm for 20 min
at 25.degree. C., and supernatant was submitted for HPLC
analysis.
[0696] Kinetic solubility was measured using the following
equation:
Kinetic .times. .times. Solubility .times. .times. in .times.
.times. M = .times. Test .times. .times. Conc . .times. M .times.
Peak .times. .times. area .times. .times. of compound .times.
.times. in .times. .times. DPBS .times. .times. same .times.
.times. ( 2 .times. % .times. .times. DMSO .times. .times. solution
) Peak .times. .times. area .times. .times. of .times. .times.
compound .times. .times. in .times. .times. 100 .times. % .times.
.times. DMSO ##EQU00001##
[0697] The kinetic solubility data of representative compounds of
the present invention are provided in Table 1 below.
TABLE-US-00007 TABLE 1 Maximum Example EC50 Fold Solubility No
Structure IUPAC name (.mu.M) induction (.mu.M) Com- parator 1
##STR00112## 1-methyl-2-(6-trifluoro- methoxy-benzothiazol-
2-ylamino)-1H-benzo- imidazole-5-carboxylic acid [2-(2-hydroxy-
ethoxy)-ethyl]-amide 0.9* ND 1h ##STR00113##
2-(benzo[d]oxazol-2-yl- amino)-1-methyl-1H- benzo[d]imidazole-5
carboxylic acid 4.4* 7-38 ND 1i ##STR00114##
2-(benzo[d]oxazol-2-yl- amino)-N-(2-methoxy- ethyl)-1-methyl-1H-
benzo[d]imidazole-5- carboxamide 0.8* 6-15 ND 2d ##STR00115##
1-(tetrahydro-2H-pyran- 4-yl)-2-((6-(trifluoro- methoxy)benzo[d]-
thiazol-2-yl)amino)-1H- benzo[d]imidazole-5- carboxylic acid N/A 10
(n = 2) ND 2e ##STR00116## N-(2-methoxyethyl)-1-
(tetrahydro-2H-pyran- 4-yl)-2-((6-(trifluoro- methoxy)benzo[d]-
thiazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 3.8* 20-33
ND 3d ##STR00117## 1-(1-methylpiperidin-4-
yl)-2-((6-(trifluorometh- oxy)benzo[d]-thiazol-2-
yl)amino)-1H-benzo[d]- imidazole-5-carboxylic- acid 9.2* 13 ND 3e
##STR00118## N-(2-methoxyethyl)-1- (1-methylpiperidin-4-
yl)-2-((6-(trifluorometh- oxy)benzo[d]thiazol-2-
yl)amino)-1H-benzo- [d]imidazole-5-carbox- amide 1.1* 6-46 ND 4d
##STR00119## 1-(1-methylpyrrolidin-3- yl)-2-((6-(trifluorometh-
oxy)benzo[d]thiazol-2- yl)amino)-1H-benzo[d]-
imidazole-5-carboxylic acid 4.7* 29-33 ND 4e ##STR00120##
N-(2-methoxyethyl)-1- (1-methylpyrrolidin-3-
yl)-2-((6-(trifluorometh- oxy)benzo[d]thiazol-2-
yl)amino)-1H-benzo- [d]imidazole-5-carbox- amide N/A 19 ND 5
##STR00121## N-(2-methoxyethyl)-1- methyl-2-((4,5,6,7-tetra-
hydrobenzo[d]thiazol- 2-yl)amino)-1H-benzo- [d]imidazole-5-carbox-
amide 1.3* 7-12 ND 6 ##STR00122## 2-((6,6-dimethyl-4,5,6,7-
tetrahydrobenzo[d]- thiazol-2-yl)amino)-1H- (2-(2-hydroxyethoxy)-
ethyl)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 3.0 41 8.1 7
##STR00123## N-(2-(2-hydroxyethoxy)- ethyl)-1-methyl-2-((6-
methyl-4,5,6,7-tetra- hydrobenzo[d]thiazol-2-
yl)amino)-1H-benzo[d]- imidazole-5-carbox- amide 2.7* 27 7.2 8
##STR00124## 2-((5,6-dihydro-4H- cyclopenta[d]thiazol-2-
yl)amino)-N-(2-meth- oxyethyl)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 2.5* 5-8 6.9 9 ##STR00125## N-(2-(2-hydroxyeth-
oxy)ethyl)-1-methyl-2- ((4,5,6,7-tetrahydro-
thiazolo[5,4-c]pyridin- 2-yl)amino)-1H-benzo-
[d]imidazole-5-carbox- amide hydrochloride ND 2 2.8 10 ##STR00126##
2-((5-acetyl-4,5,6,7- tetrahydrothiazolo[5,4-
c]pyridin-2-yl)amino)- N-(2-(2-hydroxyethoxy)- ethyl)-1-methyl-1H-
benzo[d]imidazole-5- carboxamide ND 2 8.6 11 ##STR00127##
2-((6,7-dihydro-4H- pyrano[4,3-d]thiazol-2- yl)amino)-N-(2-meth-
oxyethyl)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 6.6 5 ND 12
##STR00128## 2-((1H-benzo[d]- imidazol-2-yl)amino)-
N-(2-methoxyethyl)-1- methyl-1H-benzo[d]- imidazole-5-carbox- amide
4.5 5.5 ND 13 ##STR00129## 1-methyl-2-((5-(tri- fluoromethoxy)-1H-
benzo[d]imidazol-2- yl)amino)-benzo[d]- imidazole-5-carboxylic acid
1.9* 6-27 ND 14 ##STR00130## N-(2-methoxyethyl)-1-
methyl-2-((5-(trifluoro- methoxy)-1H-benzo[d]-
imidazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 2.3* 6-25
4.2 15 ##STR00131## 1-methyl-2-((1-methyl- 5-(trifluoromethoxy)-
1H-benzo[d]imidazol-2- yl)amino)-1H-benzo[d]-
imidazole-5-carboxylic acid 5.3* 11-13 ND 16 ##STR00132##
2-(benzo[d]oxazol-2- ylamino)-N-(2-hydroxy- ethyl)-1-methyl-1H-
benzo[d]imidazole-5- carboxamide 0.7* 8-27 11.7 17 ##STR00133##
2-(benzo[d]oxazol-2- ylamino)-N-(2-(2- hydroxyethoxy)ethyl)-
1-methyl-1H-benzo[d]- imidazole-5-carbox- amide 1.4* 11-40 11.6 18
##STR00134## N-(2-aminoethyl)-2- (benzo[d]oxazol-2-yl-
amino)-1-methyl-1H- benzo[d]imidazole-5- carboxamide hydro-
chloride 0.7* 41-52 12.4 19 ##STR00135## 2-(benzo[d]oxazol-2-
ylamino)-N-(2-(2- (dimethylamino)acet- amido)ethyl)-1-methyl-
1H-benzo[d]imidazole- 5-carboxamide 1.8* 14-26 ND 20 ##STR00136##
2-(benzo[d]oxazol-2- ylamino)-1-methyl-N- (2-morpholinoethyl)-
1H-benzo[d]imidazole- 5-carboxamide 1.0 8 7.3 21 ##STR00137##
2-(benzo[d]oxazol-2-yl- amino)-N-(2-dimethyl-
amino)ethyl)-1-methyl- 1H-benzo[d]imidazole- 5-carboxamide 1.1 14
N/A 22 ##STR00138## 2-(benzo[d]oxazol-2- ylamino)-N-(2-((4,5-
dihydro-1H-imidazol- 2-yl)amino)ethyl)-1- methyl-1H-benzo[d]-
imidazole-5-carbox- amide ND 18 3.5 23 ##STR00139##
2-(benzo[d]oxazol-2-yl- amino)-N-(2-hydroxy- propyl)-1-methyl-1H-
benzo[d]imidazole-5- carboxamide 2.1* 25-61 >20 24 ##STR00140##
2-(benzo[d]oxazol-2- ylamino)-N-(2,3- dihydroxypropyl)-1-
methyl-1H-benzo[d]- imidazole-5-carbox- amide ND 49 12.4 25
##STR00141## 2-(benzo[d]oxazol-2- ylamino)-N-(2-(2-
hydroxypropoxy)- ethyl)-1,6-dimethyl- 1H-benzo[d]imidazole-
5-carboxamide 2.2 26 6.1 26 ##STR00142## 2-(benzo[d]oxazol-2-yl-
amino)-N-((3-hydroxy- oxetan-3-yl)methyl)-1- methyl-1H-benzo[d]-
imidazole-5-carbox- amide 2.0 26 8.6 27 ##STR00143##
2-(benzo[d]oxazol-2- ylamino)-N-(2-(2- hydroxy-2-methyl-
propoxy)ethyl)-1- methyl-1H-benzo[d]- imidazole-5-carbox- amide ND
17 10.6 28 ##STR00144## 2-(benzo[d]oxazol-2- ylamino)-1-methyl-N-
(2-(pyrrolidin-1-yl)- ethyl)-1H-benzo[d]- imidazole-5-carbox- amide
1.6* 41 11.3 29 ##STR00145## 2-(2-(2-(benzo[d]-
oxazol-2-ylamino)-1- methyl-1H-benzo[d]- imidazole-5-carbox-
amido)ethoxy)acetic acid ND 12 19.3 30 ##STR00146##
2-(2-(2-(benzo[d]- oxazol-2-ylamino)-1- methyl-1H-benzo[d]-
imidazole-5-carbox- amido)-ethoxy)ethyl DL-valinate hydro- chloride
3.5* 25-53 3.2 31 ##STR00147## 1-methyl-2-((6-(tri-
fluoromethyl)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxylic acid 1.1* 25-29 14.9 32 ##STR00148##
N-(2-methoxyethyl)-1- methyl-2-((6-(trifluoro-
methyl)benzo[d]oxazol- 2-yl)amino)-1H-benzo- [d]imidazole-5-carbox-
amide 0.5* 14-50 1.4 33 ##STR00149## N-(2-hydroxyethyl)-1-
methyl-2-((6-(trifluoro- methyl)benzo[d]oxazol-
2-yl)amino)-1H-benzo- [d]imidazole-5-carbox- amide 0.3* 32-45 0.9
34 ##STR00150## N-(2-(2-hydroxyethoxy)- ethyl)-1-methyl-2-((6-
(trifluoromethyl)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide 0.8* 31-36 8.0 35 ##STR00151##
N-(2-hydroxypropyl)-1- methyl-2-((6-(trifluoro-
methyl)benzo[d]oxazol- 2-yl)amino)-1H-benzo- [d]imidazole-5-carbox-
amide 1.2* 37 <2 36 ##STR00152## 1-methyl-N-(2-
(pyrrolidin-1-yl)ethyl)- 2-((6-(trifluoromethyl)-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carbox- amide
1.3* 42 2.8 37 ##STR00153## 1-methyl-N-(2-
(piperidin-1-yl)ethyl)-2- ((6-(trifluorormethyl)-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carbox- amide
ND 28 <2 38 ##STR00154## N-(2-(2-hydroxypro-
poxy)ethyl)-1-methyl-2- ((6-(trifluoromethyl)-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carbox- amide
1.3* 30 <2 39 ##STR00155## N-(2,3-dihydroxy-
propyl)-1-methyl-2-((6- (trifluoromethyl)benzo-
[d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 0.95*
56-82 2.1 40 ##STR00156## N-(2-(2-(dimethyl-
amino)acetamido)ethyl)- 1-methyl-2-((6-(trifluoro-
methyl)benzo[d]oxazol- 2-yl)amino)-1H-benzo- [d]imidazole-5-carbox-
amide 0.69* 56-93 0.5 41 ##STR00157## 2-(2-(1-methyl-2-((6-
(trifluoromethyl)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamido)ethoxy)- acetic acid 4.8* 35-39
13.8 42 ##STR00158## N-(2-(2-hydroxy-2- methylpropoxy)ethyl)-
1-methyl-2-((6-(tri- fluoromethyl)benzo[d]- oxazol-2-yl)amino)-1H-
benzo[d]imidazole-5- carboxamide 2.3* 39 3.6 43 ##STR00159##
N-(2-(2-hydroxyethoxy)- ethyl)-1-methyl-2-((5-
(trifluoromethyl)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide 1.3* 56 8.0 44 ##STR00160##
1-methyl-2-((6-(tri- fluoromethoxy)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxylic acid 1.3* 9-14 ND 45
##STR00161## N-(2-methoxyethyl)-1- methyl-2-((6-(trifluoro-
methoxy)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxamide 0.64* 10-28 0.2 46 ##STR00162## 1-methyl-N-(1H-
pyrazol-4-yl)-2-((6- (trifluoromethoxy)- benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]- imidazole-5-carbox- amide 2.2* 14-20 <5 47
##STR00163## N-(1,3-dihydroxy-2- (hydroxymethyl)propan-
2-yl)-1-methyl-2-((6- (trifluoromethoxy)- benzo[d]oxazol-2-yl)-
amino)-1H-benzo[d]- imidazole-5-carbox- 1.6* 13-16 <2 amide 48
##STR00164## N-(1,3-dihydroxy- propan-2-yl)-1-methyl-
2-((6-(trifluorometh- oxy)benzo[d]oxazol-2- yl)amino)-1H-benzo-
[d]imidazole-5-carbox- amide 2.0* 13-20 3.9 49 ##STR00165##
N-(2-(2-(dimethyl- amino)acetamido)- ethyl)-1-methyl-2-((6-
(trifluoromethoxy)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide 0.8* 14-23 <2 50
##STR00166## 1-methyl-N-(1-methyl- 1H-pyrazol-4-yl)-2-((6-
(trifluoromethoxy)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide ND 12-18 4.0 51 ##STR00167##
1-methyl-N-(oxetan-3- yl)-2-((6-(trifluoro- methoxy)benzo[d]-
oxazol-2-yl)amino)-1H- benzo[d]imidazole-5- carboxamide 1.4* 30-57
<2 52 ##STR00168## N-((3-hydroxyoxetan-3- yl)methyl)-1-methyl-2-
((6-(trifluoromethoxy)- benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]-
imidazole-5-carbox- amide 1.0 27 <2 53 ##STR00169##
N-(2-hydroxyethyl)-1- methyl-2-((6-(trifluoro- methoxy)benzo[d]-
oxazol-2-yl)amino)-1H- benzo[d]imidazole-5- carboxamide 1.1* 29-38
7.3 54 ##STR00170## 1-methyl-N-(2-(methyl- sulfonyl)ethyl)-2-((6-
(trifluoromethoxy)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide 3.2* 31-37 ND 55 ##STR00171##
2-((6-(2-methoxy- ethoxy)benzo[d]oxazol- 2-yl)amino)-1-methyl-
1H-benzo[d]imidazole- 5-carboxylic acid 4.5 15 ND 56 ##STR00172##
2-((6-(2-methoxy- ethoxy)benzo[d]oxazol- 2-yl)amino)-N-(2-meth-
oxyethyl)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 1.4* 21-38
9.7 57 ##STR00173## N-(2-hydroxyethyl)-2- ((6-(2-methoxyeth-
oxy)benzo[d]oxazol-2- yl)amino)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 1.2* 34-40 11.2 58 ##STR00174## N-(2-(2-hydroxyeth-
oxy)ethyl)-2-((6-(2- methoxyethoxy)benzo- [d]oxazol-2-yl)amino)-
1-methyl-1H-benzo[d]- imidazole-5-carbox- amide 1.7* 41-60 7.7
59 ##STR00175## 2-((6-isopropylbenzo- [d]oxazol-2-yl)amino)-
1-methyl-1H-benzo[d]- imidazole-5-carboxylic acid 3.3 30 ND 60
##STR00176## 2-((6-isopropylbenzo- [d]oxazol-2-yl)amino)-
N-(2-methoxyethyl)-1- methyl-1H-benzo[d]- imidazole-5-carbox- amide
0.7* 42-56 0.9 61 ##STR00177## N-(2-hydroxyethyl)-2-
((6-isopropylbenzo- [d]oxazol-2-yl)amino)- 1-methyl-1H-benzo[d]-
imidazole-5-carbox- amide 1.5 60 1.2 62 ##STR00178##
2-((6-(difluorometh- oxy)benzo[d]oxazol-2- yl)amino)-1-methyl-1H-
benzo[d]imidazole-5- carboxylic acid 5.1* 15-24 16.2 63
##STR00179## 2-((6-(difluorometh- oxy)benzo[d]oxazol-2-
yl)amino)-N-(2-meth- oxyethyl)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 1.3* 11-15 0.8 64 ##STR00180## 2-((6-(difluorometh-
oxy)benzo[d]oxazol-2- yl)amino)-N-(2- hydroxyethyl)-1-
methyl-1H-benzo[d]- imidazole-5-carbox- amide 1.8* 11-18 2.0 65
##STR00181## N-(2-methoxyethyl)-1- methyl-2-((5-methyl-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carbox- amide
1.2* 15-42 ND 66 ##STR00182## 2-((5-fluorobenzo[d]-
oxazol-2-yl)amino)-1- methyl-1H-benzo[d]- imidazole-5-carboxylic
acid 5.4* 19-22 ND 67 ##STR00183## 2-((5-fluorobenzo[d]-
oxazol-2-yl)amino)-N- (2-methoxyethyl)-1- methyl-1H-benzo[d]-
imidazole-5-carbox- amide 0.91* 18-56 <5 68 ##STR00184##
2-((6-fluorobenzo[d]- oxazol-2-yl)amino)-1- methyl-1H-benzo[d]-
imidazole-5-carboxylic acid 2.0* 16-21 ND 69 ##STR00185##
2-((6-fluorobenzo[d]- oxazol-2-yl)amino)-N- (2-methoxyethyl)-1-
methyl-1H-benzo[d]- imidazole-5-carbox- amide 0.66 13-36 <5 70
##STR00186## 6-fluoro-1-methyl-2- ((6-(trifluoromethoxy)-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carboxylic
acid 3.2* 8-11 ND 71 ##STR00187## 6-fluoro-N-(2-methoxy-
ethyl)-1-methyl-2-((6- (trifluoromethoxy)benzo-
[d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 0.73*
8-12 0.3 72 ##STR00188## 2-(benzo[d]oxazol-2- ylamino)-6-fluoro-N-
(2-(2-hydroxyethoxy)- ethyl)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 1.1* 31-72 2.7 73 ##STR00189## 2-((5-fluoro-1H-benzo-
[d]imidazol-2-yl)amino)- 1-methyl-1H-benzo[d]-
imidazole-5-carboxylic acid 2.9* 8-12 ND 74 ##STR00190##
1-(2-(dimethylamino)- ethyl)-2-((6-(trifluoro- methoxy)benzo[d]-
oxazol-2-yl)amino)-1H- benzo[d]imidazole-5- carboxylic acid 3.6
17-28 ND 75 ##STR00191## 1-(2-methoxyethyl)-2-
((5-(trifluoromethoxy)- 1H-benzo[d]imidazol-2-
yl)amino)-1H-benzo[d]- imidazole-5-carboxylic acid 0.37* 15-25 11.6
76 ##STR00192## N,1-bis(2-methoxy- ethyl)-2-((5-(trifluoro-
methoxy)-1H-benzo[d]- imidazol-2-yl)amino)- 1H-benzo[d]imidazole-
5-carboxamide 2.7* 18-20 ND 77 ##STR00193## 1-(2-methoxyethyl)-2-
((6-(trifluoromethoxy)- benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]-
imidazole-5-carboxylic acid 4.1* 27-28 ND 78 ##STR00194##
N,1-bis(2-methoxy- ethyl)-2-((6-(trifluoro- methoxy)benzo[d]-
oxazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 2.2* 21-23
ND 79 ##STR00195## 1-(tetrahydro-2H-pyran- 4-yl)-2-((6-(trifluoro-
methoxy)benzo[d]- oxazol-2-yl)amino)- 1H-benzo[d]imidazole-
5-carboxylic acid 4.0* 27-51 12.4 80 ##STR00196##
N-(2-methoxyethyl)-1- (tetrahydro-2H-pyran- 4-yl)-2-((6-(trifluoro-
methoxy)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxamide 1.9* 22-23 ND 81 ##STR00197## N-(2-methoxyethyl)-1-
(tetrahydro-2H-pyran- 4-yl)-2-((5-(trifluoro- methoxy)-1H-benzo[d]-
imidazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 2.3*
19-30 ND 82 ##STR00198## 2-((5-chloro-1H-benzo-
[d]imidazol-2-yl)amino)- 1-methyl-1H-benzo[d]-
imidazole-5-carboxylic acid 2.4* 29-33 ND 83 ##STR00199##
2-((5-chloro-1H-benzo- [d]imidazol-2-yl)amino)-
N-(2-methoxyethyl)-1- methyl-1H-benzo[d]- imidazole-5-carbox- amide
1.8* 16-21 ND 84 ##STR00200## 1-ethyl-2-((6-(trifluoro-
methoxy)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxylic acid 5.4 17 ND 85 ##STR00201## 1-ethyl-N-(2-methoxy-
ethyl)-2-((6-(trifluoro- methoxy)benzo[d]- oxazol-2-yl)amino)-1H-
benzo[d]imidazole-5- carboxamide 1.3* 13-36 3.3 86 ##STR00202##
1-ethyl-N-(2-hydroxy- ethyl)-2-((6-(trifluoro- methoxy)benzo[d]-
oxazol-2-yl)amino)-1H- benzo[d]imidazole-5- carboxamide 1.3* 15-32
7.1 87 ##STR00203## 1-((tetrahydrofuran-3- yl)methyl)-2-((6-
(trifiuoromethoxy)- benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]-
imidazole-5-carboxylic acid 6.8 21 ND 88 ##STR00204##
N-(2-methoxyethyl)-1- ((tetrahydrofuran-3- yl)methyl)-2-((6-
(trifluoromethoxy)- benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]-
imidazole-5-carbox- amide 1.5* 13-37 3.9 89 ##STR00205##
1-(2-(methylsulfonyl)- ethyl)-2-((6-(trifluoro- methoxy)benzo[d]-
oxazol-2-yl)amino)-1H- benzo[d]imidazole-5- carboxylic acid ND 10
ND 90 ##STR00206## N-(2-methoxyethyl)-1- (2-(methylsulfonyl)-
ethyl)-2-((6-(trifluoro- methoxy)benzo[d]- oxazol-2-yl)amino)-1H-
benzo[d]imidazole-5- carboxamide 4.8 22 ND 91 ##STR00207##
2-((6-bromobenzo[d]- oxazol-2-yl)amino)-1- methyl-1H-benzo[d]-
imidazole-5-carboxylic acid 2.5* 17-26 2.6 92 ##STR00208##
N-(2-hydroxyethyl)-2- ((6-methoxybenzo- [d]oxazol-2-yl)amino)-
1-methyl-1H-benzo[d]- imidazole-5-carbox- amide 1.4* 12-20 3.5 93
##STR00209## 1-((3-hydroxyoxetan-3- yl)methyl)-2-((6-(tri-
fluoromethoxy)benzo- [d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole-
5-carboxylic acid ND 22 ND 94 ##STR00210## 1-((3-hydroxyoxetan-
3-yl)methyl)-N-(2- methoxyethyl)-2-((6- (trifluoromethoxy)-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carbox- amide
1.3 28 0.3 95 ##STR00211## N-(2-hydroxyethyl)-1-
((3-hydroxyoxetan-3- yl)methyl)-2-((6-(tri- fluoromethoxy)benzo-
[d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 1.6 21
ND 96 ##STR00212## 2-((6-chlorobenzo[d]- oxazol-2-yl)amino)-1-
methyl-1H-benzo[d]- imidazole-5-carboxylic acid 2.8* 39-56 ND 97
##STR00213## 2-((6-chlorobenzo[d]- oxazol-2-yl)amino)-N-
(2-hydroxyethyl)-1- methyl-1H-benzo[d]- imidazole-5-carbox- amide
1.4* 33-51 <5 98 ##STR00214## 1-methyl-2-((6-(2,2,2-
trifluoroethoxy)benzo- [d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole-
5-carboxylic acid 4.1* 36-56 ND 99 ##STR00215##
N-(2-methoxyethyl)-1- methyl-2-((6-(2,2,2- trifluoroethoxy)benzo-
[d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 0.92*
25-31 0.4 100 ##STR00216## N-(2-hydroxyethyl)-1-
methyl-2-((6-(2,2,2- trifluoroethoxy)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide 1.2* 24-35 5.3 101 ##STR00217##
2-((6-(2-hydroxyethoxy)- benzo[d]oxazol-2-yl)- amino)-1-methyl-1H-
benzo[d]imidazole-5- carboxylic acid ND 21 ND 102 ##STR00218##
2-((6-(2-hydroxyethoxy)- benzo[d]oxazol-2-yl)- amino)-N-(2-methoxy-
ethyl)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 1.3* 26-40 5.3
103 ##STR00219## 2-((6-(2-hydroxyethoxy)- benzo[d]oxazol-2-yl)-
amino)-N-(2-hydroxy- ethyl)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 3.1* 37-39 >20 104 ##STR00220##
2-((6-(2-hydroxyethoxy)- benzo[d]oxazol-2-yl)-
amino)-N-(2-(2-hydroxy- ethoxy)ethyl)-1-methyl-
1H-benzo[d]imidazole- 5-carboxamide 3.7 23 6.6 105 ##STR00221##
N-(2-aminoethyl)-2- ((6-(2-hydroxyethoxy)- benzo[d]oxazol-2-yl)-
amino)-1-methyl-1H- benzo[d]imidazole-5- carboxamide hydro-
chloride 4.1 36 ND 106 ##STR00222## N-(2-((4,5-dihydro-1H-
1H-imidazol-2-yl)- amino)ethyl)-2-((6-(2- hydroxyethoxy)benzo-
[d]oxazol-2-yl)amino)- 1-methyl-1H-benzo[d]-
imidazole-5-carboxamide ND 6 ND 107 ##STR00223##
2-((5-fluoro-6-(trifluoro- methyl)benzo[d]oxazol-
2-yl)amino)-1-methyl- 1H-benzo[d]imidazole- 5-carboxylic acid 4.5
45 ND 108 ##STR00224## 2-((5-fluoro-6-(trifluoro-
methyl)benzo[d]oxazol- 2-yl)amino)-N-(2- hydroxyethyl)-1-methyl-
1H-benzo[d]imidazole- 5-carboxamide 1.5 29 0.3 109 ##STR00225##
N-(2-methoxyethyl)-1- methyl-2-(oxazolo[5,4- b]pyridin-2-ylamino)-
1H-benzo[d]imidazole- 5-carboxamide 6.1 26 7.4 110 ##STR00226##
N-(2-hydroxyethyl)-1- methyl-2-(oxazolo[5,4- b]pyridin-2-ylamino)-
1H-benzo[d]imidazole- 5-carboxamide 7.6 60 18.9 111 ##STR00227##
1-methyl-2-(oxazolo- [4,5-b]pyridin-2-yl- amino)-1H-benzo-
[d]imidazole-5- carboxylic acid ND 3 ND 112 ##STR00228##
N-(2-methoxyethyl)-1- methyl-2-(oxazolo[4,5- b]pyridin-2-ylamino)-
1H-benzo[d]imidazole- 5-carboxamide ND 15 ND 113 ##STR00229##
N-(2-hydroxyethyl)-1- methyl-2-((5-(trifluoro-
methyl)oxazolo[5,4-b]- pyridin-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxamide ND 20 9.1 114 ##STR00230## N-(2-(2-hydroxyethoxy)-
ethyl)-1-methyl-2- (thiazolo[4,5-b]pyrazin- 2-ylamino)-1H-benzo-
[d]imidazole-5-carbox- amide ND 33 12.2 115 ##STR00231##
2-((6-cyclopropyl- benzo[d]oxazol-2-yl)- amino)-1-methyl-1H-
benzo[d]imidazole-5- carboxylic acid 6.2 71 ND 116 ##STR00232##
2-((6-cyclopropyl- benzo[d]oxazol-2-yl)- amino)-N-(2-methoxy-
ethyl)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 3.0* 32-38 ND
117 ##STR00233## N-(2-(2-hydroxyethoxy)- ethyl)-1-methyl-2-((7-
(trifluoromethyl)benzo- [d]oxazol-2-yl)amino)-
1H-benzo[d]imidazole- 5-carboxamide 1.8* 38 1.2 118 ##STR00234##
N-(2-(2-hydroxyethoxy)- ethyl)-2-((1-methyl-1H-
benzo[d]imidazol-2-yl)- amino)benzo[d]oxazole- 5-carboxamide 8.0 24
ND 119 ##STR00235## 2-(benzo[d]oxazol-2-yl- amino)-N-(2-methoxy-
ethoxy)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 0.6* 47-65
0.5 120 ##STR00236## 2-(benzo[d]oxazol-2-yl- amino)-N-(2-hydroxy-
propoxy)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 2.0 26 6.5
121 ##STR00237## 2-(benzo[d]oxazol-2-yl- amino)-N-(2-(2-(dimeth-
ylamino)acetamido)- ethoxy)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 1.4* 22-23 9.0 122 ##STR00238## N-(2-(dimethylamino)-
ethoxy)-1-methyl-2-((6- (trifluoromethyl)benzo-
[d]oxazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 0.4*
51-67 5.1 123 ##STR00239## 2-(benzo[d]oxazol-2-
ylamino)-N-(2-(dimeth- ylamino)ethoxy)-1- methyl-1H-benzo[d]-
imidazole-5-carbox- amide ND 22 10.5 124 ##STR00240##
N-(2-methoxyethoxy)-1- methyl-2-((6-(trifluoro-
methyl)benzo[d]oxazol- 2-yl)amino)-1H-benzo- [d]imidazole-5-carbox-
amide 0.2* 31-52 <2 125 ##STR00241## N-(2-hydroxyethoxy)-
1-methyl-2-((6-(tri- fluoromethyl)benzo[d]- oxazol-2-yl)amino)-1H-
benzo[d]imidazole-5- carboxamide 0.3* 32-59 3.5
126 ##STR00242## N-(2-hydroxyethoxy)-1- methyl-2-((6-(trifluoro-
methoxy)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxamide 0.5* 33-37 2.1 127 ##STR00243## N-(2-methoxyethoxy)-1-
methyl-2-((6-(trifluoro- methoxy)benzo[d]- oxazol-2-yl)amino)-1H-
benzo[d]imidazole-5- carboxamide 0.5* 27-36 <2 128 ##STR00244##
N-(2-hydroxyethoxy)-2- ((6-(2-methoxyethoxy)- benzo[d]oxazol-2-yl)-
amino)-1-methyl-1H- benzo[d]imidazole-5- carboxamide 1.2* 48-75 4.7
129 ##STR00245## N-(2-hydroxyethoxy)-2- ((6-(2-hydroxyethoxy)-
benzo[d]oxazol-2-yl)- amino)-1-methyl-1H- benzo[d]imidazole-5-
carboxamide 3.4* 54-58 14.1 130 ##STR00246##
2-((5-fluoro-6-(trifluoro- methyl)benzo[d]oxazol- 2-yl)amino)-N-(2-
hydroxyethoxy)-1- methyl-1H-benzo[d]- imidazole-5-carbox- amide
0.74* 42 <2 131 ##STR00247## N-(2-hydroxyethoxy)-1-
methyl-2-((6-methyl- 4,5,6,7-tetrahydrobenzo-
[d]thiazol-2-yl)amino)- 1H-benzo[d]imidazole- 5-carboxamide 1.4*
35-62 6.7 132 ##STR00248## 2-((6-acetylbenzo[d]-
oxazol-2-yl)amino)-N- (2-methoxyethoxy)-1- methyl-1H-benzo[d]-
imidazole-5-carbox- amide 1.5 39 3.1 133 ##STR00249##
N-(2-hydroxyethyl)-2- ((6-(2-hydroxypropan- 2-yl)benzo[d]oxazol-
2-yl)amino)-1-methyl- 1H-benzo[d]imidazole- 5-carboxamide 5.3 17
9.2 134 ##STR00250## N-(2-(2-hydroxyethoxy)- ethyl)-1-methyl-2-((6-
(thiazol-4-yl)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxamide 1.4* 42-70 <2 135 ##STR00251## N-(2-(2-hydroxyeth-
oxy)ethyl)-1-methyl-2- ((6-(3-methyl-2-oxooxa-
zolidin-5-yl)benzo[d]- oxazol-2-yl)amino)-1H- benzo[d]imidazole-5-
carboxamide NA 1 ND 136 ##STR00252## N-(2-(2-hydroxyethoxy)-
ethyl)-1-methyl-2-((6- morpholinobenzo[d]- oxazol-2-yl)amino)-1H-
benzo[d]imidazole-5- carboxamide 2.9* 36 10.6 137 ##STR00253##
N-(2-(2-hydroxy- ethoxy)ethyl)-1-methyl- 2-((6-(pyrrolidin-1-yl)-
benzo[d]oxazol-2-yl)- amino)-1H-benzo[d]- imidazole-5-carbox- amide
1.3* 24-70 6.9 138 ##STR00254## N-(2-(2-hydroxyethoxy)-
ethyl)-1-methyl-2-((6- ((tetrahydro-2H-pyran- 4-yl)oxy)benzo[d]-
oxazol-2-yl)amino)- benzo[d]oxazole-5- carboxamide 2.0* 20 ND 139
##STR00255## 1-(2-(benzo[d]oxazol-2- ylamino)-1-methyl-1H-
benzo[d]imidazol-5-yl)- 2,2,2-trifluoroethan-1- one 2.6 21 <2
140 ##STR00256## (Z)-1-(2-(benzo[d]- oxazol-2-ylamino)-1-
methyl-1H-benzo[d]- imidazol-5-yl)-2,2,2- trifluoroethan-1-one
oxime ND 19 ND 141 ##STR00257## N-(5-(1-amino-2,2,2-
trifluoroethyl)-1-methyl- 1H-benzo[d]imidazol-2-
yl)benzo[d]oxazol-2- amine 3.6* 22 9.0 142 ##STR00258##
1-(2-(benzo[d]oxazol-2- ylamino)-1-methyl-1H-
benzo[d]imidazol-5-yl)- 2,2,2-trifluoroethan-1-ol 3.3* 27 ND
*Average of 2 or more EC.sub.50 determinations ND = Not Determined
NA = Not Active
Example 145. hERG Assay
[0698] Cell Lines and Cell Culture
[0699] HEK 293 cell line stably expressing hERG channel (Cat
#K1236) was purchased from Invitrogen. The cells were cultured in
85% DMEM, 10% dialyzed FBS, 0.1 mM NEAA, 25 mM HEPES, 100 U/mL
Penicillin-Streptomycin and 5 .mu.g/mL Blasticidin and 400 .mu.g/mL
Geneticin. Cells were split using TrypLE.TM. Express about three
times a week, and maintained between .about.40% to .about.80%
confluence. Before the assay, the cells were transferred onto the
coverslips at 5.times.10.sup.5 cells/per 6 cm cell culture dish and
induced with doxycycline at 1 .mu.g/mL for 48 hours.
[0700] Solution Preparations
[0701] 1) External solution (in mM): 132 NaCl, 4 KCl, 3 CaCl.sub.2,
0.5 MgCl.sub.2, 11.1 glucose, and 10 HEPES (pH adjusted to 7.35
with NaOH)
[0702] 2) Internal solution (in mM): 140 KCl, 2 MgCl.sub.2, 10
EGTA, 10 HEPES and 5 MgATP (pH adjusted to 7.35 with KOH)
[0703] 3) hERG currents were tested in presence of 10 .mu.M
compound concentration with final concentration of DMSO of
0.1%.
[0704] Experimental Procedure
[0705] 1) Removed the coverslip from the cell culture dish and
placed it on the microscope stage in bath chamber.
[0706] 2) Located a desirable cell using the 10.times. objective.
Located the tip of the electrode under the microscope using the
10.times. objective by focusing above the plane of the cells. Once
the tip was in focus, advanced the electrode downwards towards the
cell using the coarse controls of the manipulator, while
simultaneously moving the objective to keep the tip in focus.
[0707] 3) When directly over the cell, switched to the 40.times.
objective and used the fine controls of the manipulator to approach
the surface of the cell in small steps.
[0708] 4) Applied gentle suction through the side-port of the
electrode holder to form a gigaohm seal.
[0709] 5) Used the Cfast to remove the capacity current that was in
coincidence with the voltage step. Obtained the whole cell
configuration by applying repetitive, brief, strong suction until
the membrane patch ruptured.
[0710] 6) Set membrane potential to -60 mV at this point to ensure
that hERG channels were not open. The spikes of capacity current
should then be cancelled using the Cslow on the amplifier.
[0711] 7) Set holding potential to -90 mV for 500 ms; recorded
current at 50 kHz and filtered at 10 kHz. Leaking current was
tested at -80 mV for 500 ms.
[0712] 8) The hERG current was elicited by depolarizing at +30 mV
for 4.8 seconds and then the voltage was taken back to -50 mV for
5.2 seconds to remove the inactivation and observe the deactivating
tail current. The maximum amount of tail current size was used to
determine hERG current amplitude.
[0713] 9) Recorded current for 120 seconds to assess the current
stability. Only stable cells with recording parameters above
threshold were applied for the compound administrations.
[0714] 10) Firstly vehicle control was applied to the cells to
establish the baseline. Once the hERG current was found to be
stabilized for 5 minutes, test compound was applied. hERG current
in the presence of test compound was recorded for approximately 5
minutes to reach steady state and then 5 sweeps were captured. In
order to ensure the good performance of cultured cells and
operations, the positive control, Dofetilide, with 5 dose
concentration was also used to test the same batch of cells.
[0715] Data Analysis
[0716] The following criteria were used to determine data
acceptability. [0717] 1) Initial seal resistance>1 G2; [0718] 2)
Leak currents<50% of the control peak tail currents at any time;
[0719] 3) The peak tail amplitude>250 pA; [0720] 4) Membrane
resistance Rm>500 M.OMEGA.; [0721] 5) Access resistance
(Ra)<10 M.OMEGA.; [0722] 6) Apparent run-down of peak
current<2.5% per min.
[0723] Data that met the above criteria for hERG current quality
were further analyzed as the following steps.
[0724] 1) Percent hERG current inhibition was calculated using the
following equation. [0725] Note: PatchMaster or Clampfit software
was used to extract the peak current from the original data.
[0725] Peak .times. .times. current .times. .times. inhibition = (
1 - Peak .times. .times. tail .times. .times. current compound
.times. ) Peak .times. .times. tail .times. .times. current vehicle
.times. 100 ##EQU00002##
[0726] 2) The dose response curve of test compounds was plotted
with percentage of hERG current inhibition against the
concentration of test compounds using Graphpad Prism 6.0, and fit
to a sigmoid dose-response curve with a variable slope.
[0727] hERG data for selected compounds in manual patch clamp assay
are provided in Table 2 below. Notably, hERG values were measured
only for compounds that showed >5 .mu.M solubility.
[0728] Accurate measurement of hERG activity was not possible for
compounds with solubility below 5 .mu.M.
TABLE-US-00008 TABLE 2 ##STR00259## hERG inhibition ID# X R.sub.1
R.sub.2 @ 10 uM Comparator 1 S
--CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH --OCF.sub.3 66%
Comparator 2 S --CONHCH.sub.2CH.sub.2NHCOCH.sub.2N(Me).sub.2
--OCF.sub.3 93% Compound A S
--CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH --H 20% Ex 7.sup.1 S
--CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH --CH.sub.3 6% Ex 34 O
--CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH --CF.sub.3 61% Ex 122 O
--CONHOCH.sub.2CH.sub.2N(Me).sub.2 --CF.sub.3 87% Ex 31 O --COOH
--CF.sub.3 0% Ex 137 O CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH
--N-pyrrolidine 18% Ex 16 O --CONHCH.sub.2CH.sub.2OH H 35% Ex 17 O
--CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH H 16% Ex 18 O
--CONHCH.sub.2CH.sub.2NH.sub.2 H 12% Ex 19 O
--CONHCH.sub.2CH.sub.2NHCOCH.sub.2N(Me).sub.2 H 29% Ex 23 O
--CONHCH.sub.2CH(OH)CH.sub.3 H 24% Ex 25 O
--CONHCH.sub.2CH.sub.2OCH.sub.2CH(OH)CH.sub.3 H 8% Ex 26 O
--CONHCH.sub.2C(OH)(--CH.sub.2OCH.sub.2--) H 18% Ex 20 O
--CONHCH.sub.2CH.sub.2-N-morpholine H 59% Ex 123 O
--CONHOCH.sub.2CH.sub.2N(Me).sub.2 H 54% Ex 28 O
--CONHCH.sub.2CH.sub.2-N-pyrrolidine H 64% Ex 121 O
--CONHOCH.sub.2CH.sub.2NHCOCH.sub.2N(Me).sub.2 H 66% Ex 69 O
--CONHCH.sub.2CH.sub.2OMe F 38% Ex 56 O --CONHCH.sub.2CH.sub.2OMe
--OCH.sub.2CH.sub.2OMe 35% Ex 57 O --CONHCH.sub.2CH.sub.2OH
--OCH.sub.2CH.sub.2OMe 15% Ex 58 O
--CONHCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OH --CH.sub.2CH.sub.2OMe 11%
Ex 128 O --CONHOCH.sub.2CH.sub.2OH --CH.sub.2CH.sub.2OMe 18% Ex 62
O --COOH --OCHF.sub.2 13% Ex 44 O --COOH --OCF.sub.3 15% Ex
86.sup.2 O --CONHCH.sub.2CH.sub.2OH --OCF.sub.3 64% Ex 53 O
--CONHCH.sub.2CH.sub.2OH --OCF.sub.3 70% Ex 13 NH --COOH
--OCF.sub.3 34% Ex 75.sup.3 NH --COOH --OCF.sub.3 9% Ex 73 NH
--COOH --F 5% Ex 14 NH --CONHCH.sub.2CH.sub.2OMe --OCF.sub.3 87% 1.
Example 7 is a tetrahydrobenzo[d]thiazole compound instead of a
benzothiazole compound. 2. R is ethyl. 3. R is
CH.sub.2CH.sub.2OMe.
Example 146. Microscale Thermophoresis (MST) Assay/Bach 1 Binding
Assay
Outline of Protein Expression/Production
[0729] Human BACH1 (construct-ID:
10.times.HIS-GP-BACH1(aa179-736)-Thrombin-FLAG) was expressed in
Sf9 insect cells. Protein purification was performed using affinity
chromatography, followed by size-exclusion chromatography. Quality
of resulting protein was judged using SDS-PAGE analysis.
Assay Principle
[0730] The MST technology is based on measurement of protein
movement along a temperature gradient. Thereby, fluorescently
labeled protein is loaded into capillaries, where an infrared laser
heats a small volume. Before and during heating, fluorescent
intensity is measured at the site of irradiation and the loss of
fluorescence in the IR laser focus is quantified.
[0731] Two major factors contribute to change of fluorescence
signal. First of all, the so-called TRIC (Temperature Related
Intensity Change) effect is caused by the temperature-dependency of
fluorophore's quantum yield. Herein, the extent of the temperature
dependence depends on the chemical environment, which may be
changed by the binding of a ligand (e.g. compound, peptide) to the
target. Moreover, Kd value between ligand and target can depend on
temperature. Second, thermophoresis, which is defined as movement
of fluorescent molecules along temperature gradient, is a major
contributor to change of fluorescence. Hereby, protein movement
along the gradient depends on hydrodynamic radius, charge and
hydration shell. These properties can change upon association of
the labeled protein with another species, e.g. compound. Thereby,
MST detects the differences in protein movement with increasing
ligand concentration: from this, the fraction of ligand bound
protein and a Kd value can be determined.
MST Assay Protocol
[0732] For Kd determination of compounds binding BACH1, the
following protocol was applied:
10.times.HIS-GP-BACH1(aa179-736)-Thrombin-FLAG (expressed and
purified at Proteros) was fluorescently labeled via its
lysine-residues (2nd gen NHS-NT.647 dye).
[0733] Experiments were performed using the experimental device
Monolith NT. 115 Pico, NanoTemper Technologies, with MST power set
to medium and excitation power set to 2% at a reaction temperature
of 25.degree. C.
[0734] 10 nM fluorescently labeled BACH1 was applied to reaction
buffer containing 50 mM HEPES pH 8.0, 100 mM NaCl, 5% glycerol,
0.05% Tween20 and 1 mM DTT in a reaction volume of 8 .mu.L using
Monolith NT.115 Premium Capillaries. Compounds were applied at a
maximal concentration of 103 .mu.M with 15 subsequent factor 2
dilutions.
[0735] Kd data for selected compounds in MST assay are provided in
Table 3 below.
TABLE-US-00009 TABLE 3 Example Kd Kd error Number (.mu.M) (.mu.M)
17 0.25 0.051 33 0.26 0.051 56 0.25 0.15 112 0.56 0.13 124 0.20
0.089
[0736] From the data provided in Table 3 above, it can be inferred
the compounds of the present invention also bind to Bach1.
Example 147. HMOX1 Inducers of the Invention Strongly Increase In
Vitro Expression of HMOX1
RNA Isolation and Quantification of Gene Expression
[0737] Inducing HMOX1 expression has been shown to reduce
vaso-occlusive crises (VOCs), in particular, heme-induced
vaso-occlusion in Sickle cell disease (SCD) mice (Belcher J D, et
al. Antioxid Redox Signal 2017, 26:748-762; Krishnamoorthy S, et
al. JCI Insight 2017, 2:e96409). HepG2 cells were seeded at 250
k/well in 12-well tissue culture plates coated with collagen
(collagen I, rat tail (thin plate coating); ENZO Life Sciences) for
approximately 24 hours. The seeded cells were then treated with
dose titration of the compound of Example 17 or dimethyl fumarate
(DMF) (a Nrf2 activator; Fisher Scientific) via media change, with
biological triplicates performed for each treatment. After
approximately 24 hours of treatment, cells were visually inspected
to confirm that no toxicity occurred with compound treatment. The
treated cells were washed with PBS, aspirated, parafilmed and
frozen at -80.degree. C. prior to RNA isolation. RNA was isolated
using Machery-Nagel isolation kit (NucleoSpin.RTM. RNA: catalog
740955.250) and then quantitated using ThermoFisher Nanodrop.
[0738] RNA was diluted for Nanostring gene expression analysis. The
diluted RNA at an input of 200 ng RNA was run on a Nanostring
instrument, which was supported with nCounter.RTM. SPRINT Profiler
System and nSolver4.0 Software, nCounter.RTM. SPRINT Cartridge,
nCounter.RTM. SPRINT Reagent Pack, and nCounter.RTM. SPRINT
Hybridization Buffer. Analysis was done manually using raw data
obtained from nSolver4.0 Software. CLTC, POLR2A, RPL27 and TBP were
used as reference genes for normalization. Data was graphed as fold
change compared to DMSO treatment.
[0739] The relative mRNA levels of the HMOX1 gene in HepG2 cells
treated with the compound of Example 17 or DMF were measured
according to the methods described above. Note that for gene
expression comparative analysis between the compound of Example 17
and DMF, HepG2 cells were treated with the test compound for 24
hours (results shown in FIG. 1).
[0740] It was found that the compound of Example 17 induced HMOX1
expression much more strongly than another Nrf2 activator DMF (FIG.
1A). For example, 30 .mu.M of the compound of Example 17 induced
HMOX1 expression 4 times higher than 250 .mu.M DMF.
[0741] The relative mRNA levels were also compared for several
other Bach1-responsive genes in HepG2 cells treated with the
compound of Example 17 versus Nrf2 activator DMF. Additionally, the
compound of Example 17 and DMF induced FTH1 expressions with
comparable fold increases (FIG. 1B).
Examples 148. HMOX Inducers of the Invention Reduce Vaso-Occlusion
in SCD Mice Increase Fetal Hemoglobin (HbF) in SCD Mice
Dosing Scheme of HMOX Inducers to HbSS Townes Sickle Mice
[0742] HbSS Townes sickle mice were oral gavaged once daily with
Vehicle or the compound of Example 17 listed below for 8 days. To
minimize experimental inconsistency, fresh formulation was prepared
every day and vortexed prior to drawing test article into syringe
for each dosing, and dosing was performed by the same individual
throughout the day. The last-day dose was administered by oral
gavage 4 hours prior to hemin infusion described below. [0743] 1.
Vehicle (0.5% w/v Tween 80 in 0.45% w/v methyl cellulose) [0744] 2.
the compound of Example 17 (10 mg/kg PO dosing) [0745] 3. the
compound of Example 17 (25 mg/kg PO dosing) [0746] 4. the compound
of Example 17 (50 mg/kg PO dosing)
Measurement of Vaso-Occlusion (Stasis)
[0747] Male and female sickle mice, approximately 12 weeks of age,
were weighed before surgery. Animals were anesthetized with a
mixture of ketamine (106 mg/kg) and xylazine (7.2 mg/kg) and dorsal
skin-fold chambers (DSFCs) were surgically implanted. On the same
day anesthetized mice were placed on a special intravital
microscopy stage, and 20-22 flowing subcutaneous venules in the
DSFC window were selected and mapped. After venule selection and
mapping, hemin chloride (2.677 mM; Frontier Scientific), dissolved
in sterile saline containing sodium carbonate (11.36 mM;
Sigma-Aldrich) and D-sorbitol (9.59 mM; Sigma-Aldrich), was
filtered (0.22 .mu.m), diluted 1:10 in sterile saline (267.7 .mu.M
hemin, final) and infused into the tail veins of mice (0.012 ml/g,
3.2 .mu.mols heme/kg body weight). All of the selected venules were
re-examined at 1 h after hemin infusion, and the number of static
(no flow) venules was counted and expressed as percent stasis. Four
hours after hemin infusion, mice were euthanized in a CO.sub.2
atmosphere and the liver, spleen and kidneys were removed, flash
frozen, and stored at -85.degree. C.
Measurement of F-Cells
[0748] Heparinized whole blood was collected 4 hours after hemin
infusion from the inferior vena cava of HbSS Townes mice
administered Vehicle or the compound of Example 17. F-cells were
stained on whole blood smears by the Kleihauer-Betke method using a
fetal cell stain kit (Simmler) according to the manufacturer's
instructions. F-cells and total erythrocytes were counted in 4
separate microscopic fields at 100.times. magnification for each
mouse. The F-cells were expressed as a percentage of total
erythrocytes (i.e., red blood cells). Human fetal cord blood was
used as a positive control.
[0749] Vaso-occlusion is a hallmark of SCD. To evaluate whether the
disclosed compounds can effectively reduce vaso-occlusion,
heme-induced vaso-occlusion (stasis) was measured in the
subcutaneous venules of HbSS-Townes sickle mice with implanted
dorsal skinfold chambers (DSFCs) according to the methods described
above. As shown in FIG. 2, microvascular stasis was significantly
reduced in HbSS-Townes mice administered with the compound of
Example 17 as compared with those administered with the Vehicle at
one hour after heme infusion. Furthermore, the compound of Example
17 dose responsively inhibited microvascular stasis (FIG. 2). For
the compound of Example 17, stasis was reduced to .about.17% with
10 mg/kg dosage, to .about.12% with 25 mg/kg dosage, and to
.about.5% with 50 mg/kg dosage.
[0750] At high enough concentrations, HbF can inhibit hemoglobin S
(HbS) polymerization and subsequent hemolysis and vaso-occlusion
(Krishnamoorthy S, et al. JCI Insight 2017, 2: e96409). To evaluate
whether HMOX Inducers of the Invention can effectively increase
HbF, F-cells (i.e., HbF-containing red blood cells) were measured
as a percentage of total red blood cells according to the methods
described above. As shown in FIG. 3, percent F-cells were
significantly increased in HbSS-Townes mice administered the
compound of Example 17 as compared with those administered with the
vehicle. Specifically, percent F-cells were increased to
.about.55-70% at all doses tested for the compound of Example 17,
more than doubled than the mice administered with the vehicle. The
increase in percent F-cells did not appear to be dose
responsive.
[0751] The results as shown above demonstrate that the compounds of
the present invention are HMOX inducers and Bach 1
binders/inhibitors, and can be used to treat SCD at least through
binding Bach 1, increasing HMOX1 activity, increasing HbF, and
reducing vaso-occlusion.
Example 149. Glutathione (GSH) Levels in Primary Human Endothelial
Cells
[0752] Primary human pulmonary artery endothelial cells (HPAEC)
(Lonza #CC-2530) cultured in endothelial cell growth medium-2 (EGM2
media, Lonza #CC-3162) were seeded in white 96-well plate
(Corning.RTM. #3610) at 12.5 k cells per well and placed at
37.degree. C. in 5% CO.sub.2. 18-24 hr post seeding, cells were
treated with the compound of Example 17 via media change. 24 hr
post treatment with the compound, cells were treated using a
freshly prepared hemin stock (Sigma-Aldrich #51280 in 0.1N NaOH)
alone or with the compound of Example 17. After 30 min of hemin
stress, cells were visually inspected for toxicity, with no
toxicity being noted. Media was aspirated off and GSH-Glo.TM.
Glutathione Assay (Promega #V6911) was run following the
manufacturer's protocol. White bottom plate seal (PerkinElmer
#6005199) was used during read. Analysis was done using Softmax
Pro.
[0753] The results are shown in FIG. 4. While hemin induces
oxidative stress in primary human pulmonary arterial endothelial
cells, thereby reducing GSH levels, pre-incubation with a HMOX
inducer/Bach 1 inhibitor (e.g., the compound of Example 17)
protects these cells from hemin mediated oxidative stress.
Example 150. Gene Expression in Primary Human Endothelial Cells
[0754] Inflammatory conditions in endothelial cells increase
expression of adhesion molecules, such as VCAM-1, ICAM-1 and
E-selectin through NF-kB signaling. HMOX1 -/- endothelial cells
show increased expression of VCAM-1 in response to TNF stimulation,
as compared to HMOX +/+ endothelial cells. See Seldon et al., J
Immunol Dec. 1, 2007, 179 (11) 7840-7851.
[0755] Primary human pulmonary artery endothelial cells (HPAEC)
(Lonza #CC-2530) were seeded in 12-well plates (TrueLine #TR5001)
at 200 k cells per well and placed at 37.degree. C. in 5% CO.sub.2.
18-24 hr post seeding, cells were treated with the compound of
Example 17 via media change. 24 hr post treatment with the
compound, cells were treated with 10 ng/mL TNF.alpha. (Invitrogen
#PHC3015 in H.sub.2O) alone or with the compound of Example 17.
After 4 hours of treatment, cells were visually inspected for
toxicity, with no toxicity being noted. Media was aspirated off,
cells were washed once with 1.times.PBS (Corning #21-040-CV),
aspirated dry, parafilmed and placed at -80.degree. C. until RNA
isolation. RNA was isolated with the NucleoSpin.RTM. kits
(MACHEREY-NAGEL #740955.250, USA) following kit protocol. RNA was
used to generate cDNA using the High-Capacity cDNA Reverse
Transcription Kit (ThermoFisher #4368814, USA) in 20 .mu.L
reactions. After reverse transcription was completed, cDNA was
diluted 1:10 with water. 20 ng cDNA was mixed with water, iQ.TM.
SYBR.RTM. Green Supermix (BioRad #170-8886), and 300 nM primer (IDT
#NM_001078) for a total 10 ul reaction and loaded into 384-well
white qPCR plates and subsequently analyzed using BioRad CFX384.
Raw data was exported from software (Biorad CFX Manager, USA) and
imported into a spreadsheet (Microsoft Excel, USA). To calculate
fold change, the .DELTA.Ct on a per sample basis was calculated as
Ct (Gene of interest)-Ct (Average of reference genes). The
.DELTA..DELTA.Ct was then calculated as .DELTA.Ct (experimental
sample)-Average .DELTA.Ct (control group). Fold change was
calculated as 2.sup.-.DELTA..DELTA.CT.
[0756] The results are shown in FIG. 5. Specifically, human primary
endothelial cells were activated using TNF-.alpha. stimulation. For
example, TNF-.alpha. induces expression of vascular cell adhesion
molecule (VCAM) in primary human pulmonary arterial endothelial
cells. Yet, pre-treatment with a HMOX inducer/Bach 1 inhibitor
(e.g., the compound of Example 17) reduced this TNF-.alpha.
mediated endothelial cell activation as evidenced by the reduction
of the expression of the adhesion molecule VCAM-1.
Example 151. PK Study
[0757] 9-10 week old male C57BL/6 mice were dosed orally with 50
mg/kg of the test compound formulated in 5% w/v tween 80 and 0.5%
methyl cellulose. At 0.5 and 4 h post dosing, whole blood was
collected, animals were sacrificed and brain tissues were
collected. The blood samples were immediately placed on ice, and
centrifuged within 60 min at 4.degree. C. for 3 min at 14000 rpm to
obtain plasma. Plasma was transferred by pipette to pre-labeled
Eppendorf tubes, stored at -80.degree. C. until analyzed.
[0758] Brain tissue samples were collected and rinsed with fresh
ice cold 0.9% NaCl solution, dried quickly and thereafter frozen on
dry ice/liquid nitrogen and stored at -70.+-.10.degree. C. until
analyzed. Homogenization was done using phosphate buffer saline and
used for analysis. Bioanalysis was performed using LC-MS/MS (API
4000).
[0759] The test results are provided in Table 4 below. The compound
of Example 56 compound showed good brain penetration.
TABLE-US-00010 TABLE 4 ##STR00260## ##STR00261## Comparator 1**
Matrix 0.5 hr 4 hr 0.5 hr 4 hr 1 hr 4 hr Plasma 4235 .+-. 771 72
.+-. 38 4239 .+-. 428 281 .+-. 318 2073 .+-. 137 288 .+-. 124
(ng/ml) Brain (ng/g) 188 .+-. 83 N/A* 4227 .+-. 600 122 .+-. 153
N/A N/A * Not available ** The compound of Example 17 and the
compound of Example 56 were measured in the same study. Comparator
1 was measured in a previous study.
Example 152. PD Study
[0760] 9-10 week old male C57BL/6 mice were dosed orally with 50
mg/kg of vehicle or compound formulated in 5% w/v tween 80 and 0.5%
methyl cellulose. At indicated time points (3 and 6 hours or or 4
and 8 hours post-dosing as shown in the results below), whole blood
was collected, animal was sacrificed and liver was collected. Blood
samples were transferred to vials containing 4 .mu.L of 10% w/v
EDTA, centrifuged at 6000 rpm for 8 in below 10.degree. C. to
obtain plasma. Samples were frozen and later processed for HMOX1
protein levels as indicated below:
HMOX 1 Protein Levels: Mouse Liver
Preparation of Homogenization/Lysis Buffer
[0761] The homogenization buffer was prepared according Table
A.
TABLE-US-00011 TABLE A Preparation of homogenization Buffer Stock
Final Volume Hepes (Ameresco #J848-100 ml) 1M 25 mM 2.5 ml NaCl
(BostonBioProducts #A28Q12R) 5M 300 mM 6 ml MgCl.sub.2 (Sigma
#7786-30-3) 1M 1.5 mM 150 ul EDTA (Ameresco #E177-500 ml) 0.5M 20
uM 4 ul Triton X-100 (Sigma #T8787-250 ml) 100% 0.10% 100 ul MiliQ
H2O 91.246 ml Final Volume 100 mL
[0762] Immediately prior to use, add DTT (ThermoScientific #R0861)
to a final concentration of 5 mM and 100.times. Halt Protease &
Phosphatase Inhibitor Cocktail (ThermoScientific #78440) to a final
concentration of 1.times..
Preparation of Mouse Liver Samples
[0763] Liver samples were crushed by mortar and pestle under
freezing conditions. Pulverized tissue was transferred into
pre-chilled bead ruptor OMNI tubes (OMNI International, Cat
#19-628). 1 mL of homogenization buffer (+DTT and HALT) was added
to pulverized tissue and tubes were placed on ice. Samples were
loaded and run through bead ruptor at speed 5.64 m/s, for two 20
sec cycles with 10 sec dwell between cycles and samples were
immediately returned to ice. All material was transferred to a new
chilled 2 mL Eppendorf tube. Samples were centrifuged for 5 minutes
at 2,000 rpm at 4.degree. C. Supernatant was transferred to a fresh
chilled 1.7 mL Eppendorf tube. Samples were centrifuged for 5
minutes at 2,000 rpm at 4.degree. C. The supernatant, consisting of
cytosol and microsomes, was transferred to a fresh chilled 1.7 mL
Eppendorf tube. Samples were stored at -80.degree. C. Microsome
samples were quantitated using Pierce 660 Assay (ThermoFisher Cat
#22660) with pre-diluted BSA standards (ThermoFisher Cat #23208)
ranging from 125-2000 ug/mL. Each sample was diluted to 10 ng/ul
for an ELISA input of 0.5 ug in 50 ul.
Preparation of Assay Reagents
[0764] All assay reagents were provided in the Heme Oxygenase 1
(HO1) Mouse SimpleStep ELISA Kit (Abcam #ab204524). Prior to use,
all reagents were equilibrated to room temperature. 1.times. Wash
Buffer PT was prepared by diluting 10.times. Wash Buffer PT 1:10
with deionized water. Antibody cocktail was prepared by diluting
the 10.times. Capture Antibody and 10.times. Detector Antibody to
1.times. in Antibody Diluent 5BI. Mouse heme oxygenase 1 protein
standard was reconstituted using 500 ul homogenization buffer
(Table A), mixed and held at room temperature for 10 minutes prior
to dilution. An eight point standard curve was generated by
diluting the Stock Standard 1:2 for standard curve ranging from
10,000-156.3 pg/mL.
Heme Oxygenase 1 (HO1) Mouse SimpleStep ELISA
[0765] 50 ul of all samples and standards were added to appropriate
wells in duplicate. 50 ul of 1.times. Antibody Cocktail was added
to each well. The plate was sealed with provided seal and incubated
at room temperature on a plate shaker at 400 rpm. After one hour
incubation, the Antibody Cocktail was aspirated and the wells were
washed three times with 350 ul 1.times. Wash Buffer PT, aspirating
completely between each step. After the last wash was aspirated
dry, 100 ul TMB Substrate was added to each well and the plate was
incubated in the dark at room temperature for 10 minutes on a plate
shaker at 400 rpm. After the 10 minute incubation, 100 ul of Stop
Solution was added to each well. Plate was shaken at 400 rpm for 1
minute to mix. Softmax Pro 7.0.3 was used to read OD at 450 nm as
well as for analysis.
Heme Oxygenase 1 Protein Levels in Mouse Plasma
Preparation of Assay Reagents
[0766] All assay reagents were provided in the Heme Oxygenase 1
(HO1) Mouse SimpleStep ELISA Kit (Abcam #ab204524). 1.times. Wash
Buffer PT was prepared by diluting 10.times. Wash Buffer PT 1:10
with deionized water. Antibody cocktail was prepared by diluting
the 10.times. Capture Antibody and 10.times. Detector Antibody to
1.times. in Antibody Diluent 5BI. Mouse heme oxygenase 1 protein
standard was reconstituted using 500 ul Sample Diluent NS, mixed
and held at room temperature for 10 minutes prior to dilution. An
eight point standard curve was generated by diluting the Stock
Standard 1:2 for standard curve ranging from 5,000-78.1
.mu.g/mL.
Preparation of Plasma Sample
[0767] Prior to ELISA, frozen plasma was thawed on ice. Plasma
samples were diluted 1:10 in Sample Diluent NS for a final
concentration of 10% plasma.
Heme Oxygenase 1 (HO1) Mouse SimpleStep ELISA
[0768] 50 ul of samples and standards were added to appropriate
wells in duplicate. 50 ul of 1.times. Antibody Cocktail was added
to each well. The plate was sealed with provided seal and incubated
at room temperature on a plate shaker at 400 rpm. After one hour
incubation, the Antibody Cocktail was aspirated and the wells were
washed three times with 350 ul 1.times. Wash Buffer PT, aspirating
completely between each step. After the last wash was aspirated
dry, 100 ul TMB Substrate was added to each well and the plate was
incubated in the dark at room temperature for 10 minutes on a plate
shaker at 400 rpm. After the 10 minute incubation, 100 ul of Stop
Solution was added to each well. Plate was shaken at 400 rpm for 1
minute to mix. Softmax Pro 7.0.3 was used to read OD at 450 nm as
well as for analysis.
[0769] Representative compounds of the present disclosure were
tested and the a results are provided in Table 5 blow. Plasma and
liver protein levels assessed by mouse HMOX1 ELISA assay (kit) and
were compared to time-matched vehicle control mice to give fold
induction. Carboxylic acids showed modest increase in HMOX1
protein, although concentrations were well above EC.sub.50
(30-100.times.).
TABLE-US-00012 TABLE 5 HMOX1 Plasma Liver Liver EC.sub.50 h Protein
Conc uM Protein (uM) (3 h, 6 h) (3 h, 6 h) (3 h, 6 h) Comparator 1
0.9 1.1x 12.2 1.6x 50 mpk 1.3x 1.3 3.2x Study 667 Ex. 13 Carboxylic
1.9 1.1x 63 1.8x 50 mpk Acid 0.8x 5.4 1.2x Study 667 Ex. 44
Carboxylic 2.0 1.0 217 1.6x 50 mpk Acid 1.1x 162 2.1x Study 667 Ex.
17 1.4 1.7x* 11 3.3x* 50 mpk 1.1x* 4.9 3.1x* Study 702* *Time
points were 4 and 8 hours instead of 3 and 6 hours.
* * * * *